{"doc_id": 0, "doc": {"person_id": 115973414, "visit_occurrence_id": 117251259, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2018-04-23 12:38:44", "visit_end_datetime": "2018-04-23 14:32:57", "visit_length_in_hours": 1.9036111111111111, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2018-04-23 12:38:44, ended at 2018-04-23 14:32:57\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n- Anxiety disorder\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 100, "patient_first_visit_date": "2016-07-26 12:42:51", "patient_last_visit_date": "2023-02-06 00:00:00", "end_obs_date": "2019-04-23", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 1, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 133, "cumulated_visit_num": 133, "cumulated_approximate_token_count": 26327, "visit_cumulated": "## Visit\nThis visit record, was from Office Visit, started at 2016-07-26 12:42:51, ended at 2016-07-26 15:06:50\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Headache caused by drug\n- Migraine without aura\n\n### Drug\n- methylprednisolone 4 MG Oral Tablet, through Oral route, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 4 mg by mouth 2 times a day as needed\n- 24 HR rivastigmine 0.192 MG/HR Transdermal System, through Transdermal route, presumably until 2016-08-08, with intended 0 refill(s). Instructions: apply 4.6 Patches to skin every day\n- diclofenac potassium 50 MG Powder for Oral Solution, through Oral route, started on 2016-07-26, presumably until 2016-09-07, with intended 3 refill(s). Instructions: take 10 Packets by mouth as needed (Please take it at onset of headache)\n- lorazepam 0.5 MG Oral Tablet, through Oral route, presumably until 2016-09-13, with intended 0 refill(s). Instructions: take 0.5 mg by mouth every 4 hours as needed\n- candesartan cilexetil 4 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 4 mg by mouth every morning\n- olanzapine 5 MG Oral Tablet, through Oral route, presumably until 2017-04-11, with intended 0 refill(s). Instructions: take 5 mg by mouth as needed \n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 125 mg by mouth 3 times a day\n- topiramate 50 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 50 mg by mouth 3 times a day\n- naratriptan 2.5 MG Oral Tablet, through Oral route, presumably until 2016-10-27, with intended 0 refill(s). Instructions: take 2.5 mg by mouth once as needed\n- dexamethasone 2 MG Oral Tablet, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 2 mg by mouth every morning\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, through Oral route, presumably until 2016-12-22, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 caps po q6hrs prn\n- dicyclomine hydrochloride 20 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 20 mg by mouth daily in the evening\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 25 mg by mouth 2 times a day as needed\n- sertraline 50 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 50 mg by mouth every morning\n- metoclopramide 10 MG Oral Tablet, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 10 mg by mouth 4 times a day as needed\n- naproxen sodium 550 MG Oral Tablet, through Oral route, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 550 mg by mouth 2 times a day with meals\n- ondansetron 4 MG Oral Tablet, through Oral route, presumably until 2016-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-03 00:00:00, ended at 2016-08-03 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.54 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Prothrombin time (PT): 13.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-03 12:04:39, ended at 2016-08-03 13:00:13\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 4 - 5 (per high power field)\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hematuria syndrome\n- Primary diagnosis: Generalized abdominal pain\n- Low back pain\n\n### Drug\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2016-08-03, presumably until 2016-09-07, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-03 19:40:00, ended at 2016-08-04 02:32:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.54 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Prothrombin time (PT): 13.7 (second)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Dyspnea\n- Low back pain\n- Primary diagnosis: Diarrhea\n- Left lower quadrant pain\n\n### Drug\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-23, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- naproxen 250 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-03, presumably until 2016-08-04\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-08-03, presumably until 2016-08-03\n- naproxen 500 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-04\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2016-08-03, presumably until 2016-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-05 00:00:00, ended at 2016-08-05 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.57 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.76 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.30 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-05 17:04:00, ended at 2016-08-05 19:57:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.76 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.57 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.30 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Generalized abdominal pain\n- Hypokalemia\n- Left lower quadrant pain\n- Disorder of intestine\n- Nausea and vomiting\n- Primary diagnosis: Bacterial enteritis\n- Backache\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-05\n- cyclobenzaprine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-05, presumably until 2016-08-05\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-08-05, presumably until 2016-08-05\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-10-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-07 00:00:00, ended at 2016-08-07 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Headache caused by drug\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-08 10:05:13, ended at 2016-08-08 12:55:54\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Body height: 5' 11\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.81 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.49 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Noninflammatory disorder of the vagina\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-10 00:00:00, ended at 2016-08-10 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of intestine\n- Primary diagnosis: Diarrhea\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-11 00:00:00, ended at 2016-08-11 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 2.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 217 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 242 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-11 11:20:00, ended at 2016-08-11 16:20:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 2.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 217 (unit per liter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 242 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography, abdomen and pelvis; without contrast material\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Diarrhea\n- Hypokalemia\n- Primary diagnosis: Abdominal pain\n- Loss of consciousness\n\n### Drug\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2016-08-11, presumably until 2016-08-11\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2016-08-11, presumably until 2016-08-11\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2016-08-11, presumably until 2016-08-11\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2016-08-11, presumably until 2016-11-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-11, presumably until 2016-08-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-15 15:50:00, ended at 2016-08-15 23:59:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Chronic gastritis\n- Disorder of intestine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-23 12:43:04, ended at 2016-08-23 14:09:13\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI, Rorschach, WAIS), per hour of the psychologist's or physician's time, both face-to-face time administering test\n- Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; initial assessment\n\n### Condition\n- Primary diagnosis: Headache caused by drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-30 00:00:00, ended at 2016-08-30 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-09-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-30 00:00:00, ended at 2016-08-30 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n- Nausea\n\n### Drug\n- candesartan cilexetil 4 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-12-04, with intended 3 refill(s). Instructions: take 4 mg by mouth daily\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-12-21, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2016-08-30, presumably until 2016-09-07, with intended 1 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-06 16:02:08, ended at 2016-09-06 16:39:14\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n- Gastro-esophageal reflux disease with esophagitis\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-07 12:41:22, ended at 2016-09-07 14:23:55\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychiatric diagnostic evaluation with medical services\n\n### Condition\n- Depressive disorder\n\n### Drug\n- sertraline 50 MG Oral Tablet, started on 2016-09-07, presumably until 2016-11-03, with intended 3 refill(s). Instructions: Take 1.5 tablet (75 mg) for 2 weeks then 2 tablets (100 mg) thereafter.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-12 00:00:00, ended at 2016-09-12 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-09-12, presumably until 2016-09-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-13 00:00:00, ended at 2016-09-13 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-09-13, presumably until 2016-12-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-13 00:00:00, ended at 2016-09-13 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n\n### Drug\n- 24 HR budesonide 9 MG Extended Release Oral Tablet, through Oral route, started on 2016-09-13, presumably until 2016-10-27, with intended 4 refill(s). Instructions: take 9 mg by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-14 14:33:36, ended at 2016-09-14 16:00:58\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.68 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 341 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 5 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.69 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Major depression, single episode\n- Primary diagnosis: Anesthesia of skin\n- Primary diagnosis: Paresthesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-22 09:22:52, ended at 2016-09-22 10:30:12\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paresthesia\n- Primary diagnosis: Anesthesia of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-09 11:12:08, ended at 2016-10-09 13:10:59\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-10 00:00:00, ended at 2016-10-10 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- 24 HR budesonide 9 MG Extended Release Oral Tablet, through Oral route, started on 2016-10-10, presumably until 2016-10-27, with intended 3 refill(s). Instructions: take 9 mg by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-11 12:54:43, ended at 2016-10-11 12:59:52\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute stress disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-19 08:31:28, ended at 2016-10-19 08:46:22\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-20 16:39:54, ended at 2016-10-20 16:48:39\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign paroxysmal positional vertigo\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-24 10:32:45, ended at 2016-10-24 11:30:49\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2016-10-24, presumably until 2016-10-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-26 13:30:00, ended at 2016-10-26 23:59:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-27 10:26:03, ended at 2016-10-27 11:39:49\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Major depression, single episode\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-01 00:00:00, ended at 2016-11-01 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- budesonide 3 MG Delayed Release Oral Capsule, through Oral route, started on 2016-11-01, presumably until 2016-12-19, with intended 6 refill(s). Instructions: take 3 Caps by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-03 10:18:57, ended at 2016-11-03 14:50:41\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anxiety disorder\n- Major depression, single episode\n- Nausea and vomiting\n- Primary diagnosis: Colitis\n- Diarrhea\n\n### Drug\n- fluoxetine 20 MG Oral Tablet, through Oral route, started on 2016-11-03, presumably until 2016-12-04, with intended 0 refill(s). Instructions: take 20 mg by mouth daily\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2016-11-03, presumably until 2017-04-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-23 13:04:52, ended at 2016-11-23 14:45:28\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Vitamin B deficiency\n- Primary diagnosis: Colitis\n\n### Drug\n- mesalamine 800 MG Delayed Release Oral Tablet, through Oral route, started on 2016-11-23, presumably until 2016-11-30, with intended 6 refill(s). Instructions: take 3 Tabs by mouth 2 times a day\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2016-11-23, presumably until 2016-11-23, with intended 0 refill(s). Instructions: inject 1 mL into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-11-27 00:00:00, ended at 2016-11-27 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2016-11-27, presumably until 2017-01-30, with intended 0 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-30 00:00:00, ended at 2016-11-30 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- balsalazide disodium 750 MG Oral Capsule, through Oral route, started on 2016-11-30, presumably until 2016-12-12, with intended 11 refill(s). Instructions: take 3 Caps by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-04 13:23:24, ended at 2016-12-04 13:52:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute upper respiratory infection\n- Colitis\n- Primary diagnosis: Viral disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-05 00:00:00, ended at 2016-12-05 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- benzonatate 100 MG Oral Capsule, started on 2016-12-05, presumably until 2016-12-12, with intended 0 refill(s). Instructions: Take 1-2 tablets three times daily as needed for cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-11 00:00:00, ended at 2016-12-11 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-12-11, presumably until 2017-12-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-11 09:20:14, ended at 2016-12-11 14:12:53\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-14 00:00:00, ended at 2016-12-14 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-12-14, presumably until 2017-04-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-14 11:32:16, ended at 2016-12-14 12:47:13\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n- Vitamin B deficiency\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2016-12-14, presumably until 2016-12-14, with intended 0 refill(s). Instructions: inject 1 mL into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-15 00:00:00, ended at 2016-12-15 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Latent syphilis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-18 15:38:15, ended at 2016-12-18 17:09:09\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n- Otalgia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-19 00:00:00, ended at 2016-12-19 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2016-12-21, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 4 Tabs by mouth every day take 4.8 g by mouth\n- budesonide 3 MG Delayed Release Oral Capsule, through Oral route, started on 2016-12-21, presumably until 2017-05-01, with intended 6 refill(s). Instructions: take 3 Caps by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-19 12:19:06, ended at 2016-12-19 13:06:10\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Otalgia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-21 00:00:00, ended at 2016-12-21 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2016-12-21, presumably until 2017-01-17, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-22 00:00:00, ended at 2016-12-22 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-22 00:00:00, ended at 2016-12-22 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, through Oral route, started on 2016-12-25, presumably until 2016-12-27, with intended 1 refill(s). Instructions: take 1 Cap by mouth every 4 hours as needed 2 caps po q6hrs prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-27 00:00:00, ended at 2016-12-27 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2016-12-27, presumably until 2017-04-11, with intended 1 refill(s). Instructions: 1 cap every 4-6 hours PRN. Olechowski dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-28 00:00:00, ended at 2016-12-28 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-17 00:00:00, ended at 2017-01-17 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-17 11:58:57, ended at 2017-01-17 14:04:12\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin B deficiency\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-17 11:59:16, ended at 2017-01-17 14:16:45\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-01-17, presumably until 2017-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-25 10:26:27, ended at 2017-01-25 12:42:28\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n- Primary diagnosis: Nausea\n- Disorder of intestine\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, through Oral route, presumably until 2017-01-25, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-01-30 00:00:00, ended at 2017-01-30 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2017-01-30, presumably until 2017-03-06, with intended 0 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-12 12:25:31, ended at 2017-02-12 14:22:03\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-26 14:06:35, ended at 2017-02-26 14:46:11\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pain\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-03-06 00:00:00, ended at 2017-03-06 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2017-03-07, presumably until 2017-03-12, with intended 2 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 16:12:44, ended at 2017-03-12 17:49:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n- Primary diagnosis: Migraine\n- Migraine without aura\n- Nausea\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2017-03-12, presumably until 2017-08-18, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every day take 4.8 g by mouth\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-03-12, presumably until 2017-08-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2017-03-12, presumably until 2017-08-14, with intended 0 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-16 00:00:00, ended at 2017-03-16 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-16 06:56:00, ended at 2017-03-16 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material\n\n### Condition\n- Chondromalacia of patella\n- Pain of left knee region\n- Fat pad syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-30 13:45:53, ended at 2017-03-30 15:06:48\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.9 (percent)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 286 (picogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 4.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.22 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.73 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.58 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 216 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Blood chemistry abnormal\n- Colitis\n- Verruca vulgaris\n- Anxiety disorder\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-03 00:00:00, ended at 2017-04-03 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-11 10:35:40, ended at 2017-04-11 13:33:38\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Status migrainosus\n- Primary diagnosis: Chronic intractable migraine without aura\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-04-11, presumably until 2017-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-11 10:35:40, ended at 2017-04-11 11:59:22\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Status migrainosus\n- Primary diagnosis: Chronic intractable migraine without aura\n- Nausea and vomiting\n- Diarrhea\n\n### Drug\n- frovatriptan 2.5 MG Oral Tablet, started on 2017-04-11, presumably until 2017-08-24, with intended 2 refill(s). Instructions: Take 1 tab at onset of headache. May repeat in 2 hrs if needed. Limit 2 doses/24 hours. Limit to 10 days per month.\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2017-04-11, presumably until 2017-08-16, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. Foust dose 2 days a week.\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2017-04-11, presumably until 2018-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-04-17 00:00:00, ended at 2017-04-17 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-04-17, presumably until 2017-05-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-18 09:27:00, ended at 2017-04-18 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)\n- Nerve conduction studies; 11-12 studies\n\n### Condition\n- Anesthesia of skin\n- Polyneuropathy\n- Paresthesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-25 00:00:00, ended at 2017-04-25 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-01 12:05:10, ended at 2017-05-01 15:04:51\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Monoarthritis\n\n### Drug\n- vitamin B12 1 MG Oral Tablet, through Oral route, presumably until 2017-08-24, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-07 00:00:00, ended at 2017-05-07 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dizziness and giddiness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-25 14:26:57, ended at 2017-05-25 15:37:13\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis of knee\n- Primary diagnosis: Enteropathic arthritis\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2017-05-25, presumably until 2017-08-24, with intended 2 refill(s). Instructions: Apply 4 grams to affected area (knee) up to 4 times a day.\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2017-05-25, presumably until 2018-01-25, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-04 13:39:51, ended at 2017-06-04 15:04:24\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-21 09:28:00, ended at 2017-06-21 11:53:52\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.472\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal malabsorption\n- Iron deficiency anemia\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-21 11:07:00, ended at 2017-06-21 12:04:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Coenzyme Q10.reduced/Coenzyme Q10 in Serum or Plasma: 93 (percent)\n- Glial nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Pyridoxal phosphate [Mass/volume] in Serum or Plasma: 5 (microgram per liter)\n- Ascorbate [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Voltage-gated calcium channel N type binding Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Neuronal nuclear type 2 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- PCA-1 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 33 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Glutamate decarboxylase 65 Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Thiamine pyrophosphate [Moles/volume] in Blood: 49 (nanomole per liter)\n- Voltage-gated potassium channel Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Acetylcholine receptor binding Ab [Moles/volume] in Serum: 0.01 (nanomole per liter)\n- CV2 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Coenzyme Q10.reduced [Mass/volume] in Serum or Plasma: 869.7 (microgram per liter)\n- Methylmalonate [Moles/volume] in Serum or Plasma: 0.07 (micromole per liter)\n- Neuronal nuclear type 3 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Voltage-gated calcium channel P/Q type binding Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Amphiphysin IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 34 (percent)\n- PCA-2 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Striated muscle Ab [Titer] in Serum: Negative (titer)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 33 (nanogram per milliliter)\n- Coenzyme Q10 [Mass/volume] in Serum or Plasma: 932 (microgram per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 9.5 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 98 (microgram per deciliter)\n- Neuronal nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy\n- Intestinal malabsorption\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-21 12:05:00, ended at 2017-06-21 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Testing of autonomic nervous system function; combined parasympathetic and sympathetic adrenergic function testing with at least 5 minutes of passive tilt\n- Testing of autonomic nervous system function; sudomotor, including 1 or more of the following: quantitative sudomotor axon reflex test (QSART), silastic sweat imprint, thermoregulatory sweat test, and changes in sympathetic skin potential\n\n### Condition\n- Iron deficiency anemia\n- Dizziness and giddiness\n- Intestinal malabsorption\n- Adrenal cortical hypofunction\n- Disorder of autonomic nervous system\n- Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-04 11:57:32, ended at 2017-07-04 14:33:13\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Chronic intractable migraine without aura\n- Migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-07-04, presumably until 2017-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-26 14:56:39, ended at 2017-07-26 15:35:28\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute pharyngitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-30 13:05:02, ended at 2017-07-30 15:23:46\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-14 13:12:27, ended at 2017-08-14 16:39:27\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-15 00:00:00, ended at 2017-08-15 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-08-16, presumably until 2017-08-16, with intended 3 refill(s). Instructions: TAKE 1 TAB BY MOUTH 2 TIMES A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-16 00:00:00, ended at 2017-08-16 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-08-16, presumably until 2017-10-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2017-08-16, presumably until 2017-11-07, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. Ray dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-18 00:00:00, ended at 2017-08-18 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, started on 2017-08-20, presumably until 2017-11-30, with intended 1 refill(s). Instructions: TAKE 4 TABS BY MOUTH EVERY DAY TAKE 4.8 G BY MOUTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-24 10:56:50, ended at 2017-08-24 11:51:41\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Status migrainosus\n- Anxiety disorder\n- Primary diagnosis: Chronic intractable migraine without aura\n- Major depression, single episode\n\n### Drug\n- naratriptan 2.5 MG Oral Tablet, started on 2017-08-24, presumably until 2018-04-08, with intended 3 refill(s). Instructions: Take onset of migraine and repeat in 2-4 hours if needed no more than 2 tabs in 24 hrs and limit to 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-28 12:57:38, ended at 2017-08-28 13:37:53\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Anxiety disorder\n- Major depression, single episode\n- Primary diagnosis: Chronic intractable migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-13 00:00:00, ended at 2017-09-13 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.53 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.56 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.5 (percent)\n- Salicylates [Presence] in Urine: <10 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Acetaminophen [Presence] in Urine: <2.0 (microgram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-13 14:45:59, ended at 2017-09-13 16:11:01\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anxiety disorder\n- Chronic intractable migraine without aura\n- Status migrainosus\n- Primary diagnosis: Major depression, single episode\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-13 18:33:00, ended at 2017-09-14 02:20:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Salicylates [Presence] in Urine: <10 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Acetaminophen [Presence] in Urine: <2.0 (microgram per milliliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.56 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.53 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n\n### Procedure\n- Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when per\n\n### Condition\n- Migraine without aura\n- Sleep disorder\n- Gastro-esophageal reflux disease with esophagitis\n- Benign paroxysmal positional vertigo\n- Major depression, single episode\n- Intestinal malabsorption\n- Polyneuropathy\n- Generalized anxiety disorder\n- Primary diagnosis: Anxiety disorder\n- Panic disorder without agoraphobia\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-09-13\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-10-24, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-12-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-10-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-24 10:11:25, ended at 2017-10-24 11:18:35\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n- Insomnia\n- Primary diagnosis: Dizziness and giddiness\n- Anxiety disorder\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-10-24, presumably until 2018-04-04, with intended 5 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-02 14:55:29, ended at 2017-11-02 16:11:05\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain of left knee region\n- Anxiety disorder\n\n### Drug\n- 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe, through Intramuscular route, started on 2017-11-02, presumably until 2017-11-02, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2017-11-07, presumably until 2018-04-08, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. Sommerville dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-08 08:49:56, ended at 2017-11-08 10:25:51\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n\n### Condition\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 13:24:49, ended at 2017-11-12 15:53:14\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-20 09:57:35, ended at 2017-11-20 11:22:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-11-29 00:00:00, ended at 2017-11-29 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, started on 2017-11-30, presumably until 2017-12-03, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH EVERY DAY TAKE 4.8 G BY MOUTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-03 00:00:00, ended at 2017-12-03 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2017-12-03, presumably until 2018-04-04, with intended 1 refill(s). Instructions: take 2 Tabs by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 12:44:24, ended at 2017-12-12 13:32:07\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Chronic intractable migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-12-12, presumably until 2017-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-14 00:00:00, ended at 2017-12-14 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-17 00:00:00, ended at 2017-12-17 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pain\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-17 09:07:51, ended at 2017-12-17 09:53:33\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pain\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-18 15:34:32, ended at 2017-12-18 16:06:28\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Anxiety disorder\n- Moderate recurrent major depression\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-31 08:03:06, ended at 2017-12-31 09:20:56\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n\n### Condition\n- Primary diagnosis: Joint pain\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-08 14:21:07, ended at 2018-01-08 14:50:25\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Candidiasis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-09 08:19:51, ended at 2018-01-09 09:53:33\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-21 00:00:00, ended at 2018-01-21 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2018-01-21, presumably until 2018-03-08, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis of knee\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2018-01-25, presumably until 2018-03-08, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-01-25 11:14:53, ended at 2018-01-25 13:13:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left lower limb\n\n### Drug\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-30 00:00:00, ended at 2018-01-30 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2018-01-30, presumably until 2018-03-08, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-30 09:01:16, ended at 2018-01-30 11:00:36\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n\n### Condition\n- Joint pain\n- Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-30 15:15:07, ended at 2018-01-30 16:33:54\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-02-04 22:02:00, ended at 2018-02-04 23:09:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Neck pain\n- Primary diagnosis: Complex regional pain syndrome, type II, upper limb\n- Pain in left arm\n- Gastro-esophageal reflux disease with esophagitis\n- Chest pain\n- Migraine without aura\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2018-02-04, presumably until 2018-02-09, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 08:47:24, ended at 2018-02-06 10:18:04\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-02-07 10:16:57, ended at 2018-02-07 14:50:23\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Complex regional pain syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-13 08:43:14, ended at 2018-02-13 10:02:30\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-15 08:14:27, ended at 2018-02-15 09:51:31\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebrospinal fluid leak\n- Primary diagnosis: Chronic intractable migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- naltrexone, started on 2018-02-15, presumably until 2018-04-04, with intended 3 refill(s). Instructions: Take one capsule by mouth 2 hours before sleep every night\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-25 00:00:00, ended at 2018-02-25 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of cervical spine\n- Primary diagnosis: Polyneuropathy\n- Disorder of thoracic spine\n- Nerve root disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-27 15:24:09, ended at 2018-02-27 16:04:20\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-06 09:54:30, ended at 2018-03-06 10:51:37\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-08 12:41:51, ended at 2018-03-08 13:23:36\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Chronic intractable migraine without aura\n- Primary diagnosis: Migraine without aura\n- Headache caused by drug\n- Status migrainosus\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2018-03-08, presumably until 2018-03-08\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2018-03-08, presumably until 2018-04-04, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-12 12:15:44, ended at 2018-03-12 14:05:41\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-14 00:00:00, ended at 2018-03-14 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-19 14:11:16, ended at 2018-03-19 14:24:12\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-21 12:47:47, ended at 2018-03-21 14:26:17\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebrospinal fluid leak\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-25 00:00:00, ended at 2018-03-25 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-26 14:45:01, ended at 2018-03-26 15:37:55\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-02 12:57:29, ended at 2018-04-02 14:04:19\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Anxiety disorder\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-02 14:51:43, ended at 2018-04-02 16:39:41\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Anxiety disorder\n- Joint pain\n- Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-03 08:47:24, ended at 2018-04-03 10:17:10\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Hemorrhage of rectum and anus\n- Cerebrospinal fluid leak\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-08 10:25:36, ended at 2018-04-08 14:35:18\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n- Moderate recurrent major depression\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2018-04-08, presumably until 2018-09-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- naratriptan 2.5 MG Oral Tablet, started on 2018-04-08, presumably until 2018-05-06, with intended 3 refill(s). Instructions: Take onset of migraine and repeat in 2-4 hours if needed no more than 2 tabs in 24 hrs and limit to 2 days a week.\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2018-04-08, presumably until 2018-12-25, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. South dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-09 12:48:20, ended at 2018-04-09 14:40:22\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-09 14:38:58, ended at 2018-04-09 16:06:31\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n- Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-16 13:34:41, ended at 2018-04-16 15:12:33\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Lumbar radiculopathy\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-04-16, presumably until 2018-05-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth once as needed (for MRI)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-18 16:00:00, ended at 2018-04-18 23:59:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n\n### Condition\n- Lumbar radiculopathy\n- Degeneration of lumbar intervertebral disc\n\n### Drug\n- gadobenate, through Intravenous route, started on 2018-04-18, presumably until 2018-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-23 12:38:44, ended at 2018-04-23 14:32:57\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n- Anxiety disorder\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-26 12:42:51, ended at 2016-07-26 15:06:50\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Headache caused by drug\n- Migraine without aura\n\n### Drug\n- methylprednisolone 4 MG Oral Tablet, through Oral route, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 4 mg by mouth 2 times a day as needed\n- 24 HR rivastigmine 0.192 MG/HR Transdermal System, through Transdermal route, presumably until 2016-08-08, with intended 0 refill(s). Instructions: apply 4.6 Patches to skin every day\n- diclofenac potassium 50 MG Powder for Oral Solution, through Oral route, started on 2016-07-26, presumably until 2016-09-07, with intended 3 refill(s). Instructions: take 10 Packets by mouth as needed (Please take it at onset of headache)\n- lorazepam 0.5 MG Oral Tablet, through Oral route, presumably until 2016-09-13, with intended 0 refill(s). Instructions: take 0.5 mg by mouth every 4 hours as needed\n- candesartan cilexetil 4 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 4 mg by mouth every morning\n- olanzapine 5 MG Oral Tablet, through Oral route, presumably until 2017-04-11, with intended 0 refill(s). Instructions: take 5 mg by mouth as needed \n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 125 mg by mouth 3 times a day\n- topiramate 50 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 50 mg by mouth 3 times a day\n- naratriptan 2.5 MG Oral Tablet, through Oral route, presumably until 2016-10-27, with intended 0 refill(s). Instructions: take 2.5 mg by mouth once as needed\n- dexamethasone 2 MG Oral Tablet, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 2 mg by mouth every morning\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, through Oral route, presumably until 2016-12-22, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 caps po q6hrs prn\n- dicyclomine hydrochloride 20 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 20 mg by mouth daily in the evening\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 25 mg by mouth 2 times a day as needed\n- sertraline 50 MG Oral Tablet, through Oral route, presumably until 2016-08-30, with intended 0 refill(s). Instructions: take 50 mg by mouth every morning\n- metoclopramide 10 MG Oral Tablet, through Oral route, presumably until 2016-09-07, with intended 0 refill(s). Instructions: take 10 mg by mouth 4 times a day as needed\n- naproxen sodium 550 MG Oral Tablet, through Oral route, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 550 mg by mouth 2 times a day with meals\n- ondansetron 4 MG Oral Tablet, through Oral route, presumably until 2016-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-03 00:00:00, ended at 2016-08-03 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.54 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Prothrombin time (PT): 13.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-03 12:04:39, ended at 2016-08-03 13:00:13\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 4 - 5 (per high power field)\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hematuria syndrome\n- Primary diagnosis: Generalized abdominal pain\n- Low back pain\n\n### Drug\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2016-08-03, presumably until 2016-09-07, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-03 19:40:00, ended at 2016-08-04 02:32:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.54 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Prothrombin time (PT): 13.7 (second)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Dyspnea\n- Low back pain\n- Primary diagnosis: Diarrhea\n- Left lower quadrant pain\n\n### Drug\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-23, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- naproxen 250 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-03, presumably until 2016-08-04\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-08-03, presumably until 2016-08-03\n- naproxen 500 MG Oral Tablet, through Oral route, started on 2016-08-04, presumably until 2016-08-04\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2016-08-03, presumably until 2016-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-05 00:00:00, ended at 2016-08-05 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.57 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.76 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.30 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-05 17:04:00, ended at 2016-08-05 19:57:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.76 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.57 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.30 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Generalized abdominal pain\n- Hypokalemia\n- Left lower quadrant pain\n- Disorder of intestine\n- Nausea and vomiting\n- Primary diagnosis: Bacterial enteritis\n- Backache\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-05\n- cyclobenzaprine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-05, presumably until 2016-08-05\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-08-05, presumably until 2016-08-05\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-10-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-08-05, presumably until 2016-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-07 00:00:00, ended at 2016-08-07 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Headache caused by drug\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-08 10:05:13, ended at 2016-08-08 12:55:54\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Body height: 5' 11\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.81 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.49 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Noninflammatory disorder of the vagina\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-10 00:00:00, ended at 2016-08-10 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of intestine\n- Primary diagnosis: Diarrhea\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-11 00:00:00, ended at 2016-08-11 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 2.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 217 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 242 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-08-11 11:20:00, ended at 2016-08-11 16:20:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 2.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 217 (unit per liter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 242 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography, abdomen and pelvis; without contrast material\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Diarrhea\n- Hypokalemia\n- Primary diagnosis: Abdominal pain\n- Loss of consciousness\n\n### Drug\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2016-08-11, presumably until 2016-08-11\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2016-08-11, presumably until 2016-08-11\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2016-08-11, presumably until 2016-08-11\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2016-08-11, presumably until 2016-11-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-11, presumably until 2016-08-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-15 15:50:00, ended at 2016-08-15 23:59:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Chronic gastritis\n- Disorder of intestine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-23 12:43:04, ended at 2016-08-23 14:09:13\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI, Rorschach, WAIS), per hour of the psychologist's or physician's time, both face-to-face time administering test\n- Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; initial assessment\n\n### Condition\n- Primary diagnosis: Headache caused by drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-30 00:00:00, ended at 2016-08-30 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-09-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-30 00:00:00, ended at 2016-08-30 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n- Nausea\n\n### Drug\n- candesartan cilexetil 4 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-12-04, with intended 3 refill(s). Instructions: take 4 mg by mouth daily\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-12-21, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2016-08-30, presumably until 2016-09-07, with intended 1 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-06 16:02:08, ended at 2016-09-06 16:39:14\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n- Gastro-esophageal reflux disease with esophagitis\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-07 12:41:22, ended at 2016-09-07 14:23:55\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychiatric diagnostic evaluation with medical services\n\n### Condition\n- Depressive disorder\n\n### Drug\n- sertraline 50 MG Oral Tablet, started on 2016-09-07, presumably until 2016-11-03, with intended 3 refill(s). Instructions: Take 1.5 tablet (75 mg) for 2 weeks then 2 tablets (100 mg) thereafter.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-12 00:00:00, ended at 2016-09-12 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-09-12, presumably until 2016-09-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-13 00:00:00, ended at 2016-09-13 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-09-13, presumably until 2016-12-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-13 00:00:00, ended at 2016-09-13 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n\n### Drug\n- 24 HR budesonide 9 MG Extended Release Oral Tablet, through Oral route, started on 2016-09-13, presumably until 2016-10-27, with intended 4 refill(s). Instructions: take 9 mg by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-14 14:33:36, ended at 2016-09-14 16:00:58\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.68 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 341 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 5 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.69 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Major depression, single episode\n- Primary diagnosis: Anesthesia of skin\n- Primary diagnosis: Paresthesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-22 09:22:52, ended at 2016-09-22 10:30:12\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paresthesia\n- Primary diagnosis: Anesthesia of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-09 11:12:08, ended at 2016-10-09 13:10:59\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-10 00:00:00, ended at 2016-10-10 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- 24 HR budesonide 9 MG Extended Release Oral Tablet, through Oral route, started on 2016-10-10, presumably until 2016-10-27, with intended 3 refill(s). Instructions: take 9 mg by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-11 12:54:43, ended at 2016-10-11 12:59:52\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute stress disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-19 08:31:28, ended at 2016-10-19 08:46:22\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-20 16:39:54, ended at 2016-10-20 16:48:39\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign paroxysmal positional vertigo\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-24 10:32:45, ended at 2016-10-24 11:30:49\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2016-10-24, presumably until 2016-10-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-26 13:30:00, ended at 2016-10-26 23:59:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-27 10:26:03, ended at 2016-10-27 11:39:49\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Major depression, single episode\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-01 00:00:00, ended at 2016-11-01 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- budesonide 3 MG Delayed Release Oral Capsule, through Oral route, started on 2016-11-01, presumably until 2016-12-19, with intended 6 refill(s). Instructions: take 3 Caps by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-03 10:18:57, ended at 2016-11-03 14:50:41\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anxiety disorder\n- Major depression, single episode\n- Nausea and vomiting\n- Primary diagnosis: Colitis\n- Diarrhea\n\n### Drug\n- fluoxetine 20 MG Oral Tablet, through Oral route, started on 2016-11-03, presumably until 2016-12-04, with intended 0 refill(s). Instructions: take 20 mg by mouth daily\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2016-11-03, presumably until 2017-04-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-23 13:04:52, ended at 2016-11-23 14:45:28\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Vitamin B deficiency\n- Primary diagnosis: Colitis\n\n### Drug\n- mesalamine 800 MG Delayed Release Oral Tablet, through Oral route, started on 2016-11-23, presumably until 2016-11-30, with intended 6 refill(s). Instructions: take 3 Tabs by mouth 2 times a day\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2016-11-23, presumably until 2016-11-23, with intended 0 refill(s). Instructions: inject 1 mL into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-11-27 00:00:00, ended at 2016-11-27 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2016-11-27, presumably until 2017-01-30, with intended 0 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-30 00:00:00, ended at 2016-11-30 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- balsalazide disodium 750 MG Oral Capsule, through Oral route, started on 2016-11-30, presumably until 2016-12-12, with intended 11 refill(s). Instructions: take 3 Caps by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-04 13:23:24, ended at 2016-12-04 13:52:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute upper respiratory infection\n- Colitis\n- Primary diagnosis: Viral disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-05 00:00:00, ended at 2016-12-05 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- benzonatate 100 MG Oral Capsule, started on 2016-12-05, presumably until 2016-12-12, with intended 0 refill(s). Instructions: Take 1-2 tablets three times daily as needed for cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-11 00:00:00, ended at 2016-12-11 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-12-11, presumably until 2017-12-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-11 09:20:14, ended at 2016-12-11 14:12:53\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-14 00:00:00, ended at 2016-12-14 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-12-14, presumably until 2017-04-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-14 11:32:16, ended at 2016-12-14 12:47:13\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n- Vitamin B deficiency\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2016-12-14, presumably until 2016-12-14, with intended 0 refill(s). Instructions: inject 1 mL into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-15 00:00:00, ended at 2016-12-15 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Latent syphilis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-18 15:38:15, ended at 2016-12-18 17:09:09\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n- Otalgia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-19 00:00:00, ended at 2016-12-19 00:00:00\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2016-12-21, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 4 Tabs by mouth every day take 4.8 g by mouth\n- budesonide 3 MG Delayed Release Oral Capsule, through Oral route, started on 2016-12-21, presumably until 2017-05-01, with intended 6 refill(s). Instructions: take 3 Caps by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-19 12:19:06, ended at 2016-12-19 13:06:10\nThe patient in this visit was 31 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Otalgia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-21 00:00:00, ended at 2016-12-21 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2016-12-21, presumably until 2017-01-17, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-22 00:00:00, ended at 2016-12-22 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-22 00:00:00, ended at 2016-12-22 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, through Oral route, started on 2016-12-25, presumably until 2016-12-27, with intended 1 refill(s). Instructions: take 1 Cap by mouth every 4 hours as needed 2 caps po q6hrs prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-27 00:00:00, ended at 2016-12-27 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2016-12-27, presumably until 2017-04-11, with intended 1 refill(s). Instructions: 1 cap every 4-6 hours PRN. Olechowski dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-28 00:00:00, ended at 2016-12-28 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-17 00:00:00, ended at 2017-01-17 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-17 11:58:57, ended at 2017-01-17 14:04:12\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin B deficiency\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-17 11:59:16, ended at 2017-01-17 14:16:45\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Migraine without aura\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-01-17, presumably until 2017-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-25 10:26:27, ended at 2017-01-25 12:42:28\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n- Primary diagnosis: Nausea\n- Disorder of intestine\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, through Oral route, presumably until 2017-01-25, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-01-30 00:00:00, ended at 2017-01-30 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2017-01-30, presumably until 2017-03-06, with intended 0 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-12 12:25:31, ended at 2017-02-12 14:22:03\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-26 14:06:35, ended at 2017-02-26 14:46:11\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pain\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-03-06 00:00:00, ended at 2017-03-06 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2017-03-07, presumably until 2017-03-12, with intended 2 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 16:12:44, ended at 2017-03-12 17:49:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n- Primary diagnosis: Migraine\n- Migraine without aura\n- Nausea\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2017-03-12, presumably until 2017-08-18, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every day take 4.8 g by mouth\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-03-12, presumably until 2017-08-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- dicyclomine hydrochloride 20 MG Oral Tablet, started on 2017-03-12, presumably until 2017-08-14, with intended 0 refill(s). Instructions: Take 2 tablets daily as needed for nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-16 00:00:00, ended at 2017-03-16 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-16 06:56:00, ended at 2017-03-16 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material\n\n### Condition\n- Chondromalacia of patella\n- Pain of left knee region\n- Fat pad syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-30 13:45:53, ended at 2017-03-30 15:06:48\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.9 (percent)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 286 (picogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 4.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.22 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.73 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.58 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 216 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Blood chemistry abnormal\n- Colitis\n- Verruca vulgaris\n- Anxiety disorder\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-03 00:00:00, ended at 2017-04-03 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-11 10:35:40, ended at 2017-04-11 13:33:38\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Status migrainosus\n- Primary diagnosis: Chronic intractable migraine without aura\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-04-11, presumably until 2017-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-11 10:35:40, ended at 2017-04-11 11:59:22\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Status migrainosus\n- Primary diagnosis: Chronic intractable migraine without aura\n- Nausea and vomiting\n- Diarrhea\n\n### Drug\n- frovatriptan 2.5 MG Oral Tablet, started on 2017-04-11, presumably until 2017-08-24, with intended 2 refill(s). Instructions: Take 1 tab at onset of headache. May repeat in 2 hrs if needed. Limit 2 doses/24 hours. Limit to 10 days per month.\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2017-04-11, presumably until 2017-08-16, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. Foust dose 2 days a week.\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2017-04-11, presumably until 2018-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-04-17 00:00:00, ended at 2017-04-17 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-04-17, presumably until 2017-05-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-18 09:27:00, ended at 2017-04-18 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)\n- Nerve conduction studies; 11-12 studies\n\n### Condition\n- Anesthesia of skin\n- Polyneuropathy\n- Paresthesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-25 00:00:00, ended at 2017-04-25 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-01 12:05:10, ended at 2017-05-01 15:04:51\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Monoarthritis\n\n### Drug\n- vitamin B12 1 MG Oral Tablet, through Oral route, presumably until 2017-08-24, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-07 00:00:00, ended at 2017-05-07 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dizziness and giddiness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-25 14:26:57, ended at 2017-05-25 15:37:13\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis of knee\n- Primary diagnosis: Enteropathic arthritis\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2017-05-25, presumably until 2017-08-24, with intended 2 refill(s). Instructions: Apply 4 grams to affected area (knee) up to 4 times a day.\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2017-05-25, presumably until 2018-01-25, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-04 13:39:51, ended at 2017-06-04 15:04:24\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-21 09:28:00, ended at 2017-06-21 11:53:52\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.472\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal malabsorption\n- Iron deficiency anemia\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-21 11:07:00, ended at 2017-06-21 12:04:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Coenzyme Q10.reduced/Coenzyme Q10 in Serum or Plasma: 93 (percent)\n- Glial nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Pyridoxal phosphate [Mass/volume] in Serum or Plasma: 5 (microgram per liter)\n- Ascorbate [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Voltage-gated calcium channel N type binding Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Neuronal nuclear type 2 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- PCA-1 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 33 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Glutamate decarboxylase 65 Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Thiamine pyrophosphate [Moles/volume] in Blood: 49 (nanomole per liter)\n- Voltage-gated potassium channel Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Acetylcholine receptor binding Ab [Moles/volume] in Serum: 0.01 (nanomole per liter)\n- CV2 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Coenzyme Q10.reduced [Mass/volume] in Serum or Plasma: 869.7 (microgram per liter)\n- Methylmalonate [Moles/volume] in Serum or Plasma: 0.07 (micromole per liter)\n- Neuronal nuclear type 3 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Voltage-gated calcium channel P/Q type binding Ab [Moles/volume] in Serum: 0.00 (nanomole per liter)\n- Amphiphysin IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 34 (percent)\n- PCA-2 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n- Striated muscle Ab [Titer] in Serum: Negative (titer)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 33 (nanogram per milliliter)\n- Coenzyme Q10 [Mass/volume] in Serum or Plasma: 932 (microgram per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 9.5 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 98 (microgram per deciliter)\n- Neuronal nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence: Negative (titer)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy\n- Intestinal malabsorption\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-21 12:05:00, ended at 2017-06-21 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Testing of autonomic nervous system function; combined parasympathetic and sympathetic adrenergic function testing with at least 5 minutes of passive tilt\n- Testing of autonomic nervous system function; sudomotor, including 1 or more of the following: quantitative sudomotor axon reflex test (QSART), silastic sweat imprint, thermoregulatory sweat test, and changes in sympathetic skin potential\n\n### Condition\n- Iron deficiency anemia\n- Dizziness and giddiness\n- Intestinal malabsorption\n- Adrenal cortical hypofunction\n- Disorder of autonomic nervous system\n- Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-04 11:57:32, ended at 2017-07-04 14:33:13\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Chronic intractable migraine without aura\n- Migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-07-04, presumably until 2017-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-26 14:56:39, ended at 2017-07-26 15:35:28\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute pharyngitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-30 13:05:02, ended at 2017-07-30 15:23:46\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-14 13:12:27, ended at 2017-08-14 16:39:27\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-15 00:00:00, ended at 2017-08-15 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-08-16, presumably until 2017-08-16, with intended 3 refill(s). Instructions: TAKE 1 TAB BY MOUTH 2 TIMES A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-16 00:00:00, ended at 2017-08-16 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-08-16, presumably until 2017-10-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2017-08-16, presumably until 2017-11-07, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. Ray dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-18 00:00:00, ended at 2017-08-18 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, started on 2017-08-20, presumably until 2017-11-30, with intended 1 refill(s). Instructions: TAKE 4 TABS BY MOUTH EVERY DAY TAKE 4.8 G BY MOUTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-24 10:56:50, ended at 2017-08-24 11:51:41\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Status migrainosus\n- Anxiety disorder\n- Primary diagnosis: Chronic intractable migraine without aura\n- Major depression, single episode\n\n### Drug\n- naratriptan 2.5 MG Oral Tablet, started on 2017-08-24, presumably until 2018-04-08, with intended 3 refill(s). Instructions: Take onset of migraine and repeat in 2-4 hours if needed no more than 2 tabs in 24 hrs and limit to 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-28 12:57:38, ended at 2017-08-28 13:37:53\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Anxiety disorder\n- Major depression, single episode\n- Primary diagnosis: Chronic intractable migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-13 00:00:00, ended at 2017-09-13 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.53 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.56 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.5 (percent)\n- Salicylates [Presence] in Urine: <10 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Acetaminophen [Presence] in Urine: <2.0 (microgram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-13 14:45:59, ended at 2017-09-13 16:11:01\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anxiety disorder\n- Chronic intractable migraine without aura\n- Status migrainosus\n- Primary diagnosis: Major depression, single episode\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-13 18:33:00, ended at 2017-09-14 02:20:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 203 (thousand per microliter)\n- Salicylates [Presence] in Urine: <10 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Acetaminophen [Presence] in Urine: <2.0 (microgram per milliliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.56 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.53 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n\n### Procedure\n- Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when per\n\n### Condition\n- Migraine without aura\n- Sleep disorder\n- Gastro-esophageal reflux disease with esophagitis\n- Benign paroxysmal positional vertigo\n- Major depression, single episode\n- Intestinal malabsorption\n- Polyneuropathy\n- Generalized anxiety disorder\n- Primary diagnosis: Anxiety disorder\n- Panic disorder without agoraphobia\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-09-13\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-10-24, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-12-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-10-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-24 10:11:25, ended at 2017-10-24 11:18:35\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n- Insomnia\n- Primary diagnosis: Dizziness and giddiness\n- Anxiety disorder\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2017-10-24, presumably until 2018-04-04, with intended 5 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-02 14:55:29, ended at 2017-11-02 16:11:05\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain of left knee region\n- Anxiety disorder\n\n### Drug\n- 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe, through Intramuscular route, started on 2017-11-02, presumably until 2017-11-02, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n\n### Drug\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2017-11-07, presumably until 2018-04-08, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. Sommerville dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-08 08:49:56, ended at 2017-11-08 10:25:51\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n\n### Condition\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 13:24:49, ended at 2017-11-12 15:53:14\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Colitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-20 09:57:35, ended at 2017-11-20 11:22:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-11-29 00:00:00, ended at 2017-11-29 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, started on 2017-11-30, presumably until 2017-12-03, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH EVERY DAY TAKE 4.8 G BY MOUTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-03 00:00:00, ended at 2017-12-03 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Colitis\n\n### Drug\n- mesalamine 1200 MG Delayed Release Oral Tablet, through Oral route, started on 2017-12-03, presumably until 2018-04-04, with intended 1 refill(s). Instructions: take 2 Tabs by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 12:44:24, ended at 2017-12-12 13:32:07\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Primary diagnosis: Chronic intractable migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2017-12-12, presumably until 2017-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-14 00:00:00, ended at 2017-12-14 00:00:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-17 00:00:00, ended at 2017-12-17 23:59:00\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pain\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-17 09:07:51, ended at 2017-12-17 09:53:33\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pain\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-18 15:34:32, ended at 2017-12-18 16:06:28\nThe patient in this visit was 32 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Anxiety disorder\n- Moderate recurrent major depression\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-31 08:03:06, ended at 2017-12-31 09:20:56\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n\n### Condition\n- Primary diagnosis: Joint pain\n- Pain in left lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-08 14:21:07, ended at 2018-01-08 14:50:25\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Candidiasis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-09 08:19:51, ended at 2018-01-09 09:53:33\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-21 00:00:00, ended at 2018-01-21 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2018-01-21, presumably until 2018-03-08, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis of knee\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2018-01-25, presumably until 2018-03-08, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-01-25 11:14:53, ended at 2018-01-25 13:13:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left lower limb\n\n### Drug\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-30 00:00:00, ended at 2018-01-30 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2018-01-30, presumably until 2018-03-08, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-30 09:01:16, ended at 2018-01-30 11:00:36\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n\n### Condition\n- Joint pain\n- Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-30 15:15:07, ended at 2018-01-30 16:33:54\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-02-04 22:02:00, ended at 2018-02-04 23:09:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Neck pain\n- Primary diagnosis: Complex regional pain syndrome, type II, upper limb\n- Pain in left arm\n- Gastro-esophageal reflux disease with esophagitis\n- Chest pain\n- Migraine without aura\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2018-02-04, presumably until 2018-02-09, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 08:47:24, ended at 2018-02-06 10:18:04\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-02-07 10:16:57, ended at 2018-02-07 14:50:23\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Complex regional pain syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-13 08:43:14, ended at 2018-02-13 10:02:30\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-15 08:14:27, ended at 2018-02-15 09:51:31\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebrospinal fluid leak\n- Primary diagnosis: Chronic intractable migraine without aura\n- Primary diagnosis: Status migrainosus\n\n### Drug\n- naltrexone, started on 2018-02-15, presumably until 2018-04-04, with intended 3 refill(s). Instructions: Take one capsule by mouth 2 hours before sleep every night\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-25 00:00:00, ended at 2018-02-25 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of cervical spine\n- Primary diagnosis: Polyneuropathy\n- Disorder of thoracic spine\n- Nerve root disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-27 15:24:09, ended at 2018-02-27 16:04:20\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-06 09:54:30, ended at 2018-03-06 10:51:37\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-08 12:41:51, ended at 2018-03-08 13:23:36\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)\n\n### Condition\n- Chronic intractable migraine without aura\n- Primary diagnosis: Migraine without aura\n- Headache caused by drug\n- Status migrainosus\n\n### Drug\n- onabotulinumtoxinA 200 UNT Injection, started on 2018-03-08, presumably until 2018-03-08\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2018-03-08, presumably until 2018-04-04, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-12 12:15:44, ended at 2018-03-12 14:05:41\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-14 00:00:00, ended at 2018-03-14 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Migraine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-19 14:11:16, ended at 2018-03-19 14:24:12\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-21 12:47:47, ended at 2018-03-21 14:26:17\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebrospinal fluid leak\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-25 00:00:00, ended at 2018-03-25 00:00:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-26 14:45:01, ended at 2018-03-26 15:37:55\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-02 12:57:29, ended at 2018-04-02 14:04:19\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Anxiety disorder\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-02 14:51:43, ended at 2018-04-02 16:39:41\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Anxiety disorder\n- Joint pain\n- Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-03 08:47:24, ended at 2018-04-03 10:17:10\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Hemorrhage of rectum and anus\n- Cerebrospinal fluid leak\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-08 10:25:36, ended at 2018-04-08 14:35:18\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Migraine without aura\n- Moderate recurrent major depression\n\n### Drug\n- topiramate 50 MG Oral Tablet, through Oral route, started on 2018-04-08, presumably until 2018-09-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- naratriptan 2.5 MG Oral Tablet, started on 2018-04-08, presumably until 2018-05-06, with intended 3 refill(s). Instructions: Take onset of migraine and repeat in 2-4 hours if needed no more than 2 tabs in 24 hrs and limit to 2 days a week.\n- acetaminophen 325 MG / dichloralphenazone 100 MG / isometheptene 65 MG Oral Capsule, started on 2018-04-08, presumably until 2018-12-25, with intended 3 refill(s). Instructions: 1 cap every 4-6 hours PRN. South dose 2 days a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-09 12:48:20, ended at 2018-04-09 14:40:22\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-09 14:38:58, ended at 2018-04-09 16:06:31\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Joint pain\n- Moderate recurrent major depression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-16 13:34:41, ended at 2018-04-16 15:12:33\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Lumbar radiculopathy\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-04-16, presumably until 2018-05-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth once as needed (for MRI)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-18 16:00:00, ended at 2018-04-18 23:59:00\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n\n### Condition\n- Lumbar radiculopathy\n- Degeneration of lumbar intervertebral disc\n\n### Drug\n- gadobenate, through Intravenous route, started on 2018-04-18, presumably until 2018-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-23 12:38:44, ended at 2018-04-23 14:32:57\nThe patient in this visit was 33 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 60 minutes with patient\n\n### Condition\n- Primary diagnosis: Moderate recurrent major depression\n- Anxiety disorder\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "168eecb33e2153f25645099bc0f2434bd8d15dfaa90392ae53d86b89fabb2725", "prompt_hash": "1c3c372437f8b27ea6c04e921e0e358239431ceb2de39e800404aa4293c00526", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 1, "doc": {"person_id": 115968048, "visit_occurrence_id": 45257005, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2011-09-04 10:33:00", "visit_end_datetime": "2011-09-10 15:15:00", "visit_length_in_hours": 148.7, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-04 10:33:00, ended at 2011-09-10 15:15:00\nThe patient in this visit was 83 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (milliequivalent per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.14 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- MCV [Entitic volume] by Automated count: 96.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 9.6\" (inch (US))\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Prothrombin time (PT): 15.2 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Oxygen [Partial pressure] in Blood: 11 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 59.5 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.3 (second)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Occupational therapy evaluation\n- Evaluation of oral and pharyngeal swallowing function\n- Physical therapy evaluation\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest; single view, frontal\n- Collection of venous blood by venipuncture\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and prepari\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Alzheimer's disease\n- Urinary tract infectious disease\n- Atherosclerosis of aorta\n- Altered mental status\n- Bacterial infection due to Klebsiella pneumoniae\n- Dementia associated with another disease\n- Essential hypertension\n- Infective pneumonia\n- Cough\n- Hyperlipidemia\n- Rheumatoid arthritis\n- Acute bronchitis\n- Hypoglycemia\n- Organic mental disorder\n- Viral pneumonia\n- Cardiomegaly\n- Osteoporosis\n- Rheumatoid lung disease\n- Cardiac arrhythmia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2011-09-06, presumably until 2011-09-10\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-06, presumably until 2011-09-10\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 1 mg by mouth daily.\n- guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2011-09-04, presumably until 2011-09-07\n- sertraline 25 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 50 mg by mouth daily.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-05, presumably until 2011-09-05\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2011-09-05, presumably until 2011-09-06\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2011-09-10, presumably until 2012-09-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- haloperidol 5 MG/ML Injectable Solution, started on 2011-09-07, presumably until 2011-09-07\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-09-08, presumably until 2011-09-08\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-06\n- 100 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2011-09-09, presumably until 2011-09-10\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-09-09, presumably until 2011-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-04\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-09. Instructions: take 80 mg by mouth every bedtime.\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 325 mg by mouth daily.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-09-08, presumably until 2011-09-08\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-09-04, presumably until 2011-09-04\n- 12 HR timolol 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2011-09-05, presumably until 2011-09-09. Instructions: 1 Drop by Right Eye route daily. use in affected eye(s)\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-09-07, presumably until 2011-09-07\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 200 mg by mouth daily. With food\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2011-09-05, presumably until 2011-09-09\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-09-08, presumably until 2011-09-10\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2011-09-05, presumably until 2012-09-09, with intended 0 refill(s). Instructions: 2.5 mL by Inhalation route every 8 hours as needed (shortness of breath, wheeze).\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-09-08, presumably until 2011-09-08\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-04, presumably until 2011-09-04\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 50 mg by mouth daily.\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2011-09-05, presumably until 2011-09-10\n- magnesium lactate 84 MG Extended Release Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-05\n- 150 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2011-09-04, presumably until 2011-09-08\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-06. Instructions: take 20 mg by mouth daily.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 81 mg by mouth daily.\n\n", "approximate_token_count": 2565, "patient_first_visit_date": "2008-01-11 16:10:00", "patient_last_visit_date": "2014-03-27 10:03:00", "end_obs_date": "2012-09-09", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 1, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 7, "cumulated_visit_num": 7, "cumulated_approximate_token_count": 10535, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2008-01-11 16:10:00, ended at 2008-01-12 13:22:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 10.1 (unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.3 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.26 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.9 (nanogram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.16 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 126 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.88 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 374 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-02-28 14:45:00, ended at 2008-03-03 12:16:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 89 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 249 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.87 (million per microliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 165 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.05 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.0 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 217 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 4 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.81 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 90 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 7 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.80 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.9 (nanogram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Reticulocytes [#/volume] in Blood by Automated count: 52.6 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2008-08-31 17:20:00, ended at 2008-09-02 14:17:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 94.1 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.17 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.07 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Prothrombin time (PT): 13.8 (second)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.8 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 197 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Rheumatoid arthritis\n- Urinary tract infectious disease\n- Abnormal body temperature\n- Infective pneumonia\n- Organic mental disorder\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2010-03-31. Instructions: take 50 mg by mouth daily. \n- calcium sulfate, through Oral route. Instructions: take by mouth. \n- calcium lactate, through Oral route. Instructions: take by mouth. \n- calcium phosphate dibasic, through Oral route. Instructions: take by mouth. \n- calcium acetate, through Oral route. Instructions: take by mouth. \n- acetaminophen 650 MG Rectal Suppository, through Rectal route, started on 2008-08-31, presumably until 2008-08-31\n- pyroglutamate, through Oral route. Instructions: take by mouth. \n- calcium chloride, through Oral route. Instructions: take by mouth. \n- cholecalciferol, through Oral route. Instructions: take by mouth. \n- alendronic acid 70 MG Oral Tablet, through Oral route, presumably until 2008-09-02. Instructions: take 70 mg by mouth every 7 days. \n- vitamin B12, through Oral route. Instructions: take by mouth. \n- calcium glycerophosphate, through Oral route. Instructions: take by mouth. \n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-01\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- zinc sulfate, through Oral route. Instructions: take by mouth. \n- aspirin 325 MG Oral Tablet, through Oral route, started on 2008-09-02, presumably until 2011-09-10. Instructions: take 325 mg by mouth daily. \n- calcium saccharate, through Oral route. Instructions: take by mouth. \n- calcium orotate, through Oral route. Instructions: take by mouth. \n- calcium glubionate, through Oral route. Instructions: take by mouth. \n- folic acid, through Oral route. Instructions: take by mouth. \n- calcium citrate malate, through Oral route. Instructions: take by mouth. \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-08-31, presumably until 2008-09-02\n- calcium malate, through Oral route. Instructions: take by mouth. \n- biotin 5 MG Oral Capsule, through Oral route. Instructions: take by mouth. Vit pt takes to strenghtens fingernail\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- calcium amino acid chelate, through Oral route. Instructions: take by mouth. \n- formate, through Oral route. Instructions: take by mouth. \n- calcium phosphate, through Oral route. Instructions: take by mouth. \n- calcium citrate, through Oral route. Instructions: take by mouth. \n- calcium levulinate, through Oral route. Instructions: take by mouth. \n- zinc picolinate, through Oral route. Instructions: take by mouth. \n- zinc bromide, through Oral route. Instructions: take by mouth. \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2008-08-31, presumably until 2008-09-01\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2008-09-02, presumably until 2009-09-02, with quantity of 2.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- calcium glucarate, through Oral route. Instructions: take by mouth. \n- zinc gluconate, through Oral route. Instructions: take by mouth. \n- zinc glycinate, through Oral route. Instructions: take by mouth. \n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-08-31, presumably until 2008-08-31\n- propylthiouracil 50 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2010-12-06. Instructions: take 50 mg by mouth 2 times a day. Take 2 tabs daily\n- calcium, through Oral route. Instructions: take by mouth. \n- calcium gluconate, through Oral route. Instructions: take by mouth. \n- zinc chloride, through Oral route. Instructions: take by mouth. \n- calcium gluceptate, through Oral route. Instructions: take by mouth. \n- calcium aspartate, through Oral route. Instructions: take by mouth. \n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- calcium lactobionate, through Oral route. Instructions: take by mouth. \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-08-31, presumably until 2008-08-31\n- calcium pyrophosphate, through Oral route. Instructions: take by mouth. \n- zinc succinate, through Oral route. Instructions: take by mouth. \n- zinc, through Oral route. Instructions: take by mouth. \n- calcium carbonate, through Oral route. Instructions: take by mouth. \n- zinc aspartate, through Oral route. Instructions: take by mouth. \n- alendronic acid 10 MG Oral Tablet, through Oral route. Instructions: take 10 mg by mouth every morning before breakfast. weekly\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-01\n- calcium hypophosphite, through Oral route. Instructions: take by mouth. \n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2008-09-01, presumably until 2008-09-01\n- 150 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2008-08-31, presumably until 2008-09-01\n- zinc orotate, through Oral route. Instructions: take by mouth. \n- tricalcium phosphate, through Oral route. Instructions: take by mouth. \n- dicalcium phosphate, through Oral route. Instructions: take by mouth. \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2010-12-06. Instructions: take by mouth. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2009-11-12 09:20:00, ended at 2009-11-12 14:54:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 190 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.2 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.14 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.92 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.5 (percent)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Headache\n- Malaise\n- Syncope and collapse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2010-03-31 15:04:00, ended at 2010-04-01 12:48:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.4 (percent)\n- MCH [Entitic mass] by Automated count: 32.7 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.28 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.2 (second)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 5.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.38 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 163 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- MCV [Entitic volume] by Automated count: 98.5 (femtoliter)\n- Prothrombin time (PT): 14.6 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Physical therapy evaluation\n- Collection of venous blood by venipuncture\n- Diagnostic interview and evaluation, not otherwise specified\n- Radiologic examination, chest; single view, frontal\n\n### Condition\n- Alzheimer's disease\n- Dehydration\n- Primary diagnosis: Malaise\n- Chest pain\n- Low blood pressure\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2010-03-31, presumably until 2010-04-01. Instructions: take 50 mg by mouth every bedtime. \n- prednisone 10 MG Oral Tablet, through Oral route, started on 2010-04-01, presumably until 2011-09-10. Instructions: take 10 mg by mouth daily. \n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2010-04-01, presumably until 2010-04-01. Instructions: take 200 mg by mouth daily. With food\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2010-03-31, presumably until 2010-12-10. Instructions: take 25 mg by mouth 2 times a day. \n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-31, presumably until 2010-03-31\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2010-03-31, presumably until 2010-03-31. Instructions: take by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-12-06 13:20:00, ended at 2010-12-10 14:14:00\nThe patient in this visit was 83 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Prothrombin time (PT): 13.3 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 24.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 553 (picogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.32 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.5 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.57 (micro-international unit per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.29 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Occupational therapy evaluation\n- Physical therapy evaluation\n- Computed tomography, head or brain; without contrast material\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Hyperlipidemia\n- Malaise\n- Urinary tract infectious disease\n- Alzheimer's disease\n- Rheumatoid arthritis\n- Osteoporosis\n- Anemia\n- Cough\n- Essential hypertension\n- Post-inflammatory pulmonary fibrosis\n- Thyrotoxicosis without goiter or other cause\n- Glaucoma\n- Infective pneumonia\n- Altered mental status\n- Atherosclerosis of arteries of the extremities\n- Dementia associated with another disease\n- Organic mental disorder\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 50 mg by mouth every bedtime. \n- folic acid 1 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 1 mg by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2010-12-09, presumably until 2010-12-09\n- 100 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2010-12-06, presumably until 2010-12-09\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-12-08, presumably until 2010-12-08\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2010-12-06, presumably until 2010-12-10\n- prednisolone 10 MG/ML Ophthalmic Solution, through Intraocular route. Instructions: by Right Eye route daily. \n- prednisone 10 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 10 mg by mouth daily. \n- aspirin 325 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 325 mg by mouth daily. \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-12-06, presumably until 2010-12-09\n- 12 HR timolol 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2010-12-07, presumably until 2010-12-10. Instructions: 1 Drop by Right Eye route daily. use in affected eye(s) \n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2010-12-09, presumably until 2010-12-09\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2010-12-07, presumably until 2010-12-07\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 200 mg by mouth daily. With food\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2010-12-07, presumably until 2010-12-10. Instructions: by Right Eye route daily.\n- simvastatin 80 MG Oral Tablet, through Oral route. Instructions: take 80 mg by mouth every bedtime. \n- amlodipine 2.5 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2011-09-04, with quantity of 0.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-12-07, presumably until 2010-12-07\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 50 mg by mouth daily. \n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2010-12-06, presumably until 2010-12-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-04 10:33:00, ended at 2011-09-10 15:15:00\nThe patient in this visit was 83 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (milliequivalent per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.14 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- MCV [Entitic volume] by Automated count: 96.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 9.6\" (inch (US))\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Prothrombin time (PT): 15.2 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Oxygen [Partial pressure] in Blood: 11 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 59.5 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.3 (second)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Occupational therapy evaluation\n- Evaluation of oral and pharyngeal swallowing function\n- Physical therapy evaluation\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest; single view, frontal\n- Collection of venous blood by venipuncture\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and prepari\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Alzheimer's disease\n- Urinary tract infectious disease\n- Atherosclerosis of aorta\n- Altered mental status\n- Bacterial infection due to Klebsiella pneumoniae\n- Dementia associated with another disease\n- Essential hypertension\n- Infective pneumonia\n- Cough\n- Hyperlipidemia\n- Rheumatoid arthritis\n- Acute bronchitis\n- Hypoglycemia\n- Organic mental disorder\n- Viral pneumonia\n- Cardiomegaly\n- Osteoporosis\n- Rheumatoid lung disease\n- Cardiac arrhythmia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2011-09-06, presumably until 2011-09-10\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-06, presumably until 2011-09-10\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 1 mg by mouth daily.\n- guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2011-09-04, presumably until 2011-09-07\n- sertraline 25 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 50 mg by mouth daily.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-05, presumably until 2011-09-05\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2011-09-05, presumably until 2011-09-06\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2011-09-10, presumably until 2012-09-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- haloperidol 5 MG/ML Injectable Solution, started on 2011-09-07, presumably until 2011-09-07\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-09-08, presumably until 2011-09-08\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-06\n- 100 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2011-09-09, presumably until 2011-09-10\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-09-09, presumably until 2011-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-04\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-09. Instructions: take 80 mg by mouth every bedtime.\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 325 mg by mouth daily.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-09-08, presumably until 2011-09-08\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-09-04, presumably until 2011-09-04\n- 12 HR timolol 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2011-09-05, presumably until 2011-09-09. Instructions: 1 Drop by Right Eye route daily. use in affected eye(s)\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-09-07, presumably until 2011-09-07\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 200 mg by mouth daily. With food\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2011-09-05, presumably until 2011-09-09\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-09-08, presumably until 2011-09-10\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2011-09-05, presumably until 2012-09-09, with intended 0 refill(s). Instructions: 2.5 mL by Inhalation route every 8 hours as needed (shortness of breath, wheeze).\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-09-08, presumably until 2011-09-08\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-04, presumably until 2011-09-04\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 50 mg by mouth daily.\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2011-09-05, presumably until 2011-09-10\n- magnesium lactate 84 MG Extended Release Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-05\n- 150 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2011-09-04, presumably until 2011-09-08\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-06. Instructions: take 20 mg by mouth daily.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 81 mg by mouth daily.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-01-11 16:10:00, ended at 2008-01-12 13:22:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 10.1 (unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.3 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.26 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.9 (nanogram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.16 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 126 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.88 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 374 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-02-28 14:45:00, ended at 2008-03-03 12:16:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 89 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 249 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.87 (million per microliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 165 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.05 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.0 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 217 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 4 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.81 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 90 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 7 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.80 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.9 (nanogram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Reticulocytes [#/volume] in Blood by Automated count: 52.6 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2008-08-31 17:20:00, ended at 2008-09-02 14:17:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 94.1 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.17 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.07 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Prothrombin time (PT): 13.8 (second)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.8 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 197 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Rheumatoid arthritis\n- Urinary tract infectious disease\n- Abnormal body temperature\n- Infective pneumonia\n- Organic mental disorder\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2010-03-31. Instructions: take 50 mg by mouth daily. \n- calcium sulfate, through Oral route. Instructions: take by mouth. \n- calcium lactate, through Oral route. Instructions: take by mouth. \n- calcium phosphate dibasic, through Oral route. Instructions: take by mouth. \n- calcium acetate, through Oral route. Instructions: take by mouth. \n- acetaminophen 650 MG Rectal Suppository, through Rectal route, started on 2008-08-31, presumably until 2008-08-31\n- pyroglutamate, through Oral route. Instructions: take by mouth. \n- calcium chloride, through Oral route. Instructions: take by mouth. \n- cholecalciferol, through Oral route. Instructions: take by mouth. \n- alendronic acid 70 MG Oral Tablet, through Oral route, presumably until 2008-09-02. Instructions: take 70 mg by mouth every 7 days. \n- vitamin B12, through Oral route. Instructions: take by mouth. \n- calcium glycerophosphate, through Oral route. Instructions: take by mouth. \n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-01\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- zinc sulfate, through Oral route. Instructions: take by mouth. \n- aspirin 325 MG Oral Tablet, through Oral route, started on 2008-09-02, presumably until 2011-09-10. Instructions: take 325 mg by mouth daily. \n- calcium saccharate, through Oral route. Instructions: take by mouth. \n- calcium orotate, through Oral route. Instructions: take by mouth. \n- calcium glubionate, through Oral route. Instructions: take by mouth. \n- folic acid, through Oral route. Instructions: take by mouth. \n- calcium citrate malate, through Oral route. Instructions: take by mouth. \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-08-31, presumably until 2008-09-02\n- calcium malate, through Oral route. Instructions: take by mouth. \n- biotin 5 MG Oral Capsule, through Oral route. Instructions: take by mouth. Vit pt takes to strenghtens fingernail\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- calcium amino acid chelate, through Oral route. Instructions: take by mouth. \n- formate, through Oral route. Instructions: take by mouth. \n- calcium phosphate, through Oral route. Instructions: take by mouth. \n- calcium citrate, through Oral route. Instructions: take by mouth. \n- calcium levulinate, through Oral route. Instructions: take by mouth. \n- zinc picolinate, through Oral route. Instructions: take by mouth. \n- zinc bromide, through Oral route. Instructions: take by mouth. \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2008-08-31, presumably until 2008-09-01\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2008-09-02, presumably until 2009-09-02, with quantity of 2.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- calcium glucarate, through Oral route. Instructions: take by mouth. \n- zinc gluconate, through Oral route. Instructions: take by mouth. \n- zinc glycinate, through Oral route. Instructions: take by mouth. \n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-08-31, presumably until 2008-08-31\n- propylthiouracil 50 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2010-12-06. Instructions: take 50 mg by mouth 2 times a day. Take 2 tabs daily\n- calcium, through Oral route. Instructions: take by mouth. \n- calcium gluconate, through Oral route. Instructions: take by mouth. \n- zinc chloride, through Oral route. Instructions: take by mouth. \n- calcium gluceptate, through Oral route. Instructions: take by mouth. \n- calcium aspartate, through Oral route. Instructions: take by mouth. \n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-02\n- calcium lactobionate, through Oral route. Instructions: take by mouth. \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-08-31, presumably until 2008-08-31\n- calcium pyrophosphate, through Oral route. Instructions: take by mouth. \n- zinc succinate, through Oral route. Instructions: take by mouth. \n- zinc, through Oral route. Instructions: take by mouth. \n- calcium carbonate, through Oral route. Instructions: take by mouth. \n- zinc aspartate, through Oral route. Instructions: take by mouth. \n- alendronic acid 10 MG Oral Tablet, through Oral route. Instructions: take 10 mg by mouth every morning before breakfast. weekly\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-09-01\n- calcium hypophosphite, through Oral route. Instructions: take by mouth. \n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2008-09-01, presumably until 2008-09-01\n- 150 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2008-08-31, presumably until 2008-09-01\n- zinc orotate, through Oral route. Instructions: take by mouth. \n- tricalcium phosphate, through Oral route. Instructions: take by mouth. \n- dicalcium phosphate, through Oral route. Instructions: take by mouth. \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2010-12-06. Instructions: take by mouth. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2009-11-12 09:20:00, ended at 2009-11-12 14:54:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 190 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.2 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.14 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.92 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.5 (percent)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Headache\n- Malaise\n- Syncope and collapse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2010-03-31 15:04:00, ended at 2010-04-01 12:48:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.4 (percent)\n- MCH [Entitic mass] by Automated count: 32.7 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.28 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.2 (second)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 5.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.38 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 163 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- MCV [Entitic volume] by Automated count: 98.5 (femtoliter)\n- Prothrombin time (PT): 14.6 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Physical therapy evaluation\n- Collection of venous blood by venipuncture\n- Diagnostic interview and evaluation, not otherwise specified\n- Radiologic examination, chest; single view, frontal\n\n### Condition\n- Alzheimer's disease\n- Dehydration\n- Primary diagnosis: Malaise\n- Chest pain\n- Low blood pressure\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2010-03-31, presumably until 2010-04-01. Instructions: take 50 mg by mouth every bedtime. \n- prednisone 10 MG Oral Tablet, through Oral route, started on 2010-04-01, presumably until 2011-09-10. Instructions: take 10 mg by mouth daily. \n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2010-04-01, presumably until 2010-04-01. Instructions: take 200 mg by mouth daily. With food\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2010-03-31, presumably until 2010-12-10. Instructions: take 25 mg by mouth 2 times a day. \n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-31, presumably until 2010-03-31\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2010-03-31, presumably until 2010-03-31. Instructions: take by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-12-06 13:20:00, ended at 2010-12-10 14:14:00\nThe patient in this visit was 83 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Prothrombin time (PT): 13.3 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 24.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 553 (picogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.32 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.5 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.57 (micro-international unit per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.29 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Occupational therapy evaluation\n- Physical therapy evaluation\n- Computed tomography, head or brain; without contrast material\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Hyperlipidemia\n- Malaise\n- Urinary tract infectious disease\n- Alzheimer's disease\n- Rheumatoid arthritis\n- Osteoporosis\n- Anemia\n- Cough\n- Essential hypertension\n- Post-inflammatory pulmonary fibrosis\n- Thyrotoxicosis without goiter or other cause\n- Glaucoma\n- Infective pneumonia\n- Altered mental status\n- Atherosclerosis of arteries of the extremities\n- Dementia associated with another disease\n- Organic mental disorder\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 50 mg by mouth every bedtime. \n- folic acid 1 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 1 mg by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2010-12-09, presumably until 2010-12-09\n- 100 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2010-12-06, presumably until 2010-12-09\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-12-08, presumably until 2010-12-08\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2010-12-06, presumably until 2010-12-10\n- prednisolone 10 MG/ML Ophthalmic Solution, through Intraocular route. Instructions: by Right Eye route daily. \n- prednisone 10 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 10 mg by mouth daily. \n- aspirin 325 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 325 mg by mouth daily. \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-12-06, presumably until 2010-12-09\n- 12 HR timolol 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2010-12-07, presumably until 2010-12-10. Instructions: 1 Drop by Right Eye route daily. use in affected eye(s) \n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2010-12-09, presumably until 2010-12-09\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2010-12-07, presumably until 2010-12-07\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 200 mg by mouth daily. With food\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2010-12-07, presumably until 2010-12-10. Instructions: by Right Eye route daily.\n- simvastatin 80 MG Oral Tablet, through Oral route. Instructions: take 80 mg by mouth every bedtime. \n- amlodipine 2.5 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2011-09-04, with quantity of 0.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-12-07, presumably until 2010-12-07\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2010-12-07, presumably until 2010-12-10. Instructions: take 50 mg by mouth daily. \n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2010-12-06, presumably until 2010-12-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-04 10:33:00, ended at 2011-09-10 15:15:00\nThe patient in this visit was 83 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (milliequivalent per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.14 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- MCV [Entitic volume] by Automated count: 96.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 9.6\" (inch (US))\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Prothrombin time (PT): 15.2 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Oxygen [Partial pressure] in Blood: 11 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 59.5 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.3 (second)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Occupational therapy evaluation\n- Evaluation of oral and pharyngeal swallowing function\n- Physical therapy evaluation\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest; single view, frontal\n- Collection of venous blood by venipuncture\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and prepari\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Alzheimer's disease\n- Urinary tract infectious disease\n- Atherosclerosis of aorta\n- Altered mental status\n- Bacterial infection due to Klebsiella pneumoniae\n- Dementia associated with another disease\n- Essential hypertension\n- Infective pneumonia\n- Cough\n- Hyperlipidemia\n- Rheumatoid arthritis\n- Acute bronchitis\n- Hypoglycemia\n- Organic mental disorder\n- Viral pneumonia\n- Cardiomegaly\n- Osteoporosis\n- Rheumatoid lung disease\n- Cardiac arrhythmia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2011-09-06, presumably until 2011-09-10\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-06, presumably until 2011-09-10\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 1 mg by mouth daily.\n- guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2011-09-04, presumably until 2011-09-07\n- sertraline 25 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 50 mg by mouth daily.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-05, presumably until 2011-09-05\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2011-09-05, presumably until 2011-09-06\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2011-09-10, presumably until 2012-09-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- haloperidol 5 MG/ML Injectable Solution, started on 2011-09-07, presumably until 2011-09-07\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-09-08, presumably until 2011-09-08\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-06\n- 100 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2011-09-09, presumably until 2011-09-10\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-09-09, presumably until 2011-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-04\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-09. Instructions: take 80 mg by mouth every bedtime.\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 325 mg by mouth daily.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-09-08, presumably until 2011-09-08\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-09-04, presumably until 2011-09-04\n- 12 HR timolol 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2011-09-05, presumably until 2011-09-09. Instructions: 1 Drop by Right Eye route daily. use in affected eye(s)\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-09-07, presumably until 2011-09-07\n- hydroxychloroquine sulfate 200 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 200 mg by mouth daily. With food\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2011-09-05, presumably until 2011-09-09\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-09-08, presumably until 2011-09-10\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2011-09-05, presumably until 2012-09-09, with intended 0 refill(s). Instructions: 2.5 mL by Inhalation route every 8 hours as needed (shortness of breath, wheeze).\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-09-08, presumably until 2011-09-08\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-04, presumably until 2011-09-04\n- sertraline 50 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-10. Instructions: take 50 mg by mouth daily.\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2011-09-05, presumably until 2011-09-10\n- magnesium lactate 84 MG Extended Release Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-05\n- 150 ML levofloxacin 5 MG/ML Injection, through Intravenous route, started on 2011-09-04, presumably until 2011-09-08\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2011-09-05, presumably until 2011-09-06. Instructions: take 20 mg by mouth daily.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 81 mg by mouth daily.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "d74fa069058b2435dd8dbe4507ea0db7cc281d20f1690d61529e56c5637b842a", "prompt_hash": "d5fccd2c150309f4a186f597b43a4653a2c6e6c8c1b1de806b6169f4a896aba4", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 2, "doc": {"person_id": 115971537, "visit_occurrence_id": 186363662, "death_date": "2022-07-03", "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2021-08-19 00:00:00", "visit_end_datetime": "2021-08-19 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-19 00:00:00, ended at 2021-08-19 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of temporal lobe\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 93, "patient_first_visit_date": "2017-12-05 00:00:00", "patient_last_visit_date": "2022-06-23 00:00:00", "end_obs_date": "2022-07-03", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 1, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 1, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "recurrent", "ischemic_stroke_one_year_diagnosis": 1, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 1, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 1, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 95, "cumulated_visit_num": 95, "cumulated_approximate_token_count": 16675, "visit_cumulated": "## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-05 00:00:00, ended at 2017-12-05 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ropinirole 1 MG Oral Tablet, started on 2017-12-05, presumably until 2018-07-04, with intended 0 refill(s). Instructions: TAKE 1 TABLET AT BEDTIME.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-02 00:00:00, ended at 2018-01-02 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valsartan 320 MG Oral Tablet, started on 2018-01-02, presumably until 2018-04-10, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-01-02, presumably until 2018-04-09, with intended 2 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH WITH THE EVENING MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-03 14:48:45, ended at 2018-01-03 15:58:47\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to type 2 diabetes mellitus\n- Peripheral vascular disease\n- Mixed hyperlipidemia\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2018-01-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2017-09-13, presumably until 2021-01-28, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2017-07-05, presumably until 2018-02-05, with intended 0 refill(s). Instructions: 1 Cap daily\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-11-12, presumably until 2018-01-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2018-06-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-01-03, presumably until 2018-07-12, with intended 1 refill(s). Instructions: take 1 Tab by mouth every day\n- 120 ACTUAT formoterol fumarate 0.005 MG/ACTUAT / mometasone furoate 0.1 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-10-12, presumably until 2018-07-02, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route\n- thioctic acid 300 MG Oral Capsule, started on 2016-10-30, presumably until 2020-10-26, with intended 0 refill(s). Instructions: alpha lipoic acid 300 mg capsule; take 2 in the am  and 2 in the pm; 0; 0; 10/30/2016; Hu MD, Holliman; Active\n- omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule, through Oral route, presumably until 2018-07-04, with intended 0 refill(s). Instructions: take 1 g by mouth\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2017-11-07, presumably until 2018-06-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- ascorbic acid 500 MG Oral Tablet, through Oral route, presumably until 2021-09-29, with intended 0 refill(s). Instructions: take 500 mg by mouth daily \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2019-08-28, with intended 0 refill(s). Instructions: take 81 mg by mouth daily \n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2017-11-07, presumably until 2018-06-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-03 16:03:43, ended at 2018-01-03 16:31:18\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Benign prostatic hyperplasia with outflow obstruction\n- Urinary tract obstruction\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2018-01-03, presumably until 2018-07-04, with intended 5 refill(s). Instructions: take 1 Tab by mouth daily\n- azithromycin 250 MG Oral Tablet, started on 2018-01-03, presumably until 2018-01-08, with intended 0 refill(s). Instructions: Take 2 the first day and one a day on days 2-5.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-31 00:00:00, ended at 2018-01-31 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-02-01, presumably until 2018-05-12, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-05 00:00:00, ended at 2018-02-05 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2018-02-06, presumably until 2018-05-15, with intended 5 refill(s). Instructions: TAKE 1 CAPSULE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-15 00:00:00, ended at 2018-02-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2018-02-18, presumably until 2018-09-07, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-15 00:00:00, ended at 2018-03-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350, started on 2018-03-20, presumably until 2018-07-04, with intended 3 refill(s). Instructions: One capful once to twice a day as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-19 00:00:00, ended at 2018-03-19 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 4 MG Oral Tablet, through Oral route, started on 2018-03-04, presumably until 2020-10-01, with intended 0 refill(s). Instructions: take 4 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-09 00:00:00, ended at 2018-04-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-04-11, presumably until 2018-05-13, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH WITH THE EVENING MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-10 00:00:00, ended at 2018-04-10 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valsartan 320 MG Oral Tablet, started on 2018-04-11, presumably until 2018-05-15, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-12 00:00:00, ended at 2018-05-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-05-13, presumably until 2018-06-27, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-13 00:00:00, ended at 2018-05-13 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-05-13, presumably until 2018-05-15, with intended 3 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH IN THE EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-15 00:00:00, ended at 2018-05-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2018-05-15, presumably until 2019-05-30, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n- valsartan 320 MG Oral Tablet, through Oral route, started on 2018-05-15, presumably until 2018-07-02, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-05-15, presumably until 2019-05-30, with intended 3 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH IN THE EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-09 00:00:00, ended at 2018-06-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 10 MG Oral Tablet, started on 2018-06-10, presumably until 2018-10-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY ORAL ROUTE EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-13 00:00:00, ended at 2018-06-13 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-06-13, presumably until 2018-10-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2018-06-13, presumably until 2018-07-16, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-21 09:12:56, ended at 2018-06-21 10:11:04\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute asthma\n- Cerebral infarction\n- Polyneuropathy due to type 2 diabetes mellitus\n- Hypothyroidism\n- Acute exacerbation of chronic obstructive airways disease\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-27 00:00:00, ended at 2018-06-27 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-09-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-02 00:00:00, ended at 2018-07-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- terazosin 5 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: terazosin 5 mg capsule\n- hydrochlorothiazide 25 MG / triamterene 37.5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: triamterene 37.5 mg-hydrochlorothiazide 25 mg tablet\n- 14 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Silver Creek  Diskus 250 mcg-50 mcg/dose powder for inhalation\n- diflorasone diacetate 0.5 MG/ML Topical Cream, presumably until 2018-07-04, with intended 0 refill(s). Instructions: ApexiCon E 0.05 % topical cream\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Cheratussin AC 10 mg-100 mg/5 mL oral liquid\n- atenolol 50 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: atenolol 50 mg tablet\n- amoxicillin 500 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: amoxicillin 500 mg capsule\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: hydrocodone 10 mg-acetaminophen 325 mg tablet\n- diazepam 5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: diazepam 5 mg tablet\n- simvastatin 20 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: simvastatin 20 mg tablet\n- cefdinir 300 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- hydrocortisone 10 MG/ML / neomycin 3.5 MG/ML / polymyxin B 10000 UNT/ML Otic Solution, presumably until 2018-07-04, with intended 0 refill(s). Instructions: neomycin-polymyxin-hydrocort 3.5 mg/mL-10,000 unit/mL-1 % ear solution\n- hydrochlorothiazide 25 MG / valsartan 320 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: valsartan 320 mg-hydrochlorothiazide 25 mg tablet\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Lovenox 40 mg/0.4 mL subcutaneous syringe\n- omeprazole 20 MG Disintegrating Oral Tablet, presumably until 2018-07-02, with intended 0 refill(s). Instructions: omeprazole 20 mg capsule,delayed release\n- ciprofloxacin 500 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: ciprofloxacin 500 mg tablet\n- polyethylene glycol 3350 420000 MG / potassium chloride 1480 MG / sodium bicarbonate 5720 MG / sodium chloride 11200 MG Powder for Oral Solution, presumably until 2018-07-04, with intended 0 refill(s). Instructions: GaviLyte-N 420 gram oral solution\n- rabeprazole sodium 20 MG Delayed Release Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Aciphex 20 mg tablet,delayed release\n- hydralazine hydrochloride 25 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: hydralazine 25 mg tablet\n- sucralfate 1000 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: sucralfate 1 gram tablet\n- cephalexin 500 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: cephalexin 500 mg capsule\n- olmesartan medoxomil 40 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Weller 40 mg tablet\n- tramadol hydrochloride 50 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: tramadol 50 mg tablet\n- diclofenac sodium 50 MG Delayed Release Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: diclofenac sodium 50 mg tablet,delayed release\n- oxycodone hydrochloride 10 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: oxycodone 10 mg tablet\n- naproxen 250 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: naproxen 250 mg tablet\n- gabapentin 300 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: gabapentin 300 mg capsule\n- glyburide 2.5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: glyburide 2.5 mg tablet\n- etodolac 400 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: etodolac 400 mg tablet\n- celecoxib 200 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: celecoxib 200 mg capsule\n- betamethasone 0.5 MG/ML / clotrimazole 10 MG/ML Topical Cream, presumably until 2018-07-04, with intended 0 refill(s). Instructions: clotrimazole-betamethasone 1 %-0.05 % topical cream\n- enalapril maleate 5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: enalapril maleate 5 mg tablet\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: tamsulosin 0.4 mg capsule\n- collagenase 0.25 UNT/MG Topical Ointment, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Santyl 250 unit/gram topical ointment\n- lidocaine 0.05 MG/MG Medicated Patch, presumably until 2018-07-04, with intended 0 refill(s). Instructions: lidocaine 5 % topical patch\n- 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s)\n- labetalol hydrochloride 100 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: labetalol 100 mg tablet\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-04 00:00:00, ended at 2018-07-04 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-04 14:15:30, ended at 2018-07-04 15:27:41\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report\n\n### Condition\n- Essential hypertension\n- Heart murmur\n- Mixed hyperlipidemia\n\n### Drug\n- 120 ACTUAT formoterol fumarate 0.005 MG/ACTUAT / mometasone furoate 0.1 MG/ACTUAT Metered Dose Inhaler, through Inhalation, presumably until 2019-04-24, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route daily as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-12 00:00:00, ended at 2018-07-12 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2019-07-16, with intended 3 refill(s). Instructions: TAKE 1 TAB BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-15 00:00:00, ended at 2018-07-15 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-15\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-15\n- sodium chloride 9 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-15\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-15\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2018-07-15, presumably until 2018-07-15\n- 10 ML tranexamic acid 100 MG/ML Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-07-15 10:03:00, ended at 2018-07-16 11:06:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n- Glucose [Mass/volume] in Blood: 197 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n\n### Procedure\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Radiologic examination, knee; 1 or 2 views\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n\n### Condition\n- Hypertensive heart failure\n- Urinary tract obstruction\n- Hypothyroidism\n- Polyneuropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus without complication\n- Mixed hyperlipidemia\n- Obesity\n- Benign prostatic hyperplasia with outflow obstruction\n- Gastroesophageal reflux disease without esophagitis\n- Acute exacerbation of chronic obstructive airways disease\n- Congestive heart failure\n- Primary diagnosis: Osteoarthritis of knee\n- Chronic diastolic heart failure\n- Chronic obstructive lung disease\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous gluconate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous fumarate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous ascorbate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- iron,peptonized, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous succinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- pregabalin 75 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-07-15, presumably until 2018-07-15\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- ferrous bisglycinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous cysteine glycinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-16\n- ferrous aspartate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ammonium ferrous sulfate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- soy protein-iron complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2019-01-12, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n- ferrous carbonate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous glycine sulfate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- folic acid, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-07-16, presumably until 2018-08-29, with intended 0 refill(s). Instructions: inject 0.4 mL subcutaneous (under the skin) every day\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- iron succinyl milk protein complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- iron-dextran complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- teferrol, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- ferrous asparto glycinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous cacodylate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2019-07-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-07-16, presumably until 2019-07-16, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- iron, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2019-04-24, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- ferrous oxalate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-16\n- iron sucrose, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous sulfate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- iron carbonyl, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous lactate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous chloride, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- iron sorbitex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous phosphate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- midazolam 1 MG/ML Injectable Solution, started on 2018-07-15, presumably until 2018-07-15\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2018-07-16, presumably until 2018-07-16\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-29 14:25:42, ended at 2018-08-29 14:56:06\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 129 (milligram per deciliter calculated)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent hemoglobin)\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n- Essential hypertension\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-31 00:00:00, ended at 2018-08-31 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-07 00:00:00, ended at 2018-09-07 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2018-09-10, presumably until 2018-11-14, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-07 00:00:00, ended at 2018-09-07 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2018-09-09, presumably until 2018-10-04, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY ORAL ROUTE EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-12, presumably until 2019-11-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-01 00:00:00, ended at 2018-10-01 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-02 00:00:00, ended at 2018-10-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.21 (milli-international unit per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.4 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-03 00:00:00, ended at 2018-10-03 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-10-03, presumably until 2019-11-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-04 00:00:00, ended at 2018-10-04 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-10-04, presumably until 2019-11-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2018-10-04, presumably until 2019-11-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-14 00:00:00, ended at 2018-11-14 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2018-11-14, presumably until 2019-09-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-26 14:30:58, ended at 2018-12-26 15:04:41\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2018-12-26, presumably until 2018-12-26, with intended 1 refill(s). Instructions: inject 1 Dose into a muscle One Time One time now and repeat in 2-6 months.\n- olmesartan medoxomil 40 MG Oral Tablet, through Oral route, started on 2018-12-26, presumably until 2019-12-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- gabapentin 300 MG Oral Capsule, through Oral route, presumably until 2021-01-28, with intended 0 refill(s). Instructions: take 300 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-27 00:00:00, ended at 2019-01-27 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-24 13:12:22, ended at 2019-04-24 14:12:26\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic aortic sclerosis\n- Primary diagnosis: Essential hypertension\n- Mixed hyperlipidemia\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-24 14:22:22, ended at 2019-04-24 14:54:52\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2019-04-24, presumably until 2019-04-24, with intended 1 refill(s). Instructions: inject 1 Dose into a muscle One Time for 1 dose One time now and repeat in 2-6 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-30 00:00:00, ended at 2019-05-30 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2019-05-30, presumably until 2019-11-24, with intended 1 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH DAILY\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2019-05-30, presumably until 2020-09-27, with intended 1 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH IN THE EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-28 13:21:22, ended at 2019-08-28 14:28:36\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Primary diagnosis: Essential hypertension\n- Mixed hyperlipidemia\n- Polyneuropathy due to type 2 diabetes mellitus\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-28 14:34:02, ended at 2019-08-28 15:28:18\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Urine: 77.7 (milligram per deciliter)\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 108 (milligram per deciliter calculated)\n- Body height: 5' 10\" (inch (US))\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.2 (percent hemoglobin)\n- Creatinine [Mass/volume] in Urine: 67 (milligram per deciliter)\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2019-08-28, presumably until 2019-08-28, with intended 1 refill(s). Instructions: inject 1 Dose into a muscle One Time for 1 dose One time now and repeat in 2-6 months.\n- azithromycin 250 MG Oral Tablet, started on 2019-08-28, presumably until 2019-09-01, with intended 0 refill(s). Instructions: 2 tabs first day, then one a day for 4 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-18 00:00:00, ended at 2019-09-18 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2019-09-20, presumably until 2020-12-11, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-03 00:00:00, ended at 2019-11-03 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-11-03, presumably until 2020-08-06, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-24 00:00:00, ended at 2019-11-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2019-11-25, presumably until 2020-05-21, with intended 1 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-28 00:00:00, ended at 2019-11-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 10 MG Oral Tablet, started on 2019-11-28, presumably until 2021-05-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- atorvastatin 40 MG Oral Tablet, started on 2019-11-28, presumably until 2020-11-22, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n- clopidogrel 75 MG Oral Tablet, started on 2019-11-28, presumably until 2020-12-10, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-21 00:00:00, ended at 2020-05-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2020-05-21, presumably until 2020-12-14, with intended 1 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-05 00:00:00, ended at 2020-08-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-08-06, presumably until 2021-05-16, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-09-27 08:39:35, ended at 2020-09-27 09:11:58\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Hypothyroidism\n- Essential hypertension\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n- Mixed hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-01 00:00:00, ended at 2020-10-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 4 MG Oral Tablet, through Oral route, started on 2020-10-03, presumably until 2020-11-04, with intended 5 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-13 13:47:41, ended at 2020-10-13 14:04:20\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract obstruction\n- Nocturia\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2020-10-15, presumably until 2020-11-08, with intended 0 refill(s). Instructions: take 1 Tab (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-24 00:00:00, ended at 2020-10-24 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, started on 2020-10-24, presumably until 2021-01-28, with intended 11 refill(s). Instructions: 1-2 tabs twice daily as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-26 09:52:30, ended at 2020-10-26 11:09:25\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Mixed hyperlipidemia\n- Non-rheumatic aortic sclerosis\n- Polyneuropathy due to type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Atrial premature complex\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-27 00:00:00, ended at 2020-10-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n- Primary diagnosis: Pain of right knee joint\n- Hip pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-28 10:15:33, ended at 2020-10-28 10:56:36\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urinary tract obstruction\n- Essential hypertension\n- Peripheral vascular disease\n- Benign prostatic hyperplasia with outflow obstruction\n- Primary diagnosis: Disorder of nervous system due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-02 10:02:00, ended at 2020-11-02 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain of right knee joint\n- Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-02 10:02:00, ended at 2020-11-02 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hips, bilateral, with pelvis when performed; 2 views\n\n### Condition\n- Chronic pain\n- Hip pain\n- Pain of left knee region\n- Pain of right knee joint\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-02 10:02:06, ended at 2020-11-02 11:57:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain of right knee joint\n- Chronic pain\n- Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-04 00:00:00, ended at 2020-11-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 4 MG Oral Tablet, through Oral route, started on 2020-11-04, presumably until 2021-01-17, with intended 5 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-07 00:00:00, ended at 2020-11-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2020-11-08, presumably until 2021-01-17, with intended 2 refill(s). Instructions: TAKE 1 TAB (2 MG TOTAL) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-11-22, presumably until 2021-11-09, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-10 00:00:00, ended at 2020-12-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2020-12-10, presumably until 2021-09-06, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-10 00:00:00, ended at 2020-12-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2020-12-11, presumably until 2022-01-07, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-11 00:00:00, ended at 2020-12-11 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2020-12-14, presumably until 2021-01-28, with intended 1 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-29 08:42:14, ended at 2020-12-29 09:08:59\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Disorder of nervous system due to type 2 diabetes mellitus\n- Mixed hyperlipidemia\n- Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-17 14:26:59, ended at 2021-01-17 16:01:30\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nocturia\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n- Primary diagnosis: Urinary tract obstruction\n\n### Drug\n- 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2021-01-17, presumably until 2021-02-25, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every day\n- olmesartan medoxomil 40 MG Oral Tablet, through Oral route, presumably until 2021-09-30, with intended 0 refill(s). Instructions: take 40 mg by mouth PM \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-28 00:00:00, ended at 2021-01-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Osmotic 24 HR nifedipine 90 MG Extended Release Oral Tablet, through Oral route, started on 2021-01-28, presumably until 2022-01-28, with intended 0 refill(s). Instructions: take 1 Tab (90 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-28 10:47:01, ended at 2021-01-28 11:28:30\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, started on 2021-01-28, presumably until 2021-09-29, with intended 11 refill(s). Instructions: 3 tabs twice daily as directed.\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2021-01-28, presumably until 2021-01-28, with intended 1 refill(s). Instructions: take 2 Caps (600 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-02-10 00:00:00, ended at 2021-02-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2021-02-10, presumably until 2021-02-10, with intended 6 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-02-14 00:00:00, ended at 2021-02-14 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2021-02-14, presumably until 2021-02-14, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2021-02-18 13:28:10, ended at 2021-02-18 14:10:08\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Cystourethroscopy (separate procedure)\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n\n### Condition\n- Primary diagnosis: Urinary tract obstruction\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n- Nocturia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-02-24 11:08:03, ended at 2021-02-24 11:46:02\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mixed hyperlipidemia\n- Primary diagnosis: Non-rheumatic aortic sclerosis\n- Polyneuropathy due to type 2 diabetes mellitus\n- Essential hypertension\n\n### Drug\n- doxazosin 4 MG Oral Tablet, started on 2021-01-31, presumably until 2021-03-07, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-02-25 10:51:47, ended at 2021-02-25 11:25:42\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nocturia\n- Congestive heart failure\n- Polyneuropathy due to type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Chronic diastolic heart failure\n\n### Drug\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2021-02-25, presumably until 2021-05-04, with intended 5 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-03-07 12:44:17, ended at 2021-03-07 13:34:59\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nocturia\n- Retention of urine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- silodosin 8 MG Oral Capsule, through Oral route, started on 2021-03-09, presumably until 2021-04-04, with intended 1 refill(s). Instructions: take 1 Goode (8 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-03-11 11:01:16, ended at 2021-03-11 11:56:37\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fatigue\n- Congestive heart failure\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Polyneuropathy due to type 2 diabetes mellitus\n- Chronic diastolic heart failure\n- Hypersomnia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- silodosin 8 MG Oral Capsule, through Oral route, started on 2021-04-04, presumably until 2021-04-04, with intended 1 refill(s). Instructions: take 1 Capsule (8 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-04-25 10:52:31, ended at 2021-04-25 11:37:16\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fatigue\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Hypersomnia\n- Chronic diastolic heart failure\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-04 11:11:54, ended at 2021-05-04 12:19:07\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign prostatic hyperplasia with outflow obstruction\n- Erectile dysfunction\n- Primary diagnosis: Retention of urine\n- Urinary tract obstruction\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2021-04-29, presumably until 2021-11-23, with intended 0 refill(s). Instructions: take 30 mg by mouth daily \n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2021-04-05, presumably until 2021-04-05, with intended 0 refill(s). Instructions: by Topical route as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, with intended 0 refill(s). Instructions: take 17 g by mouth as needed Twice daily as needed.\n- ketoconazole 20 MG/ML Topical Cream, through Topical route, started on 2021-04-05, presumably until 2021-10-05, with intended 0 refill(s). Instructions: by Topical route as needed \n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2021-05-04, presumably until 2021-05-19, with intended 0 refill(s). Instructions: take 1 Capsule (0.4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-05-13 00:00:00, ended at 2021-05-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2021-05-16, presumably until 2021-10-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-17 15:25:59, ended at 2021-05-17 16:47:06\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting\n\n### Condition\n- Greater trochanteric pain syndrome\n- Hip pain\n- Primary diagnosis: Pain of right knee joint\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2021-05-17, presumably until 2021-05-17\n- triamcinolone acetonide 40 MG/ML Injectable Suspension, started on 2021-05-17, presumably until 2021-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-05-19 00:00:00, ended at 2021-05-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2021-05-20, presumably until 2021-06-10, with intended 0 refill(s). Instructions: take 1 Capsule (0.4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-27 10:14:16, ended at 2021-05-27 11:54:08\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Erectile dysfunction\n- Primary diagnosis: Incomplete emptying of bladder\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n- Nocturia\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-27 11:10:39, ended at 2021-05-27 12:56:07\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to type 2 diabetes mellitus\n- Unsteady when standing\n- Malaise\n- Fatigue\n- Primary diagnosis: Asthenia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-28 14:41:00, ended at 2021-05-28 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Cerebral infarction\n- Unsteady when standing\n- Asthenia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-31 00:00:00, ended at 2021-05-31 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction\n- Hemiplegia of dominant side\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-06-04 11:42:00, ended at 2021-06-04 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of brain\n- Unsteady when standing\n- Cerebral artery occlusion\n\n### Drug\n- gadobenate, through Intravenous route, started on 2021-06-04, presumably until 2021-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-08 00:00:00, ended at 2021-06-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Asthenia\n- Primary diagnosis: Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-06-10 00:00:00, ended at 2021-06-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2021-06-10, presumably until 2021-08-24, with intended 2 refill(s). Instructions: take 1 Capsule (0.4 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-06-13 11:15:06, ended at 2021-06-13 11:37:35\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic diastolic heart failure\n- Hypersomnia\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Congestive heart failure\n- Fatigue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-23 00:00:00, ended at 2021-06-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dementia associated with another disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-03 00:00:00, ended at 2021-07-03 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-07-04 00:00:00, ended at 2021-07-04 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-07-11 11:17:00, ended at 2021-07-11 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Secondary malignant neoplasm of brain\n- Disorder of brain\n\n### Drug\n- fluorodeoxyglucose F18, through Intravenous route, started on 2021-07-11, presumably until 2021-07-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-17 00:00:00, ended at 2021-08-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of temporal lobe\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-19 00:00:00, ended at 2021-08-19 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of temporal lobe\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-05 00:00:00, ended at 2017-12-05 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ropinirole 1 MG Oral Tablet, started on 2017-12-05, presumably until 2018-07-04, with intended 0 refill(s). Instructions: TAKE 1 TABLET AT BEDTIME.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-02 00:00:00, ended at 2018-01-02 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valsartan 320 MG Oral Tablet, started on 2018-01-02, presumably until 2018-04-10, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-01-02, presumably until 2018-04-09, with intended 2 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH WITH THE EVENING MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-03 14:48:45, ended at 2018-01-03 15:58:47\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to type 2 diabetes mellitus\n- Peripheral vascular disease\n- Mixed hyperlipidemia\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2018-01-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2017-09-13, presumably until 2021-01-28, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2017-07-05, presumably until 2018-02-05, with intended 0 refill(s). Instructions: 1 Cap daily\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-11-12, presumably until 2018-01-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2018-06-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-01-03, presumably until 2018-07-12, with intended 1 refill(s). Instructions: take 1 Tab by mouth every day\n- 120 ACTUAT formoterol fumarate 0.005 MG/ACTUAT / mometasone furoate 0.1 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-10-12, presumably until 2018-07-02, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route\n- thioctic acid 300 MG Oral Capsule, started on 2016-10-30, presumably until 2020-10-26, with intended 0 refill(s). Instructions: alpha lipoic acid 300 mg capsule; take 2 in the am  and 2 in the pm; 0; 0; 10/30/2016; Hu MD, Holliman; Active\n- omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule, through Oral route, presumably until 2018-07-04, with intended 0 refill(s). Instructions: take 1 g by mouth\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2017-11-07, presumably until 2018-06-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- ascorbic acid 500 MG Oral Tablet, through Oral route, presumably until 2021-09-29, with intended 0 refill(s). Instructions: take 500 mg by mouth daily \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2019-08-28, with intended 0 refill(s). Instructions: take 81 mg by mouth daily \n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2017-11-07, presumably until 2018-06-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-03 16:03:43, ended at 2018-01-03 16:31:18\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Benign prostatic hyperplasia with outflow obstruction\n- Urinary tract obstruction\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2018-01-03, presumably until 2018-07-04, with intended 5 refill(s). Instructions: take 1 Tab by mouth daily\n- azithromycin 250 MG Oral Tablet, started on 2018-01-03, presumably until 2018-01-08, with intended 0 refill(s). Instructions: Take 2 the first day and one a day on days 2-5.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-31 00:00:00, ended at 2018-01-31 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-02-01, presumably until 2018-05-12, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-05 00:00:00, ended at 2018-02-05 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2018-02-06, presumably until 2018-05-15, with intended 5 refill(s). Instructions: TAKE 1 CAPSULE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-15 00:00:00, ended at 2018-02-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2018-02-18, presumably until 2018-09-07, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-15 00:00:00, ended at 2018-03-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350, started on 2018-03-20, presumably until 2018-07-04, with intended 3 refill(s). Instructions: One capful once to twice a day as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-19 00:00:00, ended at 2018-03-19 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 4 MG Oral Tablet, through Oral route, started on 2018-03-04, presumably until 2020-10-01, with intended 0 refill(s). Instructions: take 4 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-09 00:00:00, ended at 2018-04-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-04-11, presumably until 2018-05-13, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH WITH THE EVENING MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-10 00:00:00, ended at 2018-04-10 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valsartan 320 MG Oral Tablet, started on 2018-04-11, presumably until 2018-05-15, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-12 00:00:00, ended at 2018-05-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-05-13, presumably until 2018-06-27, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-13 00:00:00, ended at 2018-05-13 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-05-13, presumably until 2018-05-15, with intended 3 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH IN THE EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-15 00:00:00, ended at 2018-05-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2018-05-15, presumably until 2019-05-30, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n- valsartan 320 MG Oral Tablet, through Oral route, started on 2018-05-15, presumably until 2018-07-02, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2018-05-15, presumably until 2019-05-30, with intended 3 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH IN THE EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-09 00:00:00, ended at 2018-06-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 10 MG Oral Tablet, started on 2018-06-10, presumably until 2018-10-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY ORAL ROUTE EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-13 00:00:00, ended at 2018-06-13 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-06-13, presumably until 2018-10-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2018-06-13, presumably until 2018-07-16, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-21 09:12:56, ended at 2018-06-21 10:11:04\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute asthma\n- Cerebral infarction\n- Polyneuropathy due to type 2 diabetes mellitus\n- Hypothyroidism\n- Acute exacerbation of chronic obstructive airways disease\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-27 00:00:00, ended at 2018-06-27 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-09-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-02 00:00:00, ended at 2018-07-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- terazosin 5 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: terazosin 5 mg capsule\n- hydrochlorothiazide 25 MG / triamterene 37.5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: triamterene 37.5 mg-hydrochlorothiazide 25 mg tablet\n- 14 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Silver Creek  Diskus 250 mcg-50 mcg/dose powder for inhalation\n- diflorasone diacetate 0.5 MG/ML Topical Cream, presumably until 2018-07-04, with intended 0 refill(s). Instructions: ApexiCon E 0.05 % topical cream\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Cheratussin AC 10 mg-100 mg/5 mL oral liquid\n- atenolol 50 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: atenolol 50 mg tablet\n- amoxicillin 500 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: amoxicillin 500 mg capsule\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: hydrocodone 10 mg-acetaminophen 325 mg tablet\n- diazepam 5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: diazepam 5 mg tablet\n- simvastatin 20 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: simvastatin 20 mg tablet\n- cefdinir 300 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- hydrocortisone 10 MG/ML / neomycin 3.5 MG/ML / polymyxin B 10000 UNT/ML Otic Solution, presumably until 2018-07-04, with intended 0 refill(s). Instructions: neomycin-polymyxin-hydrocort 3.5 mg/mL-10,000 unit/mL-1 % ear solution\n- hydrochlorothiazide 25 MG / valsartan 320 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: valsartan 320 mg-hydrochlorothiazide 25 mg tablet\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Lovenox 40 mg/0.4 mL subcutaneous syringe\n- omeprazole 20 MG Disintegrating Oral Tablet, presumably until 2018-07-02, with intended 0 refill(s). Instructions: omeprazole 20 mg capsule,delayed release\n- ciprofloxacin 500 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: ciprofloxacin 500 mg tablet\n- polyethylene glycol 3350 420000 MG / potassium chloride 1480 MG / sodium bicarbonate 5720 MG / sodium chloride 11200 MG Powder for Oral Solution, presumably until 2018-07-04, with intended 0 refill(s). Instructions: GaviLyte-N 420 gram oral solution\n- rabeprazole sodium 20 MG Delayed Release Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Aciphex 20 mg tablet,delayed release\n- hydralazine hydrochloride 25 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: hydralazine 25 mg tablet\n- sucralfate 1000 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: sucralfate 1 gram tablet\n- cephalexin 500 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: cephalexin 500 mg capsule\n- olmesartan medoxomil 40 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Weller 40 mg tablet\n- tramadol hydrochloride 50 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: tramadol 50 mg tablet\n- diclofenac sodium 50 MG Delayed Release Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: diclofenac sodium 50 mg tablet,delayed release\n- oxycodone hydrochloride 10 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: oxycodone 10 mg tablet\n- naproxen 250 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: naproxen 250 mg tablet\n- gabapentin 300 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: gabapentin 300 mg capsule\n- glyburide 2.5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: glyburide 2.5 mg tablet\n- etodolac 400 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: etodolac 400 mg tablet\n- celecoxib 200 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: celecoxib 200 mg capsule\n- betamethasone 0.5 MG/ML / clotrimazole 10 MG/ML Topical Cream, presumably until 2018-07-04, with intended 0 refill(s). Instructions: clotrimazole-betamethasone 1 %-0.05 % topical cream\n- enalapril maleate 5 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: enalapril maleate 5 mg tablet\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, presumably until 2018-07-04, with intended 0 refill(s). Instructions: tamsulosin 0.4 mg capsule\n- collagenase 0.25 UNT/MG Topical Ointment, presumably until 2018-07-04, with intended 0 refill(s). Instructions: Santyl 250 unit/gram topical ointment\n- lidocaine 0.05 MG/MG Medicated Patch, presumably until 2018-07-04, with intended 0 refill(s). Instructions: lidocaine 5 % topical patch\n- 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s)\n- labetalol hydrochloride 100 MG Oral Tablet, presumably until 2018-07-04, with intended 0 refill(s). Instructions: labetalol 100 mg tablet\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-04 00:00:00, ended at 2018-07-04 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-04 14:15:30, ended at 2018-07-04 15:27:41\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report\n\n### Condition\n- Essential hypertension\n- Heart murmur\n- Mixed hyperlipidemia\n\n### Drug\n- 120 ACTUAT formoterol fumarate 0.005 MG/ACTUAT / mometasone furoate 0.1 MG/ACTUAT Metered Dose Inhaler, through Inhalation, presumably until 2019-04-24, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route daily as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-12 00:00:00, ended at 2018-07-12 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2019-07-16, with intended 3 refill(s). Instructions: TAKE 1 TAB BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-15 00:00:00, ended at 2018-07-15 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-15\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-15\n- sodium chloride 9 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-15\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-15\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2018-07-15, presumably until 2018-07-15\n- 10 ML tranexamic acid 100 MG/ML Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-07-15 10:03:00, ended at 2018-07-16 11:06:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n- Glucose [Mass/volume] in Blood: 197 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n\n### Procedure\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Radiologic examination, knee; 1 or 2 views\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n\n### Condition\n- Hypertensive heart failure\n- Urinary tract obstruction\n- Hypothyroidism\n- Polyneuropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus without complication\n- Mixed hyperlipidemia\n- Obesity\n- Benign prostatic hyperplasia with outflow obstruction\n- Gastroesophageal reflux disease without esophagitis\n- Acute exacerbation of chronic obstructive airways disease\n- Congestive heart failure\n- Primary diagnosis: Osteoarthritis of knee\n- Chronic diastolic heart failure\n- Chronic obstructive lung disease\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous gluconate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous fumarate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous ascorbate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- iron,peptonized, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous succinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- pregabalin 75 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-07-15, presumably until 2018-07-15\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- ferrous bisglycinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous cysteine glycinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2018-07-15, presumably until 2018-07-16\n- ferrous aspartate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ammonium ferrous sulfate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- soy protein-iron complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2019-01-12, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n- ferrous carbonate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous glycine sulfate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- folic acid, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-07-16, presumably until 2018-08-29, with intended 0 refill(s). Instructions: inject 0.4 mL subcutaneous (under the skin) every day\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- iron succinyl milk protein complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- iron-dextran complex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- teferrol, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- ferrous asparto glycinate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous cacodylate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2019-07-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-07-16, presumably until 2019-07-16, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- iron, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2019-04-24, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- ferrous oxalate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-16\n- iron sucrose, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous sulfate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- iron carbonyl, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous lactate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous chloride, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-15\n- iron sorbitex, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- ferrous phosphate, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-16, presumably until 2018-07-16\n- midazolam 1 MG/ML Injectable Solution, started on 2018-07-15, presumably until 2018-07-15\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2018-07-15, presumably until 2018-07-16\n- 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2018-07-16, presumably until 2018-07-16\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2018-07-15, presumably until 2018-07-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-29 14:25:42, ended at 2018-08-29 14:56:06\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 129 (milligram per deciliter calculated)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent hemoglobin)\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n- Essential hypertension\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-31 00:00:00, ended at 2018-08-31 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-07 00:00:00, ended at 2018-09-07 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2018-09-10, presumably until 2018-11-14, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-07 00:00:00, ended at 2018-09-07 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2018-09-09, presumably until 2018-10-04, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY ORAL ROUTE EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-12, presumably until 2019-11-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-01 00:00:00, ended at 2018-10-01 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-02 00:00:00, ended at 2018-10-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.21 (milli-international unit per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.4 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-03 00:00:00, ended at 2018-10-03 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-10-03, presumably until 2019-11-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-04 00:00:00, ended at 2018-10-04 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-10-04, presumably until 2019-11-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2018-10-04, presumably until 2019-11-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-14 00:00:00, ended at 2018-11-14 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2018-11-14, presumably until 2019-09-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-26 14:30:58, ended at 2018-12-26 15:04:41\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2018-12-26, presumably until 2018-12-26, with intended 1 refill(s). Instructions: inject 1 Dose into a muscle One Time One time now and repeat in 2-6 months.\n- olmesartan medoxomil 40 MG Oral Tablet, through Oral route, started on 2018-12-26, presumably until 2019-12-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- gabapentin 300 MG Oral Capsule, through Oral route, presumably until 2021-01-28, with intended 0 refill(s). Instructions: take 300 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-27 00:00:00, ended at 2019-01-27 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-24 13:12:22, ended at 2019-04-24 14:12:26\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic aortic sclerosis\n- Primary diagnosis: Essential hypertension\n- Mixed hyperlipidemia\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-24 14:22:22, ended at 2019-04-24 14:54:52\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2019-04-24, presumably until 2019-04-24, with intended 1 refill(s). Instructions: inject 1 Dose into a muscle One Time for 1 dose One time now and repeat in 2-6 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-30 00:00:00, ended at 2019-05-30 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2019-05-30, presumably until 2019-11-24, with intended 1 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH DAILY\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, started on 2019-05-30, presumably until 2020-09-27, with intended 1 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH IN THE EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-28 13:21:22, ended at 2019-08-28 14:28:36\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Primary diagnosis: Essential hypertension\n- Mixed hyperlipidemia\n- Polyneuropathy due to type 2 diabetes mellitus\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-28 14:34:02, ended at 2019-08-28 15:28:18\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Urine: 77.7 (milligram per deciliter)\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 108 (milligram per deciliter calculated)\n- Body height: 5' 10\" (inch (US))\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.2 (percent hemoglobin)\n- Creatinine [Mass/volume] in Urine: 67 (milligram per deciliter)\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2019-08-28, presumably until 2019-08-28, with intended 1 refill(s). Instructions: inject 1 Dose into a muscle One Time for 1 dose One time now and repeat in 2-6 months.\n- azithromycin 250 MG Oral Tablet, started on 2019-08-28, presumably until 2019-09-01, with intended 0 refill(s). Instructions: 2 tabs first day, then one a day for 4 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-18 00:00:00, ended at 2019-09-18 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2019-09-20, presumably until 2020-12-11, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-03 00:00:00, ended at 2019-11-03 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-11-03, presumably until 2020-08-06, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-24 00:00:00, ended at 2019-11-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2019-11-25, presumably until 2020-05-21, with intended 1 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-28 00:00:00, ended at 2019-11-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 10 MG Oral Tablet, started on 2019-11-28, presumably until 2021-05-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- atorvastatin 40 MG Oral Tablet, started on 2019-11-28, presumably until 2020-11-22, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n- clopidogrel 75 MG Oral Tablet, started on 2019-11-28, presumably until 2020-12-10, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-21 00:00:00, ended at 2020-05-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2020-05-21, presumably until 2020-12-14, with intended 1 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-05 00:00:00, ended at 2020-08-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-08-06, presumably until 2021-05-16, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-09-27 08:39:35, ended at 2020-09-27 09:11:58\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Hypothyroidism\n- Essential hypertension\n- Primary diagnosis: Polyneuropathy due to type 2 diabetes mellitus\n- Mixed hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-01 00:00:00, ended at 2020-10-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 4 MG Oral Tablet, through Oral route, started on 2020-10-03, presumably until 2020-11-04, with intended 5 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-13 13:47:41, ended at 2020-10-13 14:04:20\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract obstruction\n- Nocturia\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2020-10-15, presumably until 2020-11-08, with intended 0 refill(s). Instructions: take 1 Tab (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-24 00:00:00, ended at 2020-10-24 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, started on 2020-10-24, presumably until 2021-01-28, with intended 11 refill(s). Instructions: 1-2 tabs twice daily as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-26 09:52:30, ended at 2020-10-26 11:09:25\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Mixed hyperlipidemia\n- Non-rheumatic aortic sclerosis\n- Polyneuropathy due to type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Atrial premature complex\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-27 00:00:00, ended at 2020-10-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n- Primary diagnosis: Pain of right knee joint\n- Hip pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-28 10:15:33, ended at 2020-10-28 10:56:36\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urinary tract obstruction\n- Essential hypertension\n- Peripheral vascular disease\n- Benign prostatic hyperplasia with outflow obstruction\n- Primary diagnosis: Disorder of nervous system due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-02 10:02:00, ended at 2020-11-02 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain of right knee joint\n- Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-02 10:02:00, ended at 2020-11-02 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hips, bilateral, with pelvis when performed; 2 views\n\n### Condition\n- Chronic pain\n- Hip pain\n- Pain of left knee region\n- Pain of right knee joint\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-02 10:02:06, ended at 2020-11-02 11:57:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain of right knee joint\n- Chronic pain\n- Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-04 00:00:00, ended at 2020-11-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 4 MG Oral Tablet, through Oral route, started on 2020-11-04, presumably until 2021-01-17, with intended 5 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-07 00:00:00, ended at 2020-11-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2020-11-08, presumably until 2021-01-17, with intended 2 refill(s). Instructions: TAKE 1 TAB (2 MG TOTAL) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-11-22, presumably until 2021-11-09, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-10 00:00:00, ended at 2020-12-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2020-12-10, presumably until 2021-09-06, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-10 00:00:00, ended at 2020-12-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, started on 2020-12-11, presumably until 2022-01-07, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-11 00:00:00, ended at 2020-12-11 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2020-12-14, presumably until 2021-01-28, with intended 1 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-29 08:42:14, ended at 2020-12-29 09:08:59\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Disorder of nervous system due to type 2 diabetes mellitus\n- Mixed hyperlipidemia\n- Polyneuropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-17 14:26:59, ended at 2021-01-17 16:01:30\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nocturia\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n- Primary diagnosis: Urinary tract obstruction\n\n### Drug\n- 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2021-01-17, presumably until 2021-02-25, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every day\n- olmesartan medoxomil 40 MG Oral Tablet, through Oral route, presumably until 2021-09-30, with intended 0 refill(s). Instructions: take 40 mg by mouth PM \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-28 00:00:00, ended at 2021-01-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Osmotic 24 HR nifedipine 90 MG Extended Release Oral Tablet, through Oral route, started on 2021-01-28, presumably until 2022-01-28, with intended 0 refill(s). Instructions: take 1 Tab (90 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-28 10:47:01, ended at 2021-01-28 11:28:30\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, started on 2021-01-28, presumably until 2021-09-29, with intended 11 refill(s). Instructions: 3 tabs twice daily as directed.\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2021-01-28, presumably until 2021-01-28, with intended 1 refill(s). Instructions: take 2 Caps (600 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-02-10 00:00:00, ended at 2021-02-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2021-02-10, presumably until 2021-02-10, with intended 6 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-02-14 00:00:00, ended at 2021-02-14 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2021-02-14, presumably until 2021-02-14, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2021-02-18 13:28:10, ended at 2021-02-18 14:10:08\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Cystourethroscopy (separate procedure)\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n\n### Condition\n- Primary diagnosis: Urinary tract obstruction\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n- Nocturia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-02-24 11:08:03, ended at 2021-02-24 11:46:02\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mixed hyperlipidemia\n- Primary diagnosis: Non-rheumatic aortic sclerosis\n- Polyneuropathy due to type 2 diabetes mellitus\n- Essential hypertension\n\n### Drug\n- doxazosin 4 MG Oral Tablet, started on 2021-01-31, presumably until 2021-03-07, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-02-25 10:51:47, ended at 2021-02-25 11:25:42\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nocturia\n- Congestive heart failure\n- Polyneuropathy due to type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Chronic diastolic heart failure\n\n### Drug\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2021-02-25, presumably until 2021-05-04, with intended 5 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-03-07 12:44:17, ended at 2021-03-07 13:34:59\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nocturia\n- Retention of urine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- silodosin 8 MG Oral Capsule, through Oral route, started on 2021-03-09, presumably until 2021-04-04, with intended 1 refill(s). Instructions: take 1 Goode (8 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-03-11 11:01:16, ended at 2021-03-11 11:56:37\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fatigue\n- Congestive heart failure\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Polyneuropathy due to type 2 diabetes mellitus\n- Chronic diastolic heart failure\n- Hypersomnia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- silodosin 8 MG Oral Capsule, through Oral route, started on 2021-04-04, presumably until 2021-04-04, with intended 1 refill(s). Instructions: take 1 Capsule (8 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-04-25 10:52:31, ended at 2021-04-25 11:37:16\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fatigue\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Hypersomnia\n- Chronic diastolic heart failure\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-04 11:11:54, ended at 2021-05-04 12:19:07\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign prostatic hyperplasia with outflow obstruction\n- Erectile dysfunction\n- Primary diagnosis: Retention of urine\n- Urinary tract obstruction\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2021-04-29, presumably until 2021-11-23, with intended 0 refill(s). Instructions: take 30 mg by mouth daily \n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2021-04-05, presumably until 2021-04-05, with intended 0 refill(s). Instructions: by Topical route as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, with intended 0 refill(s). Instructions: take 17 g by mouth as needed Twice daily as needed.\n- ketoconazole 20 MG/ML Topical Cream, through Topical route, started on 2021-04-05, presumably until 2021-10-05, with intended 0 refill(s). Instructions: by Topical route as needed \n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2021-05-04, presumably until 2021-05-19, with intended 0 refill(s). Instructions: take 1 Capsule (0.4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-05-13 00:00:00, ended at 2021-05-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2021-05-16, presumably until 2021-10-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-17 15:25:59, ended at 2021-05-17 16:47:06\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting\n\n### Condition\n- Greater trochanteric pain syndrome\n- Hip pain\n- Primary diagnosis: Pain of right knee joint\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2021-05-17, presumably until 2021-05-17\n- triamcinolone acetonide 40 MG/ML Injectable Suspension, started on 2021-05-17, presumably until 2021-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-05-19 00:00:00, ended at 2021-05-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2021-05-20, presumably until 2021-06-10, with intended 0 refill(s). Instructions: take 1 Capsule (0.4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-27 10:14:16, ended at 2021-05-27 11:54:08\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Erectile dysfunction\n- Primary diagnosis: Incomplete emptying of bladder\n- Primary diagnosis: Benign prostatic hyperplasia with outflow obstruction\n- Nocturia\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-27 11:10:39, ended at 2021-05-27 12:56:07\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to type 2 diabetes mellitus\n- Unsteady when standing\n- Malaise\n- Fatigue\n- Primary diagnosis: Asthenia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-28 14:41:00, ended at 2021-05-28 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Cerebral infarction\n- Unsteady when standing\n- Asthenia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-31 00:00:00, ended at 2021-05-31 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction\n- Hemiplegia of dominant side\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-06-04 11:42:00, ended at 2021-06-04 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of brain\n- Unsteady when standing\n- Cerebral artery occlusion\n\n### Drug\n- gadobenate, through Intravenous route, started on 2021-06-04, presumably until 2021-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-08 00:00:00, ended at 2021-06-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Asthenia\n- Primary diagnosis: Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-06-10 00:00:00, ended at 2021-06-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2021-06-10, presumably until 2021-08-24, with intended 2 refill(s). Instructions: take 1 Capsule (0.4 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-06-13 11:15:06, ended at 2021-06-13 11:37:35\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic diastolic heart failure\n- Hypersomnia\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Congestive heart failure\n- Fatigue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-23 00:00:00, ended at 2021-06-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dementia associated with another disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-03 00:00:00, ended at 2021-07-03 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-07-04 00:00:00, ended at 2021-07-04 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-07-11 11:17:00, ended at 2021-07-11 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Secondary malignant neoplasm of brain\n- Disorder of brain\n\n### Drug\n- fluorodeoxyglucose F18, through Intravenous route, started on 2021-07-11, presumably until 2021-07-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-17 00:00:00, ended at 2021-08-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of temporal lobe\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-19 00:00:00, ended at 2021-08-19 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of temporal lobe\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "9901c3c7daf424da99c2c73ee420c33d299abdcf7a9ea07d999c92dc21efdcd1", "prompt_hash": "905eeee80eb0fbc3a0360a7c1b22fb192f0d8be8dc7fdeb160acece2eddf3683", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 3, "doc": {"person_id": 115972872, "visit_occurrence_id": 103319166, "death_date": "2020-12-27", "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2017-07-04 00:00:00", "visit_end_datetime": "2017-07-04 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-04 00:00:00, ended at 2017-07-04 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 96, "patient_first_visit_date": "2009-10-24 12:43:00", "patient_last_visit_date": "2019-02-01 00:00:00", "end_obs_date": "2018-07-04", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "recurrent", "ischemic_stroke_one_year_diagnosis": 1, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 1, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 200, "cumulated_visit_num": 200, "cumulated_approximate_token_count": 43663, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2009-10-24 12:43:00, ended at 2009-10-24 16:36:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.2 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 100 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.76 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 201 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.3 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Globulin [Mass/volume] in Serum: 5.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 11.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Base excess in Blood by calculation: 2.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, spine, cervical; 2 or 3 views\n\n### Condition\n- Degeneration of cervical intervertebral disc\n- Malaise\n- Neck pain\n- Torticollis\n\n### Drug\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-10-24, presumably until 2009-10-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-11-28 00:00:00, ended at 2009-11-28 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Musculoskeletal symptom\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-11-28 15:05:35, ended at 2009-11-28 16:21:45\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary diagnosis: Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-29 10:15:00, ended at 2009-11-29 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 7.5 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 111 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 2.5 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.76 (micro-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 98 (millimeter per hour)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 565 (picogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-12-02 00:00:00, ended at 2009-12-02 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polymyalgia rheumatica\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2009-12-02, presumably until 2009-12-10, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-12-03 00:00:00, ended at 2009-12-03 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-03 09:48:00, ended at 2009-12-03 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Malaise\n- Thoracic spondylosis without myelopathy\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Myelopathy due to cervical spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-04 10:11:00, ended at 2009-12-04 15:19:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Cerebrovascular disease\n- Disorder of basilar artery\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Degeneration of intervertebral disc\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-04 12:17:43, ended at 2009-12-04 16:44:22\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-12-04 15:00:00, ended at 2009-12-04 15:19:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-12-04 15:20:00, ended at 2009-12-12 13:38:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Triglyceride [Moles/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 23 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 208 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Body height: 5' 7.992\" (inch (US))\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Complement C3 [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.87 (million per microliter)\n- Prothrombin time (PT): 15.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 40.5 (second)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 11 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 9.1 (microgram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 80 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 86 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.83 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.43 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 194 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Venous catheterization, not elsewhere classified\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest; single view, frontal\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- General examination of patient\n\n### Condition\n- Cerebral infarction due to embolism of cerebral arteries\n- Weakness of face muscles\n- Acute and subacute bacterial endocarditis\n- Anemia\n- Cerebral atherosclerosis\n- Malaise\n- Cervical spondylosis without myelopathy\n- Neck sprain\n- Abnormal findings on diagnostic imaging of skull and head\n- Benign neoplasm of colon\n- Cyst and pseudocyst of pancreas\n- Polymyalgia rheumatica\n- Septic embolus of artery\n- Valvular endocarditis\n- Late effects of cerebrovascular disease\n- Thoracic spondylosis without myelopathy\n- Tricuspid valve disorder\n- Cerebrovascular disease\n- Mitral valve disorder\n- Sepsis due to Streptococcus group D\n- Cardiac arrhythmia\n\n### Drug\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2009-12-09, presumably until 2009-12-09\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2009-12-12\n- ampicillin 2000 MG Injection, started on 2009-12-10, presumably until 2010-01-17, with quantity of 1.0, with intended 0 refill(s). Instructions: 2000 mg by Injection route every 4 hours. \n- vancomycin 1000 MG Injection, through Intravenous route, started on 2009-12-07, presumably until 2009-12-09\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2009-12-11, presumably until 2009-12-11\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2009-12-11, presumably until 2010-03-18, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-12-07, presumably until 2009-12-07\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2009-12-09, presumably until 2009-12-09\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-12-04, presumably until 2009-12-11\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2009-12-11\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-12-12, presumably until 2010-01-20, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. To help with constipation - if diarrhea, please stop. \n- prednisone 1 MG Oral Tablet, through Oral route, started on 2009-12-10, presumably until 2009-12-12, with quantity of 3.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily. \n- prednisone 5 MG Oral Tablet, through Oral route, started on 2009-12-05, presumably until 2009-12-09\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2009-12-10, presumably until 2009-12-11\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2009-12-04, presumably until 2009-12-07\n- 50 ML gentamicin 1.2 MG/ML Injection, through Intravenous route, started on 2009-12-10, presumably until 2010-01-17, with quantity of 1.0, with intended 0 refill(s). Instructions: 60 mg by Intravenous route every 8 hours. \n- 6 ML gentamicin 10 MG/ML Injection, through Intravenous route, started on 2009-12-06, presumably until 2009-12-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2009-12-09\n- nafcillin 2000 MG Injection, through Intravenous route, started on 2009-12-06, presumably until 2009-12-07\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2010-01-02, with quantity of 45.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed \n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2009-12-09, presumably until 2009-12-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-12-20 00:00:00, ended at 2009-12-20 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-25 09:45:00, ended at 2009-12-25 10:30:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, head or brain; without contrast material\n\n### Condition\n- Cerebral ischemia\n- Diffuse cerebrovascular disease\n- Abnormal findings on diagnostic imaging of skull and head\n- Cerebrovascular disease\n- Cerebral infarction due to embolism of cerebral arteries\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-25 10:31:00, ended at 2009-12-25 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Cerebral infarction due to embolism of cerebral arteries\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-30 12:49:06, ended at 2009-12-30 17:02:47\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-02 14:02:04, ended at 2010-01-02 15:16:57\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Valvular endocarditis\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, through Oral route, started on 2010-01-02, presumably until 2010-04-11, with quantity of 16.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day. Take 4 tabs 1 hour before dental work \n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., through Subcutaneous route, started on 2010-01-02, presumably until 2010-01-03, with quantity of 1.0, with intended 0 refill(s). Instructions: 0.5 mL by SUBCUTANEOUS route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-02 15:26:00, ended at 2010-01-02 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 176 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.2 (percent)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 48 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n\n### Procedure\n- Other puncture of vein\n- Prophylactic administration of vaccine against other diseases\n- Other interview and evaluation\n\n### Condition\n- Acute and subacute bacterial endocarditis\n- Streptococcus pyogenes infection\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-20 13:17:08, ended at 2010-01-20 14:10:23\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Valvular endocarditis\n\n### Drug\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2010-01-20, presumably until 2010-03-18, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2010-01-20, presumably until 2010-03-18, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-22 08:39:11, ended at 2010-01-22 10:45:36\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-22 09:59:00, ended at 2010-01-22 09:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 61 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.1 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.57 (thousand per microliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 120 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 51 (millimeter per hour)\n- Platelets [#/volume] in Blood by Automated count: 159 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-03 08:27:00, ended at 2010-02-03 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Essential hypertension\n- Finding of head and neck region\n- Cerebral ischemia\n- Swelling / lump finding\n- Diffuse cerebrovascular disease\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-02-03 11:55:44, ended at 2010-02-03 15:43:26\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-12 13:27:00, ended at 2010-02-12 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-03-18 11:13:22, ended at 2010-03-18 12:15:47\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Neck pain\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2010-03-18, presumably until 2010-12-19, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- 0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection, through Subcutaneous route, started on 2010-03-18, presumably until 2010-03-19, with quantity of 1.0, with intended 0 refill(s). Instructions: 0.65 mL by SUBCUTANEOUS route One Time. \n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2010-03-18, presumably until 2010-12-19, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2010-03-18, presumably until 2010-12-19, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-18 12:23:00, ended at 2010-03-18 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 163 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocyte sedimentation rate: 41 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 43 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 77 (milligram per deciliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 2.5 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 69 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 58 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Neck pain\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-21 08:46:00, ended at 2010-03-21 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n\n### Condition\n- Exostosis\n- Displacement of cervical intervertebral disc without myelopathy\n- Spinal stenosis in cervical region\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-03-24 00:00:00, ended at 2010-03-24 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-04-04 00:00:00, ended at 2010-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-04 08:01:38, ended at 2010-04-04 15:38:10\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-04 09:55:00, ended at 2010-04-04 10:48:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.02 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 136 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.17 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.98 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-04 10:49:00, ended at 2010-04-04 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-04-10 00:00:00, ended at 2010-04-10 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-11 13:11:49, ended at 2010-04-11 14:13:20\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Mitral valve disorder\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2010-04-11, presumably until 2010-04-12, with intended 0 refill(s). Instructions: 0.5 mL by Intramuscular route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-11 14:59:10, ended at 2010-04-11 16:21:15\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Primary diagnosis: Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-22 14:55:28, ended at 2010-04-22 15:37:04\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Primary diagnosis: Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-02 00:00:00, ended at 2010-05-02 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Disorder of muscle\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-02 13:36:09, ended at 2010-05-02 14:07:09\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Disorder of muscle\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-06 08:01:09, ended at 2010-05-06 08:49:22\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-06-11 14:18:11, ended at 2010-06-11 14:42:43\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-06-17 08:10:39, ended at 2010-06-17 09:20:05\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Primary diagnosis: Neck pain\n- Disorder of muscle\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, started on 2010-06-17, presumably until 2010-06-18, with quantity of 1.0, with intended 0 refill(s). Instructions: 100 Units by Injection route One Time. \n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2010-06-17, presumably until 2010-06-18, with quantity of 1.0, with intended 0 refill(s). Instructions: 20 mL by Injection route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-07-04 13:16:52, ended at 2010-07-04 14:17:26\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urgent desire to urinate\n- Hyperplasia of prostate\n- Multi-infarct dementia, uncomplicated\n- Essential hypertension\n- Hyperlipidemia\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Mitral valve disorder\n- Neck pain\n- Osteoarthritis\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2010-07-04, presumably until 2010-10-10, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Cap by mouth daily. \n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-07-04, presumably until 2010-08-21, with quantity of 30.0, with intended 6 refill(s). Instructions: take 5 mg by mouth Every Day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-04 14:24:00, ended at 2010-07-04 14:34:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 239 (picogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.63 (micro-international unit per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-04 14:35:00, ended at 2010-07-04 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urgent desire to urinate\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-08 15:47:00, ended at 2010-07-08 15:47:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 3.2 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign prostatic hyperplasia with outflow obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-08 15:48:00, ended at 2010-07-08 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal urination\n- Benign prostatic hyperplasia with outflow obstruction\n- Nodular prostate without urinary obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-09 08:57:00, ended at 2010-07-09 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-16 10:34:00, ended at 2010-07-16 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy, prostate; needle or punch, single or multiple, any approach\n- Ultrasound, transrectal\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Nodular prostate without urinary obstruction\n- Urgent desire to urinate\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-07-16, presumably until 2010-07-16\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2010-07-16, presumably until 2010-07-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-07-16 12:33:00, ended at 2010-07-16 15:24:49\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure) and urethral pressure profile studies (ie, urethral closure pressure profile), any technique\n- Bladder irrigation, simple, lavage and/or instillation\n- Electromyography studies (EMG) of anal or urethral sphincter, other than needle, any technique\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n- Complex cystometrogram (ie, calibrated electronic equipment)\n- Cystography, minimum of 3 views, radiological supervision and interpretation\n- Voiding pressure studies, intra-abdominal (ie, rectal, gastric, intraperitoneal) (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Urgent desire to urinate\n\n### Drug\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2010-07-16, presumably until 2010-10-10, with quantity of 1.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-07-17 00:00:00, ended at 2010-07-17 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-11 09:47:37, ended at 2010-08-11 10:20:20\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-12 08:01:58, ended at 2010-08-12 08:56:35\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)\n\n### Condition\n- Disorder of muscle\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-08-21 00:00:00, ended at 2010-08-21 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cauda equina syndrome with neurogenic bladder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2010-08-21, presumably until 2010-09-23, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-21 08:03:27, ended at 2010-08-21 15:01:11\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Organic mental disorder\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2010-08-21, presumably until 2010-10-10, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily. Take 5mg (1/2 tab) daily for 4 weeks,  Then 10mg (1 tab) daily thereafter \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2010-08-21, presumably until 2010-12-19, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-09-23 00:00:00, ended at 2010-09-23 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cauda equina syndrome with neurogenic bladder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2010-09-23, presumably until 2010-12-19, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-10-10 14:43:06, ended at 2010-10-10 15:27:21\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Primary diagnosis: Vitamin B deficiency\n- Hyperplasia of prostate\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2010-10-10, presumably until 2010-11-11, with quantity of 1.0, with intended 0 refill(s). Instructions: 0.1 mL by Intramuscular route One Time. \n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-12-19, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- vitamin B12 1 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-11-11, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1000 mcg by mouth Every Day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-11 11:15:00, ended at 2010-11-11 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 3.6 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 71 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 127 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin B deficiency\n- Essential hypertension\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-12-18 09:47:21, ended at 2010-12-18 10:18:52\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of muscle\n- Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-12-19 00:00:00, ended at 2010-12-19 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Cauda equina syndrome with neurogenic bladder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Organic mental disorder\n- Valvular endocarditis\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- furosemide 20 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 81 mg by mouth Every Day. \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-15 10:40:34, ended at 2011-01-15 11:19:01\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Removal impacted cerumen requiring instrumentation, unilateral\n\n### Condition\n- Primary diagnosis: Otitis media\n\n### Drug\n- hydrocortisone 10 MG/ML / neomycin 3.5 MG/ML / polymyxin B 10000 UNT/ML Otic Suspension, through Otic route, started on 2011-01-15, presumably until 2011-01-28, with intended 0 refill(s). Instructions: 3 Drops by Right Ear route 4 times a day. \n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28, with quantity of 15.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed Ear pain \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-28 08:21:45, ended at 2011-01-28 08:56:09\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Essential hypertension\n- Primary diagnosis: Malaise\n- Otitis media\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-28 09:13:00, ended at 2011-01-28 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-02-02 00:00:00, ended at 2011-02-02 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Valvular endocarditis\n- Depressive disorder\n- Cauda equina syndrome with neurogenic bladder\n- Organic mental disorder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-05-01, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-12-09, with quantity of 180.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily. \n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2012-05-23, with quantity of 90.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-04-24, with quantity of 90.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily. \n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-08-28, with quantity of 90.0, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily. \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 81 mg by mouth Every Day. \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2012-02-02, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-04-24 00:00:00, ended at 2011-04-24 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2011-04-24, presumably until 2011-09-04, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-01 09:19:25, ended at 2011-05-01 10:07:04\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cauda equina syndrome with neurogenic bladder\n- Hyperlipidemia\n- Multi-infarct dementia, uncomplicated\n- Essential hypertension\n- Primary diagnosis: Mitral valve disorder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2011-05-01, presumably until 2011-09-04, with quantity of 180.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- imipramine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2011-05-01, presumably until 2011-07-06, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-01 10:37:00, ended at 2011-05-01 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 57 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 125 (thousand per microliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 2.4 (ratio)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.2 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.65 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 161 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.0 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Multi-infarct dementia, uncomplicated\n- Cauda equina syndrome with neurogenic bladder\n- Essential hypertension\n- Hyperlipidemia\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-06 12:50:00, ended at 2011-05-06 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-14 08:40:42, ended at 2011-05-14 09:49:40\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Primary diagnosis: Low compliance bladder\n- Incomplete emptying of bladder\n- Urgent desire to urinate\n- Increased frequency of urination\n- Nocturia\n\n### Drug\n- solifenacin succinate 5 MG Oral Tablet, through Oral route, started on 2011-05-14, presumably until 2011-09-04, with intended 4 refill(s). Instructions: take 5 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-07-06 00:00:00, ended at 2011-07-06 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Severe intellectual disability\n- Hyperlipidemia\n\n### Drug\n- imipramine hydrochloride 10 MG Oral Tablet, started on 2011-07-06, presumably until 2011-10-16, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-08-27 00:00:00, ended at 2011-08-27 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- escitalopram 10 MG Oral Tablet, started on 2011-08-27, presumably until 2012-12-12, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-04 08:37:07, ended at 2011-09-04 09:09:39\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Functional disorder of bladder\n- Mitral valve disorder\n- Multi-infarct dementia, uncomplicated\n- Vitamin B deficiency\n- Hyperlipidemia\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-08, with intended 1 refill(s). Instructions: take 5 mg by mouth daily.\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-10-16, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-04 09:30:00, ended at 2011-09-04 23:59:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 57 (milliliter per minute per square meter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.5 (percent)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 125 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Functional disorder of bladder\n- Vitamin B deficiency\n- Mitral valve disorder\n- Cauda equina syndrome with neurogenic bladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-09-08 00:00:00, ended at 2011-09-08 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Functional disorder of bladder\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-09-08, presumably until 2011-10-16, with intended 1 refill(s). Instructions: take 5 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-12 13:54:35, ended at 2011-10-12 14:19:48\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Mitral valve disorder\n- Ocular fistula causing hypotony of eye\n- Valvular endocarditis\n- Hyperlipidemia\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Glaucoma\n- Postprocedural blebitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-16 09:42:43, ended at 2011-10-16 14:43:48\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Essential hypertension\n- Functional disorder of bladder\n- Organic mental disorder\n- Hyperlipidemia\n- Neck pain\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-10-16, presumably until 2011-10-27, with intended 1 refill(s). Instructions: take 10 mg by mouth daily.\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2011-10-16, presumably until 2012-04-21, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-16 11:24:08, ended at 2011-10-16 16:50:01\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Functional disorder of bladder\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n- Osteoarthritis\n- Neck pain\n- Organic mental disorder\n- Mitral valve disorder\n- Hyperlipidemia\n- Essential hypertension\n- Valvular endocarditis\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-22 12:46:00, ended at 2011-10-22 23:59:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-27 10:56:51, ended at 2011-10-27 12:51:42\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Increased frequency of urination\n- Disorder of the peripheral nervous system\n- Urge incontinence of urine\n- Nocturia\n- Primary diagnosis: Functional disorder of bladder\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-10-27, presumably until 2012-05-23, with intended 11 refill(s). Instructions: take 10 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-11-09 00:00:00, ended at 2011-11-09 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Pre..., through Intramuscular route, started on 2011-11-09, presumably until 2011-11-10, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-12-09 00:00:00, ended at 2011-12-09 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-12-09, presumably until 2013-02-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-04-21 00:00:00, ended at 2012-04-21 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2012-04-21, presumably until 2015-04-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-13 14:45:04, ended at 2012-05-13 16:38:58\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-05-16 00:00:00, ended at 2012-05-16 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, started on 2012-05-16, presumably until 2013-12-14, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-05-19 00:00:00, ended at 2012-05-19 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-05-21 00:00:00, ended at 2012-05-21 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, started on 2012-05-21, presumably until 2012-05-21, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-05-23 00:00:00, ended at 2012-05-23 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Functional disorder of bladder\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2012-05-23, presumably until 2013-09-25, with intended 3 refill(s). Instructions: take 10 mg by mouth daily.\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2012-05-23, presumably until 2013-08-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-08 00:00:00, ended at 2012-06-08 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Hyperlipidemia\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-10 10:49:00, ended at 2012-06-10 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.7 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 97 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 43 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 72 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Multi-infarct dementia, uncomplicated\n- Hyperlipidemia\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-06-10 11:18:28, ended at 2012-06-10 11:54:11\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Benign neoplasm of colon\n- Hyperlipidemia\n- Essential hypertension\n- Mitral valve disorder\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-06-15 00:00:00, ended at 2012-06-15 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 420000 MG / potassium chloride 1480 MG / sodium bicarbonate 5720 MG / sodium chloride 11200 MG Powder for Oral Solution, through Oral route, started on 2012-06-15, presumably until 2012-11-07, with intended 0 refill(s). Instructions: take 420 g by mouth as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-06-22 00:00:00, ended at 2012-06-22 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- polyethylene glycol 3350 420000 MG / potassium chloride 1480 MG / sodium bicarbonate 5720 MG / sodium chloride 11200 MG Powder for Oral Solution, through Oral route, started on 2012-06-22, presumably until 2012-11-07, with intended 0 refill(s). Instructions: take 420 g by mouth as directed. Take split preparation as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-22 08:37:00, ended at 2012-06-22 13:47:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Colonoscopy, flexible; with directed submucosal injection(s), any substance\n- Injection or infusion of other therapeutic or prophylactic substance\n- Endoscopic polypectomy of large intestine\n\n### Condition\n- Benign neoplasm of colon\n- Diverticular disease of colon\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2012-06-22, presumably until 2012-06-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-07 09:35:03, ended at 2012-11-07 11:11:33\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n- Hyperlipidemia\n- Valvular endocarditis\n- Mitral valve disorder\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- 0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Pre..., through Intramuscular route, started on 2012-11-07, presumably until 2012-11-08, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-07 10:53:00, ended at 2012-11-07 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 103 (thousand per microliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperlipidemia\n- Valvular endocarditis\n- Essential hypertension\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2012-11-16 00:00:00, ended at 2012-11-16 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simethicone 66.7 MG/ML Oral Suspension, through Oral route, started on 2012-11-16, presumably until 2012-11-16\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2012-11-16, presumably until 2012-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-16 06:40:00, ended at 2012-11-16 09:53:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Colonoscopy, flexible; with biopsy, single or multiple\n- Endoscopic polypectomy of large intestine\n\n### Condition\n- Benign neoplasm of colon\n- Cerebral atherosclerosis\n- Mitral valve disorder\n- Vitamin B deficiency\n- Benign prostatic hyperplasia with outflow obstruction\n- Hyperlipidemia\n- Essential hypertension\n- Multi-infarct dementia, uncomplicated\n- Disorder of muscle\n- Functional disorder of bladder\n- Depressive disorder\n- Diverticular disease of colon\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2012-11-16, presumably until 2012-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-11-17 00:00:00, ended at 2012-11-17 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-05 09:00:00, ended at 2012-12-05 10:27:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- Genetic counseling\n- Collection of venous blood by venipuncture\n- Chromosome analysis, cytogenetic procedure AND/OR molecular biology method\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-12-12 13:04:25, ended at 2012-12-12 13:50:15\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Valvular endocarditis\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2013-02-23. Instructions: take  by mouth Every Day.  \n- escitalopram 20 MG Oral Tablet, through Oral route, presumably until 2013-02-28. Instructions: take  by mouth Every Day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-03 11:00:00, ended at 2013-01-03 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-01-05 00:00:00, ended at 2013-01-05 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-02-22 00:00:00, ended at 2013-02-22 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 20 MG Oral Tablet, started on 2013-02-22, presumably until 2014-04-26, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-02-27 00:00:00, ended at 2013-02-27 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2013-02-27, presumably until 2013-02-27. Instructions: take  by mouth Every Day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-02-28 00:00:00, ended at 2013-02-28 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2013-02-28, presumably until 2014-01-04, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-13 10:00:00, ended at 2013-03-13 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Genetic counseling\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-21 09:57:43, ended at 2013-03-21 10:47:17\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Seborrheic dermatitis\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n- Mitral valve disorder\n\n### Drug\n- ketoconazole 20 MG/ML Topical Cream, started on 2013-03-21, presumably until 2013-05-27, with intended 1 refill(s). Instructions: apply bid\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-05-27 00:00:00, ended at 2013-05-27 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ketoconazole 20 MG/ML Topical Cream, started on 2013-05-27, presumably until 2015-04-25, with intended 6 refill(s). Instructions: APPLY TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-08-25 00:00:00, ended at 2013-08-25 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 20 MG Oral Tablet, started on 2013-08-25, presumably until 2014-01-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-09-25 00:00:00, ended at 2013-09-25 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, started on 2013-09-25, presumably until 2014-01-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-30 11:11:18, ended at 2013-10-30 11:41:54\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- General examination of patient\n\n### Condition\n- Hyperlipidemia\n- Primary diagnosis: Mitral valve disorder\n- Essential hypertension\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Multi-infarct dementia, uncomplicated\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-30 11:46:00, ended at 2013-10-30 23:59:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Platelets [#/volume] in Blood by Automated count: 121 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 36 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 75 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.9 (ratio)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 36 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.98 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 137 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 97 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.2 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Hyperlipidemia\n- Osteoarthritis\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Mitral valve disorder\n- Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-31 12:28:00, ended at 2013-10-31 23:59:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-14 00:00:00, ended at 2013-12-14 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-19 00:00:00, ended at 2013-12-19 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2015-04-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2015-04-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2015-02-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2014-03-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- donepezil hydrochloride 10 MG Oral Tablet, started on 2013-12-19, presumably until 2015-04-19, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-26 10:37:42, ended at 2014-03-26 11:16:47\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Multi-infarct dementia, uncomplicated\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n- Primary diagnosis: Osteoarthritis\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, through Oral route, started on 2014-03-26, presumably until 2015-04-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-04-18 00:00:00, ended at 2014-04-18 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simethicone 66.7 MG/ML Oral Suspension, through Oral route, started on 2014-04-18, presumably until 2014-04-18\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2014-04-18, presumably until 2014-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-18 06:32:00, ended at 2014-04-18 09:16:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.5\" (inch (US))\n\n### Procedure\n- Endoscopic polypectomy of large intestine\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- [Endoscopic] polypectomy of rectum\n- Colonoscopy, flexible; with biopsy, single or multiple\n\n### Condition\n- Dementia\n- Benign neoplasm of colon\n- Depressive disorder\n- Essential hypertension\n- Benign neoplasm of rectum and anal canal\n- Diverticular disease of colon\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2014-04-18, presumably until 2014-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-04-26 00:00:00, ended at 2014-04-26 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 20 MG Oral Tablet, started on 2014-04-26, presumably until 2015-04-19, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-02-07 00:00:00, ended at 2015-02-07 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- escitalopram 10 MG Oral Tablet, started on 2015-02-07, presumably until 2015-02-11, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-02-11 00:00:00, ended at 2015-02-11 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2015-02-11, presumably until 2015-04-25, with intended 12 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-14 00:00:00, ended at 2015-04-14 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Primary diagnosis: Essential hypertension\n- Hyperlipidemia\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, started on 2015-04-14, presumably until 2015-04-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- lisinopril 40 MG Oral Tablet, started on 2015-04-14, presumably until 2015-04-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- atorvastatin 80 MG Oral Tablet, started on 2015-04-14, presumably until 2015-04-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-19 15:19:22, ended at 2015-04-19 16:15:51\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Hyperlipidemia\n- Primary diagnosis: Mitral valve disorder\n- Essential hypertension\n- Benign neoplasm of colon\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2015-04-29, with intended 12 refill(s). Instructions: take 1 Tab by mouth daily.\n- 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumo..., through Intramuscular route, started on 2015-04-19, presumably until 2015-04-20, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2015-04-25, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-19 16:46:00, ended at 2015-04-19 23:59:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Late effects of cerebrovascular disease\n- Acute upper respiratory infection\n- Mitral valve disorder\n- Essential hypertension\n- Hyperlipidemia\n- Amnesia\n- Cough\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-23 10:00:00, ended at 2015-04-23 23:59:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-04-24 00:00:00, ended at 2015-04-24 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute renal failure syndrome\n- Polycythemia vera (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2015-04-25 14:12:00, ended at 2015-04-25 18:12:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.5 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 16.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Potassium [Moles/volume] in Blood: 6.8 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 78 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 143 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: 1.16 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.2 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.25 (million per microliter)\n- Glucose [Mass/volume] in Blood: 67 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Prothrombin time (PT): 13.7 (second)\n- Sodium [Moles/volume] in Blood: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.0 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Radiologic examination, chest; single view, frontal\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Altered mental status\n- Lung field abnormal\n- Primary diagnosis: Dehydration\n- Depressive disorder\n- Malaise\n- Benign prostatic hyperplasia without outflow obstruction\n- Essential hypertension\n- Dementia\n- Hypoglycemia\n- Syncope and collapse\n- Hyperlipidemia\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 10 mg by mouth every morning\n- solifenacin succinate 5 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- atorvastatin 20 MG Oral Tablet, through Oral route, presumably until 2015-05-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2015-04-25, presumably until 2015-04-25\n- escitalopram 20 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- vitamin B12 1 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-29 11:10:50, ended at 2015-04-29 11:37:23\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Body height: 5' 7.5\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 53 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Primary diagnosis: Syncope and collapse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-29 15:56:00, ended at 2015-04-29 23:59:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hyperlipidemia\n- Essential hypertension\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-05-10 00:00:00, ended at 2015-05-10 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, started on 2015-05-10, presumably until 2015-05-10, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2015-05-10, presumably until 2015-12-02, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-24 09:32:14, ended at 2015-05-24 10:45:40\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External ocular photography with interpretation and report for documentation of medical progress (eg, close-up photography, slit lamp photography, goniophotography, stereo-photography)\n\n### Condition\n- Primary diagnosis: Excess skin of eyelid\n- Ptosis of eyelid\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take by mouth\n- dexamethasone 0.001 MG/MG / neomycin 0.0035 MG/MG / polymyxin B 10 UNT/MG Ophthalmic Ointment, through Intraocular route, started on 2015-05-24, presumably until 2015-07-31, with intended 0 refill(s). Instructions: instill to both eyes 3 times a day Apply ointment to eyelids three times per day. It is ok if ointment gets in the eyes.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-03 14:34:47, ended at 2015-06-03 16:04:22\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 15 (millimeter mercury column)\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Excess skin of eyelid\n- Ptosis of eyelid\n- Disorder of eyelid\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-06 14:09:37, ended at 2015-06-06 14:43:22\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pre-surgery evaluation\n\n### Condition\n- Disorder of eyelid\n- Chronic kidney disease stage 3\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2015-10-14, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning\n- solifenacin succinate 5 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2016-07-01, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2015-10-11, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2017-04-28, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-07 14:27:28, ended at 2015-06-07 15:53:16\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-12 15:08:10, ended at 2015-07-12 15:49:43\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-17 00:00:00, ended at 2015-07-17 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on eye; not otherwise specified\n\n### Condition\n- Ptosis of eyelid\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-07-17, presumably until 2015-07-17\n- midazolam 1 MG/ML Injectable Solution, started on 2015-07-17, presumably until 2015-07-17\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2015-07-17, presumably until 2015-07-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-17 00:00:00, ended at 2015-07-17 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2015-07-17, presumably until 2015-11-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-07-17 00:00:00, ended at 2015-07-17 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2015-07-17, presumably until 2015-07-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-17 07:27:00, ended at 2015-07-17 13:46:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Blepharoplasty, upper eyelid; with excessive skin weighting down lid\n- Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)\n- Rhytidectomy of upper eyelid\n- Canthoplasty (reconstruction of canthus)\n- Other adjustment of lid position\n\n### Condition\n- Excess skin of eyelid\n- Hyperlipidemia\n- Multi-infarct dementia, uncomplicated\n- Mitral valve disorder\n- Disorder of eyelid\n- Polycythemia vera (clinical)\n- Benign hypertensive renal disease with renal failure\n- Chronic kidney disease\n- Cerebral atherosclerosis\n- Primary diagnosis: Ptosis of eyelid\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-07-17, presumably until 2015-07-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-07-31 00:00:00, ended at 2015-07-31 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- dexamethasone 0.001 MG/MG / neomycin 0.0035 MG/MG / polymyxin B 10 UNT/MG Ophthalmic Ointment, through Intraocular route, started on 2015-08-01, presumably until 2015-11-29, with intended 2 refill(s). Instructions: instill to both eyes 3 times a day Apply ointment to eyelids three times per day. It is ok if ointment gets in the eyes.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-07 11:14:42, ended at 2015-08-07 12:34:17\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-30 15:24:21, ended at 2015-08-30 16:09:27\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-10-11 00:00:00, ended at 2015-10-11 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lisinopril 40 MG Oral Tablet, started on 2015-10-14, presumably until 2016-05-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- escitalopram 20 MG Oral Tablet, started on 2015-10-14, presumably until 2016-04-06, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-15 10:49:44, ended at 2015-11-15 11:33:52\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-29 14:53:29, ended at 2015-11-29 16:03:38\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Valvular endocarditis\n- Essential hypertension\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n- Polyp of colon\n- Secondary polycythemia\n- Vitamin B deficiency\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2015-12-02, presumably until 2016-03-20, with intended 12 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-12-02 00:00:00, ended at 2015-12-02 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-01-06 13:00:00, ended at 2016-01-06 23:59:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Non-rheumatic mitral valve disease\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-06 13:36:35, ended at 2016-01-06 16:11:43\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Essential hypertension\n- Primary diagnosis: Valvular endocarditis\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, through Oral route, presumably until 2016-09-11, with intended 0 refill(s). Instructions: take 500 mg by mouth as directed One gram prior to dental procedures\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-28 13:29:07, ended at 2016-01-28 14:13:13\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.709\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n- Hematuria syndrome\n- Urinary tract infectious disease\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2016-01-28, presumably until 2016-02-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-01-28 14:21:00, ended at 2016-01-28 23:59:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 11 - 20 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.36 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 79 (picogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 118 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Urine: 354.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.9 (percent)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 18 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 44 (nanogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.15 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 16.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.5 (percent)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 44 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-02-03 17:33:00, ended at 2016-02-03 21:38:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, head or brain; without contrast material\n- Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less\n- Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.6 cm to 7.5 cm\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Benign prostatic hyperplasia\n- Laceration of wrist\n- Contusion of head\n- Dementia\n- Disorder of brain\n- Essential hypertension\n- Hyperlipidemia\n- Laceration of forearm\n- Primary diagnosis: Injury of head\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-02-03, presumably until 2016-02-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-07 14:13:59, ended at 2016-02-07 14:50:18\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyp of colon\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-03-03 00:00:00, ended at 2016-03-03 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-10 11:18:00, ended at 2016-03-10 23:59:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 44 (picogram per milliliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Creatinine [Mass/volume] in Urine: 198.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.2 (percent)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.1 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 14 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 95 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-10 11:20:15, ended at 2016-03-10 11:50:03\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.71\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-19 00:00:00, ended at 2016-03-19 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, started on 2016-03-20, presumably until 2017-05-04, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-04-03 00:00:00, ended at 2016-04-03 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of eyelid\n- Chronic kidney disease stage 3\n\n### Drug\n- escitalopram 20 MG Oral Tablet, started on 2016-04-06, presumably until 2017-06-12, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-23 00:00:00, ended at 2016-04-23 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-21 13:43:36, ended at 2016-05-21 14:20:03\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Vascular dementia without behavioral disturbance\n- Hyperlipidemia\n- Primary diagnosis: Cerebral infarction\n\n### Drug\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-05-21, presumably until 2016-05-26, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime 1 PO BID\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-25 00:00:00, ended at 2016-05-25 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, started on 2016-05-25, presumably until 2017-05-31, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-09-11, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-02 00:00:00, ended at 2016-06-02 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-09 10:36:55, ended at 2016-06-09 11:20:54\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-09 11:28:00, ended at 2016-06-09 23:59:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.27 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 138.40 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-12 10:38:00, ended at 2016-06-12 23:59:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n\n### Condition\n- Chronic kidney disease stage 3\n- Benign prostatic hyperplasia\n- Disorder of bladder\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-30 00:00:00, ended at 2016-06-30 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, started on 2016-07-01, presumably until 2017-01-08, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-08 00:00:00, ended at 2016-07-08 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperlipidemia\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Polyp of colon\n- Cerebral infarction\n- Essential hypertension\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, started on 2016-07-08, presumably until 2016-09-11, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH AT BEDTIME.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-11 00:00:00, ended at 2016-09-11 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyp of colon\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2016-09-11, presumably until 2016-09-11, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-11 13:21:19, ended at 2016-09-11 14:00:11\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fatigue\n- Primary diagnosis: Overactive bladder\n- Malaise\n- Vitamin B deficiency\n- Vascular dementia without behavioral disturbance\n\n### Drug\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-09-11, presumably until 2016-09-21, with intended 12 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-09-20 20:02:00, ended at 2016-09-21 12:43:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.12 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Base excess in Blood by calculation: 2 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 115 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.59 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.31 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or o\n- Computed tomography, head or brain; without contrast material\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation\n- Medical team conference with interdisciplinary team of health care professionals, face-to-face with patient and/or family, 30 minutes or more, participation by nonphysician qualified health care professional\n- Radiologic examination, chest; single view, frontal\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n\n### Condition\n- Disorientated\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Heart failure\n- Major depression, single episode\n- Vitamin B deficiency\n- Chronic kidney disease due to hypertension\n- Chronic kidney disease stage 3\n- Imaging of brain abnormal\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n- Benign prostatic hyperplasia\n- Overactive bladder\n- Altered mental status\n- Malaise\n- Dementia\n- Fatigue\n- Hyperlipidemia\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-10-02, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-09-29 00:00:00, ended at 2016-09-29 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin B deficiency\n- Malaise\n- Overactive bladder\n- Fatigue\n- Primary diagnosis: Chronic kidney disease stage 3\n- Vascular dementia without behavioral disturbance\n\n### Drug\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-10-02, presumably until 2016-10-02, with intended 12 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-06 08:28:07, ended at 2016-10-06 10:15:32\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Cerebral infarction\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-07 12:36:20, ended at 2016-10-07 14:21:11\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.71\" (inch (US))\n\n### Procedure\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Nocturia\n- Poor stream of urine\n- Delay when starting to pass urine\n- Primary diagnosis: Benign prostatic hyperplasia\n- Urgent desire to urinate\n- Erectile dysfunction\n- Finding of frequency of urination\n- Splitting of urinary stream\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2016-10-07, presumably until 2017-04-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-10-12 00:00:00, ended at 2016-10-12 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-27 13:50:00, ended at 2016-10-27 23:59:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.17 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 152.93 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Platelets [#/volume] in Blood by Automated count: 114 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.00 (million per microliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 6 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Vascular dementia without behavioral disturbance\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Urinary tract infectious disease\n- Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-27 14:09:06, ended at 2016-10-27 14:47:25\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-08 12:34:59, ended at 2016-12-08 13:48:47\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye:  18 (millimeter mercury column)\n- Intraocular pressure of left eye: 17 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Senile cataract\n- Primary diagnosis: Dermatosis of eyelid\n- Pterygium\n- Cataract\n- Vitreous hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-23 08:43:11, ended at 2016-12-23 11:11:35\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 13 (millimeter mercury column)\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Nuclear senile cataract\n- Senile cataract\n- Primary diagnosis: Vitreous hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-06 00:00:00, ended at 2017-01-06 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-08 16:02:10, ended at 2017-01-08 16:55:18\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n- Impaired glucose tolerance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-01 00:00:00, ended at 2017-03-01 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-02 09:23:51, ended at 2017-03-02 12:22:47\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vascular dementia without behavioral disturbance\n- Hyperlipidemia\n- Major depression, single episode\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-02 10:23:47, ended at 2017-03-02 11:00:43\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Chronic kidney disease stage 3\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Hyperlipidemia\n- Vascular dementia without behavioral disturbance\n- Major depression, single episode\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-09 10:41:08, ended at 2017-03-09 12:40:42\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 15 (millimeter mercury column)\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n\n### Procedure\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Vitreous hemorrhage\n- Senile cataract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-15 09:29:18, ended at 2017-04-15 13:18:22\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computerized corneal topography, unilateral or bilateral, with interpretation and report\n\n### Condition\n- Primary diagnosis: Senile cataract\n\n### Drug\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2017-04-15, presumably until 2017-07-13, with intended 3 refill(s). Instructions: instill 1 Drop to right eye 4 times a day Start AFTER surgery\n- gatifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-15, presumably until 2017-06-07, with intended 2 refill(s). Instructions: instill 1 Drop to right eye 4 times a day Start 3 days BEFORE surgery; OK to substitute other fluoroquinolone if not covered by insurance\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-15, presumably until 2017-06-07, with intended 2 refill(s). Instructions: instill 1 Drop to right eye 4 times a day Start AFTER surgery; OK to substitute other NSAID if not covered by insurance\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-15 09:30:09, ended at 2017-04-15 13:40:53\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-15 09:30:40, ended at 2017-04-15 13:51:06\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation\n\n### Condition\n- Senile cataract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-04-28 00:00:00, ended at 2017-04-28 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- chondroitin sulfates, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- chondroitin 4-sulfate, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- 1.5 ML carbachol 0.1 MG/ML Injection, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-04-28, presumably until 2017-04-28\n- cefazolin 1000 MG Injection, started on 2017-04-28, presumably until 2017-04-28\n- calcium chloride 0.004 MEQ/ML / magnesium chloride 0.003 MEQ/ML / potassium chloride 0.01 MEQ/ML / sodium acetate 0.0475 MEQ/ML / sodium chloride 0.109 MEQ/ML / sodium citrate 0.012 MEQ/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- sodium chloride 9 MG/ML Injection, started on 2017-04-28, presumably until 2017-04-28\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-28, presumably until 2017-04-28\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-04-28, presumably until 2017-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-28 08:20:00, ended at 2017-04-28 10:55:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Replacement of Right Lens with Synthetic Substitute, Percutaneous Approach\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n\n### Condition\n- Chronic kidney disease due to hypertension\n- Chronic kidney disease stage 3\n- Hyperlipidemia\n- Nuclear senile cataract\n- Vascular dementia without behavioral disturbance\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Senile cataract\n\n### Drug\n- tropicamide 10 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- gatifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-28, presumably until 2017-04-28\n- phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-05-04 00:00:00, ended at 2017-05-04 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, started on 2017-05-05, presumably until 2017-06-07, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-05-17 00:00:00, ended at 2017-05-17 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- chondroitin sulfates, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- chondroitin 4-sulfate, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- 1.5 ML carbachol 0.1 MG/ML Injection, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-05-17, presumably until 2017-05-17\n- cefazolin 1000 MG Injection, started on 2017-05-17, presumably until 2017-05-17\n- calcium chloride 0.004 MEQ/ML / magnesium chloride 0.003 MEQ/ML / potassium chloride 0.01 MEQ/ML / sodium acetate 0.0475 MEQ/ML / sodium chloride 0.109 MEQ/ML / sodium citrate 0.012 MEQ/ML Ophthalmic Solution, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- sodium chloride 9 MG/ML Injection, started on 2017-05-17, presumably until 2017-05-17\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2017-05-17, presumably until 2017-05-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-05-17, presumably until 2017-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-17 12:35:00, ended at 2017-05-17 16:32:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n- Replacement of Left Lens with Synthetic Substitute, Percutaneous Approach\n\n### Condition\n- Hyperlipidemia\n- Dementia\n- Chronic kidney disease stage 3\n- Chronic kidney disease due to hypertension\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Cataract\n- Heart failure\n- Nuclear senile cataract\n- Vitreous hemorrhage\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-05-17, presumably until 2017-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-18 09:40:42, ended at 2017-05-18 15:45:39\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 16 (millimeter mercury column)\n- Intraocular pressure of left eye: 26 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-28 00:00:00, ended at 2017-05-28 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Unsteady when standing\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-05-31 00:00:00, ended at 2017-05-31 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, started on 2017-06-02, presumably until 2017-06-02, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-07 11:40:00, ended at 2017-06-07 23:59:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Essential hypertension\n- Hyperlipidemia\n- Infective endocarditis\n- Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-07 12:55:36, ended at 2017-06-07 13:31:15\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n- Infective endocarditis\n- Essential hypertension\n- Hyperlipidemia\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, presumably until 2017-11-12, with intended 0 refill(s). Instructions: take by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-12 00:00:00, ended at 2017-06-12 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of eyelid\n- Chronic kidney disease stage 3\n\n### Drug\n- escitalopram 20 MG Oral Tablet, started on 2017-06-14, presumably until 2017-06-14, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-17 10:27:02, ended at 2017-06-17 12:03:58\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of left eye: 14 (millimeter mercury column)\n- Intraocular pressure of right eye: unab (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-25 12:37:17, ended at 2017-06-25 12:47:33\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute bronchitis\n\n### Drug\n- doxycycline hyclate 100 MG Oral Capsule, through Oral route, started on 2017-06-25, presumably until 2017-07-02, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-25 12:55:00, ended at 2017-06-25 23:59:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Acute bronchitis\n- Cough\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-03 18:32:25, ended at 2017-07-03 19:31:05\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 170 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.93 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- MCV [Entitic volume] by Automated count: 93.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 203 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 159 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.79 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Primary diagnosis: Loss of appetite\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-04 00:00:00, ended at 2017-07-04 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2009-10-24 12:43:00, ended at 2009-10-24 16:36:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.2 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 100 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.76 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 201 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.3 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Globulin [Mass/volume] in Serum: 5.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 11.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Base excess in Blood by calculation: 2.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, spine, cervical; 2 or 3 views\n\n### Condition\n- Degeneration of cervical intervertebral disc\n- Malaise\n- Neck pain\n- Torticollis\n\n### Drug\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-10-24, presumably until 2009-10-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-11-28 00:00:00, ended at 2009-11-28 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Musculoskeletal symptom\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-11-28 15:05:35, ended at 2009-11-28 16:21:45\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary diagnosis: Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-29 10:15:00, ended at 2009-11-29 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 7.5 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 111 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 2.5 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.76 (micro-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 98 (millimeter per hour)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 565 (picogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-12-02 00:00:00, ended at 2009-12-02 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polymyalgia rheumatica\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2009-12-02, presumably until 2009-12-10, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-12-03 00:00:00, ended at 2009-12-03 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-03 09:48:00, ended at 2009-12-03 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Malaise\n- Thoracic spondylosis without myelopathy\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Myelopathy due to cervical spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-04 10:11:00, ended at 2009-12-04 15:19:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Cerebrovascular disease\n- Disorder of basilar artery\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Degeneration of intervertebral disc\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-04 12:17:43, ended at 2009-12-04 16:44:22\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-12-04 15:00:00, ended at 2009-12-04 15:19:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-12-04 15:20:00, ended at 2009-12-12 13:38:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Triglyceride [Moles/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 23 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 208 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Body height: 5' 7.992\" (inch (US))\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Complement C3 [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.87 (million per microliter)\n- Prothrombin time (PT): 15.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 40.5 (second)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 11 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 9.1 (microgram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 80 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 86 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.83 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.43 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 194 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Venous catheterization, not elsewhere classified\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, chest; single view, frontal\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- General examination of patient\n\n### Condition\n- Cerebral infarction due to embolism of cerebral arteries\n- Weakness of face muscles\n- Acute and subacute bacterial endocarditis\n- Anemia\n- Cerebral atherosclerosis\n- Malaise\n- Cervical spondylosis without myelopathy\n- Neck sprain\n- Abnormal findings on diagnostic imaging of skull and head\n- Benign neoplasm of colon\n- Cyst and pseudocyst of pancreas\n- Polymyalgia rheumatica\n- Septic embolus of artery\n- Valvular endocarditis\n- Late effects of cerebrovascular disease\n- Thoracic spondylosis without myelopathy\n- Tricuspid valve disorder\n- Cerebrovascular disease\n- Mitral valve disorder\n- Sepsis due to Streptococcus group D\n- Cardiac arrhythmia\n\n### Drug\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2009-12-09, presumably until 2009-12-09\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2009-12-12\n- ampicillin 2000 MG Injection, started on 2009-12-10, presumably until 2010-01-17, with quantity of 1.0, with intended 0 refill(s). Instructions: 2000 mg by Injection route every 4 hours. \n- vancomycin 1000 MG Injection, through Intravenous route, started on 2009-12-07, presumably until 2009-12-09\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2009-12-11, presumably until 2009-12-11\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2009-12-11, presumably until 2010-03-18, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-12-07, presumably until 2009-12-07\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2009-12-09, presumably until 2009-12-09\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-12-04, presumably until 2009-12-11\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2009-12-11\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-12-12, presumably until 2010-01-20, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. To help with constipation - if diarrhea, please stop. \n- prednisone 1 MG Oral Tablet, through Oral route, started on 2009-12-10, presumably until 2009-12-12, with quantity of 3.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily. \n- prednisone 5 MG Oral Tablet, through Oral route, started on 2009-12-05, presumably until 2009-12-09\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2009-12-10, presumably until 2009-12-11\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2009-12-04, presumably until 2009-12-07\n- 50 ML gentamicin 1.2 MG/ML Injection, through Intravenous route, started on 2009-12-10, presumably until 2010-01-17, with quantity of 1.0, with intended 0 refill(s). Instructions: 60 mg by Intravenous route every 8 hours. \n- 6 ML gentamicin 10 MG/ML Injection, through Intravenous route, started on 2009-12-06, presumably until 2009-12-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2009-12-09\n- nafcillin 2000 MG Injection, through Intravenous route, started on 2009-12-06, presumably until 2009-12-07\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-12-04, presumably until 2010-01-02, with quantity of 45.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed \n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2009-12-09, presumably until 2009-12-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-12-20 00:00:00, ended at 2009-12-20 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-25 09:45:00, ended at 2009-12-25 10:30:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, head or brain; without contrast material\n\n### Condition\n- Cerebral ischemia\n- Diffuse cerebrovascular disease\n- Abnormal findings on diagnostic imaging of skull and head\n- Cerebrovascular disease\n- Cerebral infarction due to embolism of cerebral arteries\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-25 10:31:00, ended at 2009-12-25 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Cerebral infarction due to embolism of cerebral arteries\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-30 12:49:06, ended at 2009-12-30 17:02:47\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-02 14:02:04, ended at 2010-01-02 15:16:57\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Valvular endocarditis\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, through Oral route, started on 2010-01-02, presumably until 2010-04-11, with quantity of 16.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day. Take 4 tabs 1 hour before dental work \n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., through Subcutaneous route, started on 2010-01-02, presumably until 2010-01-03, with quantity of 1.0, with intended 0 refill(s). Instructions: 0.5 mL by SUBCUTANEOUS route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-02 15:26:00, ended at 2010-01-02 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 176 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.2 (percent)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 48 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n\n### Procedure\n- Other puncture of vein\n- Prophylactic administration of vaccine against other diseases\n- Other interview and evaluation\n\n### Condition\n- Acute and subacute bacterial endocarditis\n- Streptococcus pyogenes infection\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-20 13:17:08, ended at 2010-01-20 14:10:23\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Valvular endocarditis\n\n### Drug\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2010-01-20, presumably until 2010-03-18, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2010-01-20, presumably until 2010-03-18, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-22 08:39:11, ended at 2010-01-22 10:45:36\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-22 09:59:00, ended at 2010-01-22 09:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 61 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.1 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.57 (thousand per microliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 120 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 51 (millimeter per hour)\n- Platelets [#/volume] in Blood by Automated count: 159 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-03 08:27:00, ended at 2010-02-03 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Essential hypertension\n- Finding of head and neck region\n- Cerebral ischemia\n- Swelling / lump finding\n- Diffuse cerebrovascular disease\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-02-03 11:55:44, ended at 2010-02-03 15:43:26\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-12 13:27:00, ended at 2010-02-12 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-03-18 11:13:22, ended at 2010-03-18 12:15:47\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Neck pain\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2010-03-18, presumably until 2010-12-19, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- 0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection, through Subcutaneous route, started on 2010-03-18, presumably until 2010-03-19, with quantity of 1.0, with intended 0 refill(s). Instructions: 0.65 mL by SUBCUTANEOUS route One Time. \n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2010-03-18, presumably until 2010-12-19, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2010-03-18, presumably until 2010-12-19, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-18 12:23:00, ended at 2010-03-18 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 163 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocyte sedimentation rate: 41 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 43 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 77 (milligram per deciliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 2.5 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 69 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 58 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Neck pain\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-21 08:46:00, ended at 2010-03-21 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n\n### Condition\n- Exostosis\n- Displacement of cervical intervertebral disc without myelopathy\n- Spinal stenosis in cervical region\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-03-24 00:00:00, ended at 2010-03-24 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-04-04 00:00:00, ended at 2010-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-04 08:01:38, ended at 2010-04-04 15:38:10\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-04 09:55:00, ended at 2010-04-04 10:48:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.02 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 136 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.17 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.98 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-04 10:49:00, ended at 2010-04-04 23:59:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-04-10 00:00:00, ended at 2010-04-10 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-11 13:11:49, ended at 2010-04-11 14:13:20\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Mitral valve disorder\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2010-04-11, presumably until 2010-04-12, with intended 0 refill(s). Instructions: 0.5 mL by Intramuscular route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-11 14:59:10, ended at 2010-04-11 16:21:15\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Primary diagnosis: Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-22 14:55:28, ended at 2010-04-22 15:37:04\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Primary diagnosis: Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-02 00:00:00, ended at 2010-05-02 00:00:00\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Disorder of muscle\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-02 13:36:09, ended at 2010-05-02 14:07:09\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Disorder of muscle\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-06 08:01:09, ended at 2010-05-06 08:49:22\nThe patient in this visit was 76 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-06-11 14:18:11, ended at 2010-06-11 14:42:43\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-06-17 08:10:39, ended at 2010-06-17 09:20:05\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 3 or more muscles\n\n### Condition\n- Primary diagnosis: Neck pain\n- Disorder of muscle\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, started on 2010-06-17, presumably until 2010-06-18, with quantity of 1.0, with intended 0 refill(s). Instructions: 100 Units by Injection route One Time. \n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2010-06-17, presumably until 2010-06-18, with quantity of 1.0, with intended 0 refill(s). Instructions: 20 mL by Injection route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-07-04 13:16:52, ended at 2010-07-04 14:17:26\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urgent desire to urinate\n- Hyperplasia of prostate\n- Multi-infarct dementia, uncomplicated\n- Essential hypertension\n- Hyperlipidemia\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Mitral valve disorder\n- Neck pain\n- Osteoarthritis\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2010-07-04, presumably until 2010-10-10, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Cap by mouth daily. \n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-07-04, presumably until 2010-08-21, with quantity of 30.0, with intended 6 refill(s). Instructions: take 5 mg by mouth Every Day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-04 14:24:00, ended at 2010-07-04 14:34:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 239 (picogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.63 (micro-international unit per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-04 14:35:00, ended at 2010-07-04 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urgent desire to urinate\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-08 15:47:00, ended at 2010-07-08 15:47:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 3.2 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign prostatic hyperplasia with outflow obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-08 15:48:00, ended at 2010-07-08 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal urination\n- Benign prostatic hyperplasia with outflow obstruction\n- Nodular prostate without urinary obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-09 08:57:00, ended at 2010-07-09 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-16 10:34:00, ended at 2010-07-16 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy, prostate; needle or punch, single or multiple, any approach\n- Ultrasound, transrectal\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Nodular prostate without urinary obstruction\n- Urgent desire to urinate\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-07-16, presumably until 2010-07-16\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2010-07-16, presumably until 2010-07-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-07-16 12:33:00, ended at 2010-07-16 15:24:49\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure) and urethral pressure profile studies (ie, urethral closure pressure profile), any technique\n- Bladder irrigation, simple, lavage and/or instillation\n- Electromyography studies (EMG) of anal or urethral sphincter, other than needle, any technique\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n- Complex cystometrogram (ie, calibrated electronic equipment)\n- Cystography, minimum of 3 views, radiological supervision and interpretation\n- Voiding pressure studies, intra-abdominal (ie, rectal, gastric, intraperitoneal) (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Urgent desire to urinate\n\n### Drug\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2010-07-16, presumably until 2010-10-10, with quantity of 1.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-07-17 00:00:00, ended at 2010-07-17 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-11 09:47:37, ended at 2010-08-11 10:20:20\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of muscle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-12 08:01:58, ended at 2010-08-12 08:56:35\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)\n\n### Condition\n- Disorder of muscle\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-08-21 00:00:00, ended at 2010-08-21 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cauda equina syndrome with neurogenic bladder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2010-08-21, presumably until 2010-09-23, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-21 08:03:27, ended at 2010-08-21 15:01:11\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Organic mental disorder\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2010-08-21, presumably until 2010-10-10, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily. Take 5mg (1/2 tab) daily for 4 weeks,  Then 10mg (1 tab) daily thereafter \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2010-08-21, presumably until 2010-12-19, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-09-23 00:00:00, ended at 2010-09-23 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cauda equina syndrome with neurogenic bladder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2010-09-23, presumably until 2010-12-19, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-10-10 14:43:06, ended at 2010-10-10 15:27:21\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Primary diagnosis: Vitamin B deficiency\n- Hyperplasia of prostate\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2010-10-10, presumably until 2010-11-11, with quantity of 1.0, with intended 0 refill(s). Instructions: 0.1 mL by Intramuscular route One Time. \n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-12-19, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- vitamin B12 1 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-11-11, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1000 mcg by mouth Every Day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-11 11:15:00, ended at 2010-11-11 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 3.6 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 71 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 127 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin B deficiency\n- Essential hypertension\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-12-18 09:47:21, ended at 2010-12-18 10:18:52\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of muscle\n- Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-12-19 00:00:00, ended at 2010-12-19 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Cauda equina syndrome with neurogenic bladder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Organic mental disorder\n- Valvular endocarditis\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- furosemide 20 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 81 mg by mouth Every Day. \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2011-02-02, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-15 10:40:34, ended at 2011-01-15 11:19:01\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Removal impacted cerumen requiring instrumentation, unilateral\n\n### Condition\n- Primary diagnosis: Otitis media\n\n### Drug\n- hydrocortisone 10 MG/ML / neomycin 3.5 MG/ML / polymyxin B 10000 UNT/ML Otic Suspension, through Otic route, started on 2011-01-15, presumably until 2011-01-28, with intended 0 refill(s). Instructions: 3 Drops by Right Ear route 4 times a day. \n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28, with quantity of 15.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed Ear pain \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-28 08:21:45, ended at 2011-01-28 08:56:09\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Essential hypertension\n- Primary diagnosis: Malaise\n- Otitis media\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-28 09:13:00, ended at 2011-01-28 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-02-02 00:00:00, ended at 2011-02-02 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Valvular endocarditis\n- Depressive disorder\n- Cauda equina syndrome with neurogenic bladder\n- Organic mental disorder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-05-01, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-12-09, with quantity of 180.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily. \n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2012-05-23, with quantity of 90.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily. \n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-04-24, with quantity of 90.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily. \n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-08-28, with quantity of 90.0, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily. \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2011-02-02, with quantity of 90.0, with intended 3 refill(s). Instructions: take 81 mg by mouth Every Day. \n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2011-02-02, presumably until 2012-02-02, with quantity of 30.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-04-24 00:00:00, ended at 2011-04-24 00:00:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2011-04-24, presumably until 2011-09-04, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-01 09:19:25, ended at 2011-05-01 10:07:04\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cauda equina syndrome with neurogenic bladder\n- Hyperlipidemia\n- Multi-infarct dementia, uncomplicated\n- Essential hypertension\n- Primary diagnosis: Mitral valve disorder\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, through Oral route, started on 2011-05-01, presumably until 2011-09-04, with quantity of 180.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- imipramine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2011-05-01, presumably until 2011-07-06, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-01 10:37:00, ended at 2011-05-01 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 57 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 125 (thousand per microliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 2.4 (ratio)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.2 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.65 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 161 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.0 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Multi-infarct dementia, uncomplicated\n- Cauda equina syndrome with neurogenic bladder\n- Essential hypertension\n- Hyperlipidemia\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-06 12:50:00, ended at 2011-05-06 23:59:00\nThe patient in this visit was 77 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-14 08:40:42, ended at 2011-05-14 09:49:40\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Primary diagnosis: Low compliance bladder\n- Incomplete emptying of bladder\n- Urgent desire to urinate\n- Increased frequency of urination\n- Nocturia\n\n### Drug\n- solifenacin succinate 5 MG Oral Tablet, through Oral route, started on 2011-05-14, presumably until 2011-09-04, with intended 4 refill(s). Instructions: take 5 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-07-06 00:00:00, ended at 2011-07-06 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Severe intellectual disability\n- Hyperlipidemia\n\n### Drug\n- imipramine hydrochloride 10 MG Oral Tablet, started on 2011-07-06, presumably until 2011-10-16, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-08-27 00:00:00, ended at 2011-08-27 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- escitalopram 10 MG Oral Tablet, started on 2011-08-27, presumably until 2012-12-12, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-04 08:37:07, ended at 2011-09-04 09:09:39\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Functional disorder of bladder\n- Mitral valve disorder\n- Multi-infarct dementia, uncomplicated\n- Vitamin B deficiency\n- Hyperlipidemia\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-09-08, with intended 1 refill(s). Instructions: take 5 mg by mouth daily.\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2011-09-04, presumably until 2011-10-16, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-04 09:30:00, ended at 2011-09-04 23:59:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 57 (milliliter per minute per square meter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.5 (percent)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 125 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Functional disorder of bladder\n- Vitamin B deficiency\n- Mitral valve disorder\n- Cauda equina syndrome with neurogenic bladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-09-08 00:00:00, ended at 2011-09-08 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Functional disorder of bladder\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-09-08, presumably until 2011-10-16, with intended 1 refill(s). Instructions: take 5 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-12 13:54:35, ended at 2011-10-12 14:19:48\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Mitral valve disorder\n- Ocular fistula causing hypotony of eye\n- Valvular endocarditis\n- Hyperlipidemia\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Glaucoma\n- Postprocedural blebitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-16 09:42:43, ended at 2011-10-16 14:43:48\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Essential hypertension\n- Functional disorder of bladder\n- Organic mental disorder\n- Hyperlipidemia\n- Neck pain\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Osteoarthritis\n- Valvular endocarditis\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-10-16, presumably until 2011-10-27, with intended 1 refill(s). Instructions: take 10 mg by mouth daily.\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2011-10-16, presumably until 2012-04-21, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-16 11:24:08, ended at 2011-10-16 16:50:01\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Functional disorder of bladder\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n- Osteoarthritis\n- Neck pain\n- Organic mental disorder\n- Mitral valve disorder\n- Hyperlipidemia\n- Essential hypertension\n- Valvular endocarditis\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-22 12:46:00, ended at 2011-10-22 23:59:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-10-27 10:56:51, ended at 2011-10-27 12:51:42\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Increased frequency of urination\n- Disorder of the peripheral nervous system\n- Urge incontinence of urine\n- Nocturia\n- Primary diagnosis: Functional disorder of bladder\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2011-10-27, presumably until 2012-05-23, with intended 11 refill(s). Instructions: take 10 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-11-09 00:00:00, ended at 2011-11-09 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Pre..., through Intramuscular route, started on 2011-11-09, presumably until 2011-11-10, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-12-09 00:00:00, ended at 2011-12-09 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-12-09, presumably until 2013-02-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-04-21 00:00:00, ended at 2012-04-21 00:00:00\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2012-04-21, presumably until 2015-04-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-13 14:45:04, ended at 2012-05-13 16:38:58\nThe patient in this visit was 78 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-05-16 00:00:00, ended at 2012-05-16 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, started on 2012-05-16, presumably until 2013-12-14, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-05-19 00:00:00, ended at 2012-05-19 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-05-21 00:00:00, ended at 2012-05-21 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tolterodine tartrate 2 MG Oral Tablet, started on 2012-05-21, presumably until 2012-05-21, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-05-23 00:00:00, ended at 2012-05-23 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Functional disorder of bladder\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2012-05-23, presumably until 2013-09-25, with intended 3 refill(s). Instructions: take 10 mg by mouth daily.\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2012-05-23, presumably until 2013-08-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-08 00:00:00, ended at 2012-06-08 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Hyperlipidemia\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-10 10:49:00, ended at 2012-06-10 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.7 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 97 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 43 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 72 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Multi-infarct dementia, uncomplicated\n- Hyperlipidemia\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-06-10 11:18:28, ended at 2012-06-10 11:54:11\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Benign neoplasm of colon\n- Hyperlipidemia\n- Essential hypertension\n- Mitral valve disorder\n- Valvular endocarditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-06-15 00:00:00, ended at 2012-06-15 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 420000 MG / potassium chloride 1480 MG / sodium bicarbonate 5720 MG / sodium chloride 11200 MG Powder for Oral Solution, through Oral route, started on 2012-06-15, presumably until 2012-11-07, with intended 0 refill(s). Instructions: take 420 g by mouth as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-06-22 00:00:00, ended at 2012-06-22 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- polyethylene glycol 3350 420000 MG / potassium chloride 1480 MG / sodium bicarbonate 5720 MG / sodium chloride 11200 MG Powder for Oral Solution, through Oral route, started on 2012-06-22, presumably until 2012-11-07, with intended 0 refill(s). Instructions: take 420 g by mouth as directed. Take split preparation as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-22 08:37:00, ended at 2012-06-22 13:47:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Colonoscopy, flexible; with directed submucosal injection(s), any substance\n- Injection or infusion of other therapeutic or prophylactic substance\n- Endoscopic polypectomy of large intestine\n\n### Condition\n- Benign neoplasm of colon\n- Diverticular disease of colon\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2012-06-22, presumably until 2012-06-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-07 09:35:03, ended at 2012-11-07 11:11:33\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n- Hyperlipidemia\n- Valvular endocarditis\n- Mitral valve disorder\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- 0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Pre..., through Intramuscular route, started on 2012-11-07, presumably until 2012-11-08, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-07 10:53:00, ended at 2012-11-07 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 103 (thousand per microliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperlipidemia\n- Valvular endocarditis\n- Essential hypertension\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2012-11-16 00:00:00, ended at 2012-11-16 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simethicone 66.7 MG/ML Oral Suspension, through Oral route, started on 2012-11-16, presumably until 2012-11-16\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2012-11-16, presumably until 2012-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-16 06:40:00, ended at 2012-11-16 09:53:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Colonoscopy, flexible; with biopsy, single or multiple\n- Endoscopic polypectomy of large intestine\n\n### Condition\n- Benign neoplasm of colon\n- Cerebral atherosclerosis\n- Mitral valve disorder\n- Vitamin B deficiency\n- Benign prostatic hyperplasia with outflow obstruction\n- Hyperlipidemia\n- Essential hypertension\n- Multi-infarct dementia, uncomplicated\n- Disorder of muscle\n- Functional disorder of bladder\n- Depressive disorder\n- Diverticular disease of colon\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2012-11-16, presumably until 2012-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-11-17 00:00:00, ended at 2012-11-17 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-05 09:00:00, ended at 2012-12-05 10:27:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- Genetic counseling\n- Collection of venous blood by venipuncture\n- Chromosome analysis, cytogenetic procedure AND/OR molecular biology method\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-12-12 13:04:25, ended at 2012-12-12 13:50:15\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Valvular endocarditis\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2013-02-23. Instructions: take  by mouth Every Day.  \n- escitalopram 20 MG Oral Tablet, through Oral route, presumably until 2013-02-28. Instructions: take  by mouth Every Day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-03 11:00:00, ended at 2013-01-03 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-01-05 00:00:00, ended at 2013-01-05 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-02-22 00:00:00, ended at 2013-02-22 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 20 MG Oral Tablet, started on 2013-02-22, presumably until 2014-04-26, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-02-27 00:00:00, ended at 2013-02-27 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2013-02-27, presumably until 2013-02-27. Instructions: take  by mouth Every Day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-02-28 00:00:00, ended at 2013-02-28 00:00:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2013-02-28, presumably until 2014-01-04, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-13 10:00:00, ended at 2013-03-13 23:59:00\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Genetic counseling\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-21 09:57:43, ended at 2013-03-21 10:47:17\nThe patient in this visit was 79 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Seborrheic dermatitis\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n- Mitral valve disorder\n\n### Drug\n- ketoconazole 20 MG/ML Topical Cream, started on 2013-03-21, presumably until 2013-05-27, with intended 1 refill(s). Instructions: apply bid\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-05-27 00:00:00, ended at 2013-05-27 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ketoconazole 20 MG/ML Topical Cream, started on 2013-05-27, presumably until 2015-04-25, with intended 6 refill(s). Instructions: APPLY TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-08-25 00:00:00, ended at 2013-08-25 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 20 MG Oral Tablet, started on 2013-08-25, presumably until 2014-01-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-09-25 00:00:00, ended at 2013-09-25 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, started on 2013-09-25, presumably until 2014-01-04, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-30 11:11:18, ended at 2013-10-30 11:41:54\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- General examination of patient\n\n### Condition\n- Hyperlipidemia\n- Primary diagnosis: Mitral valve disorder\n- Essential hypertension\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Multi-infarct dementia, uncomplicated\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-30 11:46:00, ended at 2013-10-30 23:59:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Platelets [#/volume] in Blood by Automated count: 121 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 36 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 75 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.9 (ratio)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 36 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.98 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 137 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 97 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.2 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Hyperlipidemia\n- Osteoarthritis\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Mitral valve disorder\n- Multi-infarct dementia, uncomplicated\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-31 12:28:00, ended at 2013-10-31 23:59:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-14 00:00:00, ended at 2013-12-14 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-19 00:00:00, ended at 2013-12-19 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Multi-infarct dementia, uncomplicated\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2015-04-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2015-04-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2015-02-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2014-01-04, presumably until 2014-03-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n- donepezil hydrochloride 10 MG Oral Tablet, started on 2013-12-19, presumably until 2015-04-19, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-26 10:37:42, ended at 2014-03-26 11:16:47\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mitral valve disorder\n- Multi-infarct dementia, uncomplicated\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Essential hypertension\n- Primary diagnosis: Osteoarthritis\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, through Oral route, started on 2014-03-26, presumably until 2015-04-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-04-18 00:00:00, ended at 2014-04-18 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simethicone 66.7 MG/ML Oral Suspension, through Oral route, started on 2014-04-18, presumably until 2014-04-18\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2014-04-18, presumably until 2014-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-18 06:32:00, ended at 2014-04-18 09:16:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.5\" (inch (US))\n\n### Procedure\n- Endoscopic polypectomy of large intestine\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- [Endoscopic] polypectomy of rectum\n- Colonoscopy, flexible; with biopsy, single or multiple\n\n### Condition\n- Dementia\n- Benign neoplasm of colon\n- Depressive disorder\n- Essential hypertension\n- Benign neoplasm of rectum and anal canal\n- Diverticular disease of colon\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2014-04-18, presumably until 2014-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-04-26 00:00:00, ended at 2014-04-26 00:00:00\nThe patient in this visit was 80 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 20 MG Oral Tablet, started on 2014-04-26, presumably until 2015-04-19, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-02-07 00:00:00, ended at 2015-02-07 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- escitalopram 10 MG Oral Tablet, started on 2015-02-07, presumably until 2015-02-11, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-02-11 00:00:00, ended at 2015-02-11 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2015-02-11, presumably until 2015-04-25, with intended 12 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-14 00:00:00, ended at 2015-04-14 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Primary diagnosis: Essential hypertension\n- Hyperlipidemia\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, started on 2015-04-14, presumably until 2015-04-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- lisinopril 40 MG Oral Tablet, started on 2015-04-14, presumably until 2015-04-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- atorvastatin 80 MG Oral Tablet, started on 2015-04-14, presumably until 2015-04-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-19 15:19:22, ended at 2015-04-19 16:15:51\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Hyperlipidemia\n- Primary diagnosis: Mitral valve disorder\n- Essential hypertension\n- Benign neoplasm of colon\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2015-04-29, with intended 12 refill(s). Instructions: take 1 Tab by mouth daily.\n- 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumo..., through Intramuscular route, started on 2015-04-19, presumably until 2015-04-20, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2015-04-25, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-19 16:46:00, ended at 2015-04-19 23:59:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Late effects of cerebrovascular disease\n- Acute upper respiratory infection\n- Mitral valve disorder\n- Essential hypertension\n- Hyperlipidemia\n- Amnesia\n- Cough\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-23 10:00:00, ended at 2015-04-23 23:59:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-04-24 00:00:00, ended at 2015-04-24 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute renal failure syndrome\n- Polycythemia vera (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2015-04-25 14:12:00, ended at 2015-04-25 18:12:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.5 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 16.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Potassium [Moles/volume] in Blood: 6.8 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 78 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 143 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: 1.16 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.2 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.25 (million per microliter)\n- Glucose [Mass/volume] in Blood: 67 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Prothrombin time (PT): 13.7 (second)\n- Sodium [Moles/volume] in Blood: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.0 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Radiologic examination, chest; single view, frontal\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Altered mental status\n- Lung field abnormal\n- Primary diagnosis: Dehydration\n- Depressive disorder\n- Malaise\n- Benign prostatic hyperplasia without outflow obstruction\n- Essential hypertension\n- Dementia\n- Hypoglycemia\n- Syncope and collapse\n- Hyperlipidemia\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 10 mg by mouth every morning\n- solifenacin succinate 5 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- atorvastatin 20 MG Oral Tablet, through Oral route, presumably until 2015-05-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2015-04-25, presumably until 2015-04-25\n- escitalopram 20 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- vitamin B12 1 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-29 11:10:50, ended at 2015-04-29 11:37:23\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Body height: 5' 7.5\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 53 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Mitral valve disorder\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Primary diagnosis: Syncope and collapse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-29 15:56:00, ended at 2015-04-29 23:59:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hyperlipidemia\n- Essential hypertension\n- Valvular endocarditis\n- Mitral valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-05-10 00:00:00, ended at 2015-05-10 00:00:00\nThe patient in this visit was 81 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, started on 2015-05-10, presumably until 2015-05-10, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2015-05-10, presumably until 2015-12-02, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-24 09:32:14, ended at 2015-05-24 10:45:40\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External ocular photography with interpretation and report for documentation of medical progress (eg, close-up photography, slit lamp photography, goniophotography, stereo-photography)\n\n### Condition\n- Primary diagnosis: Excess skin of eyelid\n- Ptosis of eyelid\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2015-06-06, with intended 0 refill(s). Instructions: take by mouth\n- dexamethasone 0.001 MG/MG / neomycin 0.0035 MG/MG / polymyxin B 10 UNT/MG Ophthalmic Ointment, through Intraocular route, started on 2015-05-24, presumably until 2015-07-31, with intended 0 refill(s). Instructions: instill to both eyes 3 times a day Apply ointment to eyelids three times per day. It is ok if ointment gets in the eyes.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-03 14:34:47, ended at 2015-06-03 16:04:22\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 15 (millimeter mercury column)\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Excess skin of eyelid\n- Ptosis of eyelid\n- Disorder of eyelid\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-06 14:09:37, ended at 2015-06-06 14:43:22\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pre-surgery evaluation\n\n### Condition\n- Disorder of eyelid\n- Chronic kidney disease stage 3\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2015-10-14, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning\n- solifenacin succinate 5 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2016-07-01, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- escitalopram 20 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2015-10-11, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-06-06, presumably until 2017-04-28, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-07 14:27:28, ended at 2015-06-07 15:53:16\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-12 15:08:10, ended at 2015-07-12 15:49:43\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-17 00:00:00, ended at 2015-07-17 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on eye; not otherwise specified\n\n### Condition\n- Ptosis of eyelid\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-07-17, presumably until 2015-07-17\n- midazolam 1 MG/ML Injectable Solution, started on 2015-07-17, presumably until 2015-07-17\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2015-07-17, presumably until 2015-07-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-17 00:00:00, ended at 2015-07-17 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2015-07-17, presumably until 2015-11-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-07-17 00:00:00, ended at 2015-07-17 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2015-07-17, presumably until 2015-07-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-17 07:27:00, ended at 2015-07-17 13:46:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Blepharoplasty, upper eyelid; with excessive skin weighting down lid\n- Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)\n- Rhytidectomy of upper eyelid\n- Canthoplasty (reconstruction of canthus)\n- Other adjustment of lid position\n\n### Condition\n- Excess skin of eyelid\n- Hyperlipidemia\n- Multi-infarct dementia, uncomplicated\n- Mitral valve disorder\n- Disorder of eyelid\n- Polycythemia vera (clinical)\n- Benign hypertensive renal disease with renal failure\n- Chronic kidney disease\n- Cerebral atherosclerosis\n- Primary diagnosis: Ptosis of eyelid\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-07-17, presumably until 2015-07-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-07-31 00:00:00, ended at 2015-07-31 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- dexamethasone 0.001 MG/MG / neomycin 0.0035 MG/MG / polymyxin B 10 UNT/MG Ophthalmic Ointment, through Intraocular route, started on 2015-08-01, presumably until 2015-11-29, with intended 2 refill(s). Instructions: instill to both eyes 3 times a day Apply ointment to eyelids three times per day. It is ok if ointment gets in the eyes.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-07 11:14:42, ended at 2015-08-07 12:34:17\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-30 15:24:21, ended at 2015-08-30 16:09:27\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-10-11 00:00:00, ended at 2015-10-11 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lisinopril 40 MG Oral Tablet, started on 2015-10-14, presumably until 2016-05-25, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- escitalopram 20 MG Oral Tablet, started on 2015-10-14, presumably until 2016-04-06, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-15 10:49:44, ended at 2015-11-15 11:33:52\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-29 14:53:29, ended at 2015-11-29 16:03:38\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Valvular endocarditis\n- Essential hypertension\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n- Polyp of colon\n- Secondary polycythemia\n- Vitamin B deficiency\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2015-12-02, presumably until 2016-03-20, with intended 12 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-12-02 00:00:00, ended at 2015-12-02 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-01-06 13:00:00, ended at 2016-01-06 23:59:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Non-rheumatic mitral valve disease\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-06 13:36:35, ended at 2016-01-06 16:11:43\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Essential hypertension\n- Primary diagnosis: Valvular endocarditis\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, through Oral route, presumably until 2016-09-11, with intended 0 refill(s). Instructions: take 500 mg by mouth as directed One gram prior to dental procedures\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-28 13:29:07, ended at 2016-01-28 14:13:13\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.709\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n- Hematuria syndrome\n- Urinary tract infectious disease\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2016-01-28, presumably until 2016-02-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-01-28 14:21:00, ended at 2016-01-28 23:59:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 11 - 20 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.36 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 79 (picogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 118 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Urine: 354.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.9 (percent)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 18 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 44 (nanogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.15 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 16.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.5 (percent)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 44 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-02-03 17:33:00, ended at 2016-02-03 21:38:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, head or brain; without contrast material\n- Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less\n- Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.6 cm to 7.5 cm\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Benign prostatic hyperplasia\n- Laceration of wrist\n- Contusion of head\n- Dementia\n- Disorder of brain\n- Essential hypertension\n- Hyperlipidemia\n- Laceration of forearm\n- Primary diagnosis: Injury of head\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-02-03, presumably until 2016-02-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-07 14:13:59, ended at 2016-02-07 14:50:18\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyp of colon\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-03-03 00:00:00, ended at 2016-03-03 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-10 11:18:00, ended at 2016-03-10 23:59:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 44 (picogram per milliliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Creatinine [Mass/volume] in Urine: 198.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.2 (percent)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.1 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 14 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 95 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-10 11:20:15, ended at 2016-03-10 11:50:03\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.71\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-19 00:00:00, ended at 2016-03-19 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, started on 2016-03-20, presumably until 2017-05-04, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-04-03 00:00:00, ended at 2016-04-03 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of eyelid\n- Chronic kidney disease stage 3\n\n### Drug\n- escitalopram 20 MG Oral Tablet, started on 2016-04-06, presumably until 2017-06-12, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-23 00:00:00, ended at 2016-04-23 00:00:00\nThe patient in this visit was 82 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-21 13:43:36, ended at 2016-05-21 14:20:03\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Valvular endocarditis\n- Vascular dementia without behavioral disturbance\n- Hyperlipidemia\n- Primary diagnosis: Cerebral infarction\n\n### Drug\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-05-21, presumably until 2016-05-26, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime 1 PO BID\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-25 00:00:00, ended at 2016-05-25 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, started on 2016-05-25, presumably until 2017-05-31, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-09-11, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-02 00:00:00, ended at 2016-06-02 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-09 10:36:55, ended at 2016-06-09 11:20:54\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-09 11:28:00, ended at 2016-06-09 23:59:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.27 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 138.40 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-12 10:38:00, ended at 2016-06-12 23:59:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n\n### Condition\n- Chronic kidney disease stage 3\n- Benign prostatic hyperplasia\n- Disorder of bladder\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-30 00:00:00, ended at 2016-06-30 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction\n\n### Drug\n- solifenacin succinate 10 MG Oral Tablet, started on 2016-07-01, presumably until 2017-01-08, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-08 00:00:00, ended at 2016-07-08 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperlipidemia\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Polyp of colon\n- Cerebral infarction\n- Essential hypertension\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, started on 2016-07-08, presumably until 2016-09-11, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH AT BEDTIME.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-11 00:00:00, ended at 2016-09-11 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyp of colon\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2016-09-11, presumably until 2016-09-11, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-11 13:21:19, ended at 2016-09-11 14:00:11\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fatigue\n- Primary diagnosis: Overactive bladder\n- Malaise\n- Vitamin B deficiency\n- Vascular dementia without behavioral disturbance\n\n### Drug\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-09-11, presumably until 2016-09-21, with intended 12 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-09-20 20:02:00, ended at 2016-09-21 12:43:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.12 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Base excess in Blood by calculation: 2 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 115 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.59 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.31 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or o\n- Computed tomography, head or brain; without contrast material\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation\n- Medical team conference with interdisciplinary team of health care professionals, face-to-face with patient and/or family, 30 minutes or more, participation by nonphysician qualified health care professional\n- Radiologic examination, chest; single view, frontal\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n\n### Condition\n- Disorientated\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Heart failure\n- Major depression, single episode\n- Vitamin B deficiency\n- Chronic kidney disease due to hypertension\n- Chronic kidney disease stage 3\n- Imaging of brain abnormal\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n- Benign prostatic hyperplasia\n- Overactive bladder\n- Altered mental status\n- Malaise\n- Dementia\n- Fatigue\n- Hyperlipidemia\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-10-02, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-09-21, presumably until 2016-09-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-09-29 00:00:00, ended at 2016-09-29 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin B deficiency\n- Malaise\n- Overactive bladder\n- Fatigue\n- Primary diagnosis: Chronic kidney disease stage 3\n- Vascular dementia without behavioral disturbance\n\n### Drug\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2016-10-02, presumably until 2016-10-02, with intended 12 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-06 08:28:07, ended at 2016-10-06 10:15:32\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Cerebral infarction\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-07 12:36:20, ended at 2016-10-07 14:21:11\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.71\" (inch (US))\n\n### Procedure\n- Complex uroflowmetry (eg, calibrated electronic equipment)\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Nocturia\n- Poor stream of urine\n- Delay when starting to pass urine\n- Primary diagnosis: Benign prostatic hyperplasia\n- Urgent desire to urinate\n- Erectile dysfunction\n- Finding of frequency of urination\n- Splitting of urinary stream\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2016-10-07, presumably until 2017-04-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-10-12 00:00:00, ended at 2016-10-12 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-27 13:50:00, ended at 2016-10-27 23:59:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.17 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 152.93 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Platelets [#/volume] in Blood by Automated count: 114 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.00 (million per microliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 6 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Vascular dementia without behavioral disturbance\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Urinary tract infectious disease\n- Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-27 14:09:06, ended at 2016-10-27 14:47:25\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-08 12:34:59, ended at 2016-12-08 13:48:47\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye:  18 (millimeter mercury column)\n- Intraocular pressure of left eye: 17 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Senile cataract\n- Primary diagnosis: Dermatosis of eyelid\n- Pterygium\n- Cataract\n- Vitreous hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-23 08:43:11, ended at 2016-12-23 11:11:35\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 13 (millimeter mercury column)\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Nuclear senile cataract\n- Senile cataract\n- Primary diagnosis: Vitreous hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-06 00:00:00, ended at 2017-01-06 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-08 16:02:10, ended at 2017-01-08 16:55:18\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vascular dementia without behavioral disturbance\n- Impaired glucose tolerance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-01 00:00:00, ended at 2017-03-01 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-02 09:23:51, ended at 2017-03-02 12:22:47\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vascular dementia without behavioral disturbance\n- Hyperlipidemia\n- Major depression, single episode\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-02 10:23:47, ended at 2017-03-02 11:00:43\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Chronic kidney disease stage 3\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Hyperlipidemia\n- Vascular dementia without behavioral disturbance\n- Major depression, single episode\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-09 10:41:08, ended at 2017-03-09 12:40:42\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 15 (millimeter mercury column)\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n\n### Procedure\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Vitreous hemorrhage\n- Senile cataract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-15 09:29:18, ended at 2017-04-15 13:18:22\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computerized corneal topography, unilateral or bilateral, with interpretation and report\n\n### Condition\n- Primary diagnosis: Senile cataract\n\n### Drug\n- prednisolone acetate 10 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2017-04-15, presumably until 2017-07-13, with intended 3 refill(s). Instructions: instill 1 Drop to right eye 4 times a day Start AFTER surgery\n- gatifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-15, presumably until 2017-06-07, with intended 2 refill(s). Instructions: instill 1 Drop to right eye 4 times a day Start 3 days BEFORE surgery; OK to substitute other fluoroquinolone if not covered by insurance\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-15, presumably until 2017-06-07, with intended 2 refill(s). Instructions: instill 1 Drop to right eye 4 times a day Start AFTER surgery; OK to substitute other NSAID if not covered by insurance\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-15 09:30:09, ended at 2017-04-15 13:40:53\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-15 09:30:40, ended at 2017-04-15 13:51:06\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation\n\n### Condition\n- Senile cataract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-04-28 00:00:00, ended at 2017-04-28 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- chondroitin sulfates, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- chondroitin 4-sulfate, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- 1.5 ML carbachol 0.1 MG/ML Injection, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-04-28, presumably until 2017-04-28\n- cefazolin 1000 MG Injection, started on 2017-04-28, presumably until 2017-04-28\n- calcium chloride 0.004 MEQ/ML / magnesium chloride 0.003 MEQ/ML / potassium chloride 0.01 MEQ/ML / sodium acetate 0.0475 MEQ/ML / sodium chloride 0.109 MEQ/ML / sodium citrate 0.012 MEQ/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- sodium chloride 9 MG/ML Injection, started on 2017-04-28, presumably until 2017-04-28\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-28, presumably until 2017-04-28\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-04-28, presumably until 2017-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-28 08:20:00, ended at 2017-04-28 10:55:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Replacement of Right Lens with Synthetic Substitute, Percutaneous Approach\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n\n### Condition\n- Chronic kidney disease due to hypertension\n- Chronic kidney disease stage 3\n- Hyperlipidemia\n- Nuclear senile cataract\n- Vascular dementia without behavioral disturbance\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Senile cataract\n\n### Drug\n- tropicamide 10 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- gatifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-28, presumably until 2017-04-28\n- phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-04-28, presumably until 2017-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-05-04 00:00:00, ended at 2017-05-04 00:00:00\nThe patient in this visit was 83 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 80 MG Oral Tablet, started on 2017-05-05, presumably until 2017-06-07, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-05-17 00:00:00, ended at 2017-05-17 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- chondroitin sulfates, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- chondroitin 4-sulfate, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- 1.5 ML carbachol 0.1 MG/ML Injection, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-05-17, presumably until 2017-05-17\n- cefazolin 1000 MG Injection, started on 2017-05-17, presumably until 2017-05-17\n- calcium chloride 0.004 MEQ/ML / magnesium chloride 0.003 MEQ/ML / potassium chloride 0.01 MEQ/ML / sodium acetate 0.0475 MEQ/ML / sodium chloride 0.109 MEQ/ML / sodium citrate 0.012 MEQ/ML Ophthalmic Solution, through Intraocular route, started on 2017-05-17, presumably until 2017-05-17\n- sodium chloride 9 MG/ML Injection, started on 2017-05-17, presumably until 2017-05-17\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2017-05-17, presumably until 2017-05-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-05-17, presumably until 2017-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-17 12:35:00, ended at 2017-05-17 16:32:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n- Replacement of Left Lens with Synthetic Substitute, Percutaneous Approach\n\n### Condition\n- Hyperlipidemia\n- Dementia\n- Chronic kidney disease stage 3\n- Chronic kidney disease due to hypertension\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Cataract\n- Heart failure\n- Nuclear senile cataract\n- Vitreous hemorrhage\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-05-17, presumably until 2017-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-18 09:40:42, ended at 2017-05-18 15:45:39\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of right eye: 16 (millimeter mercury column)\n- Intraocular pressure of left eye: 26 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-28 00:00:00, ended at 2017-05-28 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Unsteady when standing\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-05-31 00:00:00, ended at 2017-05-31 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, started on 2017-06-02, presumably until 2017-06-02, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-07 11:40:00, ended at 2017-06-07 23:59:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Essential hypertension\n- Hyperlipidemia\n- Infective endocarditis\n- Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-07 12:55:36, ended at 2017-06-07 13:31:15\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n- Infective endocarditis\n- Essential hypertension\n- Hyperlipidemia\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, presumably until 2017-11-12, with intended 0 refill(s). Instructions: take by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-12 00:00:00, ended at 2017-06-12 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of eyelid\n- Chronic kidney disease stage 3\n\n### Drug\n- escitalopram 20 MG Oral Tablet, started on 2017-06-14, presumably until 2017-06-14, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-17 10:27:02, ended at 2017-06-17 12:03:58\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Intraocular pressure of left eye: 14 (millimeter mercury column)\n- Intraocular pressure of right eye: unab (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-25 12:37:17, ended at 2017-06-25 12:47:33\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute bronchitis\n\n### Drug\n- doxycycline hyclate 100 MG Oral Capsule, through Oral route, started on 2017-06-25, presumably until 2017-07-02, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-25 12:55:00, ended at 2017-06-25 23:59:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Acute bronchitis\n- Cough\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-03 18:32:25, ended at 2017-07-03 19:31:05\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 170 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.93 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- MCV [Entitic volume] by Automated count: 93.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 203 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 159 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.79 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Primary diagnosis: Loss of appetite\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-04 00:00:00, ended at 2017-07-04 00:00:00\nThe patient in this visit was 84 years old, White, Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "b43154ebdd7d56de1c1e17d980f4718f79e7d96798800d05ebf5e96fcbbc682e", "prompt_hash": "2b7baa49cb87194b8ab18f46cc73eaf2abb7887e4da3debba0c2b4d11cc122ea", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 4, "doc": {"person_id": 115967573, "visit_occurrence_id": 90976092, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2016-08-14 10:55:59", "visit_end_datetime": "2016-08-14 11:34:12", "visit_length_in_hours": 0.6369444444444444, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2016-08-14 10:55:59, ended at 2016-08-14 11:34:12\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemiplegia\n- Primary diagnosis: Localization-related idiopathic epilepsy\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 97, "patient_first_visit_date": "2013-09-16 22:10:00", "patient_last_visit_date": "2018-07-11 17:02:00", "end_obs_date": "2017-08-14", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "recurrent", "ischemic_stroke_one_year_diagnosis": 1, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 1, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 108, "cumulated_visit_num": 108, "cumulated_approximate_token_count": 24970, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2013-09-16 22:10:00, ended at 2013-09-28 16:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 25.0 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 323 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 100 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.3 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.43 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 151 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 44.1 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Base excess in Blood by calculation: 0.0 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 97.8 (femtoliter)\n- Prothrombin time (PT): 15.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Left ventricular Ejection fraction: 57 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.2 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 224 (millimeter mercury column)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.7 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 118 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 167 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.73 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n\n### Procedure\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Occupational therapy evaluation\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual\n- Injection or infusion of thrombolytic agent\n- Computer assisted surgery with CT/CTA\n- Prophylactic administration of vaccine against other diseases\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Evaluation of oral and pharyngeal swallowing function\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Evaluation of speech, language, voice, communication, and/or auditory processing\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Removal of other therapeutic device\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, abdomen; single anteroposterior view\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography guidance for stereotactic localization\n- Other incision of brain\n- Physical therapy evaluation\n- Insertion or replacement of external ventricular drain [EVD]\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view, frontal\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Cardiac arrhythmia\n- Flaccid hemiplegia\n- Essential hypertension\n- Localized swelling, mass and lump, trunk\n- Primary cardiomyopathy\n- Amyloidosis\n- Cardiomegaly\n- Primary diagnosis: Cerebral hemorrhage\n- Electrocardiogram abnormal\n- Lung field abnormal\n- Supraventricular premature beats\n- Swelling / lump finding\n- Weakness of face muscles\n- Cerebral embolism\n- Inflammatory dermatosis\n- Celiac disease\n- Compression of brain\n- Dysarthria\n- Left bundle branch hemiblock\n- Pain in limb\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Hyperlipidemia\n- Atelectasis\n- Cerebrovascular disease\n- Clostridioides difficile infection\n- Dysphagia\n- Finding of head and neck region\n- Hemi-neglect\n- Disorder of brain\n- Vitamin B deficiency\n- Cerebral edema\n\n### Drug\n- vitamin K1 5 MG Oral Tablet, through Oral route, started on 2013-09-19, presumably until 2013-09-22\n- sodium chloride 1000 MG Oral Tablet, through Oral route, started on 2013-09-21, presumably until 2013-09-28, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals.\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2013-09-27, presumably until 2014-02-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed.\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2013-09-22, presumably until 2014-02-25. Instructions: take 10 mg by mouth every bedtime.\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2013-09-17, presumably until 2013-09-18\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2013-09-18, presumably until 2013-09-23\n- Lacticaseibacillus rhamnosus GG 15000000000 UNT Oral Capsule, through Oral route, started on 2013-09-28, presumably until 2013-09-28\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2013-09-18, presumably until 2013-09-23\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-25, presumably until 2013-09-27\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2013-09-22, presumably until 2013-09-26\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-22\n- 500 ML sodium chloride 30 MG/ML Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-22\n- sodium chloride 9 MG/ML Injection, started on 2013-09-19, presumably until 2013-09-19\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-09-27, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-09-23, presumably until 2014-09-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2013-09-21, presumably until 2015-02-01. Instructions: take 5 mg by mouth daily.\n- sodium chloride 234 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-18, presumably until 2013-09-18\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2013-09-24, presumably until 2013-09-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2013-09-24, presumably until 2013-11-04, with intended 0 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) every 8 hours.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-09-27, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2013-09-18, presumably until 2013-09-26\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2013-09-18, presumably until 2013-09-23\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-09-21, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily.\n- diphenhydramine hydrochloride 10 MG/ML / zinc acetate 1 MG/ML Topical Cream, through Topical route, started on 2013-09-25, presumably until 2013-11-04, with intended 0 refill(s). Instructions: by Topical route 3 times a day as needed.\n- mineral oil, through Topical route, started on 2013-09-26, presumably until 2013-11-04, with intended 0 refill(s). Instructions: by Topical route as needed.\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2013-09-25, presumably until 2013-09-28\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2013-09-25, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours.\n- amlodipine 2.5 MG Oral Tablet, through Oral route, started on 2013-09-19, presumably until 2013-09-21\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-18\n- carboxymethylcellulose sodium 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2013-09-21, presumably until 2014-02-25, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes every 8 hours.\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-23\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2013-09-23, presumably until 2013-09-23\n- petrolatum, through Topical route, started on 2013-09-26, presumably until 2013-11-04, with intended 0 refill(s). Instructions: by Topical route as needed.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2018-07-11. Instructions: take 81 mg by mouth daily.\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2013-09-19, presumably until 2013-09-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-09-17 00:00:00, ended at 2013-09-17 00:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intracranial procedures; craniotomy or craniectomy for evacuation of hematoma\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n\n### Condition\n- Hyperlipidemia\n- Essential hypertension\n- Cerebral hemorrhage\n- Compression of brain\n\n### Drug\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-17\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-17\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- remifentanil 2 MG Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-09-17 00:00:00, ended at 2013-09-17 00:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- epinephrine 0.005 MG/ML / lidocaine hydrochloride 5 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-17\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2013-09-17, presumably until 2013-09-17\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, through Topical route, started on 2013-09-17, presumably until 2013-09-17\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2013-09-17, presumably until 2013-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-29 00:00:00, ended at 2013-09-29 00:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-11-04 00:00:00, ended at 2013-11-04 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Compression of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-04 13:03:58, ended at 2013-11-04 14:19:37\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- fluoxetine 20 MG Oral Tablet, through Oral route, started on 2013-11-04, presumably until 2014-06-13, with intended 0 refill(s). Instructions: take 20 mg by mouth daily.\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2013-11-04, presumably until 2013-12-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, presumably until 2015-03-07. Instructions: inject 1,000 mcg into a muscle every month.\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, presumably until 2014-11-03. Instructions: take 1 Guariglia by mouth every morning.\n- Saccharomyces boulardii 250 MG Oral Capsule, through Oral route, presumably until 2014-01-03. Instructions: take 1 Cap by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-04 14:09:00, ended at 2013-11-04 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-02 00:00:00, ended at 2013-12-02 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2013-12-02, presumably until 2014-01-05, with intended 0 refill(s). Instructions: TAKE 1 TAB BY MOUTH EVERY BEDTIME.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-03 08:15:00, ended at 2014-01-03 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Swelling / lump finding\n- Finding of head and neck region\n- Aneurysm of artery of neck\n- Cerebral hemorrhage\n- Compression of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-01-03 10:12:03, ended at 2014-01-03 13:41:24\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-01-05 12:59:37, ended at 2014-01-05 14:37:05\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2014-01-05, presumably until 2014-02-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime. 2 tabs at bedtime as needed for sleep\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, presumably until 2014-02-25. Instructions: by Topical route. 1/2 patch on each hip daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-18 00:00:00, ended at 2014-02-18 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 750 MG Oral Tablet, through Oral route, started on 2014-02-18, presumably until 2014-02-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-02-21 00:00:00, ended at 2014-02-21 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-02-21, presumably until 2014-05-05, with intended 1 refill(s). Instructions: TAKE 2 TABLETS AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-22 00:00:00, ended at 2014-02-22 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 250 MG Oral Tablet, through Oral route, started on 2014-02-22, presumably until 2014-02-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-02-25 09:46:16, ended at 2014-02-25 13:29:10\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- simvastatin 20 MG Oral Tablet, through Oral route, presumably until 2015-03-16. Instructions: take 20 mg by mouth every bedtime.\n- levetiracetam 500 MG Oral Tablet, through Oral route, presumably until 2014-03-14. Instructions: take 500 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-07 10:15:47, ended at 2014-03-07 11:24:19\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neurogenic bladder\n\n### Drug\n- oxybutynin chloride 5 MG Oral Tablet, through Oral route, started on 2014-03-07, presumably until 2014-05-31, with intended 11 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime. May increase dose to 1 tab at bedtime if still having incontinence after 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-03-14 00:00:00, ended at 2014-03-14 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levetiracetam 250 MG Oral Tablet, started on 2014-03-14, presumably until 2014-03-14, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-14 00:00:00, ended at 2014-03-14 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2014-03-14, presumably until 2014-07-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-05 00:00:00, ended at 2014-05-05 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-05-05, presumably until 2014-06-13, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-31 11:52:34, ended at 2014-05-31 13:03:34\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral hemorrhage\n- Primary diagnosis: Neurogenic bladder\n\n### Drug\n- trospium chloride 20 MG Oral Tablet, through Oral route, started on 2014-05-31, presumably until 2014-06-27, with intended 3 refill(s). Instructions: take 20 mg by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-31 13:04:17, ended at 2014-05-31 14:57:37\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mild cognitive disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-31 15:06:00, ended at 2014-05-31 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.40 (milli-international unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Mild cognitive disorder\n- Cerebral hemorrhage\n- Neurogenic bladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-06-10 00:00:00, ended at 2014-06-10 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-06-10, presumably until 2014-06-10, with intended 0 refill(s). Instructions: TAKE 2 TABLET BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2014-06-11 02:00:00, ended at 2014-06-13 18:25:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.42 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Base deficit in Blood: 4.0 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- MCV [Entitic volume] by Automated count: 93.3 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 221 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 114 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 5 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.7 (percent)\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Radiologic examination, abdomen; single anteroposterior view\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Physical therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Hospital discharge day management; 30 minutes or less\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cerebral hemorrhage\n- Dehydration\n- Hemiplegia as late effect of cerebrovascular disease\n- Low blood pressure\n- Mild cognitive disorder\n- Celiac disease\n- Hypokalemia\n- Primary cardiomyopathy\n- Primary diagnosis: Vomiting\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Diarrhea\n- Functional disorder of intestine\n- Tachycardia\n- Essential hypertension\n- Hyperlipidemia\n- Neurogenic bladder\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2014-06-12, presumably until 2014-06-13\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2014-06-12, presumably until 2015-06-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day as needed for Diarrhea.\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2014-06-11, presumably until 2014-06-12\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2014-06-12, presumably until 2014-06-12\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-12\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-06-11, presumably until 2014-06-13\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2014-06-12, presumably until 2014-06-12\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-12\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- sennosides, USP 8.6 MG Oral Capsule, through Oral route, started on 2014-06-13, presumably until 2014-06-27, with intended 3 refill(s). Instructions: take 2 Caps by mouth daily as needed (no bowel movement for 24 hours).\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-06-13, presumably until 2014-06-27, with intended 3 refill(s). Instructions: take 1 Packet by mouth daily as needed (no bowel movement for 24 hours).\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2014-06-11, presumably until 2014-06-12\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- triamcinolone acetonide 1 MG/ML Topical Cream, through Topical route, started on 2014-06-13, presumably until 2014-10-25, with intended 0 refill(s). Instructions: Apply to rash once daily. Reassess with your doctor in 2-3 weeks for improvement.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-06-13 00:00:00, ended at 2014-06-13 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-06-13, presumably until 2014-09-05, with intended 0 refill(s). Instructions: TAKE 2 TABLET BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-14 17:13:00, ended at 2014-06-14 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Seizure\n- Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-27 14:29:11, ended at 2014-06-27 16:26:49\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Infectious diarrheal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-06 15:15:25, ended at 2014-07-06 17:33:59\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- fluoxetine 20 MG Oral Capsule, through Oral route, presumably until 2015-02-01, with intended 0 refill(s). Instructions: take  by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-07-15 00:00:00, ended at 2014-07-15 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2014-07-15, presumably until 2014-07-15, with intended 0 refill(s). Instructions: APPLY TO RASH DAILY REASSESS WITH YOUR DOCTOR IN 2-3 WEEKS FOR IMPROVEMENT\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-07-18 00:00:00, ended at 2014-07-18 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levetiracetam 500 MG Oral Tablet, started on 2014-07-18, presumably until 2014-10-25, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-09-05 00:00:00, ended at 2014-09-05 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-09-05, presumably until 2014-10-25, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-05 00:00:00, ended at 2014-10-05 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Localization-related epilepsy\n- Cerebral hemorrhage\n\n### Drug\n- lacosamide 50 MG Oral Tablet, through Oral route, started on 2014-10-05, presumably until 2014-10-25, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Start 50 mg twice a day by mouth; continue for 7 days; increase to 100 mg bid. Once on 100 mg bid for 5 days, stop keppra.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-06 00:00:00, ended at 2014-10-06 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eruption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-20 00:00:00, ended at 2014-10-20 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Mild cognitive disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-25 08:42:00, ended at 2014-10-25 11:09:19\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Localization-related epilepsy\n- Neurogenic bladder\n- Anemia\n- Cerebral hemorrhage\n- Vitamin B deficiency\n- Hyperplasia of prostate\n- Adjustment disorder with depressed mood\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2014-10-25, presumably until 2015-11-03, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n- hydroxyzine hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2014-10-25, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime.\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2014-10-25, presumably until 2014-10-26, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- 0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection, through Subcutaneous route, started on 2014-10-25, presumably until 2014-10-26, with intended 0 refill(s). Instructions: inject 0.65 mL subcutaneous (under the skin) One Time.\n- lacosamide 100 MG Oral Tablet, through Oral route, presumably until 2015-01-21, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day.\n- trazodone hydrochloride 100 MG Oral Tablet, through Oral route, presumably until 2014-12-12, with intended 0 refill(s). Instructions: take 100 mg by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-25 11:18:00, ended at 2014-10-25 23:59:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 282 (microgram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 111 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 71 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 25 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cerebral hemorrhage\n- Vitamin B deficiency\n- Adjustment disorder with depressed mood\n- Hyperplasia of prostate\n- Anemia\n- Localization-related epilepsy\n- Neurogenic bladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-25 14:09:39, ended at 2014-10-25 15:22:27\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)\n\n### Condition\n- Verruca vulgaris\n- Pruritus of skin\n- Benign neoplasm of skin of trunk\n- Primary diagnosis: Inflammatory dermatosis\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- triamcinolone acetonide 0.001 MG/MG Topical Ointment, started on 2014-10-25, presumably until 2015-10-25, with intended 12 refill(s). Instructions: Apply topically as directed daily alternate with moisturizer\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2014-10-25, presumably until 2015-01-31, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime. Take 30 minutes before bedtime as needed.\n- fluocinonide 0.5 MG/ML Topical Solution, started on 2014-10-25, presumably until 2016-01-17, with intended 12 refill(s). Instructions: Apply topically twice daily to scalp for itching\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-28 00:00:00, ended at 2014-10-28 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2014-10-28, presumably until 2015-02-01, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-28 00:00:00, ended at 2014-10-28 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2014-10-28, presumably until 2015-02-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth Every Day. Start after completion of KEFLEX antibiotic\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-03 00:00:00, ended at 2014-11-03 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2014-11-03, presumably until 2015-11-08, with intended 3 refill(s). Instructions: take 1 Gillihan by mouth every morning.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-12-11 00:00:00, ended at 2014-12-11 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-12-11, presumably until 2015-03-16, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-05 00:00:00, ended at 2015-01-05 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Hemiplegia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-17 15:36:18, ended at 2015-01-17 16:41:28\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n- Chemodenervation of trunk muscle(s); 1-5 muscle(s)\n- Chemodenervation of one extremity; 1-4 muscle(s)\n\n### Condition\n- Hemiplegia as late effect of cerebrovascular disease\n- Spasm\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, through Intramuscular route, started on 2015-01-17, presumably until 2015-04-11, with intended 0 refill(s). Instructions: inject 200 Units into a muscle One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-20 00:00:00, ended at 2015-01-20 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2015-01-20, presumably until 2015-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-01-21 00:00:00, ended at 2015-01-21 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lacosamide 100 MG Oral Tablet, started on 2015-01-21, presumably until 2015-04-12, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-21 15:43:00, ended at 2015-01-21 23:59:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-31 13:12:28, ended at 2015-01-31 13:59:47\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Inflammatory dermatosis\n- Pruritus of skin\n- Dermatographic urticaria\n- Inflamed seborrheic keratosis\n- Sebaceous cyst of skin\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-01-31, presumably until 2015-12-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime. Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-01 11:06:03, ended at 2015-02-01 13:10:26\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Neurogenic bladder\n- Hallucinations\n- Urinary tract infectious disease\n- Primary diagnosis: Dysuria\n\n### Drug\n- 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumo..., through Intramuscular route, started on 2015-02-01, presumably until 2015-02-02, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- methenamine hippurate 1000 MG Oral Tablet, through Oral route, started on 2015-02-01, presumably until 2015-05-04, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, through Oral route, started on 2015-02-01, presumably until 2016-01-30, with intended 11 refill(s). Instructions: take 1 Cap by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-16 14:07:36, ended at 2015-02-16 17:13:02\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dementia\n- Primary diagnosis: Hallucinations\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-17 00:00:00, ended at 2015-02-17 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mild cognitive disorder\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, started on 2015-02-17, presumably until 2015-07-14, with intended 3 refill(s). Instructions: Take 2.5 mg (1/2 tab) daily for 2 weeks PO then increase by 2.5 mg (1/2 tab) every two weeks until you reach 10 mg per day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-07 00:00:00, ended at 2015-03-07 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2015-03-07, presumably until 2016-01-17, with intended 12 refill(s). Instructions: inject 1 mL into a muscle every month.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-03-13 00:00:00, ended at 2015-03-13 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-14 14:07:06, ended at 2015-03-14 16:22:30\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Altered mental status\n\n### Drug\n- clotrimazole 10 MG/ML Topical Cream, started on 2015-03-14, presumably until 2015-05-04, with intended 0 refill(s). Instructions: Apply twice daily to affected areas for 7 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-16 00:00:00, ended at 2015-03-16 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2015-03-16, presumably until 2016-06-07, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-16 00:00:00, ended at 2015-03-16 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2015-03-16, presumably until 2016-01-16, with intended 1 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-11 15:59:56, ended at 2015-04-11 17:00:37\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of one extremity; 1-4 muscle(s)\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Hemiplegia as late effect of cerebrovascular disease\n- Spasm\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, through Intramuscular route, started on 2015-04-11, presumably until 2015-04-11, with intended 0 refill(s). Instructions: inject 400 Units into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2015-04-12 10:40:00, ended at 2015-04-12 15:09:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 226 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.63 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest; single view, frontal\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Computed tomography, head or brain; without contrast material\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Seizure\n- Hyperlipidemia\n- Lung field abnormal\n- Essential hypertension\n- Localization-related epilepsy\n- Celiac disease\n- Disorder of brain\n- Depressive disorder\n- Epilepsy\n- Benign prostatic hyperplasia without outflow obstruction\n\n### Drug\n- lacosamide 150 MG Oral Tablet, through Oral route, started on 2015-04-12, presumably until 2015-04-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-04-14 00:00:00, ended at 2015-04-14 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n- Primary diagnosis: Refractory epilepsy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-19 00:00:00, ended at 2015-04-19 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lacosamide 150 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2015-04-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-04-19 00:00:00, ended at 2015-04-19 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- lacosamide 200 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2016-01-16, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-04 10:22:49, ended at 2015-05-04 11:32:01\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Mild cognitive disorder\n- Electrocardiogram abnormal\n- Primary diagnosis: Benign essential hypertension\n- Left bundle branch hemiblock\n- Cardiomegaly\n\n### Drug\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2015-05-04, presumably until 2015-07-14, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime as needed\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2015-05-04, presumably until 2016-01-17, with intended 1 refill(s). Instructions: take 0.5 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-04 11:36:00, ended at 2015-05-04 23:59:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mild cognitive disorder\n- Benign essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-05-08 00:00:00, ended at 2015-05-08 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-06-15 00:00:00, ended at 2015-06-15 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-28 09:51:18, ended at 2015-06-28 15:13:51\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 250 MG Oral Tablet, started on 2015-06-28, presumably until 2016-01-16, with intended 10 refill(s). Instructions: Take two tablets BID\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-03 00:00:00, ended at 2015-07-03 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Localization-related epilepsy\n\n### Drug\n- oxcarbazepine 300 MG Oral Tablet, through Oral route, started on 2015-07-03, presumably until 2016-01-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-07-12 00:00:00, ended at 2015-07-12 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, started on 2015-07-14, presumably until 2015-07-14, with intended 0 refill(s). Instructions: TAKE 2.5MG(1/2 TABLET) BY MOUTH EVERY DAY FOR 2 WEEKS THEN INCREASE 2.5MG(1/2 TABLET) EVERY TWO WEEKS UNTIL YOU REACH 10MG PER DAY\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-07-14, presumably until 2016-07-13, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-13 00:00:00, ended at 2015-07-13 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2015-07-14, presumably until 2015-08-14, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-14 00:00:00, ended at 2015-08-14 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, through Oral route, started on 2015-08-14, presumably until 2016-01-09, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-15 12:41:00, ended at 2015-08-15 14:13:14\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Squamous cell carcinoma of upper extremity\n- Neoplasm of uncertain behavior of skin\n- Inflammatory dermatosis\n- Sebaceous cyst of skin\n- Primary diagnosis: Pruritus of skin\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-08-15, presumably until 2015-12-25, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2015-08-15, presumably until 2015-12-26, with intended 3 refill(s). Instructions: Apply topically as directed twice daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-09-07 00:00:00, ended at 2015-09-07 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pruritus of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-09-15 00:00:00, ended at 2015-09-15 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pruritus of skin\n\n### Drug\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-09-27, presumably until 2016-01-16, with intended 3 refill(s). Instructions: take 1 Cap by mouth 3 times a day Start 1 tab daily on day 1, then 1 tab twice a day on day 2 and then increase to 1 tab 3 times a day thereafter.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-31 10:03:41, ended at 2015-10-31 10:54:57\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of one extremity; 1-4 muscle(s)\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Spasm\n- Spastic hemiplegia of nondominant side\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, through Intramuscular route, started on 2015-10-31, presumably until 2015-10-31, with intended 0 refill(s). Instructions: inject 300 Units into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- finasteride 5 MG Oral Tablet, started on 2015-11-03, presumably until 2016-08-14, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-08 00:00:00, ended at 2015-11-08 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, started on 2015-11-08, presumably until 2016-02-08, with intended 0 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-12-25 00:00:00, ended at 2015-12-25 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Inflammatory dermatosis\n- Primary diagnosis: Pruritic rash\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-12-25, presumably until 2015-12-26, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-26 10:08:02, ended at 2015-12-26 11:36:10\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Epidermoid cyst\n- Inflammatory dermatosis\n- Primary diagnosis: Pruritic rash\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-12-26, presumably until 2016-06-06, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2015-12-26, presumably until 2016-01-18, with intended 3 refill(s). Instructions: Apply topically as directed twice daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-09 00:00:00, ended at 2016-01-09 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, started on 2016-01-10, presumably until 2016-02-27, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2016-01-16 13:20:00, ended at 2016-01-18 13:21:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.21 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.79 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.3 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.1 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Left ventricular Ejection fraction: 52.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.41 (micro-international unit per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Hospital discharge day management; 30 minutes or less\n- Physical therapy evaluation\n- Collection of venous blood by venipuncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Occupational therapy evaluation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Evaluation of oral and pharyngeal swallowing function\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Excision of Abdomen Skin, External Approach, Diagnostic\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n\n### Condition\n- Lesion of oral mucosa\n- Cardiomegaly\n- Celiac disease\n- Essential hypertension\n- Hyperlipidemia\n- Localization-related idiopathic epilepsy\n- Tachycardia\n- Blood chemistry abnormal\n- Disorder of nail\n- Primary diagnosis: Generalized skin eruption caused by drug and medicament\n- Late effects of cerebrovascular disease\n- Restlessness and agitation\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n- Pruritic rash\n- Myocarditis\n- Chest pain\n- Neurogenic bladder\n- Electrocardiogram abnormal\n- Major depression, single episode\n- Urticaria\n- Benign prostatic hyperplasia\n- Inflammatory dermatosis\n- Cough\n- Eosinophil count raised\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-01-16, presumably until 2016-01-16\n- triamcinolone acetonide 0.001 MG/MG Topical Ointment, through Topical route, started on 2016-01-16, presumably until 2016-01-19, with intended 0 refill(s). Instructions: Apply thin layer to body rash twice a day\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-17\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2016-01-16, presumably until 2017-01-16, with intended 0 refill(s). Instructions: Apply twice a day to face rash\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-16\n- cetirizine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-01-18, presumably until 2017-01-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning after breakfast\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-17\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2016-01-16, presumably until 2016-04-10, with intended 0 refill(s). Instructions: 5 mL by Swish & Swallow route 4 times a day\n- cholecalciferol 0.025 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2017-01-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2016-01-16, presumably until 2016-01-16\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-01-18, presumably until 2016-01-18\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2016-01-16, presumably until 2016-01-16\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2017-01-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day Dose will be adjusted at neurology clinic appointment\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2015-10-26, presumably until 2017-06-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- camphor 5 MG/ML / menthol 5 MG/ML Topical Lotion, through Topical route, started on 2016-01-18, presumably until 2017-07-09, with intended 0 refill(s). Instructions: by Topical route every hour as needed\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-01-16, presumably until 2016-01-17\n- prednisone 50 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-31, with intended 0 refill(s). Instructions: take 1.5 Tabs by mouth daily For at least 1 week - dose tapering will be adjusted at dermatology appointment\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2017-01-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- methylprednisolone 125 MG Injection, started on 2016-01-16, presumably until 2016-01-16\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-17\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2016-01-17, presumably until 2017-01-16, with intended 3 refill(s). Instructions: Apply topically - thin film, twice daily to entire body rash.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-23 00:00:00, ended at 2016-01-23 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pruritic rash\n\n### Drug\n- fluocinonide 0.5 MG/ML Topical Solution, started on 2016-01-23, presumably until 2016-01-23, with intended 1 refill(s). Instructions: Apply topically twice daily to scalp for itching\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-25 10:02:14, ended at 2016-01-25 10:34:51\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Generalized skin eruption caused by drug and medicament\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2016-01-25, presumably until 2016-02-12, with intended 1 refill(s). Instructions: Take 1- 2 tablets daily as directed.  Follow written taper directions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-01-25 12:47:00, ended at 2016-01-25 16:22:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 89 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.2 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 339 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.46 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.78 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Cardiomyopathy\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n- Disorientated\n- Left anterior fascicular block\n- Essential hypertension\n- Conduct disorder\n- Electrocardiogram abnormal\n- Epilepsy\n- Hyperlipidemia\n- Ventricular premature complex\n- Dependence on wheelchair\n- Primary diagnosis: Restlessness and agitation\n\n### Drug\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-25, presumably until 2016-03-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-30 00:00:00, ended at 2016-01-30 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, started on 2016-02-01, presumably until 2016-08-14, with intended 11 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-31 09:35:47, ended at 2016-01-31 10:35:18\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized skin eruption caused by drug and medicament\n- Primary diagnosis: Refractory migraine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-06 15:07:50, ended at 2016-02-06 15:41:07\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Spontaneous cerebral hemorrhage\n- Generalized skin eruption caused by drug and medicament\n- Primary diagnosis: Spastic hemiplegia\n- Abnormal involuntary movement\n- Cerebral infarction\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-02-08 00:00:00, ended at 2016-02-08 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, started on 2016-02-08, presumably until 2016-08-14, with intended 12 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-23 00:00:00, ended at 2016-02-23 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hematuria co-occurrent and due to acute cystitis\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2016-02-23, presumably until 2016-03-04, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-02-27 00:00:00, ended at 2016-02-27 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, through Oral route, started on 2016-02-27, presumably until 2016-02-27, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-27 00:00:00, ended at 2016-02-27 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, through Oral route, started on 2016-02-27, presumably until 2017-03-27, with intended 11 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-02-27 00:00:00, ended at 2016-02-27 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized skin eruption caused by drug and medicament\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2016-02-27, presumably until 2016-04-10, with intended 1 refill(s). Instructions: Take 3 tablets daily as directed.  Follow written taper directions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-01 00:00:00, ended at 2016-03-01 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2016-03-01, presumably until 2016-08-06, with intended 4 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-06 00:00:00, ended at 2016-03-06 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07, with intended 0 refill(s). Instructions: INJECT 1 ML INTO A MUSCLE EVERY MONTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-03-16 15:52:00, ended at 2016-03-16 16:47:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 11 - 20 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute cystitis\n- Dysuria\n- Cardiomyopathy\n- Essential hypertension\n- Insomnia\n- Finding of frequency of urination\n- Hyperlipidemia\n- Neurogenic bladder\n- Benign prostatic hyperplasia\n- Major depression, single episode\n- Sick sinus syndrome\n- Localization-related idiopathic epilepsy\n- Celiac disease\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2016-03-16, presumably until 2016-03-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-21 13:45:00, ended at 2016-03-21 23:59:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 53.1 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Myocarditis\n- Generalized skin eruption caused by drug and medicament\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-04-10 00:00:00, ended at 2016-04-10 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2016-04-10, presumably until 2017-07-09, with intended 11 refill(s). Instructions: 1-2 Sprays by Nasal route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-10 10:23:36, ended at 2016-04-10 11:12:02\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related idiopathic epilepsy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-18 00:00:00, ended at 2016-04-18 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-18 00:00:00, ended at 2016-04-18 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-18 10:41:55, ended at 2016-04-18 17:29:12\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Urinary tract infectious disease\n- Primary diagnosis: Acute cystitis\n- Dysuria\n\n### Drug\n- ciprofloxacin 250 MG Oral Tablet, through Oral route, started on 2016-04-18, presumably until 2016-05-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-04-18, presumably until 2016-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, started on 2016-05-01, presumably until 2017-06-12, with intended 12 refill(s). Instructions: INJECT 1 ML INTO A MUSCLE EVERY MONTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-01 13:15:57, ended at 2016-05-01 15:30:05\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urge incontinence of urine\n- Nocturia\n- Urgent desire to urinate\n- Primary diagnosis: Urinary tract infectious disease\n- Finding of frequency of urination\n- Neurogenic bladder\n\n### Drug\n- cephalexin 250 MG Oral Tablet, through Oral route, started on 2016-05-01, presumably until 2017-05-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-06 00:00:00, ended at 2016-06-06 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pruritic rash\n- Inflammatory dermatosis\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-06-10, presumably until 2016-06-11, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-07 00:00:00, ended at 2016-06-07 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simvastatin 20 MG Oral Tablet, started on 2016-06-07, presumably until 2017-06-12, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-11 00:00:00, ended at 2016-06-11 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Inflammatory dermatosis\n- Pruritic rash\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-06-11, presumably until 2017-06-11, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-18 15:11:56, ended at 2016-06-18 15:42:17\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n- Chemodenervation of one extremity; 1-4 muscle(s)\n\n### Condition\n- Cerebral infarction\n- Spastic hemiplegia\n- Muscle contracture\n- Spasm\n- Spastic hemiplegia of nondominant side\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, started on 2016-06-18, presumably until 2016-06-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-22 00:00:00, ended at 2016-07-22 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-07-22, presumably until 2017-02-25, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-06 00:00:00, ended at 2016-08-06 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- divalproex sodium 500 MG Delayed Release Oral Tablet, started on 2016-08-07, presumably until 2016-12-02, with intended 6 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-14 10:55:59, ended at 2016-08-14 11:34:12\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemiplegia\n- Primary diagnosis: Localization-related idiopathic epilepsy\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-09-16 22:10:00, ended at 2013-09-28 16:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 25.0 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 323 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 100 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.3 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.43 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 151 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 44.1 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Base excess in Blood by calculation: 0.0 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 97.8 (femtoliter)\n- Prothrombin time (PT): 15.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Left ventricular Ejection fraction: 57 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.2 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 224 (millimeter mercury column)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.7 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 118 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 167 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.73 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n\n### Procedure\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Occupational therapy evaluation\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual\n- Injection or infusion of thrombolytic agent\n- Computer assisted surgery with CT/CTA\n- Prophylactic administration of vaccine against other diseases\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Evaluation of oral and pharyngeal swallowing function\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Evaluation of speech, language, voice, communication, and/or auditory processing\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Removal of other therapeutic device\n- Computed tomography, head or brain; without contrast material\n- Radiologic examination, abdomen; single anteroposterior view\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography guidance for stereotactic localization\n- Other incision of brain\n- Physical therapy evaluation\n- Insertion or replacement of external ventricular drain [EVD]\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view, frontal\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Cardiac arrhythmia\n- Flaccid hemiplegia\n- Essential hypertension\n- Localized swelling, mass and lump, trunk\n- Primary cardiomyopathy\n- Amyloidosis\n- Cardiomegaly\n- Primary diagnosis: Cerebral hemorrhage\n- Electrocardiogram abnormal\n- Lung field abnormal\n- Supraventricular premature beats\n- Swelling / lump finding\n- Weakness of face muscles\n- Cerebral embolism\n- Inflammatory dermatosis\n- Celiac disease\n- Compression of brain\n- Dysarthria\n- Left bundle branch hemiblock\n- Pain in limb\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Hyperlipidemia\n- Atelectasis\n- Cerebrovascular disease\n- Clostridioides difficile infection\n- Dysphagia\n- Finding of head and neck region\n- Hemi-neglect\n- Disorder of brain\n- Vitamin B deficiency\n- Cerebral edema\n\n### Drug\n- vitamin K1 5 MG Oral Tablet, through Oral route, started on 2013-09-19, presumably until 2013-09-22\n- sodium chloride 1000 MG Oral Tablet, through Oral route, started on 2013-09-21, presumably until 2013-09-28, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals.\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2013-09-27, presumably until 2014-02-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed.\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2013-09-22, presumably until 2014-02-25. Instructions: take 10 mg by mouth every bedtime.\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2013-09-17, presumably until 2013-09-18\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2013-09-18, presumably until 2013-09-23\n- Lacticaseibacillus rhamnosus GG 15000000000 UNT Oral Capsule, through Oral route, started on 2013-09-28, presumably until 2013-09-28\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2013-09-18, presumably until 2013-09-23\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-25, presumably until 2013-09-27\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2013-09-22, presumably until 2013-09-26\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-22\n- 500 ML sodium chloride 30 MG/ML Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-22\n- sodium chloride 9 MG/ML Injection, started on 2013-09-19, presumably until 2013-09-19\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-09-27, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-09-23, presumably until 2014-09-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2013-09-21, presumably until 2015-02-01. Instructions: take 5 mg by mouth daily.\n- sodium chloride 234 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-18, presumably until 2013-09-18\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2013-09-24, presumably until 2013-09-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2013-09-24, presumably until 2013-11-04, with intended 0 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) every 8 hours.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-09-27, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2013-09-18, presumably until 2013-09-26\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2013-09-18, presumably until 2013-09-23\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-09-21, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily.\n- diphenhydramine hydrochloride 10 MG/ML / zinc acetate 1 MG/ML Topical Cream, through Topical route, started on 2013-09-25, presumably until 2013-11-04, with intended 0 refill(s). Instructions: by Topical route 3 times a day as needed.\n- mineral oil, through Topical route, started on 2013-09-26, presumably until 2013-11-04, with intended 0 refill(s). Instructions: by Topical route as needed.\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2013-09-25, presumably until 2013-09-28\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2013-09-25, presumably until 2013-11-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours.\n- amlodipine 2.5 MG Oral Tablet, through Oral route, started on 2013-09-19, presumably until 2013-09-21\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-18\n- carboxymethylcellulose sodium 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2013-09-21, presumably until 2014-02-25, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes every 8 hours.\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-23\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2013-09-23, presumably until 2013-09-23\n- petrolatum, through Topical route, started on 2013-09-26, presumably until 2013-11-04, with intended 0 refill(s). Instructions: by Topical route as needed.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2018-07-11. Instructions: take 81 mg by mouth daily.\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2013-09-19, presumably until 2013-09-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-09-17 00:00:00, ended at 2013-09-17 00:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intracranial procedures; craniotomy or craniectomy for evacuation of hematoma\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n\n### Condition\n- Hyperlipidemia\n- Essential hypertension\n- Cerebral hemorrhage\n- Compression of brain\n\n### Drug\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-17\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-17\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- remifentanil 2 MG Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-09-17, presumably until 2013-09-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-17, presumably until 2013-09-17\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-09-17 00:00:00, ended at 2013-09-17 00:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- epinephrine 0.005 MG/ML / lidocaine hydrochloride 5 MG/ML Injectable Solution, started on 2013-09-17, presumably until 2013-09-17\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2013-09-17, presumably until 2013-09-17\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, through Topical route, started on 2013-09-17, presumably until 2013-09-17\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2013-09-17, presumably until 2013-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-29 00:00:00, ended at 2013-09-29 00:00:00\nThe patient in this visit was 79 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-11-04 00:00:00, ended at 2013-11-04 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Compression of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-04 13:03:58, ended at 2013-11-04 14:19:37\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- fluoxetine 20 MG Oral Tablet, through Oral route, started on 2013-11-04, presumably until 2014-06-13, with intended 0 refill(s). Instructions: take 20 mg by mouth daily.\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2013-11-04, presumably until 2013-12-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, presumably until 2015-03-07. Instructions: inject 1,000 mcg into a muscle every month.\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, presumably until 2014-11-03. Instructions: take 1 Guariglia by mouth every morning.\n- Saccharomyces boulardii 250 MG Oral Capsule, through Oral route, presumably until 2014-01-03. Instructions: take 1 Cap by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-04 14:09:00, ended at 2013-11-04 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-02 00:00:00, ended at 2013-12-02 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2013-12-02, presumably until 2014-01-05, with intended 0 refill(s). Instructions: TAKE 1 TAB BY MOUTH EVERY BEDTIME.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-03 08:15:00, ended at 2014-01-03 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Swelling / lump finding\n- Finding of head and neck region\n- Aneurysm of artery of neck\n- Cerebral hemorrhage\n- Compression of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-01-03 10:12:03, ended at 2014-01-03 13:41:24\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-01-05 12:59:37, ended at 2014-01-05 14:37:05\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2014-01-05, presumably until 2014-02-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime. 2 tabs at bedtime as needed for sleep\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, presumably until 2014-02-25. Instructions: by Topical route. 1/2 patch on each hip daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-18 00:00:00, ended at 2014-02-18 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 750 MG Oral Tablet, through Oral route, started on 2014-02-18, presumably until 2014-02-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-02-21 00:00:00, ended at 2014-02-21 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-02-21, presumably until 2014-05-05, with intended 1 refill(s). Instructions: TAKE 2 TABLETS AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-22 00:00:00, ended at 2014-02-22 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 250 MG Oral Tablet, through Oral route, started on 2014-02-22, presumably until 2014-02-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-02-25 09:46:16, ended at 2014-02-25 13:29:10\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- simvastatin 20 MG Oral Tablet, through Oral route, presumably until 2015-03-16. Instructions: take 20 mg by mouth every bedtime.\n- levetiracetam 500 MG Oral Tablet, through Oral route, presumably until 2014-03-14. Instructions: take 500 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-07 10:15:47, ended at 2014-03-07 11:24:19\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neurogenic bladder\n\n### Drug\n- oxybutynin chloride 5 MG Oral Tablet, through Oral route, started on 2014-03-07, presumably until 2014-05-31, with intended 11 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime. May increase dose to 1 tab at bedtime if still having incontinence after 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-03-14 00:00:00, ended at 2014-03-14 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levetiracetam 250 MG Oral Tablet, started on 2014-03-14, presumably until 2014-03-14, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-14 00:00:00, ended at 2014-03-14 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2014-03-14, presumably until 2014-07-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-05 00:00:00, ended at 2014-05-05 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-05-05, presumably until 2014-06-13, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-31 11:52:34, ended at 2014-05-31 13:03:34\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral hemorrhage\n- Primary diagnosis: Neurogenic bladder\n\n### Drug\n- trospium chloride 20 MG Oral Tablet, through Oral route, started on 2014-05-31, presumably until 2014-06-27, with intended 3 refill(s). Instructions: take 20 mg by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-31 13:04:17, ended at 2014-05-31 14:57:37\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mild cognitive disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-31 15:06:00, ended at 2014-05-31 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.40 (milli-international unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Mild cognitive disorder\n- Cerebral hemorrhage\n- Neurogenic bladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-06-10 00:00:00, ended at 2014-06-10 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-06-10, presumably until 2014-06-10, with intended 0 refill(s). Instructions: TAKE 2 TABLET BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2014-06-11 02:00:00, ended at 2014-06-13 18:25:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.42 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Base deficit in Blood: 4.0 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- MCV [Entitic volume] by Automated count: 93.3 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 221 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 114 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 5 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.7 (percent)\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Radiologic examination, abdomen; single anteroposterior view\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Physical therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Hospital discharge day management; 30 minutes or less\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cerebral hemorrhage\n- Dehydration\n- Hemiplegia as late effect of cerebrovascular disease\n- Low blood pressure\n- Mild cognitive disorder\n- Celiac disease\n- Hypokalemia\n- Primary cardiomyopathy\n- Primary diagnosis: Vomiting\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Diarrhea\n- Functional disorder of intestine\n- Tachycardia\n- Essential hypertension\n- Hyperlipidemia\n- Neurogenic bladder\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2014-06-12, presumably until 2014-06-13\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2014-06-12, presumably until 2015-06-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day as needed for Diarrhea.\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2014-06-11, presumably until 2014-06-12\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2014-06-12, presumably until 2014-06-12\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-12\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-06-11, presumably until 2014-06-13\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2014-06-12, presumably until 2014-06-12\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-12\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- sennosides, USP 8.6 MG Oral Capsule, through Oral route, started on 2014-06-13, presumably until 2014-06-27, with intended 3 refill(s). Instructions: take 2 Caps by mouth daily as needed (no bowel movement for 24 hours).\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-06-13, presumably until 2014-06-27, with intended 3 refill(s). Instructions: take 1 Packet by mouth daily as needed (no bowel movement for 24 hours).\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2014-06-11, presumably until 2014-06-12\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2014-06-11, presumably until 2014-06-13\n- triamcinolone acetonide 1 MG/ML Topical Cream, through Topical route, started on 2014-06-13, presumably until 2014-10-25, with intended 0 refill(s). Instructions: Apply to rash once daily. Reassess with your doctor in 2-3 weeks for improvement.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-06-13 00:00:00, ended at 2014-06-13 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-06-13, presumably until 2014-09-05, with intended 0 refill(s). Instructions: TAKE 2 TABLET BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-14 17:13:00, ended at 2014-06-14 23:59:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Seizure\n- Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-27 14:29:11, ended at 2014-06-27 16:26:49\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Infectious diarrheal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-06 15:15:25, ended at 2014-07-06 17:33:59\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- fluoxetine 20 MG Oral Capsule, through Oral route, presumably until 2015-02-01, with intended 0 refill(s). Instructions: take  by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-07-15 00:00:00, ended at 2014-07-15 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2014-07-15, presumably until 2014-07-15, with intended 0 refill(s). Instructions: APPLY TO RASH DAILY REASSESS WITH YOUR DOCTOR IN 2-3 WEEKS FOR IMPROVEMENT\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-07-18 00:00:00, ended at 2014-07-18 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levetiracetam 500 MG Oral Tablet, started on 2014-07-18, presumably until 2014-10-25, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-09-05 00:00:00, ended at 2014-09-05 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-09-05, presumably until 2014-10-25, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-05 00:00:00, ended at 2014-10-05 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Localization-related epilepsy\n- Cerebral hemorrhage\n\n### Drug\n- lacosamide 50 MG Oral Tablet, through Oral route, started on 2014-10-05, presumably until 2014-10-25, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Start 50 mg twice a day by mouth; continue for 7 days; increase to 100 mg bid. Once on 100 mg bid for 5 days, stop keppra.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-06 00:00:00, ended at 2014-10-06 00:00:00\nThe patient in this visit was 80 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eruption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-20 00:00:00, ended at 2014-10-20 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Mild cognitive disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-25 08:42:00, ended at 2014-10-25 11:09:19\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Localization-related epilepsy\n- Neurogenic bladder\n- Anemia\n- Cerebral hemorrhage\n- Vitamin B deficiency\n- Hyperplasia of prostate\n- Adjustment disorder with depressed mood\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2014-10-25, presumably until 2015-11-03, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n- hydroxyzine hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2014-10-25, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime.\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2014-10-25, presumably until 2014-10-26, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- 0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection, through Subcutaneous route, started on 2014-10-25, presumably until 2014-10-26, with intended 0 refill(s). Instructions: inject 0.65 mL subcutaneous (under the skin) One Time.\n- lacosamide 100 MG Oral Tablet, through Oral route, presumably until 2015-01-21, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day.\n- trazodone hydrochloride 100 MG Oral Tablet, through Oral route, presumably until 2014-12-12, with intended 0 refill(s). Instructions: take 100 mg by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-25 11:18:00, ended at 2014-10-25 23:59:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 282 (microgram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 111 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 71 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 25 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cerebral hemorrhage\n- Vitamin B deficiency\n- Adjustment disorder with depressed mood\n- Hyperplasia of prostate\n- Anemia\n- Localization-related epilepsy\n- Neurogenic bladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-25 14:09:39, ended at 2014-10-25 15:22:27\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)\n\n### Condition\n- Verruca vulgaris\n- Pruritus of skin\n- Benign neoplasm of skin of trunk\n- Primary diagnosis: Inflammatory dermatosis\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- triamcinolone acetonide 0.001 MG/MG Topical Ointment, started on 2014-10-25, presumably until 2015-10-25, with intended 12 refill(s). Instructions: Apply topically as directed daily alternate with moisturizer\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2014-10-25, presumably until 2015-01-31, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime. Take 30 minutes before bedtime as needed.\n- fluocinonide 0.5 MG/ML Topical Solution, started on 2014-10-25, presumably until 2016-01-17, with intended 12 refill(s). Instructions: Apply topically twice daily to scalp for itching\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-28 00:00:00, ended at 2014-10-28 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2014-10-28, presumably until 2015-02-01, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-28 00:00:00, ended at 2014-10-28 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2014-10-28, presumably until 2015-02-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth Every Day. Start after completion of KEFLEX antibiotic\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-03 00:00:00, ended at 2014-11-03 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2014-11-03, presumably until 2015-11-08, with intended 3 refill(s). Instructions: take 1 Gillihan by mouth every morning.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-12-11 00:00:00, ended at 2014-12-11 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2014-12-11, presumably until 2015-03-16, with intended 0 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-05 00:00:00, ended at 2015-01-05 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Hemiplegia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-17 15:36:18, ended at 2015-01-17 16:41:28\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n- Chemodenervation of trunk muscle(s); 1-5 muscle(s)\n- Chemodenervation of one extremity; 1-4 muscle(s)\n\n### Condition\n- Hemiplegia as late effect of cerebrovascular disease\n- Spasm\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, through Intramuscular route, started on 2015-01-17, presumably until 2015-04-11, with intended 0 refill(s). Instructions: inject 200 Units into a muscle One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-20 00:00:00, ended at 2015-01-20 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2015-01-20, presumably until 2015-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-01-21 00:00:00, ended at 2015-01-21 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lacosamide 100 MG Oral Tablet, started on 2015-01-21, presumably until 2015-04-12, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-21 15:43:00, ended at 2015-01-21 23:59:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-31 13:12:28, ended at 2015-01-31 13:59:47\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Inflammatory dermatosis\n- Pruritus of skin\n- Dermatographic urticaria\n- Inflamed seborrheic keratosis\n- Sebaceous cyst of skin\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-01-31, presumably until 2015-12-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime. Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-01 11:06:03, ended at 2015-02-01 13:10:26\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Neurogenic bladder\n- Hallucinations\n- Urinary tract infectious disease\n- Primary diagnosis: Dysuria\n\n### Drug\n- 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumo..., through Intramuscular route, started on 2015-02-01, presumably until 2015-02-02, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- methenamine hippurate 1000 MG Oral Tablet, through Oral route, started on 2015-02-01, presumably until 2015-05-04, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, through Oral route, started on 2015-02-01, presumably until 2016-01-30, with intended 11 refill(s). Instructions: take 1 Cap by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-16 14:07:36, ended at 2015-02-16 17:13:02\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dementia\n- Primary diagnosis: Hallucinations\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-17 00:00:00, ended at 2015-02-17 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mild cognitive disorder\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, started on 2015-02-17, presumably until 2015-07-14, with intended 3 refill(s). Instructions: Take 2.5 mg (1/2 tab) daily for 2 weeks PO then increase by 2.5 mg (1/2 tab) every two weeks until you reach 10 mg per day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-07 00:00:00, ended at 2015-03-07 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, through Intramuscular route, started on 2015-03-07, presumably until 2016-01-17, with intended 12 refill(s). Instructions: inject 1 mL into a muscle every month.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-03-13 00:00:00, ended at 2015-03-13 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-14 14:07:06, ended at 2015-03-14 16:22:30\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Altered mental status\n\n### Drug\n- clotrimazole 10 MG/ML Topical Cream, started on 2015-03-14, presumably until 2015-05-04, with intended 0 refill(s). Instructions: Apply twice daily to affected areas for 7 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-16 00:00:00, ended at 2015-03-16 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2015-03-16, presumably until 2016-06-07, with intended 12 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-16 00:00:00, ended at 2015-03-16 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2015-03-16, presumably until 2016-01-16, with intended 1 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH AT BEDTIME AS NEEDED FOR SLEEP\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-11 15:59:56, ended at 2015-04-11 17:00:37\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of one extremity; 1-4 muscle(s)\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Hemiplegia as late effect of cerebrovascular disease\n- Spasm\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, through Intramuscular route, started on 2015-04-11, presumably until 2015-04-11, with intended 0 refill(s). Instructions: inject 400 Units into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2015-04-12 10:40:00, ended at 2015-04-12 15:09:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 226 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.63 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest; single view, frontal\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Computed tomography, head or brain; without contrast material\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Seizure\n- Hyperlipidemia\n- Lung field abnormal\n- Essential hypertension\n- Localization-related epilepsy\n- Celiac disease\n- Disorder of brain\n- Depressive disorder\n- Epilepsy\n- Benign prostatic hyperplasia without outflow obstruction\n\n### Drug\n- lacosamide 150 MG Oral Tablet, through Oral route, started on 2015-04-12, presumably until 2015-04-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-04-14 00:00:00, ended at 2015-04-14 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n- Primary diagnosis: Refractory epilepsy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-19 00:00:00, ended at 2015-04-19 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lacosamide 150 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2015-04-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-04-19 00:00:00, ended at 2015-04-19 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- lacosamide 200 MG Oral Tablet, through Oral route, started on 2015-04-19, presumably until 2016-01-16, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-04 10:22:49, ended at 2015-05-04 11:32:01\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Mild cognitive disorder\n- Electrocardiogram abnormal\n- Primary diagnosis: Benign essential hypertension\n- Left bundle branch hemiblock\n- Cardiomegaly\n\n### Drug\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2015-05-04, presumably until 2015-07-14, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime as needed\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2015-05-04, presumably until 2016-01-17, with intended 1 refill(s). Instructions: take 0.5 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-04 11:36:00, ended at 2015-05-04 23:59:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mild cognitive disorder\n- Benign essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-05-08 00:00:00, ended at 2015-05-08 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-06-15 00:00:00, ended at 2015-06-15 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-28 09:51:18, ended at 2015-06-28 15:13:51\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related epilepsy\n\n### Drug\n- levetiracetam 250 MG Oral Tablet, started on 2015-06-28, presumably until 2016-01-16, with intended 10 refill(s). Instructions: Take two tablets BID\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-03 00:00:00, ended at 2015-07-03 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n- Localization-related epilepsy\n\n### Drug\n- oxcarbazepine 300 MG Oral Tablet, through Oral route, started on 2015-07-03, presumably until 2016-01-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-07-12 00:00:00, ended at 2015-07-12 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, started on 2015-07-14, presumably until 2015-07-14, with intended 0 refill(s). Instructions: TAKE 2.5MG(1/2 TABLET) BY MOUTH EVERY DAY FOR 2 WEEKS THEN INCREASE 2.5MG(1/2 TABLET) EVERY TWO WEEKS UNTIL YOU REACH 10MG PER DAY\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-07-14, presumably until 2016-07-13, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-13 00:00:00, ended at 2015-07-13 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2015-07-14, presumably until 2015-08-14, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-14 00:00:00, ended at 2015-08-14 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, through Oral route, started on 2015-08-14, presumably until 2016-01-09, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-15 12:41:00, ended at 2015-08-15 14:13:14\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Squamous cell carcinoma of upper extremity\n- Neoplasm of uncertain behavior of skin\n- Inflammatory dermatosis\n- Sebaceous cyst of skin\n- Primary diagnosis: Pruritus of skin\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-08-15, presumably until 2015-12-25, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2015-08-15, presumably until 2015-12-26, with intended 3 refill(s). Instructions: Apply topically as directed twice daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-09-07 00:00:00, ended at 2015-09-07 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pruritus of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-09-15 00:00:00, ended at 2015-09-15 00:00:00\nThe patient in this visit was 81 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pruritus of skin\n\n### Drug\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-09-27, presumably until 2016-01-16, with intended 3 refill(s). Instructions: take 1 Cap by mouth 3 times a day Start 1 tab daily on day 1, then 1 tab twice a day on day 2 and then increase to 1 tab 3 times a day thereafter.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-31 10:03:41, ended at 2015-10-31 10:54:57\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemodenervation of one extremity; 1-4 muscle(s)\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Cerebral infarction due to thrombosis of cerebral arteries\n- Spasm\n- Spastic hemiplegia of nondominant side\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, through Intramuscular route, started on 2015-10-31, presumably until 2015-10-31, with intended 0 refill(s). Instructions: inject 300 Units into a muscle One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- finasteride 5 MG Oral Tablet, started on 2015-11-03, presumably until 2016-08-14, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-08 00:00:00, ended at 2015-11-08 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, started on 2015-11-08, presumably until 2016-02-08, with intended 0 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-12-25 00:00:00, ended at 2015-12-25 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Inflammatory dermatosis\n- Primary diagnosis: Pruritic rash\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-12-25, presumably until 2015-12-26, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-26 10:08:02, ended at 2015-12-26 11:36:10\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Epidermoid cyst\n- Inflammatory dermatosis\n- Primary diagnosis: Pruritic rash\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2015-12-26, presumably until 2016-06-06, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2015-12-26, presumably until 2016-01-18, with intended 3 refill(s). Instructions: Apply topically as directed twice daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-09 00:00:00, ended at 2016-01-09 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, started on 2016-01-10, presumably until 2016-02-27, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2016-01-16 13:20:00, ended at 2016-01-18 13:21:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.21 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.79 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.3 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.1 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Left ventricular Ejection fraction: 52.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.41 (micro-international unit per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Hospital discharge day management; 30 minutes or less\n- Physical therapy evaluation\n- Collection of venous blood by venipuncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Occupational therapy evaluation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Evaluation of oral and pharyngeal swallowing function\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Excision of Abdomen Skin, External Approach, Diagnostic\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n\n### Condition\n- Lesion of oral mucosa\n- Cardiomegaly\n- Celiac disease\n- Essential hypertension\n- Hyperlipidemia\n- Localization-related idiopathic epilepsy\n- Tachycardia\n- Blood chemistry abnormal\n- Disorder of nail\n- Primary diagnosis: Generalized skin eruption caused by drug and medicament\n- Late effects of cerebrovascular disease\n- Restlessness and agitation\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n- Pruritic rash\n- Myocarditis\n- Chest pain\n- Neurogenic bladder\n- Electrocardiogram abnormal\n- Major depression, single episode\n- Urticaria\n- Benign prostatic hyperplasia\n- Inflammatory dermatosis\n- Cough\n- Eosinophil count raised\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-01-16, presumably until 2016-01-16\n- triamcinolone acetonide 0.001 MG/MG Topical Ointment, through Topical route, started on 2016-01-16, presumably until 2016-01-19, with intended 0 refill(s). Instructions: Apply thin layer to body rash twice a day\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-17\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2016-01-16, presumably until 2017-01-16, with intended 0 refill(s). Instructions: Apply twice a day to face rash\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-16\n- cetirizine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-01-18, presumably until 2017-01-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning after breakfast\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-17\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2016-01-16, presumably until 2016-04-10, with intended 0 refill(s). Instructions: 5 mL by Swish & Swallow route 4 times a day\n- cholecalciferol 0.025 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2017-01-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2016-01-16, presumably until 2016-01-16\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-01-18, presumably until 2016-01-18\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2016-01-16, presumably until 2016-01-16\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2017-01-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day Dose will be adjusted at neurology clinic appointment\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2015-10-26, presumably until 2017-06-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- camphor 5 MG/ML / menthol 5 MG/ML Topical Lotion, through Topical route, started on 2016-01-18, presumably until 2017-07-09, with intended 0 refill(s). Instructions: by Topical route every hour as needed\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-01-16, presumably until 2016-01-17\n- prednisone 50 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-31, with intended 0 refill(s). Instructions: take 1.5 Tabs by mouth daily For at least 1 week - dose tapering will be adjusted at dermatology appointment\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2017-01-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-17, presumably until 2016-01-18\n- methylprednisolone 125 MG Injection, started on 2016-01-16, presumably until 2016-01-16\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-01-16, presumably until 2016-01-17\n- triamcinolone acetonide 1 MG/ML Topical Cream, started on 2016-01-17, presumably until 2017-01-16, with intended 3 refill(s). Instructions: Apply topically - thin film, twice daily to entire body rash.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-23 00:00:00, ended at 2016-01-23 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pruritic rash\n\n### Drug\n- fluocinonide 0.5 MG/ML Topical Solution, started on 2016-01-23, presumably until 2016-01-23, with intended 1 refill(s). Instructions: Apply topically twice daily to scalp for itching\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-25 10:02:14, ended at 2016-01-25 10:34:51\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Generalized skin eruption caused by drug and medicament\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2016-01-25, presumably until 2016-02-12, with intended 1 refill(s). Instructions: Take 1- 2 tablets daily as directed.  Follow written taper directions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-01-25 12:47:00, ended at 2016-01-25 16:22:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 89 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.2 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 339 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.46 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.78 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Cardiomyopathy\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n- Disorientated\n- Left anterior fascicular block\n- Essential hypertension\n- Conduct disorder\n- Electrocardiogram abnormal\n- Epilepsy\n- Hyperlipidemia\n- Ventricular premature complex\n- Dependence on wheelchair\n- Primary diagnosis: Restlessness and agitation\n\n### Drug\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-25, presumably until 2016-03-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-30 00:00:00, ended at 2016-01-30 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, started on 2016-02-01, presumably until 2016-08-14, with intended 11 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-31 09:35:47, ended at 2016-01-31 10:35:18\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized skin eruption caused by drug and medicament\n- Primary diagnosis: Refractory migraine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-06 15:07:50, ended at 2016-02-06 15:41:07\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Spontaneous cerebral hemorrhage\n- Generalized skin eruption caused by drug and medicament\n- Primary diagnosis: Spastic hemiplegia\n- Abnormal involuntary movement\n- Cerebral infarction\n- Paralytic syndrome on one side of the body as late effect of cerebrovascular accident\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-02-08 00:00:00, ended at 2016-02-08 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, started on 2016-02-08, presumably until 2016-08-14, with intended 12 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-23 00:00:00, ended at 2016-02-23 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hematuria co-occurrent and due to acute cystitis\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2016-02-23, presumably until 2016-03-04, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-02-27 00:00:00, ended at 2016-02-27 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, through Oral route, started on 2016-02-27, presumably until 2016-02-27, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-27 00:00:00, ended at 2016-02-27 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- quetiapine 50 MG Oral Tablet, through Oral route, started on 2016-02-27, presumably until 2017-03-27, with intended 11 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-02-27 00:00:00, ended at 2016-02-27 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized skin eruption caused by drug and medicament\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2016-02-27, presumably until 2016-04-10, with intended 1 refill(s). Instructions: Take 3 tablets daily as directed.  Follow written taper directions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-01 00:00:00, ended at 2016-03-01 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2016-03-01, presumably until 2016-08-06, with intended 4 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-06 00:00:00, ended at 2016-03-06 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07, with intended 0 refill(s). Instructions: INJECT 1 ML INTO A MUSCLE EVERY MONTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-03-16 15:52:00, ended at 2016-03-16 16:47:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 11 - 20 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute cystitis\n- Dysuria\n- Cardiomyopathy\n- Essential hypertension\n- Insomnia\n- Finding of frequency of urination\n- Hyperlipidemia\n- Neurogenic bladder\n- Benign prostatic hyperplasia\n- Major depression, single episode\n- Sick sinus syndrome\n- Localization-related idiopathic epilepsy\n- Celiac disease\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2016-03-16, presumably until 2016-03-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-21 13:45:00, ended at 2016-03-21 23:59:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 53.1 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Myocarditis\n- Generalized skin eruption caused by drug and medicament\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-04-10 00:00:00, ended at 2016-04-10 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2016-04-10, presumably until 2017-07-09, with intended 11 refill(s). Instructions: 1-2 Sprays by Nasal route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-10 10:23:36, ended at 2016-04-10 11:12:02\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localization-related idiopathic epilepsy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-18 00:00:00, ended at 2016-04-18 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-18 00:00:00, ended at 2016-04-18 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-18 10:41:55, ended at 2016-04-18 17:29:12\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Urinary tract infectious disease\n- Primary diagnosis: Acute cystitis\n- Dysuria\n\n### Drug\n- ciprofloxacin 250 MG Oral Tablet, through Oral route, started on 2016-04-18, presumably until 2016-05-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-04-18, presumably until 2016-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin B12 1 MG/ML Injectable Solution, started on 2016-05-01, presumably until 2017-06-12, with intended 12 refill(s). Instructions: INJECT 1 ML INTO A MUSCLE EVERY MONTH\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-01 13:15:57, ended at 2016-05-01 15:30:05\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Urge incontinence of urine\n- Nocturia\n- Urgent desire to urinate\n- Primary diagnosis: Urinary tract infectious disease\n- Finding of frequency of urination\n- Neurogenic bladder\n\n### Drug\n- cephalexin 250 MG Oral Tablet, through Oral route, started on 2016-05-01, presumably until 2017-05-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-06 00:00:00, ended at 2016-06-06 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pruritic rash\n- Inflammatory dermatosis\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-06-10, presumably until 2016-06-11, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-07 00:00:00, ended at 2016-06-07 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simvastatin 20 MG Oral Tablet, started on 2016-06-07, presumably until 2017-06-12, with intended 12 refill(s). Instructions: TAKE 1 TABLET BY MOUTH AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-11 00:00:00, ended at 2016-06-11 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Inflammatory dermatosis\n- Pruritic rash\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-06-11, presumably until 2017-06-11, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime as needed for Itching Take 30 minutes before bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-18 15:11:56, ended at 2016-06-18 15:42:17\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)\n- Chemodenervation of one extremity; 1-4 muscle(s)\n\n### Condition\n- Cerebral infarction\n- Spastic hemiplegia\n- Muscle contracture\n- Spasm\n- Spastic hemiplegia of nondominant side\n\n### Drug\n- onabotulinumtoxinA 100 UNT Injection, started on 2016-06-18, presumably until 2016-06-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-22 00:00:00, ended at 2016-07-22 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-07-22, presumably until 2017-02-25, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-06 00:00:00, ended at 2016-08-06 00:00:00\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- divalproex sodium 500 MG Delayed Release Oral Tablet, started on 2016-08-07, presumably until 2016-12-02, with intended 6 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-14 10:55:59, ended at 2016-08-14 11:34:12\nThe patient in this visit was 82 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemiplegia\n- Primary diagnosis: Localization-related idiopathic epilepsy\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "015e41a9dc25a6538076d0a813d85976e46faad6d8d89d4fafdb6dd002710b39", "prompt_hash": "08dba59ef3b12b47ec01c09afd188c373703dac14d0f2edf61ea1544a697dea1", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 5, "doc": {"person_id": 115968604, "visit_occurrence_id": 59135860, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2013-12-31 11:11:06", "visit_end_datetime": "2013-12-31 12:25:25", "visit_length_in_hours": 1.238611111111111, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2013-12-31 11:11:06, ended at 2013-12-31 12:25:25\nThe patient in this visit was 78 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Primary diagnosis: Closed fracture of femoral condyle of femur\n- Knee joint effusion\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 102, "patient_first_visit_date": "2008-10-29 00:00:00", "patient_last_visit_date": "2015-08-04 00:00:00", "end_obs_date": "2014-12-31", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 1, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 1, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "recurrent", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 47, "cumulated_visit_num": 47, "cumulated_approximate_token_count": 27704, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-29 00:00:00, ended at 2008-10-29 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.83 (million per microliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 389 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- MCV [Entitic volume] by Automated count: 83.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-10-30 07:18:00, ended at 2008-10-30 14:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-31 00:00:00, ended at 2008-10-31 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Retention of urine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-04-13 21:15:00, ended at 2009-04-25 11:15:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.90 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 73.7 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 25.4 (microgram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Body height: 6' 3\" (inch (US))\n- Erythrocyte sedimentation rate: >140 (millimeter per hour)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 182 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.36 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 117 (millimeter mercury column)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.9 (femtoliter)\n- Prothrombin time (PT): 23.5 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 48 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 38.7 (millimeter mercury column)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.78 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.2 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.47 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.0 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 64.3 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 25.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1415 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood: 28 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 34 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 185 (microgram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Blood: 4.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: 1.25 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.7 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 499 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 2.39 (percent)\n- Sodium [Moles/volume] in Blood: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.5 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 18 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of prosthetic joint\n- Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-04-13, presumably until 2009-04-14\n- polysaccharide iron complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous gluconate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous fumarate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- terbinafine 250 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-16. Instructions: take by mouth.\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2009-04-15, presumably until 2009-04-15\n- mineral oil 1000 MG/ML Enema, through Rectal route, started on 2009-04-15, presumably until 2009-04-15\n- ferrous ascorbate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-25\n- iron,peptonized, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous succinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-04-14, presumably until 2009-04-21\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-04-21, presumably until 2009-04-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2009-04-25, presumably until 2009-07-20, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-04-13, presumably until 2014-03-06. Instructions: 1 Puff by Inhalation route 2 times a day. 500 not 100 per Pt's spouse\n- 14 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-04-14, presumably until 2009-04-21\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2009-04-14, presumably until 2009-04-20\n- ferrous bisglycinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous cysteine glycinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous aspartate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ammonium ferrous sulfate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- soy protein-iron complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-07-20, with quantity of 80.0, with intended 0 refill(s). Instructions: take by mouth. \n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- ferrous carbonate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-25\n- ferrous glycine sulfate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- folic acid, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-04-25. Instructions: take by mouth. \n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-04-22\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2009-04-14, presumably until 2009-04-14\n- iron succinyl milk protein complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- iron-dextran complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- teferrol, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-18. Instructions: take by mouth.\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-04-20, presumably until 2009-04-24\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-04-22, presumably until 2009-04-23\n- bupropion hydrochloride 75 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-04-14, presumably until 2009-04-25\n- ferrous asparto glycinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous cacodylate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-04-17, presumably until 2009-04-21\n- metoprolol tartrate 50 MG Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-04-24\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-21. Instructions: take by mouth.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-23\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2009-04-14, presumably until 2009-04-14\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2009-04-14, presumably until 2009-04-25\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2009-04-15, presumably until 2009-04-19\n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2009-04-15, presumably until 2009-04-21\n- iron, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous oxalate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2009-04-22, presumably until 2009-05-30, with quantity of 42.0, with intended 0 refill(s). Instructions: 200 mL by Intravenous route daily. \n- fluoxetine 40 MG Oral Capsule, through Oral route, presumably until 2009-06-17. Instructions: take by mouth. \n- iron sucrose, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous sulfate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- iron carbonyl, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous lactate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous chloride, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-04-16, presumably until 2009-04-20\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-18\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-17\n- iron sorbitex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous phosphate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2009-04-15, presumably until 2009-05-16, with quantity of 20.0, with intended 0 refill(s). Instructions: 0.5-1 mL by Intravenous route every 4 hours as needed \n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-04-13, presumably until 2009-04-21\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-14\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2009-04-16, presumably until 2009-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-06-01 00:00:00, ended at 2009-06-01 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.0 (percent)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 320 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 49 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 5.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Erythrocyte sedimentation rate: 120 (millimeter per hour)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 5.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.74 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-06-22 12:02:00, ended at 2009-07-20 11:15:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 165 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Body height: 6' 3\" (inch (US))\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 6 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 176 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Prothrombin time (PT): N/A (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.20 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.66 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 624 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.31 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.4 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 6 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.57 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 90 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 7.3 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mixed urinary incontinence\n\n### Drug\n- psyllium, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-06-24, presumably until 2010-07-20, with quantity of 30.0, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed for Bronchospasm/Wheezing. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-22, presumably until 2009-06-22\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2009-07-01, presumably until 2009-07-01\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2009-06-29, presumably until 2009-07-12\n- haloperidol 0.5 MG Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-07-02\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2009-07-02, presumably until 2009-07-12\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2009-06-22, presumably until 2009-06-22\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2009-06-29, presumably until 2009-07-15\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-06-24, presumably until 2009-07-20\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2009-06-23, presumably until 2009-07-20\n- 100 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2009-07-09, presumably until 2009-07-10\n- acetaminophen 650 MG Rectal Suppository, through Rectal route, started on 2009-06-23, presumably until 2009-07-11\n- 0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-07-14, presumably until 2010-07-20, with quantity of 30.0, with intended 0 refill(s). Instructions: 0.3 mL by SUBCUTANEOUS route every 7 days. \n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2009-07-18, presumably until 2009-07-18\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2009-07-12, presumably until 2009-07-12\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2009-06-24, presumably until 2009-10-05, with quantity of 30.0, with intended 0 refill(s). Instructions: take 2 Caps by mouth daily. \n- belladonna alkaloids 16.2 MG / opium 60 MG Rectal Suppository, through Rectal route, started on 2009-07-10, presumably until 2009-07-10\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-06-30, presumably until 2009-07-12\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-16\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2009-07-01, presumably until 2009-07-02\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2009-07-01, presumably until 2009-07-01\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2009-06-24, presumably until 2009-06-26\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-06-23, presumably until 2009-07-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-18\n- 1 ML epoetin alfa 10000 UNT/ML Injection, started on 2009-07-13, presumably until 2009-07-13\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2009-06-25, presumably until 2009-06-26\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2009-07-12, presumably until 2009-07-12\n- ispaghula husk, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-23, presumably until 2009-07-01\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2009-06-22, presumably until 2009-07-09\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2009-06-22, presumably until 2009-06-28\n- purified protein derivative of tuberculin 50 UNT/ML Injectable Solution, through Intradermal route, started on 2009-07-17, presumably until 2009-07-17\n- 0.5 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, started on 2009-07-07, presumably until 2009-07-07\n- 10 ML furosemide 10 MG/ML Injection, started on 2009-06-29, presumably until 2009-07-10\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2009-07-03, presumably until 2009-07-16\n- 24 HR metoprolol succinate 50 MG Extended Release Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-08\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-07-14, presumably until 2009-07-20\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2009-06-27, presumably until 2009-07-17\n- soybean oil 200 MG/ML Injectable Suspension, through Intravenous route, started on 2009-07-01, presumably until 2009-07-13\n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2009-07-12, presumably until 2009-10-05, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2009-06-30, presumably until 2009-07-02\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2009-07-14, presumably until 2010-07-20, with quantity of 50.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed \n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2009-06-23, presumably until 2009-06-24\n- 1 ML lorazepam 2 MG/ML Cartridge, started on 2009-07-13, presumably until 2009-07-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-06-25, presumably until 2009-07-14\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-24, presumably until 2009-07-11\n- pravastatin sodium 10 MG Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-26, presumably until 2009-07-15\n- Plantago seed, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- 2 ML heparin sodium, porcine 1000 UNT/ML Injection, started on 2009-07-10, presumably until 2009-07-18\n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2009-06-28, presumably until 2009-07-20\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2009-07-08, presumably until 2009-07-20\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2009-06-25, presumably until 2009-07-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2009-06-22, presumably until 2009-07-07\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-04, presumably until 2010-01-16, with quantity of 50.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2009-07-01, presumably until 2009-07-01\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2009-07-15, presumably until 2009-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-07 11:32:01, ended at 2009-09-07 13:01:11\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance\n\n### Condition\n- Reactive arthritis triad\n- Reactive arthropathy of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-10-05 00:00:00, ended at 2009-10-05 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transient cerebral ischemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-10-05 10:49:15, ended at 2009-10-05 14:10:05\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint pain\n\n### Drug\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2009-10-26. Instructions: by SUBCUTANEOUS route daily. \n- alprazolam 0.5 MG Oral Tablet, through Oral route, presumably until 2011-01-09. Instructions: take by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-08 11:30:00, ended at 2009-10-08 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extracranial arteries; complete bilateral study\n\n### Condition\n- Cerebrovascular disease\n- Disorder of carotid artery\n- Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-10-08 11:35:46, ended at 2009-10-08 15:49:02\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transient cerebral ischemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-10-20 15:06:00, ended at 2009-10-26 14:40:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Body height: 6' 3\" (inch (US))\n- INR in Platelet poor plasma by Coagulation assay: 2.5 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.53 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 352 (millimeter mercury column)\n- Prothrombin time (PT): 26.9 (second)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.49 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.30 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 344 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 18.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 50 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 88 (millimeter per hour)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Base deficit in Blood: 6.0 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 29.8 (millimeter mercury column)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.42 (million per microliter)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 100 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.9 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, knee; 1 or 2 views\n- Division of joint capsule, ligament, or cartilage, knee\n- Revision of knee replacement\n- Radiologic examination, chest; single view, frontal\n- Packed blood cell transfusion\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Local excision of lesion or tissue of tibia and fibula\n- Physical therapy evaluation\n- Synovectomy of knee joint\n- Removal of (cement) spacer\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Occupational therapy evaluation\n\n### Condition\n- Acquired deformity of knee\n- Acute posthemorrhagic anemia\n- Iatrogenic hypotension\n- Chronic obstructive lung disease\n- Coronary arteriosclerosis\n- Lung field abnormal\n- Obstructive sleep apnea syndrome\n- Anxiety state\n- Chronic kidney disease\n- Hyperlipidemia\n- Pleural effusion\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-10-21, presumably until 2009-10-26\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-10-20, presumably until 2009-10-20\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2009-10-24, presumably until 2009-10-26\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-10-20, presumably until 2009-10-20\n- sennosides, USP 1.76 MG/ML Oral Solution, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2009-10-21, presumably until 2009-10-21\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-10-21, presumably until 2009-10-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-10-20, presumably until 2009-10-26\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2009-10-21, presumably until 2009-10-26\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-10-24, presumably until 2009-10-26\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-10-26, presumably until 2009-10-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-23\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-10-21, presumably until 2009-10-23\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-10-23, presumably until 2010-10-26, with quantity of 90.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 4 hours as needed \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-10-27, presumably until 2009-10-27, with intended 0 refill(s). Instructions: 0.4 mL by SUBCUTANEOUS route daily. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2009-10-21, presumably until 2009-10-23\n- alprazolam 1 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2009-10-23\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-10-20, presumably until 2010-10-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2009-10-26, presumably until 2009-10-26\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2009-10-25, presumably until 2010-10-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. Please monitor with INR, have Facility MD and Primary MD work to monitor INR dosage. \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-10-23, presumably until 2009-10-23\n- metoprolol tartrate 50 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-31, with quantity of 10.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2009-10-26, presumably until 2009-10-26\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-26\n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2009-10-24, presumably until 2009-10-24\n- pravastatin sodium 10 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-10-23, presumably until 2009-10-24\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2010-04-24, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-17 07:38:00, ended at 2009-11-17 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-11-17 12:25:35, ended at 2009-11-17 13:33:57\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Knee pyogenic arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-26 12:51:15, ended at 2010-01-26 14:19:52\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Knee pyogenic arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-26 13:42:00, ended at 2010-01-26 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; both knees, standing, anteroposterior\n- Radiologic examination, knee; 1 or 2 views\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-27 12:48:40, ended at 2010-04-27 15:08:24\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2010-12-02. Instructions: take 81 mg by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-11-03 12:05:23, ended at 2010-11-03 16:23:05\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n- Collection of venous blood by venipuncture\n- Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Selective catheter placement, arterial system; initial third order or more selective thoracic or brachiocephalic branch, within a vascular family\n- Transcranial Doppler study of the intracranial arteries; complete study\n- Angiography, carotid, cervical, bilateral, radiological supervision and interpretation\n- Angiography, carotid, cerebral, bilateral, radiological supervision and interpretation\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material\n- Ultrasound, abdominal, real time with image documentation; complete\n- Radiologic examination, chest; single view, frontal\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Physical therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material\n- Angiography, external carotid, bilateral, selective, radiological supervision and interpretation\n- Evaluation of oral and pharyngeal swallowing function\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, thoracic or brachiocephalic branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriate)\n- Electroencephalogram (EEG) extended monitoring; 61-119 minutes\n- Angiography, vertebral, cervical, and/or intracranial, radiological supervision and interpretation\n- Arterial puncture, withdrawal of blood for diagnosis\n- Computed tomography, head or brain; without contrast material\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Occupational therapy evaluation\n- Evaluation of speech, language, voice, communication, and/or auditory processing\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Magnetic resonance angiography, head; without contrast material(s)\n- Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family\n\n### Condition\n- Primary diagnosis: Myelopathy due to cervical spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-11-03 15:16:00, ended at 2010-11-10 14:45:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n- Carbon dioxide [Partial pressure] in Blood: 29.3 (millimeter mercury column)\n- Erythrocyte sedimentation rate: 40 (millimeter per hour)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Osmolality of Urine: 392 (milliosmole per kilogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Osmolality of Serum or Plasma: 288 (milliosmole per kilogram)\n- Prothrombin time (PT): 14.4 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.13 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 299 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Base deficit in Blood: 8.0 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 19.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 27.9 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.02 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Complement C3 [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 372 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.08 (millimole per liter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 113 (millimeter mercury column)\n- Oxygen [Partial pressure] in Blood: 24 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 74 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.1 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.16 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 35.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.8 (percent)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Insertion of catheter into artery\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Radiologic examination, chest; single view, frontal\n- Angiography, carotid, cervical, bilateral, radiological supervision and interpretation\n- Transcranial Doppler study of the intracranial arteries; complete study\n- Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family\n- Magnetic resonance angiography, head; without contrast material(s)\n- Angiography, vertebral, cervical, and/or intracranial, radiological supervision and interpretation\n- Spinal puncture, lumbar, diagnostic\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Selective catheter placement, arterial system; initial third order or more selective thoracic or brachiocephalic branch, within a vascular family\n- Angiography, carotid, cerebral, bilateral, radiological supervision and interpretation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Collection of venous blood by venipuncture\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Computed tomography, head or brain; without contrast material\n- Physical therapy evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Lumbar puncture\n\n### Condition\n- Acquired spondylolisthesis\n- Constipation\n- Diffuse cerebrovascular disease\n- Disease of liver\n- Disorder of posterior pituitary\n- Essential hypertension\n- Benign hypertensive renal disease with renal failure\n- Pulmonary embolism with pulmonary infarction\n- Renal failure syndrome\n- Urinary tract infectious disease\n- Acute renal failure syndrome\n- Cerebral degeneration\n- Headache\n- Chronic kidney disease stage 3\n- Coronary arteriosclerosis\n- Diverticular disease of colon\n- Blood coagulation disorder\n- Cerebral hemorrhage\n- Congestive heart failure\n- Depressive disorder\n- Spinal stenosis of lumbar region\n- Asthma\n- Low back pain\n- Obstructive sleep apnea syndrome\n- Cerebral ischemia\n- Chronic kidney disease\n- Coronary atherosclerosis\n- Delirium\n- Disorder of brain\n- Dysthymia\n- Hyperlipidemia\n- Intellectual disability\n- Mixed urinary incontinence\n- Cervical spondylosis without myelopathy\n- Malaise\n\n### Drug\n- sodium chloride 1000 MG Oral Tablet, through Oral route, started on 2010-11-07, presumably until 2010-12-02, with quantity of 42.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day with meals. Take three times daily for one week, then two times daily for one week, then once daily for one week, then off. \n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2010-11-04, presumably until 2010-11-10. Instructions: take by mouth.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-11-04, presumably until 2010-11-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-11-05, presumably until 2010-11-10\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-11-05, presumably until 2010-11-05\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2010-11-04, presumably until 2010-11-10. Instructions: take by mouth 2 times a day.\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2010-11-05, presumably until 2010-11-10\n- 500 ML sodium chloride 30 MG/ML Injection, through Intravenous route, started on 2010-11-04, presumably until 2010-11-05\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-11-04, presumably until 2010-11-10\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2010-11-07, presumably until 2010-12-31, with quantity of 120.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2010-11-04, presumably until 2010-11-09. Instructions: take by mouth.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2010-11-04, presumably until 2010-11-05\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-03, presumably until 2010-11-04\n- acetylcysteine 200 MG/ML Inhalation Solution, started on 2010-11-04, presumably until 2010-11-05\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2010-11-04, presumably until 2010-11-05\n- nimodipine 30 MG Oral Capsule, through Oral route, started on 2010-11-04, presumably until 2010-11-04\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-03, presumably until 2011-05-09, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2010-11-04, presumably until 2010-11-09. Instructions: take by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-11-10 19:02:00, ended at 2010-12-02 14:20:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.04 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 39 (milliliter per minute per square meter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 6' 3\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.19 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Osmolality of Urine: 350 (milliosmole per kilogram)\n- Platelets [#/volume] in Blood by Automated count: 342 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Prothrombin time (PT): 14.7 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.38 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.2 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 243 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.9 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 6 (microgram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Osmolality of Serum or Plasma: 301 (milliosmole per kilogram)\n- Sodium [Moles/volume] in Serum or Plasma: 151 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.92 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.66 (thousand per microliter)\n\n### Procedure\n- Angiography, carotid, cervical, bilateral, radiological supervision and interpretation\n- Venous catheterization, not elsewhere classified\n- Angiography, carotid, cerebral, bilateral, radiological supervision and interpretation\n- Ventricular shunt to extracranial site NEC\n- Ventricular shunt to abdominal cavity and organs\n- Selective catheter placement, arterial system; initial third order or more selective thoracic or brachiocephalic branch, within a vascular family\n- Computed tomography, head or brain; without contrast material\n- Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family\n- Electroencephalogram\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, thoracic or brachiocephalic branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriate)\n- Noninvasive ventilation\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material\n- Lumbar puncture\n- Angiography, external carotid, bilateral, selective, radiological supervision and interpretation\n- Angiography, vertebral, cervical, and/or intracranial, radiological supervision and interpretation\n- Magnetic resonance angiography, head; without contrast material(s)\n- Arteriography of cerebral arteries\n- Ultrasound, abdominal, real time with image documentation; complete\n- Ultrasonography of head and neck\n- Open biopsy of brain tissue\n- Radiologic examination, chest; single view, frontal\n\n### Condition\n- Altered mental status\n- Coronary arteriosclerosis\n- Coronary atherosclerosis\n- Depressive disorder\n- Dysthymia\n- Spinal stenosis in cervical region\n- Atelectasis\n- Atherosclerosis of aorta\n- Communicating hydrocephalus\n- Headache\n- Leukocytosis\n- Low back pain\n- Subarachnoid hemorrhage\n- Thoracic spondylosis without myelopathy\n- Cholelithiasis without obstruction\n- Disorder of nervous system\n- Abdominal pain\n- Asthma\n- Cerebral hemorrhage\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Cellular immune defect\n- Diffuse cerebrovascular disease\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Pleural effusion\n- Acute renal failure syndrome\n- Benign hypertensive renal disease with renal failure\n- Disorder of posterior pituitary\n- Essential hypertension\n- Fever\n- Lumbosacral spondylosis without myelopathy\n- Pulmonary embolism with pulmonary infarction\n- Aphasia\n- Cerebral degeneration\n- Dementia associated with another disease\n- Bacterial infection due to Pseudomonas\n- Cerebral ischemia\n- Cervical spondylosis without myelopathy\n- Chronic kidney disease stage 3\n- Compression of brain\n- Urinary tract infectious disease\n- Obstructive sleep apnea syndrome\n- Seizure\n- Tachypnea\n\n### Drug\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2010-11-22, presumably until 2010-11-22\n- sodium chloride 1000 MG Oral Tablet, started on 2010-11-11, presumably until 2010-11-29. Instructions: take 1 Tab by mouth 3 times a day with meals. Take three times daily for one week, then two times daily for one week, then once daily for one week, then off.\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2010-11-11, presumably until 2010-12-02. Instructions: by Inhalation route.\n- 5 ML levetiracetam 100 MG/ML Injection, through Intravenous route, started on 2010-11-11, presumably until 2010-11-26\n- haloperidol 5 MG/ML Injectable Solution, started on 2010-11-13, presumably until 2010-11-25\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2010-11-10, presumably until 2010-11-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-11-13, presumably until 2010-12-02\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-16, presumably until 2010-12-01\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2010-11-22, presumably until 2010-11-22\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-11-12, presumably until 2010-12-01\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-11-12, presumably until 2010-11-12\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2010-11-14, presumably until 2010-11-16\n- 500 ML sodium chloride 30 MG/ML Injection, through Intravenous route, started on 2010-11-12, presumably until 2010-11-26\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-11, presumably until 2010-11-11\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-11-22, presumably until 2010-12-01\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-11-13, presumably until 2010-12-01\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2010-11-13, presumably until 2010-12-31, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n- acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet, through Oral route, started on 2010-11-20, presumably until 2010-11-20\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2010-11-11, presumably until 2010-12-01\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2010-11-29, presumably until 2010-11-30\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2010-11-11, presumably until 2011-01-09, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-19, presumably until 2010-11-19\n- acetylcysteine 200 MG/ML Inhalation Solution, started on 2010-11-17, presumably until 2010-11-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-11-19, presumably until 2010-11-23\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2010-11-11, presumably until 2010-11-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-23, presumably until 2010-11-28\n- 0.5 ML sumatriptan 12 MG/ML Injection, through Subcutaneous route, started on 2010-11-21, presumably until 2010-11-21\n- cefepime 1000 MG Injection, through Intravenous route, started on 2010-11-30, presumably until 2010-12-31, with quantity of 7.0, with intended 0 refill(s). Instructions: 1000 mg by Injection route Every Day. End date:  12/09/2010 \n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2010-11-24, presumably until 2010-12-02\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2010-11-24, presumably until 2010-11-27\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-11-20, presumably until 2010-11-20\n- midazolam 1 MG/ML Injectable Solution, started on 2010-11-11, presumably until 2010-11-11\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-14, presumably until 2010-11-22\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2010-11-22, presumably until 2010-11-22\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2010-11-22, presumably until 2010-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-25 12:46:00, ended at 2010-11-25 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Cerebrovascular disease\n- Obstructive hydrocephalus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-14 00:00:00, ended at 2010-12-14 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-22 00:00:00, ended at 2010-12-22 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-12-31 09:39:34, ended at 2010-12-31 14:16:51\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-12-31 11:08:00, ended at 2011-01-09 13:58:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n- Base deficit in Blood: 12.0 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 18.5 (millimeter mercury column)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.4 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.31 (millimole per liter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 215 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 42 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.26 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.1 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 122 (millimeter mercury column)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.6 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 12.6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.00 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 488 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Prothrombin time (PT): 14.7 (second)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Body height: 6' 3\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 91 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.15 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 790 (nanogram per milliliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.6 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.19 (micro-international unit per milliliter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Physical therapy evaluation\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Radiologic examination, abdomen; single anteroposterior view\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Prophylactic administration of vaccine against other diseases\n- Noninvasive ventilation\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n- Radiologic examination, chest; single view, frontal\n- Occupational therapy evaluation\n- Computed tomography, head or brain; without contrast material\n- Collection of venous blood by venipuncture\n- Pulmonary perfusion imaging, particulate, with ventilation imaging, aerosol, 1 or multiple projections\n- Arterial puncture, withdrawal of blood for diagnosis\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n\n### Condition\n- Asthma\n- Urinary tract infectious disease\n- Atelectasis\n- Essential hypertension\n- Late effect of radiation\n- Obstructive sleep apnea syndrome\n- Congestive heart failure\n- Dyspnea\n- Irradiation cystitis\n- Pain in limb\n- Acute renal failure syndrome\n- Cerebral hemorrhage\n- Disorder of kidney and/or ureter\n- Acute systolic heart failure\n- Coronary arteriosclerosis\n- Coronary atherosclerosis\n- Hypo-osmolality and or hyponatremia\n- Iron deficiency anemia\n- Constipation\n- Depressive disorder\n- Pulmonary embolism with pulmonary infarction\n- Alkalosis\n- Benign hypertensive renal disease with renal failure\n- Chronic kidney disease stage 3\n- Dysthymia\n- Intracranial hemorrhage\n- Late effect of complications of procedure\n- Pleural effusion\n- Acidosis\n- Hyperlipidemia\n- Low back pain\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2011-01-06, presumably until 2012-01-09, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2011-01-01, presumably until 2011-01-03\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2011-01-01, presumably until 2011-01-09\n- 0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, started on 2011-01-06, presumably until 2011-01-06\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-01-02, presumably until 2011-01-03\n- alprazolam 1 MG Oral Tablet, through Oral route, started on 2011-01-08, presumably until 2011-07-08, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 3 times a day. \n- ciprofloxacin 250 MG Oral Tablet, through Oral route, started on 2011-01-08, presumably until 2011-01-09\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2011-01-02, presumably until 2011-01-08\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-12-31, presumably until 2010-12-31\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-01-01, presumably until 2011-01-09\n- 10 ML furosemide 10 MG/ML Injection, started on 2010-12-31, presumably until 2011-01-02\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2011-01-01, presumably until 2011-01-08\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2011-01-05, presumably until 2011-01-08\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2011-01-05, presumably until 2011-01-09\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2011-01-02, presumably until 2011-01-08\n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2011-01-03, presumably until 2011-01-09\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2010-12-31, presumably until 2011-01-06. Instructions: take 1 Tab by mouth 2 times a day.\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2010-12-31, presumably until 2011-01-01\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2011-01-04, presumably until 2011-01-04\n- fluoxetine 10 MG Oral Capsule, through Oral route, started on 2011-01-01, presumably until 2011-01-09\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2011-01-07, presumably until 2011-01-07\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-01-01, presumably until 2011-01-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-31 15:00:00, ended at 2010-12-31 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-05 08:12:54, ended at 2011-01-05 12:27:22\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-03-13 08:22:03, ended at 2012-03-13 09:53:43\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- 0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, presumably until 2013-06-18. Instructions: by Injection route. weekly \n- alprazolam 0.5 MG Oral Tablet, through Oral route, presumably until 2014-03-06. Instructions: take  by mouth 3 times a day.  \n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, presumably until 2014-03-06. Instructions: take  by mouth.  \n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, presumably until 2013-04-04. Instructions: take  by mouth as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-02-07 19:57:00, ended at 2013-02-10 13:15:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.2 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 144 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 6' 2\" (inch (US))\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 14.88 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.60 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 144 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 57 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 87 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.2 (ratio)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 272 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 86 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 71 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Physical therapy evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Pulmonary ventilation (eg, aerosol or gas) and perfusion imaging\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Noninvasive ventilation\n\n### Condition\n- Benign hypertensive renal disease with renal failure\n- Embolism and thrombosis of the vena cava\n- Chronic deep venous thrombosis of lower extremity\n- Hyperlipidemia\n- Pure hypercholesterolemia\n- Wheezing\n- Chronic kidney disease stage 4\n- Coronary arteriosclerosis\n- Obstructive sleep apnea syndrome\n- Chronic kidney disease\n- Anemia\n- Primary diagnosis: Cough\n- Dysthymia\n- Acute deep vein thrombosis of lower limb\n- Dyspnea\n- Acute asthma\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2015-08-03. Instructions: take 650 mg by mouth 2 times a day.  \n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2013-02-07, presumably until 2013-02-07\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2013-02-08, presumably until 2013-02-10\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2013-02-08, presumably until 2013-02-10\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- hydrocortisone 25 MG/ML Rectal Cream, through Rectal route, presumably until 2013-03-12. Instructions: insert  into the rectum.  \n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2013-02-07, presumably until 2013-03-12, with intended 3 refill(s). Instructions: 3 mL by Inhalation route every 4 hours.\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2013-02-08, presumably until 2013-02-08\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-10\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-02-08, presumably until 2014-03-06. Instructions: take 17 g by mouth One Time.  \n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-10\n- hydrocortisone 1.67 MG/ML Enema, through Rectal route, presumably until 2013-04-04. Instructions: insert  into the rectum.  \n- prednisone 50 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- nystatin 100 UNT/MG Topical Powder, through Topical route, presumably until 2014-03-06. Instructions: by Topical route 4 times a day.  \n- prednisone 20 MG Oral Tablet, started on 2013-02-10, presumably until 2013-03-12, with intended 0 refill(s). Instructions: Take 60mg for 3 days (2/26 - 2/28), take 40mg for 3 days (3/1-3/3), take 20mg for 3 days (3/4-3/6)\n- methylprednisolone 125 MG Injection, started on 2013-02-07, presumably until 2013-02-10\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, presumably until 2013-09-17. Instructions: insert  into the rectum.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-12 10:52:03, ended at 2013-03-12 13:32:57\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary embolism with pulmonary infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-03-25 20:18:00, ended at 2013-04-04 13:35:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 6' 2\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.22 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.96 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.33 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.69 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.4 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 58 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.8 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Prothrombin time (PT): 19.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n\n### Procedure\n- Occupational therapy evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation\n- Radiologic examination, knee; 1 or 2 views\n- Radiologic examination, chest; single view, frontal\n- Open reduction of fracture of femur with internal fixation\n- Computed tomography, head or brain; without contrast material\n- Noninvasive ventilation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, pelvis; 1 or 2 views\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Packed blood cell transfusion\n- Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Splitting of blood or blood products, each unit\n- Wheelchair management (eg, assessment, fitting, training), each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Collection of venous blood by venipuncture\n- Radiologic examination, abdomen; single anteroposterior view\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Anxiety state\n- Benign hypertensive renal disease with renal failure\n- Breathing painful\n- Closed fracture of femur, distal end\n- Low back pain\n- Pleural effusion\n- Acute deep vein thrombosis of lower limb\n- Chronic kidney disease stage 4\n- Coronary atherosclerosis\n- Dyspnea\n- Superficial injury to head, excluding eye\n- Closed fracture of shaft of femur\n- Depressive disorder\n- Obstructive sleep apnea syndrome\n- Pulmonary embolism with pulmonary infarction\n- Abdominal pain\n- Lung field abnormal\n- Pulmonary congestion and hypostasis\n- Abrasion and/or friction burn of skin\n- Asthma\n- Closed fracture of neck of femur\n- Coronary arteriosclerosis\n- Cough\n- Joint pain of pelvic region\n- Pain in limb\n- Paralytic ileus\n- Chronic kidney disease stage 3\n- Primary diagnosis: Closed fracture of femur\n- Essential hypertension\n- Hyperlipidemia\n- Cerebral hemorrhage\n- Degenerative joint disease of pelvis\n- Spinal stenosis of lumbar region\n- Urinary tract infectious disease\n- Bacterial infection due to Pseudomonas\n- Contusion of head and/or neck\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-04\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-03-29, presumably until 2013-03-29\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2013-03-26, presumably until 2013-04-04\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2013-03-26, presumably until 2013-04-04\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2013-03-30, presumably until 2013-04-02\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2013-03-26, presumably until 2013-04-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-04\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-03-26\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2013-04-02, presumably until 2013-04-02\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-03-30, presumably until 2013-04-01\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-09-17, with intended 5 refill(s). Instructions: take 2 Tabs by mouth every 6 hours.\n- cefazolin 1000 MG Injection, started on 2013-03-28, presumably until 2013-03-28\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-01\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-25, presumably until 2013-04-03\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-04-04\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-04-03\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-04-02\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2013-03-30, presumably until 2013-04-04\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-03-25, presumably until 2013-04-02\n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-04-04\n- hypromellose 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2013-03-27, presumably until 2013-03-27\n- hydrocortisone 1.67 MG/ML Enema, through Rectal route, started on 2013-04-01, presumably until 2014-04-02, with intended 5 refill(s). Instructions: insert 60 mL into the rectum every bedtime.\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2013-03-28, presumably until 2013-03-28\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-25, presumably until 2013-04-01\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-03-30, presumably until 2013-04-03\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2013-03-25, presumably until 2013-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-26, presumably until 2013-03-30\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-03-26, presumably until 2013-03-28\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2013-03-28, presumably until 2013-04-04\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-03-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-03-28, presumably until 2013-03-28\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2013-03-29, presumably until 2013-03-29\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-03-26, presumably until 2013-03-27\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2013-03-29, presumably until 2013-04-03\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2013-03-28, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-27 00:00:00, ended at 2013-03-27 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for open procedures involving upper two-thirds of femur; not otherwise specified\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Periprosthetic fracture\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- calcium gluconate 100 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-04-16 00:00:00, ended at 2013-04-16 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n- Chronic kidney disease stage 3\n- Coronary atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-16 00:00:00, ended at 2013-04-16 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-18 08:00:00, ended at 2013-04-18 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Anemia\n- Primary diagnosis: Delusional disorder\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-04-18, presumably until 2013-04-18\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2013-04-18, presumably until 2013-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-07 11:08:18, ended at 2013-05-07 12:41:03\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of femoral condyle of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 11:10:00, ended at 2013-05-07 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Periprosthetic fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-18 11:11:54, ended at 2013-06-18 13:57:45\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- 1 ML epoetin alfa 10000 UNT/ML Injection, presumably until 2014-03-06. Instructions: by Injection route.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-18 11:13:00, ended at 2013-06-18 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-08-06 11:18:32, ended at 2013-08-06 13:22:41\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-06 11:26:00, ended at 2013-08-06 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-17 11:16:55, ended at 2013-09-17 12:28:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-17 11:22:00, ended at 2013-09-17 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Degenerative joint disease of pelvis\n- Joint pain of pelvic region\n- Periprosthetic fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-29 11:25:08, ended at 2013-10-29 12:45:57\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-29 11:27:00, ended at 2013-10-29 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Closed fracture of shaft of femur\n- Disorder of bone and articular cartilage\n- Osteoarthritis of knee\n- Knee joint effusion\n- Atherosclerosis of arteries of the extremities\n- Periprosthetic fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-12-31 11:10:00, ended at 2013-12-31 23:59:00\nThe patient in this visit was 78 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Knee joint effusion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-31 11:11:06, ended at 2013-12-31 12:25:25\nThe patient in this visit was 78 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Primary diagnosis: Closed fracture of femoral condyle of femur\n- Knee joint effusion\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-29 00:00:00, ended at 2008-10-29 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.83 (million per microliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 389 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- MCV [Entitic volume] by Automated count: 83.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-10-30 07:18:00, ended at 2008-10-30 14:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-31 00:00:00, ended at 2008-10-31 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Retention of urine\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-04-13 21:15:00, ended at 2009-04-25 11:15:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.90 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 73.7 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 25.4 (microgram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Body height: 6' 3\" (inch (US))\n- Erythrocyte sedimentation rate: >140 (millimeter per hour)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 182 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.36 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 117 (millimeter mercury column)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.9 (femtoliter)\n- Prothrombin time (PT): 23.5 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 48 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 38.7 (millimeter mercury column)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.78 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.2 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.47 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.0 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 64.3 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 25.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1415 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood: 28 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 34 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 185 (microgram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Blood: 4.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: 1.25 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.7 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 499 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 2.39 (percent)\n- Sodium [Moles/volume] in Blood: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.5 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 18 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of prosthetic joint\n- Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-04-13, presumably until 2009-04-14\n- polysaccharide iron complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous gluconate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous fumarate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- terbinafine 250 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-16. Instructions: take by mouth.\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2009-04-15, presumably until 2009-04-15\n- mineral oil 1000 MG/ML Enema, through Rectal route, started on 2009-04-15, presumably until 2009-04-15\n- ferrous ascorbate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-25\n- iron,peptonized, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous succinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-04-14, presumably until 2009-04-21\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-04-21, presumably until 2009-04-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2009-04-25, presumably until 2009-07-20, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-04-13, presumably until 2014-03-06. Instructions: 1 Puff by Inhalation route 2 times a day. 500 not 100 per Pt's spouse\n- 14 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-04-14, presumably until 2009-04-21\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2009-04-14, presumably until 2009-04-20\n- ferrous bisglycinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous cysteine glycinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous aspartate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ammonium ferrous sulfate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- soy protein-iron complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-07-20, with quantity of 80.0, with intended 0 refill(s). Instructions: take by mouth. \n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- ferrous carbonate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-25\n- ferrous glycine sulfate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- folic acid, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-04-25. Instructions: take by mouth. \n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-04-22\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2009-04-14, presumably until 2009-04-14\n- iron succinyl milk protein complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- iron-dextran complex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- teferrol, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-18. Instructions: take by mouth.\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-04-20, presumably until 2009-04-24\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-04-22, presumably until 2009-04-23\n- bupropion hydrochloride 75 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-04-14, presumably until 2009-04-25\n- ferrous asparto glycinate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous cacodylate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-04-17, presumably until 2009-04-21\n- metoprolol tartrate 50 MG Oral Tablet, through Oral route, started on 2009-04-22, presumably until 2009-04-24\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-21. Instructions: take by mouth.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-23\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2009-04-14, presumably until 2009-04-14\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2009-04-14, presumably until 2009-04-25\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2009-04-15, presumably until 2009-04-19\n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2009-04-15, presumably until 2009-04-21\n- iron, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous oxalate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2009-04-22, presumably until 2009-05-30, with quantity of 42.0, with intended 0 refill(s). Instructions: 200 mL by Intravenous route daily. \n- fluoxetine 40 MG Oral Capsule, through Oral route, presumably until 2009-06-17. Instructions: take by mouth. \n- iron sucrose, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous sulfate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- iron carbonyl, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous lactate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous chloride, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-04-16, presumably until 2009-04-20\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-18\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2009-04-15, presumably until 2009-04-17\n- iron sorbitex, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ferrous phosphate, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-21\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2009-04-15, presumably until 2009-05-16, with quantity of 20.0, with intended 0 refill(s). Instructions: 0.5-1 mL by Intravenous route every 4 hours as needed \n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-04-13, presumably until 2009-04-21\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2009-04-14, presumably until 2009-04-14\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2009-04-16, presumably until 2009-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-06-01 00:00:00, ended at 2009-06-01 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.0 (percent)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 320 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 49 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 5.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Erythrocyte sedimentation rate: 120 (millimeter per hour)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 5.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.74 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-06-22 12:02:00, ended at 2009-07-20 11:15:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 165 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Body height: 6' 3\" (inch (US))\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 6 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 176 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Prothrombin time (PT): N/A (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.20 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.66 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 624 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.31 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.4 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 6 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.57 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 90 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 7.3 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mixed urinary incontinence\n\n### Drug\n- psyllium, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-06-24, presumably until 2010-07-20, with quantity of 30.0, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed for Bronchospasm/Wheezing. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-22, presumably until 2009-06-22\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2009-07-01, presumably until 2009-07-01\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2009-06-29, presumably until 2009-07-12\n- haloperidol 0.5 MG Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-07-02\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2009-07-02, presumably until 2009-07-12\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2009-06-22, presumably until 2009-06-22\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2009-06-29, presumably until 2009-07-15\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-06-24, presumably until 2009-07-20\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2009-06-23, presumably until 2009-07-20\n- 100 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2009-07-09, presumably until 2009-07-10\n- acetaminophen 650 MG Rectal Suppository, through Rectal route, started on 2009-06-23, presumably until 2009-07-11\n- 0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-07-14, presumably until 2010-07-20, with quantity of 30.0, with intended 0 refill(s). Instructions: 0.3 mL by SUBCUTANEOUS route every 7 days. \n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2009-07-18, presumably until 2009-07-18\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2009-07-12, presumably until 2009-07-12\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2009-06-24, presumably until 2009-10-05, with quantity of 30.0, with intended 0 refill(s). Instructions: take 2 Caps by mouth daily. \n- belladonna alkaloids 16.2 MG / opium 60 MG Rectal Suppository, through Rectal route, started on 2009-07-10, presumably until 2009-07-10\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-06-30, presumably until 2009-07-12\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-16\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2009-07-01, presumably until 2009-07-02\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2009-07-01, presumably until 2009-07-01\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2009-06-24, presumably until 2009-06-26\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-06-23, presumably until 2009-07-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-18\n- 1 ML epoetin alfa 10000 UNT/ML Injection, started on 2009-07-13, presumably until 2009-07-13\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2009-06-25, presumably until 2009-06-26\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2009-07-12, presumably until 2009-07-12\n- ispaghula husk, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-23, presumably until 2009-07-01\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2009-06-22, presumably until 2009-07-09\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2009-06-22, presumably until 2009-06-28\n- purified protein derivative of tuberculin 50 UNT/ML Injectable Solution, through Intradermal route, started on 2009-07-17, presumably until 2009-07-17\n- 0.5 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, started on 2009-07-07, presumably until 2009-07-07\n- 10 ML furosemide 10 MG/ML Injection, started on 2009-06-29, presumably until 2009-07-10\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2009-07-03, presumably until 2009-07-16\n- 24 HR metoprolol succinate 50 MG Extended Release Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-08\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-07-14, presumably until 2009-07-20\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2009-06-27, presumably until 2009-07-17\n- soybean oil 200 MG/ML Injectable Suspension, through Intravenous route, started on 2009-07-01, presumably until 2009-07-13\n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2009-07-12, presumably until 2009-10-05, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2009-06-30, presumably until 2009-07-02\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2009-07-14, presumably until 2010-07-20, with quantity of 50.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed \n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2009-06-23, presumably until 2009-06-24\n- 1 ML lorazepam 2 MG/ML Cartridge, started on 2009-07-13, presumably until 2009-07-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-06-25, presumably until 2009-07-14\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-24, presumably until 2009-07-11\n- pravastatin sodium 10 MG Oral Tablet, through Oral route, started on 2009-06-24, presumably until 2009-07-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-26, presumably until 2009-07-15\n- Plantago seed, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- 2 ML heparin sodium, porcine 1000 UNT/ML Injection, started on 2009-07-10, presumably until 2009-07-18\n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2009-06-28, presumably until 2009-07-20\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2009-07-08, presumably until 2009-07-20\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2009-06-25, presumably until 2009-07-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2009-06-22, presumably until 2009-07-07\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-04, presumably until 2010-01-16, with quantity of 50.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2009-07-17, presumably until 2009-07-20\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2009-07-01, presumably until 2009-07-01\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2009-07-15, presumably until 2009-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-07 11:32:01, ended at 2009-09-07 13:01:11\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance\n\n### Condition\n- Reactive arthritis triad\n- Reactive arthropathy of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-10-05 00:00:00, ended at 2009-10-05 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transient cerebral ischemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-10-05 10:49:15, ended at 2009-10-05 14:10:05\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint pain\n\n### Drug\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2009-10-26. Instructions: by SUBCUTANEOUS route daily. \n- alprazolam 0.5 MG Oral Tablet, through Oral route, presumably until 2011-01-09. Instructions: take by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-08 11:30:00, ended at 2009-10-08 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extracranial arteries; complete bilateral study\n\n### Condition\n- Cerebrovascular disease\n- Disorder of carotid artery\n- Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-10-08 11:35:46, ended at 2009-10-08 15:49:02\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transient cerebral ischemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-10-20 15:06:00, ended at 2009-10-26 14:40:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Body height: 6' 3\" (inch (US))\n- INR in Platelet poor plasma by Coagulation assay: 2.5 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.53 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 352 (millimeter mercury column)\n- Prothrombin time (PT): 26.9 (second)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.49 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.30 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 344 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 18.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 50 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 88 (millimeter per hour)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Base deficit in Blood: 6.0 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 29.8 (millimeter mercury column)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.42 (million per microliter)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 100 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.9 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, knee; 1 or 2 views\n- Division of joint capsule, ligament, or cartilage, knee\n- Revision of knee replacement\n- Radiologic examination, chest; single view, frontal\n- Packed blood cell transfusion\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Local excision of lesion or tissue of tibia and fibula\n- Physical therapy evaluation\n- Synovectomy of knee joint\n- Removal of (cement) spacer\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Occupational therapy evaluation\n\n### Condition\n- Acquired deformity of knee\n- Acute posthemorrhagic anemia\n- Iatrogenic hypotension\n- Chronic obstructive lung disease\n- Coronary arteriosclerosis\n- Lung field abnormal\n- Obstructive sleep apnea syndrome\n- Anxiety state\n- Chronic kidney disease\n- Hyperlipidemia\n- Pleural effusion\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-10-21, presumably until 2009-10-26\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-10-20, presumably until 2009-10-20\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2009-10-24, presumably until 2009-10-26\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-10-20, presumably until 2009-10-20\n- sennosides, USP 1.76 MG/ML Oral Solution, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2009-10-21, presumably until 2009-10-21\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-10-21, presumably until 2009-10-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2009-10-20, presumably until 2009-10-26\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2009-10-21, presumably until 2009-10-26\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-10-24, presumably until 2009-10-26\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-10-26, presumably until 2009-10-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-23\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-10-21, presumably until 2009-10-23\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-10-23, presumably until 2010-10-26, with quantity of 90.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 4 hours as needed \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-10-27, presumably until 2009-10-27, with intended 0 refill(s). Instructions: 0.4 mL by SUBCUTANEOUS route daily. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2009-10-21, presumably until 2009-10-23\n- alprazolam 1 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2009-10-23\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-10-20, presumably until 2010-10-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2009-10-26, presumably until 2009-10-26\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2009-10-25, presumably until 2010-10-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. Please monitor with INR, have Facility MD and Primary MD work to monitor INR dosage. \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-10-23, presumably until 2009-10-23\n- metoprolol tartrate 50 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-31, with quantity of 10.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2009-10-26, presumably until 2009-10-26\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-26\n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2009-10-24, presumably until 2009-10-24\n- pravastatin sodium 10 MG Oral Tablet, through Oral route, started on 2009-10-20, presumably until 2009-10-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-10-23, presumably until 2009-10-24\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2009-10-22\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-10-22, presumably until 2010-04-24, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-17 07:38:00, ended at 2009-11-17 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-11-17 12:25:35, ended at 2009-11-17 13:33:57\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Knee pyogenic arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-01-26 12:51:15, ended at 2010-01-26 14:19:52\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Knee pyogenic arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-26 13:42:00, ended at 2010-01-26 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; both knees, standing, anteroposterior\n- Radiologic examination, knee; 1 or 2 views\n\n### Condition\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-04-27 12:48:40, ended at 2010-04-27 15:08:24\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2010-12-02. Instructions: take 81 mg by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-11-03 12:05:23, ended at 2010-11-03 16:23:05\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n- Collection of venous blood by venipuncture\n- Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Selective catheter placement, arterial system; initial third order or more selective thoracic or brachiocephalic branch, within a vascular family\n- Transcranial Doppler study of the intracranial arteries; complete study\n- Angiography, carotid, cervical, bilateral, radiological supervision and interpretation\n- Angiography, carotid, cerebral, bilateral, radiological supervision and interpretation\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material\n- Ultrasound, abdominal, real time with image documentation; complete\n- Radiologic examination, chest; single view, frontal\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Physical therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material\n- Angiography, external carotid, bilateral, selective, radiological supervision and interpretation\n- Evaluation of oral and pharyngeal swallowing function\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, thoracic or brachiocephalic branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriate)\n- Electroencephalogram (EEG) extended monitoring; 61-119 minutes\n- Angiography, vertebral, cervical, and/or intracranial, radiological supervision and interpretation\n- Arterial puncture, withdrawal of blood for diagnosis\n- Computed tomography, head or brain; without contrast material\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Occupational therapy evaluation\n- Evaluation of speech, language, voice, communication, and/or auditory processing\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Magnetic resonance angiography, head; without contrast material(s)\n- Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family\n\n### Condition\n- Primary diagnosis: Myelopathy due to cervical spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-11-03 15:16:00, ended at 2010-11-10 14:45:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n- Carbon dioxide [Partial pressure] in Blood: 29.3 (millimeter mercury column)\n- Erythrocyte sedimentation rate: 40 (millimeter per hour)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Osmolality of Urine: 392 (milliosmole per kilogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Osmolality of Serum or Plasma: 288 (milliosmole per kilogram)\n- Prothrombin time (PT): 14.4 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.13 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 299 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Base deficit in Blood: 8.0 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 19.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 27.9 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.02 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Complement C3 [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 372 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.08 (millimole per liter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 113 (millimeter mercury column)\n- Oxygen [Partial pressure] in Blood: 24 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 74 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.1 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.16 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 35.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.8 (percent)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Insertion of catheter into artery\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Radiologic examination, chest; single view, frontal\n- Angiography, carotid, cervical, bilateral, radiological supervision and interpretation\n- Transcranial Doppler study of the intracranial arteries; complete study\n- Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family\n- Magnetic resonance angiography, head; without contrast material(s)\n- Angiography, vertebral, cervical, and/or intracranial, radiological supervision and interpretation\n- Spinal puncture, lumbar, diagnostic\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Selective catheter placement, arterial system; initial third order or more selective thoracic or brachiocephalic branch, within a vascular family\n- Angiography, carotid, cerebral, bilateral, radiological supervision and interpretation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Collection of venous blood by venipuncture\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Computed tomography, head or brain; without contrast material\n- Physical therapy evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Lumbar puncture\n\n### Condition\n- Acquired spondylolisthesis\n- Constipation\n- Diffuse cerebrovascular disease\n- Disease of liver\n- Disorder of posterior pituitary\n- Essential hypertension\n- Benign hypertensive renal disease with renal failure\n- Pulmonary embolism with pulmonary infarction\n- Renal failure syndrome\n- Urinary tract infectious disease\n- Acute renal failure syndrome\n- Cerebral degeneration\n- Headache\n- Chronic kidney disease stage 3\n- Coronary arteriosclerosis\n- Diverticular disease of colon\n- Blood coagulation disorder\n- Cerebral hemorrhage\n- Congestive heart failure\n- Depressive disorder\n- Spinal stenosis of lumbar region\n- Asthma\n- Low back pain\n- Obstructive sleep apnea syndrome\n- Cerebral ischemia\n- Chronic kidney disease\n- Coronary atherosclerosis\n- Delirium\n- Disorder of brain\n- Dysthymia\n- Hyperlipidemia\n- Intellectual disability\n- Mixed urinary incontinence\n- Cervical spondylosis without myelopathy\n- Malaise\n\n### Drug\n- sodium chloride 1000 MG Oral Tablet, through Oral route, started on 2010-11-07, presumably until 2010-12-02, with quantity of 42.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day with meals. Take three times daily for one week, then two times daily for one week, then once daily for one week, then off. \n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2010-11-04, presumably until 2010-11-10. Instructions: take by mouth.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-11-04, presumably until 2010-11-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-11-05, presumably until 2010-11-10\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-11-05, presumably until 2010-11-05\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2010-11-04, presumably until 2010-11-10. Instructions: take by mouth 2 times a day.\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2010-11-05, presumably until 2010-11-10\n- 500 ML sodium chloride 30 MG/ML Injection, through Intravenous route, started on 2010-11-04, presumably until 2010-11-05\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-11-04, presumably until 2010-11-10\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2010-11-07, presumably until 2010-12-31, with quantity of 120.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2010-11-04, presumably until 2010-11-09. Instructions: take by mouth.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2010-11-04, presumably until 2010-11-05\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-03, presumably until 2010-11-04\n- acetylcysteine 200 MG/ML Inhalation Solution, started on 2010-11-04, presumably until 2010-11-05\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2010-11-04, presumably until 2010-11-05\n- nimodipine 30 MG Oral Capsule, through Oral route, started on 2010-11-04, presumably until 2010-11-04\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-03, presumably until 2011-05-09, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2010-11-04, presumably until 2010-11-09. Instructions: take by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-11-10 19:02:00, ended at 2010-12-02 14:20:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.04 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 39 (milliliter per minute per square meter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 6' 3\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.19 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Osmolality of Urine: 350 (milliosmole per kilogram)\n- Platelets [#/volume] in Blood by Automated count: 342 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Prothrombin time (PT): 14.7 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.38 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.2 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 243 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.9 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 6 (microgram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Osmolality of Serum or Plasma: 301 (milliosmole per kilogram)\n- Sodium [Moles/volume] in Serum or Plasma: 151 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.92 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.66 (thousand per microliter)\n\n### Procedure\n- Angiography, carotid, cervical, bilateral, radiological supervision and interpretation\n- Venous catheterization, not elsewhere classified\n- Angiography, carotid, cerebral, bilateral, radiological supervision and interpretation\n- Ventricular shunt to extracranial site NEC\n- Ventricular shunt to abdominal cavity and organs\n- Selective catheter placement, arterial system; initial third order or more selective thoracic or brachiocephalic branch, within a vascular family\n- Computed tomography, head or brain; without contrast material\n- Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family\n- Electroencephalogram\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, thoracic or brachiocephalic branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriate)\n- Noninvasive ventilation\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material\n- Lumbar puncture\n- Angiography, external carotid, bilateral, selective, radiological supervision and interpretation\n- Angiography, vertebral, cervical, and/or intracranial, radiological supervision and interpretation\n- Magnetic resonance angiography, head; without contrast material(s)\n- Arteriography of cerebral arteries\n- Ultrasound, abdominal, real time with image documentation; complete\n- Ultrasonography of head and neck\n- Open biopsy of brain tissue\n- Radiologic examination, chest; single view, frontal\n\n### Condition\n- Altered mental status\n- Coronary arteriosclerosis\n- Coronary atherosclerosis\n- Depressive disorder\n- Dysthymia\n- Spinal stenosis in cervical region\n- Atelectasis\n- Atherosclerosis of aorta\n- Communicating hydrocephalus\n- Headache\n- Leukocytosis\n- Low back pain\n- Subarachnoid hemorrhage\n- Thoracic spondylosis without myelopathy\n- Cholelithiasis without obstruction\n- Disorder of nervous system\n- Abdominal pain\n- Asthma\n- Cerebral hemorrhage\n- Cerebral infarction due to thrombosis of cerebral arteries\n- Cellular immune defect\n- Diffuse cerebrovascular disease\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Pleural effusion\n- Acute renal failure syndrome\n- Benign hypertensive renal disease with renal failure\n- Disorder of posterior pituitary\n- Essential hypertension\n- Fever\n- Lumbosacral spondylosis without myelopathy\n- Pulmonary embolism with pulmonary infarction\n- Aphasia\n- Cerebral degeneration\n- Dementia associated with another disease\n- Bacterial infection due to Pseudomonas\n- Cerebral ischemia\n- Cervical spondylosis without myelopathy\n- Chronic kidney disease stage 3\n- Compression of brain\n- Urinary tract infectious disease\n- Obstructive sleep apnea syndrome\n- Seizure\n- Tachypnea\n\n### Drug\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2010-11-22, presumably until 2010-11-22\n- sodium chloride 1000 MG Oral Tablet, started on 2010-11-11, presumably until 2010-11-29. Instructions: take 1 Tab by mouth 3 times a day with meals. Take three times daily for one week, then two times daily for one week, then once daily for one week, then off.\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2010-11-11, presumably until 2010-12-02. Instructions: by Inhalation route.\n- 5 ML levetiracetam 100 MG/ML Injection, through Intravenous route, started on 2010-11-11, presumably until 2010-11-26\n- haloperidol 5 MG/ML Injectable Solution, started on 2010-11-13, presumably until 2010-11-25\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2010-11-10, presumably until 2010-11-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-11-13, presumably until 2010-12-02\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-16, presumably until 2010-12-01\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2010-11-22, presumably until 2010-11-22\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-11-12, presumably until 2010-12-01\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-11-12, presumably until 2010-11-12\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2010-11-14, presumably until 2010-11-16\n- 500 ML sodium chloride 30 MG/ML Injection, through Intravenous route, started on 2010-11-12, presumably until 2010-11-26\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-11, presumably until 2010-11-11\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-11-22, presumably until 2010-12-01\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-11-13, presumably until 2010-12-01\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2010-11-13, presumably until 2010-12-31, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime. \n- acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet, through Oral route, started on 2010-11-20, presumably until 2010-11-20\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2010-11-11, presumably until 2010-12-01\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2010-11-29, presumably until 2010-11-30\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2010-11-11, presumably until 2011-01-09, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-19, presumably until 2010-11-19\n- acetylcysteine 200 MG/ML Inhalation Solution, started on 2010-11-17, presumably until 2010-11-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-11-19, presumably until 2010-11-23\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2010-11-11, presumably until 2010-11-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-11-23, presumably until 2010-11-28\n- 0.5 ML sumatriptan 12 MG/ML Injection, through Subcutaneous route, started on 2010-11-21, presumably until 2010-11-21\n- cefepime 1000 MG Injection, through Intravenous route, started on 2010-11-30, presumably until 2010-12-31, with quantity of 7.0, with intended 0 refill(s). Instructions: 1000 mg by Injection route Every Day. End date:  12/09/2010 \n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2010-11-24, presumably until 2010-12-02\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2010-11-24, presumably until 2010-11-27\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-11-20, presumably until 2010-11-20\n- midazolam 1 MG/ML Injectable Solution, started on 2010-11-11, presumably until 2010-11-11\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-14, presumably until 2010-11-22\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2010-11-22, presumably until 2010-11-22\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2010-11-22, presumably until 2010-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-25 12:46:00, ended at 2010-11-25 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Cerebrovascular disease\n- Obstructive hydrocephalus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-14 00:00:00, ended at 2010-12-14 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-22 00:00:00, ended at 2010-12-22 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-12-31 09:39:34, ended at 2010-12-31 14:16:51\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral hemorrhage\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-12-31 11:08:00, ended at 2011-01-09 13:58:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n- Base deficit in Blood: 12.0 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 18.5 (millimeter mercury column)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.4 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.31 (millimole per liter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 215 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 42 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.26 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.1 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 122 (millimeter mercury column)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.6 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 12.6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.00 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 488 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Prothrombin time (PT): 14.7 (second)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Body height: 6' 3\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 91 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.15 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 790 (nanogram per milliliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.6 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.19 (micro-international unit per milliliter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Physical therapy evaluation\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Radiologic examination, abdomen; single anteroposterior view\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Prophylactic administration of vaccine against other diseases\n- Noninvasive ventilation\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n- Radiologic examination, chest; single view, frontal\n- Occupational therapy evaluation\n- Computed tomography, head or brain; without contrast material\n- Collection of venous blood by venipuncture\n- Pulmonary perfusion imaging, particulate, with ventilation imaging, aerosol, 1 or multiple projections\n- Arterial puncture, withdrawal of blood for diagnosis\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n\n### Condition\n- Asthma\n- Urinary tract infectious disease\n- Atelectasis\n- Essential hypertension\n- Late effect of radiation\n- Obstructive sleep apnea syndrome\n- Congestive heart failure\n- Dyspnea\n- Irradiation cystitis\n- Pain in limb\n- Acute renal failure syndrome\n- Cerebral hemorrhage\n- Disorder of kidney and/or ureter\n- Acute systolic heart failure\n- Coronary arteriosclerosis\n- Coronary atherosclerosis\n- Hypo-osmolality and or hyponatremia\n- Iron deficiency anemia\n- Constipation\n- Depressive disorder\n- Pulmonary embolism with pulmonary infarction\n- Alkalosis\n- Benign hypertensive renal disease with renal failure\n- Chronic kidney disease stage 3\n- Dysthymia\n- Intracranial hemorrhage\n- Late effect of complications of procedure\n- Pleural effusion\n- Acidosis\n- Hyperlipidemia\n- Low back pain\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2011-01-06, presumably until 2012-01-09, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2011-01-01, presumably until 2011-01-03\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2011-01-01, presumably until 2011-01-09\n- 0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, started on 2011-01-06, presumably until 2011-01-06\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-01-02, presumably until 2011-01-03\n- alprazolam 1 MG Oral Tablet, through Oral route, started on 2011-01-08, presumably until 2011-07-08, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 3 times a day. \n- ciprofloxacin 250 MG Oral Tablet, through Oral route, started on 2011-01-08, presumably until 2011-01-09\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2011-01-02, presumably until 2011-01-08\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-12-31, presumably until 2010-12-31\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-01-01, presumably until 2011-01-09\n- 10 ML furosemide 10 MG/ML Injection, started on 2010-12-31, presumably until 2011-01-02\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2011-01-01, presumably until 2011-01-08\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2011-01-05, presumably until 2011-01-08\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2011-01-05, presumably until 2011-01-09\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2011-01-02, presumably until 2011-01-08\n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2011-01-03, presumably until 2011-01-09\n- levetiracetam 500 MG Oral Tablet, through Oral route, started on 2010-12-31, presumably until 2011-01-06. Instructions: take 1 Tab by mouth 2 times a day.\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2010-12-31, presumably until 2011-01-01\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2011-01-04, presumably until 2011-01-04\n- fluoxetine 10 MG Oral Capsule, through Oral route, started on 2011-01-01, presumably until 2011-01-09\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2011-01-07, presumably until 2011-01-07\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-01-01, presumably until 2011-01-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-31 15:00:00, ended at 2010-12-31 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-05 08:12:54, ended at 2011-01-05 12:27:22\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-03-13 08:22:03, ended at 2012-03-13 09:53:43\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- 0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe, presumably until 2013-06-18. Instructions: by Injection route. weekly \n- alprazolam 0.5 MG Oral Tablet, through Oral route, presumably until 2014-03-06. Instructions: take  by mouth 3 times a day.  \n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, presumably until 2014-03-06. Instructions: take  by mouth.  \n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, presumably until 2013-04-04. Instructions: take  by mouth as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-02-07 19:57:00, ended at 2013-02-10 13:15:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.2 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 144 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 6' 2\" (inch (US))\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 14.88 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.60 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 144 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 57 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 87 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.2 (ratio)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 272 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 86 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 71 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Physical therapy evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Pulmonary ventilation (eg, aerosol or gas) and perfusion imaging\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Noninvasive ventilation\n\n### Condition\n- Benign hypertensive renal disease with renal failure\n- Embolism and thrombosis of the vena cava\n- Chronic deep venous thrombosis of lower extremity\n- Hyperlipidemia\n- Pure hypercholesterolemia\n- Wheezing\n- Chronic kidney disease stage 4\n- Coronary arteriosclerosis\n- Obstructive sleep apnea syndrome\n- Chronic kidney disease\n- Anemia\n- Primary diagnosis: Cough\n- Dysthymia\n- Acute deep vein thrombosis of lower limb\n- Dyspnea\n- Acute asthma\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2015-08-03. Instructions: take 650 mg by mouth 2 times a day.  \n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2013-02-07, presumably until 2013-02-07\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2013-02-08, presumably until 2013-02-10\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2013-02-08, presumably until 2013-02-10\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- hydrocortisone 25 MG/ML Rectal Cream, through Rectal route, presumably until 2013-03-12. Instructions: insert  into the rectum.  \n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2013-02-07, presumably until 2013-03-12, with intended 3 refill(s). Instructions: 3 mL by Inhalation route every 4 hours.\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2013-02-08, presumably until 2013-02-08\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-10\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-02-08, presumably until 2014-03-06. Instructions: take 17 g by mouth One Time.  \n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-10\n- hydrocortisone 1.67 MG/ML Enema, through Rectal route, presumably until 2013-04-04. Instructions: insert  into the rectum.  \n- prednisone 50 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- nystatin 100 UNT/MG Topical Powder, through Topical route, presumably until 2014-03-06. Instructions: by Topical route 4 times a day.  \n- prednisone 20 MG Oral Tablet, started on 2013-02-10, presumably until 2013-03-12, with intended 0 refill(s). Instructions: Take 60mg for 3 days (2/26 - 2/28), take 40mg for 3 days (3/1-3/3), take 20mg for 3 days (3/4-3/6)\n- methylprednisolone 125 MG Injection, started on 2013-02-07, presumably until 2013-02-10\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2013-02-08, presumably until 2013-02-09\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, presumably until 2013-09-17. Instructions: insert  into the rectum.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-12 10:52:03, ended at 2013-03-12 13:32:57\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary embolism with pulmonary infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-03-25 20:18:00, ended at 2013-04-04 13:35:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 6' 2\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.22 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.96 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.33 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.69 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.4 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 58 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.8 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Prothrombin time (PT): 19.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n\n### Procedure\n- Occupational therapy evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation\n- Radiologic examination, knee; 1 or 2 views\n- Radiologic examination, chest; single view, frontal\n- Open reduction of fracture of femur with internal fixation\n- Computed tomography, head or brain; without contrast material\n- Noninvasive ventilation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, pelvis; 1 or 2 views\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Packed blood cell transfusion\n- Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Splitting of blood or blood products, each unit\n- Wheelchair management (eg, assessment, fitting, training), each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Collection of venous blood by venipuncture\n- Radiologic examination, abdomen; single anteroposterior view\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Anxiety state\n- Benign hypertensive renal disease with renal failure\n- Breathing painful\n- Closed fracture of femur, distal end\n- Low back pain\n- Pleural effusion\n- Acute deep vein thrombosis of lower limb\n- Chronic kidney disease stage 4\n- Coronary atherosclerosis\n- Dyspnea\n- Superficial injury to head, excluding eye\n- Closed fracture of shaft of femur\n- Depressive disorder\n- Obstructive sleep apnea syndrome\n- Pulmonary embolism with pulmonary infarction\n- Abdominal pain\n- Lung field abnormal\n- Pulmonary congestion and hypostasis\n- Abrasion and/or friction burn of skin\n- Asthma\n- Closed fracture of neck of femur\n- Coronary arteriosclerosis\n- Cough\n- Joint pain of pelvic region\n- Pain in limb\n- Paralytic ileus\n- Chronic kidney disease stage 3\n- Primary diagnosis: Closed fracture of femur\n- Essential hypertension\n- Hyperlipidemia\n- Cerebral hemorrhage\n- Degenerative joint disease of pelvis\n- Spinal stenosis of lumbar region\n- Urinary tract infectious disease\n- Bacterial infection due to Pseudomonas\n- Contusion of head and/or neck\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-04\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-03-29, presumably until 2013-03-29\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2013-03-26, presumably until 2013-04-04\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2013-03-26, presumably until 2013-04-04\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2013-03-30, presumably until 2013-04-02\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2013-03-26, presumably until 2013-04-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-04\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-03-26\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2013-04-02, presumably until 2013-04-02\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-03-30, presumably until 2013-04-01\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-09-17, with intended 5 refill(s). Instructions: take 2 Tabs by mouth every 6 hours.\n- cefazolin 1000 MG Injection, started on 2013-03-28, presumably until 2013-03-28\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-01\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-25, presumably until 2013-04-03\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-04-04\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-04-03\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-04-02\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2013-03-30, presumably until 2013-04-04\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-03-25, presumably until 2013-04-02\n- 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-04-04\n- hypromellose 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2013-03-27, presumably until 2013-03-27\n- hydrocortisone 1.67 MG/ML Enema, through Rectal route, started on 2013-04-01, presumably until 2014-04-02, with intended 5 refill(s). Instructions: insert 60 mL into the rectum every bedtime.\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2013-03-28, presumably until 2013-03-28\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-25, presumably until 2013-04-01\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-03-30, presumably until 2013-04-03\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2013-03-25, presumably until 2013-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-26, presumably until 2013-03-30\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-03-26, presumably until 2013-03-28\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2013-03-28, presumably until 2013-04-04\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2013-03-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-03-28, presumably until 2013-03-28\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2013-03-29, presumably until 2013-03-29\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-03-26, presumably until 2013-03-27\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2013-03-29, presumably until 2013-04-03\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2013-03-28, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-27 00:00:00, ended at 2013-03-27 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for open procedures involving upper two-thirds of femur; not otherwise specified\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Periprosthetic fracture\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- calcium gluconate 100 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-04-16 00:00:00, ended at 2013-04-16 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n- Chronic kidney disease stage 3\n- Coronary atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-16 00:00:00, ended at 2013-04-16 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-18 08:00:00, ended at 2013-04-18 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Anemia\n- Primary diagnosis: Delusional disorder\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-04-18, presumably until 2013-04-18\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2013-04-18, presumably until 2013-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-07 11:08:18, ended at 2013-05-07 12:41:03\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of femoral condyle of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 11:10:00, ended at 2013-05-07 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Periprosthetic fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-18 11:11:54, ended at 2013-06-18 13:57:45\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- 1 ML epoetin alfa 10000 UNT/ML Injection, presumably until 2014-03-06. Instructions: by Injection route.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-18 11:13:00, ended at 2013-06-18 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-08-06 11:18:32, ended at 2013-08-06 13:22:41\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-06 11:26:00, ended at 2013-08-06 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-17 11:16:55, ended at 2013-09-17 12:28:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-17 11:22:00, ended at 2013-09-17 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Degenerative joint disease of pelvis\n- Joint pain of pelvic region\n- Periprosthetic fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-29 11:25:08, ended at 2013-10-29 12:45:57\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of shaft of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-29 11:27:00, ended at 2013-10-29 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Closed fracture of shaft of femur\n- Disorder of bone and articular cartilage\n- Osteoarthritis of knee\n- Knee joint effusion\n- Atherosclerosis of arteries of the extremities\n- Periprosthetic fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-12-31 11:10:00, ended at 2013-12-31 23:59:00\nThe patient in this visit was 78 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Knee joint effusion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-31 11:11:06, ended at 2013-12-31 12:25:25\nThe patient in this visit was 78 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, femur, 2 views\n\n### Condition\n- Primary diagnosis: Closed fracture of femoral condyle of femur\n- Knee joint effusion\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "1c8d623bb05aa66631ae89c8d3e7578c8854a368a2a71d5ce3395b3c3aa951d4", "prompt_hash": "2b802734812707b0b501c9934975d3069e55360ed4e0c1ade7a70d4889a34255", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 6, "doc": {"person_id": 115969527, "visit_occurrence_id": 177577155, "death_date": null, "visit_concept_name": "Emergency Room Visit", "visit_start_datetime": "2021-05-11 12:35:00", "visit_end_datetime": "2021-05-11 13:29:00", "visit_length_in_hours": 0.9, "integrated_visit_record": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-11 12:35:00, ended at 2021-05-11 13:29:00\nThe patient in this visit was 81 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 11.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.11 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 103.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 138 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Catecholamines [Interpretation] in Plasma Narrative: 44.5 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n- Essential hypertension\n- Spontaneous ecchymosis\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 469, "patient_first_visit_date": "2015-03-17 14:13:00", "patient_last_visit_date": "2022-06-09 13:56:00", "end_obs_date": "2022-05-11", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 4, "cumulated_visit_num": 4, "cumulated_approximate_token_count": 1834, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-17 14:13:00, ended at 2015-03-17 14:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 36 (milliliter per minute per square meter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Kidney stone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-17 15:00:00, ended at 2015-03-17 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, abdomen; single anteroposterior view\n\n### Condition\n- Kidney stone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2020-07-10 09:11:00, ended at 2020-07-10 13:43:00\nThe patient in this visit was 80 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 11.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.1 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.15 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Catecholamines [Interpretation] in Plasma Narrative: 41.1 (femtoliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- MCV [Entitic volume] by Automated count: 100.0 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.5 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.52 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, chest; single view\n- Collection of venous blood by venipuncture\n\n### Condition\n- Electrocardiogram abnormal\n- Prediabetes\n- Abnormal findings on diagnostic imaging of lung\n- Chronic kidney disease due to hypertension\n- Primary diagnosis: Chest pain\n- Hyperlipidemia\n- Palpitations\n- Fatigue\n- Bradycardia\n- Chronic kidney disease stage 3\n\n### Drug\n- amlodipine 2.5 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25, with intended 0 refill(s). Instructions: take 2 Tablets (5 mg total) by mouth 2 times a day\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-05-26, presumably until 2020-05-26, with intended 0 refill(s). Instructions: take 1 Tablet (5 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-11 12:35:00, ended at 2021-05-11 13:29:00\nThe patient in this visit was 81 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 11.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.11 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 103.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 138 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Catecholamines [Interpretation] in Plasma Narrative: 44.5 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n- Essential hypertension\n- Spontaneous ecchymosis\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-17 14:13:00, ended at 2015-03-17 14:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 36 (milliliter per minute per square meter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Kidney stone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-17 15:00:00, ended at 2015-03-17 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, abdomen; single anteroposterior view\n\n### Condition\n- Kidney stone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2020-07-10 09:11:00, ended at 2020-07-10 13:43:00\nThe patient in this visit was 80 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 11.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.1 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.15 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Catecholamines [Interpretation] in Plasma Narrative: 41.1 (femtoliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- MCV [Entitic volume] by Automated count: 100.0 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.5 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.52 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, chest; single view\n- Collection of venous blood by venipuncture\n\n### Condition\n- Electrocardiogram abnormal\n- Prediabetes\n- Abnormal findings on diagnostic imaging of lung\n- Chronic kidney disease due to hypertension\n- Primary diagnosis: Chest pain\n- Hyperlipidemia\n- Palpitations\n- Fatigue\n- Bradycardia\n- Chronic kidney disease stage 3\n\n### Drug\n- amlodipine 2.5 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25, with intended 0 refill(s). Instructions: take 2 Tablets (5 mg total) by mouth 2 times a day\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-05-26, presumably until 2020-05-26, with intended 0 refill(s). Instructions: take 1 Tablet (5 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-11 12:35:00, ended at 2021-05-11 13:29:00\nThe patient in this visit was 81 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 11.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.11 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 103.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 138 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Catecholamines [Interpretation] in Plasma Narrative: 44.5 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n- Essential hypertension\n- Spontaneous ecchymosis\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "c9b0b9ec1de0068e6a7d5b0aae5eb8305f80f944acb70013e55e22e63b957d18", "prompt_hash": "aa7ea8435e7e62fa06ddf8445074865f9dd6f54a1c00423c36af913a9233a863", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 7, "doc": {"person_id": 115971221, "visit_occurrence_id": 58686504, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2013-11-23 13:11:23", "visit_end_datetime": "2013-11-23 13:45:25", "visit_length_in_hours": 0.5672222222222222, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2013-11-23 13:11:23, ended at 2013-11-23 13:45:25\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)\n\n### Condition\n- Subacute delirium\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 126, "patient_first_visit_date": "2008-04-03 19:56:00", "patient_last_visit_date": "2017-03-18 00:00:00", "end_obs_date": "2014-11-23", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 1, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 1, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 1, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 46, "cumulated_visit_num": 46, "cumulated_approximate_token_count": 17764, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2008-04-03 19:56:00, ended at 2008-04-04 13:35:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.22 (thousand per microliter)\n- Prothrombin time (PT): 14.2 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 3\" (inch (US))\n- Erythrocytes [#/volume] in Blood by Automated count: 4.10 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.02 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.3 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 410 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.93 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.20 (micro-international unit per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.7 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic obstructive lung disease\n- Asthma\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2008-04-04, presumably until 2009-04-04, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route as needed \n- oxycodone hydrochloride 5 MG Oral Capsule, through Oral route, presumably until 2011-08-08. Instructions: take 5-10 mg by mouth every 4 hours as needed \n- 1 ML etanercept 50 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2008-12-27. Instructions: by SUBCUTANEOUS route. \n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2008-04-03, presumably until 2011-08-08. Instructions: take 80 mg by mouth every 12 hours as needed \n- prednisone 10 MG Oral Tablet, through Oral route, started on 2008-04-05, presumably until 2008-12-27, with quantity of 10.0, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily. \n- moxifloxacin 400 MG Oral Tablet, through Oral route, started on 2008-04-03, presumably until 2008-12-27, with quantity of 6.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-04-04, presumably until 2008-04-04\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2011-07-21. Instructions: take 20 mg by mouth every 12 hours as needed \n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2008-04-03, presumably until 2008-04-03\n- prednisone 5 MG Oral Tablet, through Oral route, presumably until 2008-04-04. Instructions: take 5 mg by mouth daily. \n- 12 HR guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2009-04-11, with quantity of 30.0, with intended 2 refill(s). Instructions: take by mouth.\n- thyroid (USP) 240 MG Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2011-08-08. Instructions: take by mouth. \n- prednisone 20 MG Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2008-04-04. Instructions: take 5 mg by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2008-12-20 00:42:00, ended at 2008-12-21 16:40:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.41 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.46 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Base excess in Blood by calculation: 3.0 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- MCV [Entitic volume] by Automated count: 87.0 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Body height: 5' 2\" (inch (US))\n- Erythrocytes [#/volume] in Blood by Automated count: 3.79 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 205 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.38 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 128 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 310 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Asthma\n- Chronic obstructive lung disease\n- Disorder of biliary tract\n- Sequela\n- Shoulder joint pain\n- Acquired hypothyroidism\n- Disorder of lung\n- Depressive disorder\n- Fever\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2008-12-19, presumably until 2008-12-19\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2008-12-20, presumably until 2008-12-21. Instructions: 2 Puffs by Inhalation route as needed \n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-20, presumably until 2008-12-21. Instructions: take 80 mg by mouth every 12 hours as needed \n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2008-12-19, presumably until 2008-12-19\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-12-20, presumably until 2008-12-21\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2008-12-19, presumably until 2008-12-19\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2008-12-19, presumably until 2008-12-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2008-12-24 14:34:00, ended at 2008-12-27 12:36:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Body height: 5' 2\" (inch (US))\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.65 (micro-international unit per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 288 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.37 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.67 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 449 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Base excess in Blood by calculation: 3.0 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.0 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.9 (femtoliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 16.2 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Rheumatoid arthritis\n- Systemic inflammatory response syndrome\n- Altered mental status\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2008-12-24, presumably until 2008-12-25\n- 1 ML etanercept 50 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2008-12-27. Instructions: by SUBCUTANEOUS route. Once a week\n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-27\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2008-12-26, presumably until 2009-11-28, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2008-12-25, presumably until 2009-03-05, with quantity of 7.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2008-12-24, presumably until 2008-12-25\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-12-24, presumably until 2008-12-26\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2008-12-23, presumably until 2008-12-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-12-24, presumably until 2008-12-24\n- 12 HR guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24. Instructions: take 1 Tab by mouth every 12 hours. \n- azithromycin 250 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-25\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24\n- 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-25, presumably until 2008-12-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-08-17 00:00:00, ended at 2009-08-17 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-27 19:30:00, ended at 2009-08-27 23:59:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-19 15:00:00, ended at 2009-09-19 23:59:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.10 (millimole per liter)\n\n### Procedure\n- Carbon monoxide diffusing capacity (eg, single breath, steady state)\n- Functional residual capacity or residual volume: helium method, nitrogen open circuit method, or other method\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n\n### Condition\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-10 14:36:59, ended at 2010-05-10 17:00:42\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Primary diagnosis: Fever\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2010-05-10, presumably until 2010-05-22, with quantity of 10.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-13 20:38:00, ended at 2010-05-13 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-17 00:00:00, ended at 2010-05-17 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Chronic obstructive lung disease\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-19 21:21:00, ended at 2010-05-19 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Chronic obstructive lung disease\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-05-21 00:00:00, ended at 2010-05-21 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Rheumatoid arthritis\n- Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-21 15:15:00, ended at 2010-05-21 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Chronic obstructive lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-22 00:00:00, ended at 2010-05-22 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic obstructive lung disease\n- Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-22 06:12:00, ended at 2010-05-22 14:39:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.93 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Erythrocyte sedimentation rate: 79 (millimeter per hour)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.09 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.73 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 392 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Infective pneumonia\n- Rheumatoid arthritis\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-22 14:05:17, ended at 2010-05-22 16:05:07\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Tachycardia\n- Infective pneumonia\n- Rheumatoid arthritis\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2010-05-22, presumably until 2011-05-22, with intended 3 refill(s). Instructions: 0.[000000] Sprays by Nasal route 2 times a day. \n- loratadine 10 MG Oral Tablet, through Oral route, started on 2010-05-22, presumably until 2011-05-22, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-22 14:40:00, ended at 2010-05-22 15:22:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic obstructive lung disease\n- Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-22 15:23:00, ended at 2010-05-22 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Palpitations\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-24 00:00:00, ended at 2010-05-24 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-07-16 20:42:00, ended at 2011-07-21 15:04:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n- Erythrocyte sedimentation rate: 63 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.4 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 2.2 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 32 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 45 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Basophils/100 leukocytes in Blood by Manual count: 2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 5 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.20 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Cells counted [#] in Chorionic villus sample by Molecular genetics method: 55 (cells)\n- Platelets [#/volume] in Blood by Automated count: 359 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 16.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.1 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 142 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 8.0 (millimole per liter)\n- Body height: 5' 6\" (inch (US))\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 28 (percent)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.43 (micro-international unit per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: <20.0 (unit per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: <10.0 (unit per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.04 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.8 (percent)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Physical therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Lumbar puncture\n- Electroencephalogram (EEG) extended monitoring; 61-119 minutes\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n- Computed tomography, head or brain; without contrast material\n- Occupational therapy evaluation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n\n### Condition\n- Fever\n- Localized osteoarthrosis uncertain if primary OR secondary\n- Anemia of chronic disease\n- Organic mental disorder\n- Altered mental status\n- Depressive disorder\n- Lung field abnormal\n- Chronic obstructive lung disease\n- Chronic pain\n- Acquired hypothyroidism\n- Arthritis of shoulder region joint\n- Rheumatoid arthritis\n- Asthma\n\n### Drug\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-07-19, presumably until 2011-07-19\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-07-21, presumably until 2011-07-21\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-07-17, presumably until 2011-07-21\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2011-07-20, presumably until 2011-08-08, with intended 0 refill(s). Instructions: take 2 Caps by mouth 3 times a day.\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2011-07-17, presumably until 2011-07-17\n- eszopiclone 1 MG Oral Tablet, through Oral route, started on 2011-07-21, presumably until 2011-08-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed for Insomnia.\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-21, presumably until 2011-07-21\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-07-26 16:23:00, ended at 2011-08-08 16:45:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.2 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 39 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 2.0 (nanogram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 289 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.13 (micro-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 20.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.04 (thousand per microliter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.95 (million per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.50 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.9 (percent)\n- MCV [Entitic volume] by Automated count: 91.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.37 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 278 (unit per liter)\n\n### Procedure\n- Physical therapy evaluation\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Replacement of indwelling catheter of urinary bladder\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Insertion of indwelling catheter into urinary bladder\n- Injection of antibiotic\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Collection of venous blood by venipuncture\n- Computed tomography, head or brain; without contrast material\n\n### Condition\n- Acquired hypothyroidism\n- Infection due to Escherichia coli\n- Urinary tract infectious disease\n- Degeneration of intervertebral disc\n- Retention of urine\n- Primary diagnosis: Altered mental status\n- Dementia associated with another disease\n- Thyrotoxicosis without goiter or other cause\n- Tobacco dependence syndrome\n- Disturbance of consciousness\n- Hypokalemia\n- Mitral and aortic incompetence\n- Post-inflammatory pulmonary fibrosis\n- Asthma\n- Dementia with behavioral disturbance\n- Frontotemporal dementia\n- Major depression, single episode\n- Organic mental disorder\n- Blood chemistry abnormal\n- Rheumatoid arthritis\n- Chronic obstructive lung disease\n\n### Drug\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2011-08-01, presumably until 2011-08-03\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-07-27\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-07-28. Instructions: take by mouth.\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-07-27, presumably until 2011-07-28\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-07-27, presumably until 2011-08-08\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-08-05, presumably until 2011-08-05\n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-08-04. Instructions: take 80 mg by mouth every 12 hours as needed\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-08\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-07-27, presumably until 2011-08-08\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-30, presumably until 2012-02-04, with intended 1 refill(s). Instructions: take 80 mg by mouth every 12 hours as needed\n- celecoxib 100 MG Oral Capsule, through Oral route, started on 2011-08-06, presumably until 2011-08-08\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2011-08-05, presumably until 2012-06-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Until pill are gone\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2011-07-30, presumably until 2011-07-30\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-07-30, presumably until 2011-08-08\n- olanzapine 10 MG Injection, through Intramuscular route, started on 2011-07-28, presumably until 2011-07-28\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-08-05, presumably until 2012-08-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2011-07-29, presumably until 2011-08-07\n- olanzapine 5 MG Disintegrating Oral Tablet, through Oral route, started on 2011-07-29, presumably until 2011-08-01\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2011-08-08, presumably until 2012-08-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-08-01, presumably until 2011-08-01\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2011-08-05, presumably until 2012-08-07, with intended 1 refill(s). Instructions: take 1 Cap by mouth daily.\n- risperidone 0.5 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2012-08-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- methotrexate 2.5 MG Oral Tablet, presumably until 2011-08-08\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-30, presumably until 2011-08-05\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2011-08-04, presumably until 2011-08-06. Instructions: take 80 mg by mouth every 12 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-07-29\n- risperidone 0.5 MG Disintegrating Oral Tablet, through Oral route, started on 2011-07-29, presumably until 2011-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-05 14:55:44, ended at 2011-11-05 16:53:38\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, presumably until 2015-03-21. Instructions: take 1 tablet by mouth daily in the morning.\n- diazepam 2 MG Oral Tablet, through Oral route, presumably until 2013-08-09. Instructions: take  by mouth as needed.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2016-07-22. Instructions: take 81 mg by mouth every other day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-06 09:23:22, ended at 2011-11-06 13:37:17\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)\n\n### Condition\n- Acute esophagitis\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-12-03 11:49:46, ended at 2011-12-03 11:56:32\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-06-17 11:59:14, ended at 2012-06-17 13:14:50\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-17 14:01:00, ended at 2012-06-17 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.98 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 40.5 (percent)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 58 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-29 00:00:00, ended at 2012-06-29 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-07-14 10:10:35, ended at 2012-07-14 11:53:22\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n- Rheumatoid arthritis\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-14 12:01:00, ended at 2012-07-14 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-03 14:10:00, ended at 2012-08-03 14:11:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Fever\n- Disorder of pancreas\n- Acquired renal cystic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-03 14:12:00, ended at 2012-08-03 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired renal cystic disease\n- Lymphadenopathy\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-04 10:12:46, ended at 2012-08-04 10:50:17\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Lung field abnormal\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-17 14:20:00, ended at 2012-08-17 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Fever\n- Acquired renal cystic disease\n- Lymphadenopathy\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-24 11:15:43, ended at 2012-08-24 13:17:26\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized, primary osteoarthritis of the shoulder region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-24 11:19:00, ended at 2012-08-24 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, shoulder; complete, minimum of 2 views\n\n### Condition\n- Degenerative joint disease of shoulder region\n- Acquired hypothyroidism\n- Localized, primary osteoarthritis of the shoulder region\n- Osteoarthritis\n- Shoulder joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-21 11:30:00, ended at 2012-09-21 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)\n\n### Condition\n- Imaging of musculoskeletal system abnormal\n- Acquired hypothyroidism\n- Localized, primary osteoarthritis of the shoulder region\n- Shoulder joint pain\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-09-21 13:32:29, ended at 2012-09-21 14:21:55\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-09-28 11:14:58, ended at 2012-09-28 12:33:56\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Inflammatory dermatosis\n- Primary diagnosis: Fever\n\n### Drug\n- fluocinonide 0.0005 MG/MG Topical Ointment, started on 2012-09-28, presumably until 2013-09-28, with intended 0 refill(s). Instructions: Apply to affected area twice a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-28 11:59:00, ended at 2012-09-28 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.5 (percent)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.15 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 365 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-30 16:01:12, ended at 2013-05-30 16:49:37\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- 1 ML etanercept 50 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2013-08-09. Instructions: inject 1 Syringe subcutaneous (under the skin) every 7 days.\n- methotrexate 2.5 MG Oral Tablet, through Oral route, presumably until 2013-08-09. Instructions: take  by mouth every 7 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-07-12 09:07:44, ended at 2013-07-12 10:23:13\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-08-01 21:05:00, ended at 2013-08-09 19:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 5' 5.984\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 58 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 25 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Eosinophils [#/volume] in Blood by Manual count: 0.6 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.53 (milli-international unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 125 (unit per liter)\n- Neutrophils [#/volume] in Blood by Manual count: 6.0 (thousand per microliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.3 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 324 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Physical therapy evaluation\n- Arterial puncture, withdrawal of blood for diagnosis\n- Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\n- Computed tomography, head or brain; without contrast material\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Depressive disorder\n- Difficulty walking\n- Primary diagnosis: Altered mental status\n- Dementia associated with another disease\n- Acquired hypothyroidism\n- Lung field abnormal\n- Disturbance of consciousness\n- Asthma\n- Degenerative joint disease of shoulder region\n- Chronic obstructive lung disease\n- Delirium\n- Frontotemporal dementia\n- Post-inflammatory pulmonary fibrosis\n- Insomnia\n- Rheumatoid arthritis\n\n### Drug\n- haloperidol 5 MG/ML Injectable Solution, started on 2013-08-02, presumably until 2013-08-02\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-09\n- risperidone 1 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-03\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2013-08-01, presumably until 2013-08-01\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2013-08-08, presumably until 2013-08-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-09\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-09\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2013-08-02, presumably until 2013-08-03\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime.\n- rivastigmine 1.5 MG Oral Capsule, through Oral route, started on 2013-08-09, presumably until 2013-08-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth Every Day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-08-03, presumably until 2013-08-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-08-02, presumably until 2013-08-02\n- risperidone 0.5 MG Oral Tablet, through Oral route, started on 2013-08-05, presumably until 2013-08-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-08-02, presumably until 2013-08-09\n- 2 ML diazepam 5 MG/ML Auto-Injector, started on 2013-08-01, presumably until 2013-08-02\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2013-08-02, presumably until 2013-08-02\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-08-06, presumably until 2015-03-21. Instructions: take 5 mg by mouth every 6 hours.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2013-08-06, presumably until 2013-08-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2013-08-10 22:10:00, ended at 2013-08-16 18:10:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Base excess in Blood by calculation: 2.0 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 341 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Body height: 5' 5.984\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.37 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.89 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Cardiac arrhythmia\n- Dementia\n- Hypo-osmolality and or hyponatremia\n- Asthma\n- Nausea\n- Post-inflammatory pulmonary fibrosis\n- Tachycardia\n- Urinary incontinence\n- Chronic obstructive lung disease\n- Electrocardiogram abnormal\n- Psychologic conversion disorder\n- Rheumatoid arthritis\n- Depressive disorder\n- Acquired hypothyroidism\n- Altered mental status\n- Acute renal failure syndrome\n- Organic mental disorder\n- Pulmonary tuberculosis\n\n### Drug\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2013-08-16, presumably until 2014-02-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed.\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2013-08-16\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-08-13, presumably until 2013-08-16\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-08-15\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2014-08-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning.\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2013-08-15, presumably until 2013-08-15\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2014-08-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-08-14, presumably until 2013-08-16\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2013-08-16\n- rivastigmine 1.5 MG Oral Capsule, through Oral route, started on 2013-08-12, presumably until 2013-10-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-08-11, presumably until 2013-08-11\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2013-08-11, presumably until 2013-08-11\n- risperidone 0.5 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-10-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-08-12\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-08-13, presumably until 2013-08-13\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2013-08-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-28 12:33:18, ended at 2013-09-28 13:47:46\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychiatric diagnostic evaluation with medical services\n\n### Condition\n- Primary diagnosis: Subacute delirium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-07 09:45:31, ended at 2013-10-07 12:10:43\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Organic mental disorder\n\n### Drug\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2013-07-01, presumably until 2014-07-21. Instructions: take 5 mg by mouth every bedtime as needed. Patient is aware of the risk for respiratory depression with using benzo and opiates.  She does not exceed prescribed dose.  Medication prescribed by her Rheumatologist\n- 1 ML etanercept 50 MG/ML Auto-Injector, started on 2013-09-14, presumably until 2015-03-21\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2013-09-13, presumably until 2013-10-10. Instructions: take 125 mg by mouth 2 times a day with meals.\n- ondansetron 4 MG Disintegrating Oral Tablet, started on 2013-07-11, presumably until 2013-07-11\n- methotrexate 2.5 MG Oral Tablet, started on 2013-07-11, presumably until 2015-03-21\n- modafinil 200 MG Oral Tablet, started on 2013-07-11, presumably until 2013-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-10 13:31:02, ended at 2013-10-10 14:14:18\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)\n\n### Condition\n- Primary diagnosis: Altered mental status\n\n### Drug\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2013-10-10, presumably until 2014-02-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n- rivastigmine 1.5 MG Oral Capsule, through Oral route, started on 2013-10-10, presumably until 2014-04-14, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-23 13:11:23, ended at 2013-11-23 13:45:25\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)\n\n### Condition\n- Subacute delirium\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2008-04-03 19:56:00, ended at 2008-04-04 13:35:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.22 (thousand per microliter)\n- Prothrombin time (PT): 14.2 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 3\" (inch (US))\n- Erythrocytes [#/volume] in Blood by Automated count: 4.10 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.02 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.3 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 410 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.93 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.20 (micro-international unit per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.7 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic obstructive lung disease\n- Asthma\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2008-04-04, presumably until 2009-04-04, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route as needed \n- oxycodone hydrochloride 5 MG Oral Capsule, through Oral route, presumably until 2011-08-08. Instructions: take 5-10 mg by mouth every 4 hours as needed \n- 1 ML etanercept 50 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2008-12-27. Instructions: by SUBCUTANEOUS route. \n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2008-04-03, presumably until 2011-08-08. Instructions: take 80 mg by mouth every 12 hours as needed \n- prednisone 10 MG Oral Tablet, through Oral route, started on 2008-04-05, presumably until 2008-12-27, with quantity of 10.0, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily. \n- moxifloxacin 400 MG Oral Tablet, through Oral route, started on 2008-04-03, presumably until 2008-12-27, with quantity of 6.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-04-04, presumably until 2008-04-04\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2011-07-21. Instructions: take 20 mg by mouth every 12 hours as needed \n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2008-04-03, presumably until 2008-04-03\n- prednisone 5 MG Oral Tablet, through Oral route, presumably until 2008-04-04. Instructions: take 5 mg by mouth daily. \n- 12 HR guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2009-04-11, with quantity of 30.0, with intended 2 refill(s). Instructions: take by mouth.\n- thyroid (USP) 240 MG Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2011-08-08. Instructions: take by mouth. \n- prednisone 20 MG Oral Tablet, through Oral route, started on 2008-04-04, presumably until 2008-04-04. Instructions: take 5 mg by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2008-12-20 00:42:00, ended at 2008-12-21 16:40:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.41 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.46 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Base excess in Blood by calculation: 3.0 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- MCV [Entitic volume] by Automated count: 87.0 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Body height: 5' 2\" (inch (US))\n- Erythrocytes [#/volume] in Blood by Automated count: 3.79 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 205 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.38 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 128 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 310 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Asthma\n- Chronic obstructive lung disease\n- Disorder of biliary tract\n- Sequela\n- Shoulder joint pain\n- Acquired hypothyroidism\n- Disorder of lung\n- Depressive disorder\n- Fever\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2008-12-19, presumably until 2008-12-19\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2008-12-20, presumably until 2008-12-21. Instructions: 2 Puffs by Inhalation route as needed \n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-20, presumably until 2008-12-21. Instructions: take 80 mg by mouth every 12 hours as needed \n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2008-12-19, presumably until 2008-12-19\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-12-20, presumably until 2008-12-21\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2008-12-19, presumably until 2008-12-19\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2008-12-19, presumably until 2008-12-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2008-12-24 14:34:00, ended at 2008-12-27 12:36:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Body height: 5' 2\" (inch (US))\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.65 (micro-international unit per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 288 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.37 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.67 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 449 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Base excess in Blood by calculation: 3.0 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.0 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.9 (femtoliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 16.2 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Rheumatoid arthritis\n- Systemic inflammatory response syndrome\n- Altered mental status\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2008-12-24, presumably until 2008-12-25\n- 1 ML etanercept 50 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2008-12-27. Instructions: by SUBCUTANEOUS route. Once a week\n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-27\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2008-12-26, presumably until 2009-11-28, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2008-12-25, presumably until 2009-03-05, with quantity of 7.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2008-12-24, presumably until 2008-12-25\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-12-24, presumably until 2008-12-26\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2008-12-23, presumably until 2008-12-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-12-24, presumably until 2008-12-24\n- 12 HR guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24. Instructions: take 1 Tab by mouth every 12 hours. \n- azithromycin 250 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-25\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-12-24, presumably until 2008-12-24\n- 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-25, presumably until 2008-12-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-08-17 00:00:00, ended at 2009-08-17 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-27 19:30:00, ended at 2009-08-27 23:59:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-19 15:00:00, ended at 2009-09-19 23:59:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.10 (millimole per liter)\n\n### Procedure\n- Carbon monoxide diffusing capacity (eg, single breath, steady state)\n- Functional residual capacity or residual volume: helium method, nitrogen open circuit method, or other method\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n\n### Condition\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-10 14:36:59, ended at 2010-05-10 17:00:42\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Primary diagnosis: Fever\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2010-05-10, presumably until 2010-05-22, with quantity of 10.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-13 20:38:00, ended at 2010-05-13 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-17 00:00:00, ended at 2010-05-17 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Chronic obstructive lung disease\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-19 21:21:00, ended at 2010-05-19 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Chronic obstructive lung disease\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2010-05-21 00:00:00, ended at 2010-05-21 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Rheumatoid arthritis\n- Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-21 15:15:00, ended at 2010-05-21 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Infective pneumonia\n- Chronic obstructive lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-22 00:00:00, ended at 2010-05-22 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic obstructive lung disease\n- Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-22 06:12:00, ended at 2010-05-22 14:39:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.93 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Erythrocyte sedimentation rate: 79 (millimeter per hour)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.09 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.73 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 392 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Infective pneumonia\n- Rheumatoid arthritis\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-22 14:05:17, ended at 2010-05-22 16:05:07\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Tachycardia\n- Infective pneumonia\n- Rheumatoid arthritis\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2010-05-22, presumably until 2011-05-22, with intended 3 refill(s). Instructions: 0.[000000] Sprays by Nasal route 2 times a day. \n- loratadine 10 MG Oral Tablet, through Oral route, started on 2010-05-22, presumably until 2011-05-22, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-22 14:40:00, ended at 2010-05-22 15:22:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic obstructive lung disease\n- Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-22 15:23:00, ended at 2010-05-22 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Palpitations\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-24 00:00:00, ended at 2010-05-24 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Infective pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-07-16 20:42:00, ended at 2011-07-21 15:04:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n- Erythrocyte sedimentation rate: 63 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.4 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 2.2 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 32 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 45 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Basophils/100 leukocytes in Blood by Manual count: 2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 5 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.20 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Cells counted [#] in Chorionic villus sample by Molecular genetics method: 55 (cells)\n- Platelets [#/volume] in Blood by Automated count: 359 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 16.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.1 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 142 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 8.0 (millimole per liter)\n- Body height: 5' 6\" (inch (US))\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 28 (percent)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.43 (micro-international unit per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: <20.0 (unit per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: <10.0 (unit per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.04 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.8 (percent)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Physical therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Lumbar puncture\n- Electroencephalogram (EEG) extended monitoring; 61-119 minutes\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n- Computed tomography, head or brain; without contrast material\n- Occupational therapy evaluation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n\n### Condition\n- Fever\n- Localized osteoarthrosis uncertain if primary OR secondary\n- Anemia of chronic disease\n- Organic mental disorder\n- Altered mental status\n- Depressive disorder\n- Lung field abnormal\n- Chronic obstructive lung disease\n- Chronic pain\n- Acquired hypothyroidism\n- Arthritis of shoulder region joint\n- Rheumatoid arthritis\n- Asthma\n\n### Drug\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-07-19, presumably until 2011-07-19\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-07-21, presumably until 2011-07-21\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-21\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-07-17, presumably until 2011-07-21\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2011-07-20, presumably until 2011-08-08, with intended 0 refill(s). Instructions: take 2 Caps by mouth 3 times a day.\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2011-07-17, presumably until 2011-07-17\n- eszopiclone 1 MG Oral Tablet, through Oral route, started on 2011-07-21, presumably until 2011-08-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed for Insomnia.\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-21, presumably until 2011-07-21\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-07-26 16:23:00, ended at 2011-08-08 16:45:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.2 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 39 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 2.0 (nanogram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 289 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.13 (micro-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 20.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.04 (thousand per microliter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.95 (million per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.50 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.9 (percent)\n- MCV [Entitic volume] by Automated count: 91.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.37 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 278 (unit per liter)\n\n### Procedure\n- Physical therapy evaluation\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Replacement of indwelling catheter of urinary bladder\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Insertion of indwelling catheter into urinary bladder\n- Injection of antibiotic\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Collection of venous blood by venipuncture\n- Computed tomography, head or brain; without contrast material\n\n### Condition\n- Acquired hypothyroidism\n- Infection due to Escherichia coli\n- Urinary tract infectious disease\n- Degeneration of intervertebral disc\n- Retention of urine\n- Primary diagnosis: Altered mental status\n- Dementia associated with another disease\n- Thyrotoxicosis without goiter or other cause\n- Tobacco dependence syndrome\n- Disturbance of consciousness\n- Hypokalemia\n- Mitral and aortic incompetence\n- Post-inflammatory pulmonary fibrosis\n- Asthma\n- Dementia with behavioral disturbance\n- Frontotemporal dementia\n- Major depression, single episode\n- Organic mental disorder\n- Blood chemistry abnormal\n- Rheumatoid arthritis\n- Chronic obstructive lung disease\n\n### Drug\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2011-08-01, presumably until 2011-08-03\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-07-27\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-07-28. Instructions: take by mouth.\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-07-27, presumably until 2011-07-28\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-07-27, presumably until 2011-08-08\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-08-05, presumably until 2011-08-05\n- 12 HR oxycodone hydrochloride 40 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-08-04. Instructions: take 80 mg by mouth every 12 hours as needed\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-08\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-07-27, presumably until 2011-08-08\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-07-30, presumably until 2012-02-04, with intended 1 refill(s). Instructions: take 80 mg by mouth every 12 hours as needed\n- celecoxib 100 MG Oral Capsule, through Oral route, started on 2011-08-06, presumably until 2011-08-08\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2011-08-05, presumably until 2012-06-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Until pill are gone\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2011-07-30, presumably until 2011-07-30\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-07-30, presumably until 2011-08-08\n- olanzapine 10 MG Injection, through Intramuscular route, started on 2011-07-28, presumably until 2011-07-28\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-08-05, presumably until 2012-08-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2011-07-29, presumably until 2011-08-07\n- olanzapine 5 MG Disintegrating Oral Tablet, through Oral route, started on 2011-07-29, presumably until 2011-08-01\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2011-08-08, presumably until 2012-08-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-08-01, presumably until 2011-08-01\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2011-08-05, presumably until 2012-08-07, with intended 1 refill(s). Instructions: take 1 Cap by mouth daily.\n- risperidone 0.5 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2012-08-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- methotrexate 2.5 MG Oral Tablet, presumably until 2011-08-08\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-30, presumably until 2011-08-05\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2011-08-04, presumably until 2011-08-06. Instructions: take 80 mg by mouth every 12 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-27, presumably until 2011-07-29\n- risperidone 0.5 MG Disintegrating Oral Tablet, through Oral route, started on 2011-07-29, presumably until 2011-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-05 14:55:44, ended at 2011-11-05 16:53:38\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, presumably until 2015-03-21. Instructions: take 1 tablet by mouth daily in the morning.\n- diazepam 2 MG Oral Tablet, through Oral route, presumably until 2013-08-09. Instructions: take  by mouth as needed.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2016-07-22. Instructions: take 81 mg by mouth every other day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-06 09:23:22, ended at 2011-11-06 13:37:17\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)\n\n### Condition\n- Acute esophagitis\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-12-03 11:49:46, ended at 2011-12-03 11:56:32\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-06-17 11:59:14, ended at 2012-06-17 13:14:50\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-17 14:01:00, ended at 2012-06-17 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.98 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 40.5 (percent)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 58 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-29 00:00:00, ended at 2012-06-29 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-07-14 10:10:35, ended at 2012-07-14 11:53:22\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n- Rheumatoid arthritis\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-14 12:01:00, ended at 2012-07-14 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-03 14:10:00, ended at 2012-08-03 14:11:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Fever\n- Disorder of pancreas\n- Acquired renal cystic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-03 14:12:00, ended at 2012-08-03 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired renal cystic disease\n- Lymphadenopathy\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-04 10:12:46, ended at 2012-08-04 10:50:17\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Lung field abnormal\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-17 14:20:00, ended at 2012-08-17 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Fever\n- Acquired renal cystic disease\n- Lymphadenopathy\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-24 11:15:43, ended at 2012-08-24 13:17:26\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized, primary osteoarthritis of the shoulder region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-24 11:19:00, ended at 2012-08-24 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, shoulder; complete, minimum of 2 views\n\n### Condition\n- Degenerative joint disease of shoulder region\n- Acquired hypothyroidism\n- Localized, primary osteoarthritis of the shoulder region\n- Osteoarthritis\n- Shoulder joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-21 11:30:00, ended at 2012-09-21 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)\n\n### Condition\n- Imaging of musculoskeletal system abnormal\n- Acquired hypothyroidism\n- Localized, primary osteoarthritis of the shoulder region\n- Shoulder joint pain\n- Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-09-21 13:32:29, ended at 2012-09-21 14:21:55\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-09-28 11:14:58, ended at 2012-09-28 12:33:56\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Inflammatory dermatosis\n- Primary diagnosis: Fever\n\n### Drug\n- fluocinonide 0.0005 MG/MG Topical Ointment, started on 2012-09-28, presumably until 2013-09-28, with intended 0 refill(s). Instructions: Apply to affected area twice a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-28 11:59:00, ended at 2012-09-28 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.5 (percent)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.15 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 365 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-30 16:01:12, ended at 2013-05-30 16:49:37\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- 1 ML etanercept 50 MG/ML Prefilled Syringe, through Subcutaneous route, presumably until 2013-08-09. Instructions: inject 1 Syringe subcutaneous (under the skin) every 7 days.\n- methotrexate 2.5 MG Oral Tablet, through Oral route, presumably until 2013-08-09. Instructions: take  by mouth every 7 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-07-12 09:07:44, ended at 2013-07-12 10:23:13\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rheumatoid arthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-08-01 21:05:00, ended at 2013-08-09 19:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 5' 5.984\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 58 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 25 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Eosinophils [#/volume] in Blood by Manual count: 0.6 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.53 (milli-international unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 125 (unit per liter)\n- Neutrophils [#/volume] in Blood by Manual count: 6.0 (thousand per microliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.3 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 324 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Physical therapy evaluation\n- Arterial puncture, withdrawal of blood for diagnosis\n- Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\n- Computed tomography, head or brain; without contrast material\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Depressive disorder\n- Difficulty walking\n- Primary diagnosis: Altered mental status\n- Dementia associated with another disease\n- Acquired hypothyroidism\n- Lung field abnormal\n- Disturbance of consciousness\n- Asthma\n- Degenerative joint disease of shoulder region\n- Chronic obstructive lung disease\n- Delirium\n- Frontotemporal dementia\n- Post-inflammatory pulmonary fibrosis\n- Insomnia\n- Rheumatoid arthritis\n\n### Drug\n- haloperidol 5 MG/ML Injectable Solution, started on 2013-08-02, presumably until 2013-08-02\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-09\n- risperidone 1 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-03\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2013-08-01, presumably until 2013-08-01\n- risperidone 0.25 MG Oral Tablet, through Oral route, started on 2013-08-08, presumably until 2013-08-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-09\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-09\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2013-08-02, presumably until 2013-08-03\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-08-03, presumably until 2013-08-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime.\n- rivastigmine 1.5 MG Oral Capsule, through Oral route, started on 2013-08-09, presumably until 2013-08-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth Every Day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-08-03, presumably until 2013-08-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-08-02, presumably until 2013-08-02\n- risperidone 0.5 MG Oral Tablet, through Oral route, started on 2013-08-05, presumably until 2013-08-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-08-02, presumably until 2013-08-09\n- 2 ML diazepam 5 MG/ML Auto-Injector, started on 2013-08-01, presumably until 2013-08-02\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2013-08-02, presumably until 2013-08-02\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-08-06, presumably until 2015-03-21. Instructions: take 5 mg by mouth every 6 hours.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2013-08-06, presumably until 2013-08-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2013-08-10 22:10:00, ended at 2013-08-16 18:10:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Base excess in Blood by calculation: 2.0 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 341 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Body height: 5' 5.984\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.37 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.89 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Cardiac arrhythmia\n- Dementia\n- Hypo-osmolality and or hyponatremia\n- Asthma\n- Nausea\n- Post-inflammatory pulmonary fibrosis\n- Tachycardia\n- Urinary incontinence\n- Chronic obstructive lung disease\n- Electrocardiogram abnormal\n- Psychologic conversion disorder\n- Rheumatoid arthritis\n- Depressive disorder\n- Acquired hypothyroidism\n- Altered mental status\n- Acute renal failure syndrome\n- Organic mental disorder\n- Pulmonary tuberculosis\n\n### Drug\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2013-08-16, presumably until 2014-02-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed.\n- thyroid (USP) 120 MG Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2013-08-16\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-08-13, presumably until 2013-08-16\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-08-15\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2014-08-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning.\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2013-08-15, presumably until 2013-08-15\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2014-08-16, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-08-14, presumably until 2013-08-16\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2013-08-16\n- rivastigmine 1.5 MG Oral Capsule, through Oral route, started on 2013-08-12, presumably until 2013-10-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-08-11, presumably until 2013-08-11\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2013-08-11, presumably until 2013-08-11\n- risperidone 0.5 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-10-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-08-12\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-08-13, presumably until 2013-08-13\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2013-08-11, presumably until 2013-08-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-28 12:33:18, ended at 2013-09-28 13:47:46\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychiatric diagnostic evaluation with medical services\n\n### Condition\n- Primary diagnosis: Subacute delirium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-07 09:45:31, ended at 2013-10-07 12:10:43\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Organic mental disorder\n\n### Drug\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2013-07-01, presumably until 2014-07-21. Instructions: take 5 mg by mouth every bedtime as needed. Patient is aware of the risk for respiratory depression with using benzo and opiates.  She does not exceed prescribed dose.  Medication prescribed by her Rheumatologist\n- 1 ML etanercept 50 MG/ML Auto-Injector, started on 2013-09-14, presumably until 2015-03-21\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2013-09-13, presumably until 2013-10-10. Instructions: take 125 mg by mouth 2 times a day with meals.\n- ondansetron 4 MG Disintegrating Oral Tablet, started on 2013-07-11, presumably until 2013-07-11\n- methotrexate 2.5 MG Oral Tablet, started on 2013-07-11, presumably until 2015-03-21\n- modafinil 200 MG Oral Tablet, started on 2013-07-11, presumably until 2013-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-10 13:31:02, ended at 2013-10-10 14:14:18\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)\n\n### Condition\n- Primary diagnosis: Altered mental status\n\n### Drug\n- divalproex sodium 125 MG Delayed Release Oral Tablet, through Oral route, started on 2013-10-10, presumably until 2014-02-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n- rivastigmine 1.5 MG Oral Capsule, through Oral route, started on 2013-10-10, presumably until 2014-04-14, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-23 13:11:23, ended at 2013-11-23 13:45:25\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)\n\n### Condition\n- Subacute delirium\n- Primary diagnosis: Depressive disorder\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "b4ebe066e303f02c55f8975aad2ddbca5367c0d295cf834dafc69b2ed41acb89", "prompt_hash": "6fc53f3b0cff8883145a65c8aec8860e6c7328fab54d16976d64ee9d4304f292", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 8, "doc": {"person_id": 115973659, "visit_occurrence_id": 104385557, "death_date": null, "visit_concept_name": "Telehealth", "visit_start_datetime": "2017-07-07 00:00:00", "visit_end_datetime": "2017-07-07 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Telehealth, started at 2017-07-07 00:00:00, ended at 2017-07-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 88, "patient_first_visit_date": "2012-09-14 10:10:24", "patient_last_visit_date": "2021-11-13 00:00:00", "end_obs_date": "2018-07-07", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 23, "cumulated_visit_num": 23, "cumulated_approximate_token_count": 8256, "visit_cumulated": "## Visit\nThis visit record, was from Office Visit, started at 2012-09-14 10:10:24, ended at 2012-09-14 11:51:17\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in limb\n- Parkinson's disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2017-05-28 15:51:00, ended at 2017-06-02 15:46:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.83 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 57.32 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.90 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- IgG [Mass/volume] in Serum or Plasma: 707 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.99 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Prothrombin time (PT): 13.2 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 126 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- IgA [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 161 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein/Creatinine [Mass Ratio] in Urine: 2.20 (milligram per milligram)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.7 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Extraction of Iliac Bone Marrow, Percutaneous Approach, Diagnostic\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Excision of Thoracic Vertebra, Percutaneous Approach, Diagnostic\n- Computed tomography, cervical spine; without contrast material\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Computed tomography, thoracic spine; without contrast material\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Computed tomography, lumbar spine; without contrast material\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Constipation\n- Low back pain\n- Lymphocytopenia\n- Parkinson's disease\n- Pathologic fracture of bone at site of neoplasm\n- Primary malignant neoplasm of spinal cord\n- Multiple myeloma\n- Primary diagnosis: Spinal stenosis of thoracic region\n- Anemia\n- Hypokalemia\n- Chronic pain\n- Urge incontinence of urine\n- Disorder of bone\n- Illness\n- Plasmacytoma\n- Spinal stenosis\n- Neoplasm of uncertain behavior of endocrine glands and nervous system\n- Spinal cord compression\n\n### Drug\n- nortriptyline 25 MG Oral Capsule, through Oral route, started on 2017-05-28, presumably until 2017-06-01, with intended 0 refill(s). Instructions: take 100 mg by mouth every bedtime \n- mirtazapine 30 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 15 mg by mouth 2 times a day \n- mineral oil 1000 MG/ML Enema, through Rectal route, started on 2017-05-29, presumably until 2017-05-29\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- mirtazapine 15 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-02\n- carbidopa 25 MG / levodopa 100 MG Oral Tablet, through Oral route, started on 2017-05-29, presumably until 2017-06-02, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 4 times a day 6am, 10am, 2pm, 6pm \n- carbidopa 25 MG / levodopa 100 MG Disintegrating Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-05-29\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-01, presumably until 2017-06-01\n- amantadine hydrochloride 100 MG Oral Capsule, through Oral route, started on 2017-05-29, presumably until 2019-03-21, with intended 0 refill(s). Instructions: take 100 mg by mouth every day\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-06-01, presumably until 2017-06-01\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-06-02, presumably until 2017-06-02, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-05-28, presumably until 2018-06-02, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-05-30, presumably until 2017-06-02, with intended 0 refill(s)\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2017-05-29, presumably until 2017-06-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-06-01, presumably until 2017-06-01\n- dexamethasone 2 MG Oral Tablet, started on 2017-06-02, presumably until 2017-06-19, with intended 0 refill(s). Instructions: Please take 8mg BID x 2 days, 6mg BID x 2 days, 4mg BID x 2 days, 2mg BID x 2 days, 1mg BID x 2 days, 1mg daily x 2 days, then off.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2018-06-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- valacyclovir 500 MG Oral Tablet, through Oral route, presumably until 2017-06-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-05-28, presumably until 2017-06-02\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-05-28, presumably until 2017-05-28\n- carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2017-05-31, presumably until 2018-06-02, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-05-29, presumably until 2017-05-29\n- dutasteride 0.5 MG / tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 1 Cap by mouth every day\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2017-06-02, presumably until 2017-06-27, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-05-30, presumably until 2017-05-30\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-05-29 00:00:00, ended at 2017-05-29 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)\n- Biopsy, bone, trocar, or needle; deep (eg, vertebral body, femur)\n\n### Condition\n- Disorder of bone\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-05-30 09:30:49, ended at 2017-05-30 09:31:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-05-30 12:45:00, ended at 2017-05-30 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; simple\n- Therapeutic radiology simulation-aided field setting; simple\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Spinal cord compression\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-01 10:54:00, ended at 2017-06-01 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-02 00:00:00, ended at 2017-06-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-02 13:24:00, ended at 2017-06-02 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-03 12:45:00, ended at 2017-06-03 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-04 12:41:00, ended at 2017-06-04 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-05 12:40:00, ended at 2017-06-05 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, >/=1 MeV; complex\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 07:17:00, ended at 2017-06-09 12:13:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n\n### Condition\n- Multiple myeloma\n- Spinal stenosis\n\n### Drug\n- gadobenate, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-09 09:25:19, ended at 2017-06-09 10:54:11\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Multiple myeloma\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- dexamethasone 1 MG Oral Tablet, started on 2017-06-02, presumably until 2017-06-27, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 12:14:00, ended at 2017-06-09 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n- Spinal stenosis\n- Spinal stenosis of thoracic region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-10 11:18:00, ended at 2017-06-10 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Spinal cord compression\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-11 00:00:00, ended at 2017-06-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Spinal stenosis of thoracic region\n- Primary diagnosis: Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-11 11:20:00, ended at 2017-06-11 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-11, presumably until 2017-06-26, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-19 00:00:00, ended at 2017-06-19 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Multiple myeloma\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-06-19, presumably until 2017-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- dexamethasone 2 MG Oral Tablet, started on 2017-06-19, presumably until 2017-06-27, with intended 0 refill(s). Instructions: 8 mg BID\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-19 00:00:00, ended at 2017-06-19 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of thoracic region\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-22 00:00:00, ended at 2017-06-22 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for extensive spine and spinal cord procedures (eg, spinal instrumentation or vascular procedures)\n\n### Condition\n- Neoplasm of uncertain behavior of endocrine glands and nervous system\n- Pathologic fracture of bone at site of neoplasm\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- remifentanil 2 MG Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-06-22, presumably until 2017-06-22\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-06-22, presumably until 2017-06-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- ketamine 100 MG/ML Injectable Solution, started on 2017-06-22, presumably until 2017-06-22\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2017-06-22, presumably until 2017-06-22\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-06-22 00:00:00, ended at 2017-06-22 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-06-22, presumably until 2017-06-22\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-06-22, presumably until 2017-06-22\n- bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injectable Solution, started on 2017-06-22, presumably until 2017-06-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-22 10:02:00, ended at 2017-06-27 12:16:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 282.0 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Bicarbonate [Moles/volume] in Specimen: 22.5 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Body height: 5' 9\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.75 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 182 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.12 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 38.2 (millimeter mercury column)\n- Prothrombin time (PT): 15.3 (second)\n- Base excess in Arterial blood by calculation: -3.5 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n\n### Procedure\n- Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 7 to 12 vertebral segments (List separately in addition to code for primary procedure)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs\n- Monitoring of Peripheral Nervous Electrical Activity, Intraoperative, External Approach\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)\n- Arthrodesis, posterior or posterolateral technique, single interspace; each additional interspace (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Needle electromyography; 2 extremities with or without related paraspinal areas\n- Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\n- Vertebral corpectomy (vertebral body resection), partial or complete, lateral extracavitary approach with decompression of spinal cord and/or nerve root(s) (eg, for tumor or retropulsed bone fragments); thoracic, single segment\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Arthrodesis, posterior or posterolateral technique, single interspace; thoracic (with lateral transverse technique, when performed)\n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Fusion of 2 to 7 Thoracic Vertebral Joints with Nonautologous Tissue Substitute, Posterior Approach, Posterior Column, Open Approach\n\n### Condition\n- Dementia associated with another disease\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Spinal stenosis of thoracic region\n- Delirium\n- Neoplasm of uncertain behavior of bone and articular cartilage\n- Illness\n- Pathologic fracture of bone at site of neoplasm\n- Acute posthemorrhagic anemia\n- Chronic pain\n- Insomnia\n- Chest pain\n- Spinal cord compression\n- Multiple myeloma\n- Neoplasm of uncertain behavior of endocrine glands and nervous system\n- Urinary tract obstruction\n- Benign prostatic hyperplasia with outflow obstruction\n- Senile dementia of the Lewy body type\n- Spinal cord disease\n\n### Drug\n- nortriptyline 25 MG Oral Capsule, through Oral route, started on 2017-06-22, presumably until 2017-06-26\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2017-06-23, presumably until 2017-06-26\n- calcium carbonate 1000 MG Chewable Tablet, through Oral route, started on 2017-06-23, presumably until 2017-06-23\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- mirtazapine 15 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- carbidopa 25 MG / levodopa 100 MG Oral Tablet, through Oral route, started on 2017-06-23, presumably until 2017-06-27\n- amantadine hydrochloride 100 MG Oral Capsule, through Oral route, started on 2017-06-23, presumably until 2017-06-27\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed for Muscle spasms\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2017-06-26, presumably until 2018-06-27, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily in the evening\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-06-23, presumably until 2017-06-27\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-06-23, presumably until 2017-06-27\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-06-23, presumably until 2018-06-26, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-26\n- carboxymethylcellulose sodium 0.01 MG/MG Ophthalmic Gel, through Intraocular route, started on 2017-06-23, presumably until 2018-06-26, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes as needed\n- dutasteride 0.5 MG / tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2017-06-25, presumably until 2017-06-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-07-26, with intended 0 refill(s). Instructions: take 1-3 Tabs by mouth every 4 hours as needed for Pain (moderate to severe pain)\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2017-06-24, presumably until 2017-06-26\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-07-07 00:00:00, ended at 2017-07-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-09-14 10:10:24, ended at 2012-09-14 11:51:17\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in limb\n- Parkinson's disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2017-05-28 15:51:00, ended at 2017-06-02 15:46:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.83 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 57.32 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.90 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- IgG [Mass/volume] in Serum or Plasma: 707 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.99 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Prothrombin time (PT): 13.2 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 126 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- IgA [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 161 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein/Creatinine [Mass Ratio] in Urine: 2.20 (milligram per milligram)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.7 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Extraction of Iliac Bone Marrow, Percutaneous Approach, Diagnostic\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Excision of Thoracic Vertebra, Percutaneous Approach, Diagnostic\n- Computed tomography, cervical spine; without contrast material\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Computed tomography, thoracic spine; without contrast material\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Computed tomography, lumbar spine; without contrast material\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Constipation\n- Low back pain\n- Lymphocytopenia\n- Parkinson's disease\n- Pathologic fracture of bone at site of neoplasm\n- Primary malignant neoplasm of spinal cord\n- Multiple myeloma\n- Primary diagnosis: Spinal stenosis of thoracic region\n- Anemia\n- Hypokalemia\n- Chronic pain\n- Urge incontinence of urine\n- Disorder of bone\n- Illness\n- Plasmacytoma\n- Spinal stenosis\n- Neoplasm of uncertain behavior of endocrine glands and nervous system\n- Spinal cord compression\n\n### Drug\n- nortriptyline 25 MG Oral Capsule, through Oral route, started on 2017-05-28, presumably until 2017-06-01, with intended 0 refill(s). Instructions: take 100 mg by mouth every bedtime \n- mirtazapine 30 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 15 mg by mouth 2 times a day \n- mineral oil 1000 MG/ML Enema, through Rectal route, started on 2017-05-29, presumably until 2017-05-29\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- mirtazapine 15 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-02\n- carbidopa 25 MG / levodopa 100 MG Oral Tablet, through Oral route, started on 2017-05-29, presumably until 2017-06-02, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 4 times a day 6am, 10am, 2pm, 6pm \n- carbidopa 25 MG / levodopa 100 MG Disintegrating Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-05-29\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-01, presumably until 2017-06-01\n- amantadine hydrochloride 100 MG Oral Capsule, through Oral route, started on 2017-05-29, presumably until 2019-03-21, with intended 0 refill(s). Instructions: take 100 mg by mouth every day\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-06-01, presumably until 2017-06-01\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-06-02, presumably until 2017-06-02, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-05-28, presumably until 2018-06-02, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-05-30, presumably until 2017-06-02, with intended 0 refill(s)\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2017-05-29, presumably until 2017-06-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-06-01, presumably until 2017-06-01\n- dexamethasone 2 MG Oral Tablet, started on 2017-06-02, presumably until 2017-06-19, with intended 0 refill(s). Instructions: Please take 8mg BID x 2 days, 6mg BID x 2 days, 4mg BID x 2 days, 2mg BID x 2 days, 1mg BID x 2 days, 1mg daily x 2 days, then off.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2018-06-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- valacyclovir 500 MG Oral Tablet, through Oral route, presumably until 2017-06-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-05-28, presumably until 2017-06-02\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-05-28, presumably until 2017-05-28\n- carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2017-05-31, presumably until 2018-06-02, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-05-29, presumably until 2017-05-29\n- dutasteride 0.5 MG / tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 1 Cap by mouth every day\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2017-06-02, presumably until 2017-06-27, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-05-30, presumably until 2017-05-30\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2017-05-28, presumably until 2017-06-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-05-29 00:00:00, ended at 2017-05-29 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)\n- Biopsy, bone, trocar, or needle; deep (eg, vertebral body, femur)\n\n### Condition\n- Disorder of bone\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-05-30 09:30:49, ended at 2017-05-30 09:31:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-05-30 12:45:00, ended at 2017-05-30 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; simple\n- Therapeutic radiology simulation-aided field setting; simple\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Spinal cord compression\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-01 10:54:00, ended at 2017-06-01 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-02 00:00:00, ended at 2017-06-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-02 13:24:00, ended at 2017-06-02 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-03 12:45:00, ended at 2017-06-03 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-04 12:41:00, ended at 2017-06-04 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-05 12:40:00, ended at 2017-06-05 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, >/=1 MeV; complex\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 07:17:00, ended at 2017-06-09 12:13:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n\n### Condition\n- Multiple myeloma\n- Spinal stenosis\n\n### Drug\n- gadobenate, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-09 09:25:19, ended at 2017-06-09 10:54:11\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Multiple myeloma\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- dexamethasone 1 MG Oral Tablet, started on 2017-06-02, presumably until 2017-06-27, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 12:14:00, ended at 2017-06-09 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n- Spinal stenosis\n- Spinal stenosis of thoracic region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-10 11:18:00, ended at 2017-06-10 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Spinal cord compression\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-11 00:00:00, ended at 2017-06-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Spinal stenosis of thoracic region\n- Primary diagnosis: Spinal cord compression\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-11 11:20:00, ended at 2017-06-11 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n\n### Condition\n- Multiple myeloma\n- Spinal cord compression\n\n### Drug\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-11, presumably until 2017-06-26, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-19 00:00:00, ended at 2017-06-19 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Multiple myeloma\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-06-19, presumably until 2017-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- dexamethasone 2 MG Oral Tablet, started on 2017-06-19, presumably until 2017-06-27, with intended 0 refill(s). Instructions: 8 mg BID\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-19 00:00:00, ended at 2017-06-19 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of thoracic region\n- Multiple myeloma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-22 00:00:00, ended at 2017-06-22 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for extensive spine and spinal cord procedures (eg, spinal instrumentation or vascular procedures)\n\n### Condition\n- Neoplasm of uncertain behavior of endocrine glands and nervous system\n- Pathologic fracture of bone at site of neoplasm\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- remifentanil 2 MG Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-06-22, presumably until 2017-06-22\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-06-22, presumably until 2017-06-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- ketamine 100 MG/ML Injectable Solution, started on 2017-06-22, presumably until 2017-06-22\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2017-06-22, presumably until 2017-06-22\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-06-22 00:00:00, ended at 2017-06-22 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-06-22, presumably until 2017-06-22\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-06-22, presumably until 2017-06-22\n- bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injectable Solution, started on 2017-06-22, presumably until 2017-06-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-06-22 10:02:00, ended at 2017-06-27 12:16:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 282.0 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Bicarbonate [Moles/volume] in Specimen: 22.5 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Body height: 5' 9\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.75 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 182 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.12 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 38.2 (millimeter mercury column)\n- Prothrombin time (PT): 15.3 (second)\n- Base excess in Arterial blood by calculation: -3.5 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n\n### Procedure\n- Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 7 to 12 vertebral segments (List separately in addition to code for primary procedure)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs\n- Monitoring of Peripheral Nervous Electrical Activity, Intraoperative, External Approach\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)\n- Arthrodesis, posterior or posterolateral technique, single interspace; each additional interspace (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Needle electromyography; 2 extremities with or without related paraspinal areas\n- Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\n- Vertebral corpectomy (vertebral body resection), partial or complete, lateral extracavitary approach with decompression of spinal cord and/or nerve root(s) (eg, for tumor or retropulsed bone fragments); thoracic, single segment\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Arthrodesis, posterior or posterolateral technique, single interspace; thoracic (with lateral transverse technique, when performed)\n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Fusion of 2 to 7 Thoracic Vertebral Joints with Nonautologous Tissue Substitute, Posterior Approach, Posterior Column, Open Approach\n\n### Condition\n- Dementia associated with another disease\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Spinal stenosis of thoracic region\n- Delirium\n- Neoplasm of uncertain behavior of bone and articular cartilage\n- Illness\n- Pathologic fracture of bone at site of neoplasm\n- Acute posthemorrhagic anemia\n- Chronic pain\n- Insomnia\n- Chest pain\n- Spinal cord compression\n- Multiple myeloma\n- Neoplasm of uncertain behavior of endocrine glands and nervous system\n- Urinary tract obstruction\n- Benign prostatic hyperplasia with outflow obstruction\n- Senile dementia of the Lewy body type\n- Spinal cord disease\n\n### Drug\n- nortriptyline 25 MG Oral Capsule, through Oral route, started on 2017-06-22, presumably until 2017-06-26\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2017-06-23, presumably until 2017-06-26\n- calcium carbonate 1000 MG Chewable Tablet, through Oral route, started on 2017-06-23, presumably until 2017-06-23\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- mirtazapine 15 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- carbidopa 25 MG / levodopa 100 MG Oral Tablet, through Oral route, started on 2017-06-23, presumably until 2017-06-27\n- amantadine hydrochloride 100 MG Oral Capsule, through Oral route, started on 2017-06-23, presumably until 2017-06-27\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-08-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed for Muscle spasms\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-06-22, presumably until 2017-06-27\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2017-06-26, presumably until 2018-06-27, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily in the evening\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-06-23, presumably until 2017-06-27\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-06-23, presumably until 2017-06-27\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-06-23, presumably until 2018-06-26, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-22\n- carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-06-26\n- carboxymethylcellulose sodium 0.01 MG/MG Ophthalmic Gel, through Intraocular route, started on 2017-06-23, presumably until 2018-06-26, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes as needed\n- dutasteride 0.5 MG / tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2017-06-25, presumably until 2017-06-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-22, presumably until 2017-07-26, with intended 0 refill(s). Instructions: take 1-3 Tabs by mouth every 4 hours as needed for Pain (moderate to severe pain)\n- 24 HR mirabegron 50 MG Extended Release Oral Tablet, through Oral route, started on 2017-06-24, presumably until 2017-06-26\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-06-22, presumably until 2017-06-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-07-07 00:00:00, ended at 2017-07-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of thoracic region\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "e615b52aa0ce2f9c1ab23d650bcf9258f7040a7424550f2698c4d976416f9972", "prompt_hash": "c45c50d57310d58d5f461daf5a4c42e2c9c0510c3d8dcb1ca8463f49f5afed78", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 9, "doc": {"person_id": 115968990, "visit_occurrence_id": 131528679, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2019-01-23 12:32:55", "visit_end_datetime": "2019-01-23 13:37:07", "visit_length_in_hours": 1.07, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2019-01-23 12:32:55, ended at 2019-01-23 13:37:07\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 87, "patient_first_visit_date": "2015-09-19 10:15:00", "patient_last_visit_date": "2022-06-18 00:00:00", "end_obs_date": "2020-01-23", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "recurrent", "prostate_cancer_one_year_diagnosis": 1, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "recurrent", "dementia_one_year_diagnosis": 1, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 48, "cumulated_visit_num": 48, "cumulated_approximate_token_count": 15914, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2015-09-19 10:15:00, ended at 2015-09-19 16:05:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Sodium [Moles/volume] in Blood: 137 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 11.9 (gram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Hematocrit [Volume Fraction] of Blood: 35 (percent)\n- Potassium [Moles/volume] in Blood: 3.8 (millimole per liter)\n\n### Procedure\n- Fluoroscopy of Multiple Coronary Arteries using Low Osmolar Contrast\n- Collection of blood specimen from a completely implantable venous access device\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Coronary arteriosclerosis\n- Dyspnea\n- Hypothyroidism\n- Primary diagnosis: Angina pectoris\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, presumably until 2019-09-17, with intended 0 refill(s). Instructions: take 20 mg by mouth daily \n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 50 mcg by mouth every morning before breakfast\n- fatty acids, omega-6, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2015-09-19, presumably until 2015-09-19\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2015-09-19, presumably until 2015-09-19\n- amlodipine 10 MG Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 0.1 mg by mouth 2 times a day\n- fluocinonide 0.5 MG/ML Topical Cream, through Topical route, presumably until 2015-09-19, with intended 0 refill(s). Instructions: 1 Application by Topical route 2 times a day as needed (dermatitis)\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2015-11-01, with intended 0 refill(s). Instructions: take 81 mg by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-09-19, presumably until 2015-09-19\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2015-09-19, presumably until 2015-09-19\n- astaxanthin, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- omega-3 acid ethyl esters (USP), through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- docosahexaenoate, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 20 mg by mouth daily\n- gabapentin 600 MG Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 600 mg by mouth 2 times a day\n- eicosapentaenoate, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- omega-3 fatty acids, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 100 mg by mouth daily\n- krill oil, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- dicyclomine hydrochloride 10 MG Oral Capsule, through Oral route, presumably until 2015-09-19, with intended 0 refill(s). Instructions: take 10 mg by mouth 3 times a day as needed (cramping or GI distress)\n- egg yolk phospholipids, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, presumably until 2015-10-10, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2015-10-17 18:20:00, ended at 2015-10-17 23:15:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Prothrombin time (PT): 13.1 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.45 (million per microliter)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary diagnosis: Chest pain\n- Primary malignant neoplasm of prostate\n- Hyperlipidemia\n- Hypothyroidism\n- Nicotine dependence\n- Bradycardia\n- Dyspnea\n- Coronary artery graft present\n- Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n\n### Drug\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2015-10-17, presumably until 2015-10-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-11-01 00:00:00, ended at 2015-11-01 00:00:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2015-11-01, presumably until 2015-11-01\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-01\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2015-11-01, presumably until 2015-11-01\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2015-11-01, presumably until 2015-11-01\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2015-11-01, presumably until 2015-11-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-01 07:07:00, ended at 2015-11-12 13:00:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 43.4 (millimeter mercury column)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 536 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 176 (unit per liter)\n- Oxygen [Partial pressure] in Arterial blood: >500.0 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.3 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.16 (microliter per milliliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 5.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.70 (micro-international unit per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 115 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Body height: 5' 6\" (inch (US))\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 50.2 (millimeter mercury column)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 380 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Base excess in Arterial blood by calculation: 2.4 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Lactate [Moles/volume] in Blood: 5.2 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.66 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 27.6 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.21 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.6 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 98 (millimeter mercury column)\n- Base excess in Blood by calculation: 5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.43 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lidocaine [Mass/volume] in Serum or Plasma: 3.2 (microgram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 98 (thousand per microliter)\n- Thrombin time: 13.9 (second)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.8 (nanogram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 86.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n\n### Procedure\n- Drainage of Left Pleura with Drainage Device, Percutaneous Approach\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Ultrasound, chest (includes mediastinum), real time with image documentation\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Controlled ventilation procedure and therapy, initiation and management\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Performance of Cardiac Output, Continuous\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open Approach\n- Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach\n- Radiologic examination, chest; single view, frontal\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Radiologic examination, abdomen; single anteroposterior view\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Evaluation of oral and pharyngeal swallowing function\n- Occupational therapy evaluation\n- Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- Abdominal pain\n- Chronic pulmonary edema\n- Delirium\n- Abnormal findings on diagnostic imaging of lung\n- Acute renal failure syndrome\n- Abdominal aortic aneurysm without rupture\n- Acquired absence of organ\n- Acute posthemorrhagic anemia\n- Psychotic disorder\n- Aortocoronary bypass graft present\n- Atelectasis\n- Atrial fibrillation\n- Chronic kidney disease stage 2\n- Disorder of digestive system\n- Hyperlipidemia\n- Hypovolemic shock\n- Angina pectoris\n- Disorientated\n- Essential hypertension\n- Old myocardial infarction\n- Primary malignant neoplasm of prostate\n- Sleep apnea\n- Atherosclerosis of coronary artery without angina pectoris\n- Coronary artery graft present\n- Persistent pain following procedure\n- Pneumothorax\n- Electrocardiogram abnormal\n- Gastroesophageal reflux disease without esophagitis\n- Hypothyroidism\n- Pleural effusion\n- Retention of urine\n- Primary diagnosis: Angina co-occurrent and due to coronary arteriosclerosis\n- Bradycardia\n- Chronic kidney disease due to hypertension\n- Hypoxemia\n- Iatrogenic hypotension\n- Postoperative state\n- Spinal stenosis of lumbar region\n- Paroxysmal atrial fibrillation\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2015-11-02, presumably until 2015-11-02\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day For 2 weeks. Than take 1 tab by mouth 1 time a day for 2 weeks. Then stop.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-03\n- ascorbic acid 250 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-03\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-11-11\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-04\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2015-11-12\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2015-11-08, presumably until 2015-11-08\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2015-11-02, presumably until 2015-11-12\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2015-11-02, presumably until 2015-11-03\n- 24 HR nicotine 0.583 MG/HR Transdermal System, through Transdermal route, started on 2015-11-02, presumably until 2015-11-04\n- haloperidol 5 MG/ML Injectable Solution, started on 2015-11-02, presumably until 2015-11-08\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-12-09, with intended 0 refill(s). Instructions: Take 20 mg daily for 10 days, then stop\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-11-04, presumably until 2015-11-11\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-02\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2015-11-05, presumably until 2015-11-12\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-03\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2015-11-09, presumably until 2015-11-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-11-07, presumably until 2015-11-07\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2015-11-03, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day as needed for Constipation\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2015-11-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2015-11-11, with intended 0 refill(s). Instructions: take 5 mg by mouth 2 times a day\n- cefazolin 1000 MG Injection, started on 2015-11-01, presumably until 2015-11-02\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2015-11-07, presumably until 2015-11-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 3 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2015-11-19, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-12-05, with intended 0 refill(s). Instructions: Take 25 mg for 5 days, then stop\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-11\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2015-11-03, presumably until 2015-11-06\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-02\n- 10 ML furosemide 10 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-09\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-05\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2015-11-08, presumably until 2015-11-09\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2015-11-04, presumably until 2015-11-05\n- ferrous sulfate 140 MG Extended Release Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-12-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2015-11-05, presumably until 2015-11-07\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2015-11-08, presumably until 2015-11-12\n- chlorothiazide 500 MG Injection, through Intravenous route, started on 2015-11-06, presumably until 2015-11-07\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2015-11-05, presumably until 2015-11-11\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2015-11-03, presumably until 2015-11-06\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-11-11, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-05\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2015-11-07, presumably until 2015-11-07\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2015-11-03, presumably until 2015-11-09\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2015-11-01, presumably until 2015-11-01\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-05\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-08\n- 1 ML methylene blue 10 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-02\n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-10\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2015-11-07, presumably until 2015-11-07\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2015-11-08, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-11-02, presumably until 2015-11-04\n- 100 ML amiodarone hydrochloride 1.5 MG/ML Injection, through Intravenous route, started on 2015-11-03, presumably until 2015-11-05\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-07\n- 100 ML potassium chloride 0.2 MEQ/ML Injection, through Intravenous route, started on 2015-11-06, presumably until 2015-11-06\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2015-11-05, presumably until 2015-11-12\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-02, presumably until 2016-05-09, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 4 hours as needed for Pain\n- doxylamine succinate 25 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2015-11-11\n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2015-11-01, presumably until 2015-11-01\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-11-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2015-11-12\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2015-11-02, presumably until 2015-11-02\n- 100 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-05\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2015-11-08, presumably until 2015-11-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-05 13:05:15, ended at 2015-12-05 13:59:51\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative state\n- Primary diagnosis: Aortocoronary bypass graft present\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, presumably until 2016-12-09, with intended 0 refill(s). Instructions: take 20 mEq by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-09-03 14:11:00, ended at 2016-09-03 18:42:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.37 (thousand per microliter)\n- Prothrombin time (PT): 13.3 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.60 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.9 (picogram)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCV [Entitic volume] by Automated count: 87.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.5 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.4 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Melena\n- Left upper quadrant pain\n- Primary malignant neoplasm of prostate\n- Acute posthemorrhagic anemia\n- Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperlipidemia\n- Atrial fibrillation\n- Hypothyroidism\n- Bradycardia\n- Gastritis\n- Primary diagnosis: Stool finding\n- Aortocoronary bypass graft present\n- Electrocardiogram abnormal\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-09-03, presumably until 2016-12-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2016-09-03, presumably until 2016-09-03\n- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2016-09-03, presumably until 2016-09-03\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2016-09-03, presumably until 2016-09-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-16 11:24:35, ended at 2016-09-16 14:49:48\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Degeneration of lumbosacral intervertebral disc\n- Spinal stenosis of lumbar region\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-07 13:55:24, ended at 2016-12-07 15:58:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Minimal cognitive impairment\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-09 00:00:00, ended at 2016-12-09 00:00:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2016-12-09, presumably until 2016-12-09\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2016-12-09, presumably until 2016-12-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2016-12-09, presumably until 2016-12-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-09 08:46:00, ended at 2016-12-09 10:39:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)\n- Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach\n- Fluoroscopy of Lumbar Facet Joint(s) using Other Contrast\n- Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level\n\n### Condition\n- Chronic pain\n- Coronary artery graft present\n- Essential hypertension\n- Hyperlipidemia\n- Atherosclerosis of coronary artery without angina pectoris\n- Low back pain\n- Hypothyroidism\n- Lumbar spondylosis\n- Disorder of musculoskeletal system\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2016-08-12, presumably until 2022-01-11, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2016-01-02, presumably until 2016-01-02, with intended 0 refill(s). Instructions: take 100 mg by mouth daily\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2016-04-14, presumably until 2017-04-07, with intended 0 refill(s). Instructions: take 600 mg by mouth every bedtime\n- 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, through Oral route, started on 2016-07-24, presumably until 2019-05-07, with intended 0 refill(s). Instructions: take 50 mg by mouth daily \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-09 09:49:23, ended at 2016-12-09 10:01:16\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of musculoskeletal system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-10 00:00:00, ended at 2017-01-10 00:00:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-11 11:51:00, ended at 2017-01-11 14:06:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 870 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 160.9 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Iron [Mass/volume] in Serum or Plasma: 113 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 146 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 54.6 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.0 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 37 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Erythropoietin (EPO) [Units/volume] in Serum or Plasma: 16.9 (milli-international unit per milliliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.07 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.34 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of prostate\n- Anemia of chronic disease\n- Blood chemistry abnormal\n- Flushing\n- Generalized hyperhidrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-11 14:07:00, ended at 2017-01-11 23:59:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Generalized hyperhidrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-25 12:50:00, ended at 2017-03-25 12:50:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-04-01 00:00:00, ended at 2017-04-01 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2017-04-01, presumably until 2017-04-01\n- 1 ML dexamethasone phosphate 10 MG/ML Injection, started on 2017-04-01, presumably until 2017-04-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-01 11:54:00, ended at 2017-04-01 14:50:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach\n- Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach\n- Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperlipidemia\n- Lumbar radiculopathy\n- Coronary artery graft present\n- Hypothyroidism\n- Low back pain\n- Lumbosacral stenosis\n- Lumbosacral radiculopathy\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-01 13:57:34, ended at 2017-04-01 14:18:02\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-07 14:25:58, ended at 2017-04-07 15:09:26\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lumbar radiculopathy\n- Chronic pain\n- Lumbago with sciatica\n\n### Drug\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2017-04-07, presumably until 2018-04-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- gabapentin 800 MG Oral Tablet, through Oral route, started on 2017-04-07, presumably until 2018-04-07, with intended 2 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-11 14:23:00, ended at 2017-04-11 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material\n\n### Condition\n- Degeneration of lumbar intervertebral disc\n- Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-31 00:00:00, ended at 2017-05-31 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-02 12:24:00, ended at 2017-06-02 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), with qualified health care professional interpretation and report, administered by technician, per hour of technician time\n- Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time int\n- Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professio\n\n### Condition\n- Amnesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-10 09:52:13, ended at 2017-06-10 10:51:15\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n- Haptoglobin [Mass/volume] in Serum or Plasma: 283 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n\n### Condition\n- Generalized hyperhidrosis\n- Bradycardia\n- Anemia of chronic disease\n- Primary malignant neoplasm of prostate\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-10 10:54:00, ended at 2017-06-10 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Reticulocytes [#/volume] in Blood by Automated count: 83.3 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.73 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.07 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 196 (unit per liter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 98.6 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.66 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 279 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 87.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 2.23 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of prostate\n- Anemia\n- Amnesia\n- Anemia of chronic disease\n- Generalized hyperhidrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-10 11:58:45, ended at 2017-06-10 12:48:59\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-08 00:00:00, ended at 2017-09-08 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2017-09-08, presumably until 2017-09-08\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2017-09-08, presumably until 2017-09-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-08 07:50:00, ended at 2017-09-08 11:08:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach\n- Fluoroscopy of Lumbar Facet Joint(s) using Other Contrast\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)\n\n### Condition\n- Hypothyroidism\n- Pain\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperlipidemia\n- Lumbar spondylosis\n- Coronary artery graft present\n- Primary diagnosis: Low back pain\n- Primary diagnosis: Chronic pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-19 00:00:00, ended at 2017-09-19 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-22 00:00:00, ended at 2017-09-22 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-22, presumably until 2017-09-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-22 07:33:00, ended at 2017-09-22 11:48:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)\n- Fluoroscopy of Lumbar Facet Joint(s) using Low Osmolar Contrast\n- Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Lumbar spondylosis\n- Hyperlipidemia\n- Low back pain\n- Arthropathy\n- Hypothyroidism\n- Primary malignant neoplasm of prostate\n- Chronic pain\n- Essential hypertension\n- Lumbosacral spondylosis without myelopathy\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-09-22, presumably until 2017-09-22\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, presumably until 2019-02-27, with intended 0 refill(s). Instructions: take 0.1 mg by mouth every day \n- tadalafil 20 MG Oral Tablet, through Oral route, started on 2015-08-11, presumably until 2019-02-27, with intended 0 refill(s). Instructions: 20 mg by Swish & Swallow route\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-22 08:02:00, ended at 2017-09-22 13:58:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-22 12:41:20, ended at 2017-09-22 15:40:38\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Primary diagnosis: Anemia of chronic disease\n- Generalized hyperhidrosis\n- Primary malignant neoplasm of prostate\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-22 13:59:00, ended at 2017-09-22 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 84.9 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.29 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 158 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-04 10:41:32, ended at 2017-10-04 11:06:12\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low back pain\n- Primary diagnosis: Chronic pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-14 14:06:24, ended at 2018-03-14 14:06:34\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-04-07 00:00:00, ended at 2018-04-07 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, started on 2018-04-07, presumably until 2018-05-09, with intended 0 refill(s). Instructions: 1/2 tablet each morning x2 weeks, then have EKG check.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-09 00:00:00, ended at 2018-05-09 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-05-11, presumably until 2018-09-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily in the morning with food\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-19 00:00:00, ended at 2018-05-19 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-26 09:30:00, ended at 2018-05-26 23:59:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Bone necrosis\n- Hip pain\n- Bone cyst\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-26 09:46:10, ended at 2018-05-26 12:02:47\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Bone cyst\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-07 00:00:00, ended at 2018-07-07 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- 24 HR rivastigmine 0.192 MG/HR Transdermal System, through Transdermal route, started on 2018-07-07, presumably until 2018-09-26, with intended 3 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-12 00:00:00, ended at 2018-07-12 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR rivastigmine 0.192 MG/HR Transdermal System, through Transdermal route, started on 2018-08-11, presumably until 2018-08-11, with intended 3 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-01 11:02:49, ended at 2018-09-01 12:14:45\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n- Dementia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-05 09:32:00, ended at 2018-09-05 23:59:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance\n- Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)\n\n### Condition\n- Hip pain\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2018-09-05, presumably until 2018-09-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-25 00:00:00, ended at 2018-09-25 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- 24 HR rivastigmine 0.396 MG/HR Transdermal System, through Transdermal route, started on 2018-09-26, presumably until 2019-02-27, with intended 3 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-06 00:00:00, ended at 2018-12-06 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-06 15:17:00, ended at 2018-12-06 23:59:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Disorder of thigh\n- Aseptic necrosis of bone of hip\n- Hip pain\n- Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-23 12:32:55, ended at 2019-01-23 13:37:07\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Dementia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-09-19 10:15:00, ended at 2015-09-19 16:05:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Sodium [Moles/volume] in Blood: 137 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 11.9 (gram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Hematocrit [Volume Fraction] of Blood: 35 (percent)\n- Potassium [Moles/volume] in Blood: 3.8 (millimole per liter)\n\n### Procedure\n- Fluoroscopy of Multiple Coronary Arteries using Low Osmolar Contrast\n- Collection of blood specimen from a completely implantable venous access device\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Coronary arteriosclerosis\n- Dyspnea\n- Hypothyroidism\n- Primary diagnosis: Angina pectoris\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, presumably until 2019-09-17, with intended 0 refill(s). Instructions: take 20 mg by mouth daily \n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 50 mcg by mouth every morning before breakfast\n- fatty acids, omega-6, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2015-09-19, presumably until 2015-09-19\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2015-09-19, presumably until 2015-09-19\n- amlodipine 10 MG Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 0.1 mg by mouth 2 times a day\n- fluocinonide 0.5 MG/ML Topical Cream, through Topical route, presumably until 2015-09-19, with intended 0 refill(s). Instructions: 1 Application by Topical route 2 times a day as needed (dermatitis)\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2015-11-01, with intended 0 refill(s). Instructions: take 81 mg by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-09-19, presumably until 2015-09-19\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2015-09-19, presumably until 2015-09-19\n- astaxanthin, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- omega-3 acid ethyl esters (USP), through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- docosahexaenoate, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 20 mg by mouth daily\n- gabapentin 600 MG Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 600 mg by mouth 2 times a day\n- eicosapentaenoate, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- omega-3 fatty acids, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 100 mg by mouth daily\n- krill oil, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- dicyclomine hydrochloride 10 MG Oral Capsule, through Oral route, presumably until 2015-09-19, with intended 0 refill(s). Instructions: take 10 mg by mouth 3 times a day as needed (cramping or GI distress)\n- egg yolk phospholipids, through Oral route, presumably until 2015-11-12, with intended 0 refill(s). Instructions: take 1 Cap by mouth\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, presumably until 2015-10-10, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2015-10-17 18:20:00, ended at 2015-10-17 23:15:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Prothrombin time (PT): 13.1 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.45 (million per microliter)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary diagnosis: Chest pain\n- Primary malignant neoplasm of prostate\n- Hyperlipidemia\n- Hypothyroidism\n- Nicotine dependence\n- Bradycardia\n- Dyspnea\n- Coronary artery graft present\n- Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n\n### Drug\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2015-10-17, presumably until 2015-10-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-11-01 00:00:00, ended at 2015-11-01 00:00:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2015-11-01, presumably until 2015-11-01\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-01\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2015-11-01, presumably until 2015-11-01\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2015-11-01, presumably until 2015-11-01\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2015-11-01, presumably until 2015-11-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-01 07:07:00, ended at 2015-11-12 13:00:00\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 43.4 (millimeter mercury column)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 536 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 176 (unit per liter)\n- Oxygen [Partial pressure] in Arterial blood: >500.0 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.3 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.16 (microliter per milliliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 5.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.70 (micro-international unit per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 115 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Body height: 5' 6\" (inch (US))\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 50.2 (millimeter mercury column)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 380 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Base excess in Arterial blood by calculation: 2.4 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Lactate [Moles/volume] in Blood: 5.2 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.66 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 27.6 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.21 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.6 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 98 (millimeter mercury column)\n- Base excess in Blood by calculation: 5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.43 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lidocaine [Mass/volume] in Serum or Plasma: 3.2 (microgram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 98 (thousand per microliter)\n- Thrombin time: 13.9 (second)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.8 (nanogram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 86.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n\n### Procedure\n- Drainage of Left Pleura with Drainage Device, Percutaneous Approach\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Ultrasound, chest (includes mediastinum), real time with image documentation\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Controlled ventilation procedure and therapy, initiation and management\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Performance of Cardiac Output, Continuous\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open Approach\n- Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach\n- Radiologic examination, chest; single view, frontal\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Radiologic examination, abdomen; single anteroposterior view\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Evaluation of oral and pharyngeal swallowing function\n- Occupational therapy evaluation\n- Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- Abdominal pain\n- Chronic pulmonary edema\n- Delirium\n- Abnormal findings on diagnostic imaging of lung\n- Acute renal failure syndrome\n- Abdominal aortic aneurysm without rupture\n- Acquired absence of organ\n- Acute posthemorrhagic anemia\n- Psychotic disorder\n- Aortocoronary bypass graft present\n- Atelectasis\n- Atrial fibrillation\n- Chronic kidney disease stage 2\n- Disorder of digestive system\n- Hyperlipidemia\n- Hypovolemic shock\n- Angina pectoris\n- Disorientated\n- Essential hypertension\n- Old myocardial infarction\n- Primary malignant neoplasm of prostate\n- Sleep apnea\n- Atherosclerosis of coronary artery without angina pectoris\n- Coronary artery graft present\n- Persistent pain following procedure\n- Pneumothorax\n- Electrocardiogram abnormal\n- Gastroesophageal reflux disease without esophagitis\n- Hypothyroidism\n- Pleural effusion\n- Retention of urine\n- Primary diagnosis: Angina co-occurrent and due to coronary arteriosclerosis\n- Bradycardia\n- Chronic kidney disease due to hypertension\n- Hypoxemia\n- Iatrogenic hypotension\n- Postoperative state\n- Spinal stenosis of lumbar region\n- Paroxysmal atrial fibrillation\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2015-11-02, presumably until 2015-11-02\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day For 2 weeks. Than take 1 tab by mouth 1 time a day for 2 weeks. Then stop.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-03\n- ascorbic acid 250 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-03\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-11-11\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-04\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2015-11-12\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2015-11-08, presumably until 2015-11-08\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2015-11-02, presumably until 2015-11-12\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2015-11-02, presumably until 2015-11-03\n- 24 HR nicotine 0.583 MG/HR Transdermal System, through Transdermal route, started on 2015-11-02, presumably until 2015-11-04\n- haloperidol 5 MG/ML Injectable Solution, started on 2015-11-02, presumably until 2015-11-08\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-12-09, with intended 0 refill(s). Instructions: Take 20 mg daily for 10 days, then stop\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-11-04, presumably until 2015-11-11\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-02\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2015-11-05, presumably until 2015-11-12\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-03\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2015-11-09, presumably until 2015-11-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-11-07, presumably until 2015-11-07\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2015-11-03, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day as needed for Constipation\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2015-11-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2015-11-11, with intended 0 refill(s). Instructions: take 5 mg by mouth 2 times a day\n- cefazolin 1000 MG Injection, started on 2015-11-01, presumably until 2015-11-02\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2015-11-07, presumably until 2015-11-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 3 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2015-11-19, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-12-05, with intended 0 refill(s). Instructions: Take 25 mg for 5 days, then stop\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-11\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2015-11-03, presumably until 2015-11-06\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-02\n- 10 ML furosemide 10 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-09\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-05\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2015-11-08, presumably until 2015-11-09\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2015-11-04, presumably until 2015-11-05\n- ferrous sulfate 140 MG Extended Release Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2016-12-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2015-11-05, presumably until 2015-11-07\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2015-11-08, presumably until 2015-11-12\n- chlorothiazide 500 MG Injection, through Intravenous route, started on 2015-11-06, presumably until 2015-11-07\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2015-11-05, presumably until 2015-11-11\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2015-11-03, presumably until 2015-11-06\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-11-11, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-05\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2015-11-07, presumably until 2015-11-07\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2015-11-03, presumably until 2015-11-09\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2015-11-01, presumably until 2015-11-01\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-05\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-08\n- 1 ML methylene blue 10 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-02\n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-10\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2015-11-07, presumably until 2015-11-07\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2015-11-08, presumably until 2016-11-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-11-02, presumably until 2015-11-04\n- 100 ML amiodarone hydrochloride 1.5 MG/ML Injection, through Intravenous route, started on 2015-11-03, presumably until 2015-11-05\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2015-11-02, presumably until 2015-11-07\n- 100 ML potassium chloride 0.2 MEQ/ML Injection, through Intravenous route, started on 2015-11-06, presumably until 2015-11-06\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2015-11-05, presumably until 2015-11-12\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-02, presumably until 2016-05-09, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 4 hours as needed for Pain\n- doxylamine succinate 25 MG Oral Tablet, through Oral route, started on 2015-11-11, presumably until 2015-11-11\n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2015-11-01, presumably until 2015-11-01\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-11-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2015-11-06, presumably until 2015-11-12\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2015-11-02, presumably until 2015-11-02\n- 100 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2015-11-01, presumably until 2015-11-05\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2015-11-08, presumably until 2015-11-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-05 13:05:15, ended at 2015-12-05 13:59:51\nThe patient in this visit was 75 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative state\n- Primary diagnosis: Aortocoronary bypass graft present\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, presumably until 2016-12-09, with intended 0 refill(s). Instructions: take 20 mEq by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-09-03 14:11:00, ended at 2016-09-03 18:42:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.37 (thousand per microliter)\n- Prothrombin time (PT): 13.3 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.60 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.9 (picogram)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCV [Entitic volume] by Automated count: 87.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.5 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.4 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Melena\n- Left upper quadrant pain\n- Primary malignant neoplasm of prostate\n- Acute posthemorrhagic anemia\n- Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperlipidemia\n- Atrial fibrillation\n- Hypothyroidism\n- Bradycardia\n- Gastritis\n- Primary diagnosis: Stool finding\n- Aortocoronary bypass graft present\n- Electrocardiogram abnormal\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-09-03, presumably until 2016-12-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2016-09-03, presumably until 2016-09-03\n- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2016-09-03, presumably until 2016-09-03\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2016-09-03, presumably until 2016-09-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-16 11:24:35, ended at 2016-09-16 14:49:48\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Degeneration of lumbosacral intervertebral disc\n- Spinal stenosis of lumbar region\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-07 13:55:24, ended at 2016-12-07 15:58:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Minimal cognitive impairment\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-09 00:00:00, ended at 2016-12-09 00:00:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2016-12-09, presumably until 2016-12-09\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2016-12-09, presumably until 2016-12-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2016-12-09, presumably until 2016-12-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-09 08:46:00, ended at 2016-12-09 10:39:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)\n- Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach\n- Fluoroscopy of Lumbar Facet Joint(s) using Other Contrast\n- Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level\n\n### Condition\n- Chronic pain\n- Coronary artery graft present\n- Essential hypertension\n- Hyperlipidemia\n- Atherosclerosis of coronary artery without angina pectoris\n- Low back pain\n- Hypothyroidism\n- Lumbar spondylosis\n- Disorder of musculoskeletal system\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2016-08-12, presumably until 2022-01-11, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2016-01-02, presumably until 2016-01-02, with intended 0 refill(s). Instructions: take 100 mg by mouth daily\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2016-04-14, presumably until 2017-04-07, with intended 0 refill(s). Instructions: take 600 mg by mouth every bedtime\n- 24 HR metoprolol succinate 100 MG Extended Release Oral Tablet, through Oral route, started on 2016-07-24, presumably until 2019-05-07, with intended 0 refill(s). Instructions: take 50 mg by mouth daily \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-09 09:49:23, ended at 2016-12-09 10:01:16\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of musculoskeletal system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-10 00:00:00, ended at 2017-01-10 00:00:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-11 11:51:00, ended at 2017-01-11 14:06:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 870 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 160.9 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Iron [Mass/volume] in Serum or Plasma: 113 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 146 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 54.6 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.0 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 37 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Erythropoietin (EPO) [Units/volume] in Serum or Plasma: 16.9 (milli-international unit per milliliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.07 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.34 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of prostate\n- Anemia of chronic disease\n- Blood chemistry abnormal\n- Flushing\n- Generalized hyperhidrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-11 14:07:00, ended at 2017-01-11 23:59:00\nThe patient in this visit was 76 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Generalized hyperhidrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-25 12:50:00, ended at 2017-03-25 12:50:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-04-01 00:00:00, ended at 2017-04-01 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2017-04-01, presumably until 2017-04-01\n- 1 ML dexamethasone phosphate 10 MG/ML Injection, started on 2017-04-01, presumably until 2017-04-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-01 11:54:00, ended at 2017-04-01 14:50:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach\n- Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach\n- Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperlipidemia\n- Lumbar radiculopathy\n- Coronary artery graft present\n- Hypothyroidism\n- Low back pain\n- Lumbosacral stenosis\n- Lumbosacral radiculopathy\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-01 13:57:34, ended at 2017-04-01 14:18:02\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-07 14:25:58, ended at 2017-04-07 15:09:26\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lumbar radiculopathy\n- Chronic pain\n- Lumbago with sciatica\n\n### Drug\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2017-04-07, presumably until 2018-04-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- gabapentin 800 MG Oral Tablet, through Oral route, started on 2017-04-07, presumably until 2018-04-07, with intended 2 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-11 14:23:00, ended at 2017-04-11 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material\n\n### Condition\n- Degeneration of lumbar intervertebral disc\n- Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-31 00:00:00, ended at 2017-05-31 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-02 12:24:00, ended at 2017-06-02 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), with qualified health care professional interpretation and report, administered by technician, per hour of technician time\n- Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time int\n- Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professio\n\n### Condition\n- Amnesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-10 09:52:13, ended at 2017-06-10 10:51:15\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n- Haptoglobin [Mass/volume] in Serum or Plasma: 283 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n\n### Condition\n- Generalized hyperhidrosis\n- Bradycardia\n- Anemia of chronic disease\n- Primary malignant neoplasm of prostate\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-10 10:54:00, ended at 2017-06-10 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Reticulocytes [#/volume] in Blood by Automated count: 83.3 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.73 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.07 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 196 (unit per liter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 98.6 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.66 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 279 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 87.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 2.23 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of prostate\n- Anemia\n- Amnesia\n- Anemia of chronic disease\n- Generalized hyperhidrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-10 11:58:45, ended at 2017-06-10 12:48:59\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-08 00:00:00, ended at 2017-09-08 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2017-09-08, presumably until 2017-09-08\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2017-09-08, presumably until 2017-09-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-08 07:50:00, ended at 2017-09-08 11:08:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach\n- Fluoroscopy of Lumbar Facet Joint(s) using Other Contrast\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)\n\n### Condition\n- Hypothyroidism\n- Pain\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperlipidemia\n- Lumbar spondylosis\n- Coronary artery graft present\n- Primary diagnosis: Low back pain\n- Primary diagnosis: Chronic pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-19 00:00:00, ended at 2017-09-19 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-22 00:00:00, ended at 2017-09-22 00:00:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-22, presumably until 2017-09-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-22 07:33:00, ended at 2017-09-22 11:48:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)\n- Fluoroscopy of Lumbar Facet Joint(s) using Low Osmolar Contrast\n- Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Lumbar spondylosis\n- Hyperlipidemia\n- Low back pain\n- Arthropathy\n- Hypothyroidism\n- Primary malignant neoplasm of prostate\n- Chronic pain\n- Essential hypertension\n- Lumbosacral spondylosis without myelopathy\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-09-22, presumably until 2017-09-22\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, presumably until 2019-02-27, with intended 0 refill(s). Instructions: take 0.1 mg by mouth every day \n- tadalafil 20 MG Oral Tablet, through Oral route, started on 2015-08-11, presumably until 2019-02-27, with intended 0 refill(s). Instructions: 20 mg by Swish & Swallow route\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-22 08:02:00, ended at 2017-09-22 13:58:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-22 12:41:20, ended at 2017-09-22 15:40:38\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Primary diagnosis: Anemia of chronic disease\n- Generalized hyperhidrosis\n- Primary malignant neoplasm of prostate\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-22 13:59:00, ended at 2017-09-22 23:59:00\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 84.9 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.29 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 158 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-04 10:41:32, ended at 2017-10-04 11:06:12\nThe patient in this visit was 77 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low back pain\n- Primary diagnosis: Chronic pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-14 14:06:24, ended at 2018-03-14 14:06:34\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-04-07 00:00:00, ended at 2018-04-07 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, started on 2018-04-07, presumably until 2018-05-09, with intended 0 refill(s). Instructions: 1/2 tablet each morning x2 weeks, then have EKG check.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-09 00:00:00, ended at 2018-05-09 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- donepezil hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-05-11, presumably until 2018-09-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily in the morning with food\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-19 00:00:00, ended at 2018-05-19 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-26 09:30:00, ended at 2018-05-26 23:59:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Bone necrosis\n- Hip pain\n- Bone cyst\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-26 09:46:10, ended at 2018-05-26 12:02:47\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Bone cyst\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-07 00:00:00, ended at 2018-07-07 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- 24 HR rivastigmine 0.192 MG/HR Transdermal System, through Transdermal route, started on 2018-07-07, presumably until 2018-09-26, with intended 3 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-12 00:00:00, ended at 2018-07-12 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR rivastigmine 0.192 MG/HR Transdermal System, through Transdermal route, started on 2018-08-11, presumably until 2018-08-11, with intended 3 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-01 11:02:49, ended at 2018-09-01 12:14:45\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n- Dementia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-05 09:32:00, ended at 2018-09-05 23:59:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance\n- Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)\n\n### Condition\n- Hip pain\n\n### Drug\n- iopamidol, through Intrathecal route, started on 2018-09-05, presumably until 2018-09-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-25 00:00:00, ended at 2018-09-25 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Amnesia\n\n### Drug\n- 24 HR rivastigmine 0.396 MG/HR Transdermal System, through Transdermal route, started on 2018-09-26, presumably until 2019-02-27, with intended 3 refill(s). Instructions: apply 1 Patch to skin daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-06 00:00:00, ended at 2018-12-06 00:00:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-06 15:17:00, ended at 2018-12-06 23:59:00\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Disorder of thigh\n- Aseptic necrosis of bone of hip\n- Hip pain\n- Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-23 12:32:55, ended at 2019-01-23 13:37:07\nThe patient in this visit was 78 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hip pain\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Dementia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of dementia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "88bf64acece35f9807b793e6d451886c3c6e227e6c2ed35f6fc618b43cdd991f", "prompt_hash": "84386c3adae5f24f3a0b86db4ab1aee428b7bc8fd608988ad001f77860c719a6", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
